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     In the past three years, evidence based medicine emerged as a powerful force in an 
effort to improve quality and health outcomes, and to reduce cost of care. Computerized 
physician order entry (CPOE) applications brought safety and efficiency features to 
clinical settings, including ease of ordering medications via pre-defined sets. Order sets 
offer promise of standardized care beyond convenience features through evidence-based 
practices built upon a growing and powerful knowledge of clinical professionals to 
achieve potentially more consistent health outcomes with patients and to reduce 
frequency of medical errors, adverse drug effects, and unintended side effects during 
treatment. While order sets existed in paper form prior to the introduction of CPOE, their 
true potential was only unleashed with support of clinical informatics, at those healthcare 
facilities that installed CPOE systems and reap rewards of standardized care.  
     Despite ongoing utilization of order sets at facilities that implemented CPOE, there is 
a lack of quantitative evidence behind their benefits. Comprehensive research into their 
impact requires a history of electronic medical records necessary to produce large 
population samples to achieve statistically significant results. The study, conducted at a 
large Midwest healthcare system consisting of several community and academic 
hospitals, was aimed at quantitatively analyzing benefits of the order sets applied to 
prevent venous thromboembolism (VTE) and treat pneumonia, congestive heart failure 
(CHF), and acute myocardial infarction (AMI) – testing hospital mortality, readmission, 
complications, and length of stay (LOS) as health outcomes.  
     Results indicated reduction of acute VTE rates among non-surgical patients in the 
experimental group, while LOS and complications benefits were inconclusive. 
Pneumonia patients in the experimental group had lower mortality, readmissions, LOS, 
and complications rates. CHF patients benefited from order sets in terms of mortality and 
LOS, while there was no sufficient data to display results for readmissions and 
complications. Utilization of AMI order sets was insufficient to produce statistically 
significant results. Results will (1) empower health providers with evidence to justify 
implementation of order sets due to their effectiveness in driving improvements in health 
outcomes and efficiency of care and (2) provide researchers with new ideas to conduct 
health outcomes research. 
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Chapter 1 
Introduction 
 
Background and Problem Statement 
     In the medical field, order set is a product that utilizes standard combinations of drugs 
and procedures for treating typical clinical cases. Multidisciplinary teams of professionals 
represented by physicians, pharmacists, nurses, and other clinicians approve these sets. 
Paper-based order sets have existed for over two decades but lack popularity among 
physicians due to inefficient access and excessive processing routines. Medical 
information technology, in particular computerized physician order entry (CPOE) 
systems, have made order sets more popular through easy access, knowledge database 
support, and a perceived probability of reducing medication error rates. Consequently the 
study of order sets is related closely to three major research subjects: (1) CPOE systems 
implementation and resulting health outcomes, (2) adverse drug effects (ADE) and their 
effect on quality of care, and (3) standardization of patient care and application of the 
evidence-based medicine methods to achieve consistency and quality of health outcomes.  
     CPOE is a relatively new information technology concept that is not only costly but 
also is politically charged to implement, particularly given that health care professionals 
have demonstrated long-standing aversion to technological change in many areas. Order 
set is one element of CPOE, with few studies of its effect on health outcomes reported. 
2 
 
 
 
Yet, order sets promise great potential in improving quality of care, reducing the health 
and financial effects of ADE, and standardize medication prescription practices to 
achieve consistent patient care outcomes (Zafar & Dixon, 2009). 
     Clinical informatics professionals believe that electronic medication order sets: (1) 
improve health outcomes, (2) reduce preventable adverse drug effects and their impact on 
quality of care, and (3) lower cost of care (Zafar & Dixon, 2009). However, despite 
growing reliance on order sets to standardize care and improve safety, little quantitative 
evidence of effects on care has been documented and published in the literature. This 
study was aimed at contributing to a better understanding of the effects of the practices. 
Specifically, despite ongoing heavy utilization of evidence-based treatment methods in 
hospitals, there is a lack of quantitative evidence of the impact of CPOE-based 
medication order sets on patients’ health outcomes. In other words, no scientifically 
proven link between utilization of standardized evidence-based medication sets and 
quality of care has been established. 
     Both positive and negative effects determined in such a study add value in the clinical 
information systems domain, pointing multidisciplinary teams involved with different 
aspects of clinical informatics to the most and least effective ways to offer CPOE 
products to customers. Consequently, this research study warrants follow-up studies to 
determine effects of specific evidence-based methods on treatment of illnesses that fall 
outside of the scope of this dissertation. 
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Dissertation Goal 
     Based on the problem statement, the principal goal of this dissertation was to 
quantitatively to determine the effectiveness of evidence-based medication order sets 
using specific health outcomes from experimental and control groups in CPOE 
application, utilizing several types of order sets adjusted to varied clinical settings and 
patient demographics. 
     Physicians’ skills, experience, and actions vary, especially considering time pressures 
in a high-volume clinical environment. Evidence-based order sets enable standardization 
of care for certain common situations based on feedback from interdisciplinary teams of 
professionals who compile these sets (Payne, Hoey, Nichol, & Lovis, 2003). However, 
while several organizations, worldwide, have adopted utilization of the order sets, few 
research studies have gone as far as determining health outcomes in situations when 
voluntary use of order sets was/was not executed. Physicians are typically not 
accustomed to requirements for mandatory utilization of order sets, outside of situations 
when doctors are recruited for experimental studies. The latter are covered as part of the 
literature review. The detailed outline of the goals of this project is as follows: (1) to 
determine the effect of several common order sets on quality of care based on actual 
health outcomes for patients who received/did not receive evidence-based medications, 
(2) to determine variability between different types of sets and illnesses and whether 
order set utilization is a positive solution under all or only some clinical circumstances, 
(3) to explore effectiveness of the order sets based on some intervening variables, such as 
clinical settings (teaching vs. non-teaching facilities), age of a patient, and disease 
complications, (4) to recommend/not recommend utilization of order sets by healthcare 
4 
 
 
 
facilities worldwide, and (5) to identify recommendations for further research based on 
results of this study. 
Research Site 
     The research was performed at Advocate Health Care, the large integrated healthcare 
provider in Illinois. Advocate’s extensive network includes ten hospitals, home care 
services, rehabilitation facilities, outpatient imaging centers, consolidated labs, hospice 
care, pharmacies, and thousands of employed and partner physicians. The research did 
not involve any experiments with patients at sites and focused on utilization of electronic 
medical records and physician orders to mine a wealth of history data to answer the 
research questions outlined for this study. Select inpatient facilities with the longest 
history of electronic medical records utilization were the main sources of patient data. 
Advocate began early adoption of clinical information systems in 2001 and rolled out 
dozens of different clinical applications from Cerner, Inc. under the internal project name 
Care Connection. The rollout included computerized physician order entry functionality 
that enabled utilization of electronic order sets for prescribing and standardizing 
procedures and medications to treat well-known patient conditions. A decade of 
electronic records maintenance, coupled with introduction of the Enterprise Data 
Warehouse in 2007, enabled collection of sufficient data to conduct quantitative research 
on the effectiveness of order sets in improving quality of patient care. Specific hospitals 
that participated in the study are introduced as part of the research methodology in 
Chapter 3. 
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Overview of the Research Questions and Hypotheses 
     This report is split into four sections, each providing quantitative coverage and 
analysis for one of the patient conditions listed below. This section contains high-level 
questions and hypotheses, with a complete detailed listing available in Chapter 3. The 
main independent variable applicable to all four studies is utilization of the order sets. 
This variable sets up experimental (utilization = yes) and control (utilization = no) 
groups. There are four dependent variables representing health outcomes to measure 
effectiveness of the order sets: mortality, readmissions, complications/comorbidity, and 
length of stay. Not all of these variables are applicable to each condition. There are also 
independent variables of secondary importance to examine external influences on patient 
conditions and health outcomes: age, sex, and race. These are descriptive pre-existing 
conditions that might be important in predicting health outcomes of the patients and/or 
interfere with the role of order sets in ensuring effectiveness of the evidence-based 
practices.  
Venous Thromboembolism (VTE) 
     Questions were aimed at (1) investigating whether utilization of the VTE medication 
order sets will be effective in preventing acute VTE among eligible inpatients; (2) 
exploring the relationship between utilization of the order sets and length of hospital stay, 
determining whether complications or pre-existing medical conditions contributed to this 
relationship; and (3) analyzing and comparing several factors such as race, sex, and age 
in terms of their influence on acute VTE. Among health outcomes utilized for the overall 
study of order sets, mortality and readmissions are not considered directly linked to VTE, 
so these dependent variables were dropped from the list of VTE health outcomes. 
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Questions (1) and (3) represent relationships between independent variables in the study, 
while question (2) examines relationship between independent and dependent variables.  
     VTE study has a unique setup consisting of two main independent variables, outside 
of the ones representing pre-existing conditions – utilization of the order sets and acute 
VTE. While in the cases of pneumonia, CHF, and AMI the patient condition is a given 
(patient diagnosed before treatment occurred), acute VTE is typically a secondary 
condition that may or may not occur among various categories of patients. This situation 
presents a challenge of accounting for the presence or the lack of one for potential VTE 
patients, as well as exclusion of the chronic VTE patients with principal diagnosis of 
VTE from the study - focusing on prophylaxis instead. Therefore, there is an opportunity 
to examine the relationship between independent variables of utilization of the order sets 
and acute VTE, as well as a complex relationship between all independent and dependent 
variables involved in the study.  
     Hypotheses derived from these questions took the form of null statements. Statistical 
manipulations reported in the final stage of the dissertation process either accept or reject 
the null hypotheses, thus answering the research questions outlined in Chapter 3. More 
research questions and hypotheses emerged from further categorization of medical 
records into smaller categories based on sex and surgical qualification of the patients.  
Pneumonia 
     Pneumonia study has a simpler setup compared to VTE, with one independent 
variable of utilization of the order sets and four dependent ones, adding mortality and 
readmissions to the list of health outcomes. Investigation of the effects of pre-existing 
factors of age, sex, and race still applies to pneumonia, as well as all four of the patient 
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conditions. Surgical qualifications do not apply to pneumonia cases, and data samples are 
too small to afford categorization of patients by sex, as evident from monthly utilization 
of the pneumonia order sets provided in Appendix B.  
Congestive Heart Failure (CHF) and Acute Myocardial Infarction (AMI) 
     Questions and hypotheses for these two patient conditions are identical to pneumonia, 
with unique differences in setup, inclusions, and exclusions for each of these two studies. 
As in the case of pneumonia, data samples are too small compared to VTE to enable 
categorization, other than reporting results by individual hospital. 
Relevance and Significance 
     Due to minimal research performed on order sets using actual CPOE data and their 
possible effect on health outcomes, this study was timely and relevant. As the literature 
review revealed, the need for such foundational research has been established in 
professional and academic circles. Results of this study have potential to influence 
decisions to promote evidence-based medicine utilization among physicians, both at 
healthcare facilities with established CPOE systems and culture, as well as those planning 
migration to electronic medical records (EMR) and upgrade to incorporate CPOE 
component.  
     Between 2010 and 2012 several articles on medication order sets appeared in journals 
and conferences, compared to none or order sets being secondary subjects in articles 
covering other aspects of healthcare in the past - indicating growing interest in care 
practice standardization among researchers. In particular, these recent studies were 
conducted by Formea, Picha, Griffin, Schaller, and Lee (2010) at Mayo Clinic, Khanna, 
Vittinghoff, Maselli, and Auerbach (2011) at University of California at San Francisco, 
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Wright et al. (2010) at Harvard Medical School, and Ballard et al. (2010) at Baylor 
Health. However, comprehensive quantitative research necessary to back claims of the 
evidence-based approach health outcomes requires extensive electronic data collected 
with significant level of detail after implementation of CPOE systems. Once 
implemented, clinical committees must create, review, and test medication order sets 
before releasing for general use. After release, data should accumulate for a number of 
years (longer for smaller healthcare facilities) in order to generate a sufficiently large 
sample for quantitative study using statistical methodology and techniques. Majority of 
the aforementioned articles recently published by well-known and highly regarded 
research institutions cover order sets through either qualitative methods of assessment 
(i.e. physician surveys), investigation of efficiency of the medication order entry 
(usability and/or graphical user interface study), or utilization and quality of the order 
sets. A few studies have approached analyzing health benefits and unintended effects of 
the medication order sets by performing small experiments with relatively few 
participants among physicians and patients. Most of these studies returned positive results 
in favor of the order sets and serve as encouragement for greater effort and more 
comprehensive studies, such as the one proposed as part of this dissertation research. 
     Any clinical study that targets patient care outcomes deserves attention due to its 
potential to save and/or improve more lives. The literature indicates potential for 
evidence-based medicine to improve health outcomes, and any evidence of improvement 
would be welcomed by providers and patients alike. Even a small percentage of 
improvement in outcomes leads to saved lives, one patient at a time. A larger percentage 
of improvement also carries significant financial implications through shorter lengths of 
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hospital stay and fewer procedures performed on patients – at a time when the nation 
struggles to contain escalating health care costs that already represent a large and 
growing portion of the gross domestic product.      
     This study represents the application of knowledge management in a specialized 
niche. Years of clinical research and experience, enhanced by communication and 
collaboration among clinical professionals and scientists, combine forces to produce 
evidence-based standards for treating known and well-defined patient cases. This 
knowledge, once digitized and leveraged through computer technology, provides 
professionals in the field with easy access to medication orders that are verified against 
databases containing medication doses, side effects, impact on care, and more. The 
effectiveness of order sets to improve quality of care is well suited to strengthen the use 
of knowledge management to drive change in a field that has trailed many others in terms 
of technology adoption and interdisciplinary approaches. 
Barriers and Issues 
     Conducting this study required human interaction with members of multiple technical 
teams managing EMR, billing, data warehousing, and other systems. It also required 
challenging manual and computer programming efforts to extract data from several 
disparate information sources. Since few similar studies of this scope have been 
published, conducting this research involved charting complex methodology and 
performing many trial and error steps before the study took logical form and shape that is 
generalizable to many clinical settings and was ready for presentation as a completed 
dissertation. 
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     While this study did not require human subjects, it entailed mining several years of 
patient data from historical CPOE databases. Thus, patient data was utilized, which 
required obtaining the IRB approval. Such process took time. Since all hospitals within 
the scope of this study belong to one healthcare system, only one IRB authorization is 
necessary in order to obtain permission to access, manipulate, and analyze data. Advocate 
Health Care’s corporate policy requires IRB approval for any studies that involve patient 
data, regardless of clinical involvement, risk to the patient, and historical nature of the 
analysis. In this case, an exception was requested and granted under the expedited review 
category. Such review required the same paperwork as the full review but expedited the 
process by skipping board review and allowing the IRB leader to sign off on paperwork. 
Advocate’s IRB approval has been obtained in January 2011 for 12 months and required 
application for extension beyond the allocated period of time. Any further extensions 
require a review and submission of the research project status. The NSU IRB committee 
had its own unique requirements in this case. The NSU IRB application was submitted 
and approved in the exempt status in conjunction with the Research Proposal document.  
     As already mentioned, EMR data for this research was scattered among several 
computer systems that have not always had interfaces between them. For example, 
patient records must be obtained initially from a patient billing/accounting system 
because this is the only system that maintains chief complaint and/or primary diagnosis 
for billing purposes. Patient records were then inserted into a data query from a CPOE 
system to obtain data such as order set utilization, age, and hospital name/location. Only 
then could the same patient record number be utilized to obtain corresponding health 
outcomes data. Such inter-system complexities complicated the study but did not result in 
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an inability to obtain valid data. Extracted from multiple sources, such data had to be 
sorted and categorized for validity and verified to match, before proceeding with 
statistical analysis. This was another time-consuming process. To address this concern, 
data was obtained from the Enterprise Data Warehouse (EDW). The EDW has existing 
interfaces piping data into one repository that maintains it in its original form without 
further manipulations. Obtaining data from the EDW led to creation of the “raw” Excel 
data files suitable for editing and statistical analysis in SPSS. 
     Every hospital in the system uses its own order sets for each of the studied patient 
conditions. These sets look similar by title but contain different medications, requiring 
splitting the study into several individual cases by hospital. Due to differences in the 
order set content, effect on health outcomes differed as well and was consequently 
explained by different variables, especially when the analysis led to differences in the 
cases where variances were detected between hospitals within the Advocate’s healthcare 
system. However, a case-based approach helped meet one of the goals of this study to 
identify differences in medication order set utilization between teaching and non-teaching 
hospitals, without performing additional data manipulations.  
     There is also no common identifier for sets listed in various records and computer 
systems. All sets selected for the study had to be moved into individual worksheets and 
manually verified with clinicians for validity. The multitude of order sets available in the 
EMR had to be sorted by preventive and treatment goals, with no single standard for the 
four categories contained in this research study. More specifically, only prophylaxis VTE 
order sets were selected for the study, with prevention being the principal and most valid 
utilization goal. Treatment effectiveness can produce varied results that may be difficult 
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to verify for validity. All other sets must be in the treatment category due to their purpose 
of responding to symptoms in patients. Health outcomes are contained in yet another 
system and were displayed in a variety of spreadsheets that had to be organized and 
translated into a common data language for use in queries.  
     Due to lack of corporate policy enforcing rules of medication order set utilization, 
experimental group samples were much smaller compared to control groups. Statistical 
tests for significance validated results of the study and shed light into the quantitative 
validity of the study. At the same time, the summary report from this study has the 
potential to catalyze change toward greater utilization of order sets and standardization of 
processes around evidence-based medicine practices. Dealing with small samples 
required workarounds, including elimination of splits into more groups of patients among 
population selected for this research. For example, based on monthly utilization figures 
for VTE order sets and patient volumes, the initial data sample for this study was 
expected to exceed 100,000 – making it a candidate for splits into groups and several 
manipulations to determine impact of multiple variables on health outcomes. However, in 
the case of pneumonia, the total number of patient encounters pulled for the study just 
barely exceeded 5,000 – suggesting that statistically significant results could come from a 
combination of all patients from all hospitals and not splits into multiple groups to study 
additional factors influencing health outcomes. Further adoption of the order sets over 
time may enable a more effective follow-up study within several years of completing this 
dissertation. Scarcity of data also explained why so little research is published on the 
subject – it requires a significant buildup of data in CPOE systems which are too new, 
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immature, and expensive to implement. Few organizations possess sufficient data to 
undertake such a study. 
     Data contained in CPOE does not yet contain sufficient detail to perform 
comprehensive cause-and-effect analysis of all factors influencing patient health 
outcomes. Statistical links between utilization of the order sets to treat pneumonia and the 
Charlson Comorbidity Index representing the rate of complications, are not as direct as 
this research study originally assumed. If the Index is compiled of serious illnesses like 
diabetes, cancer, and heart disease – pneumonia might be just one of the factors that 
contribute to change in this score. There is not sufficient detail in the patient records to 
date to account for all possible factors. Again, further maturity of CPOE software will 
help address this issue in the future. For now, establishing statistical evidence of a 
relationship between variables in this study will at least point to order sets making a 
positive/negative difference in patient care, and at this point it is a significant step 
forward for clinical informatics and knowledge management fields. 
     The Charlson Comorbidity Index is a debatable subject among researchers and 
clinicians in terms of its meaning and cause/effect relationship with complications. This 
debate has not been addressed in literature to date and remains internal discussion among 
academics and professionals involved with clinical quality assessment, data analysis, and 
design of quality metrics. Much of the discussion below represents informal feedback 
from individuals involved with clinical quality data analysis rather than a mature 
published study. Comorbidity might be used to interchangeably to serve as a rate of 
patient complications and a barometer of the effect of pre-existing conditions on patient 
outcomes. In this study, comorbidity was utilized to explore the relationship between 
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utilization of the order sets and complications as a measure of health outcomes. On the 
other hand, comorbidity may explain other relationships between health outcomes and 
application of the order sets to prescribe medications. For example, lower rate of acute 
VTE occurrence coupled with longer hospital stay could be a confusing benefit of the 
order sets (improved result for the independent variable and undesired effect on the 
dependent variable of health outcomes), until comorbidity enters the picture. In this case, 
higher comorbidity would explain longer hospital stay due to pre-existing conditions that 
are unrelated to the VTE order set study. The same applies to a completely positive 
outcome in favor of the order sets: shorter hospital stay could be explained by utilization 
of the order sets or the fact that a healthier patient was treated and required shorter 
recovery due to better general state of health. The dual role of comorbidity is also 
analyzed in Chapters 4 and 5, where results and their implications on patient care are 
discussed. 
     Data in some fields in the Excel files that were extracted from EDW had missing 
values. This was due to either lack of requirements for physicians to complete all fields in 
the record or other factors leading to missing data. To address this issue the researcher 
performed initial cleanup to ensure that only valid data entered SPSS for analysis and 
then set proper cases within SPSS to include only valid sets of data. Missing values were 
the cause for differences between descriptive statistics provided for each case study that 
is based on the total number of entries in each column and population listed as parts of 
output from statistical manipulations that take only valid data from each column that 
satisfy the entire set of conditions for the case. The safety net is that summary reports are 
based on statistics coming out of the actual SPSS cases that contain valid data 
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combinations, so slight differences with descriptive statistics are not important relative to 
goals of the study. 
     Order sets are configured in CPOE in such a way that physicians can either click on 
the entire medication set to prescribe to a patient or deselect any of the 
medications/orders from the set. While there are logs maintained in the CPOE indicating 
whether entire or custom set of medications was selected as part of the order, there are no 
reliable data structures retrievable from EDW or SQL database behind CPOE to match 
order set utilization statistics with the actual content of each incomplete custom set order. 
Accordingly, there are no records indicating what was selected within the set. There was 
no remediation for this issue, so one of the assumptions for this study is that all or most 
of the entries within medication order sets are selected by physicians when they choose to 
utilize sets. Otherwise no set selection is recorded in CPOE, triggering a change in the 
value of independent variable managing set utilization in the study to 0 (none). Future 
generations of CPOE software will come with more mature data structures that better 
address research needs for manipulating extracted data. At this point, the researchers have 
to resort to utilizing data structures currently available to them, despite the fact that logs 
are generally available for manual review of each particular order. Such manual review 
could grow into a follow-up study with narrower scope and aim to analyze certain 
restricted conditions within each data subset using fewer patient records. 
     While not directly related to the study, it is important to note that some physicians still 
utilize paper-based order forms for medication sets. The percentage of these paper orders 
relative to CPOE has recently shrunk to 5%-10%, due to CPOE utilization growth and 
preference of physicians who are trained to place orders via CPOE to utilize electronic 
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sets. While the study could be enhanced through inclusion of all applicable and available 
orders, accounting for paper sets was not technically feasible due to a short retention 
history and a manual analysis process, except for rare cases when utilization of paper sets 
is reliably documented. Majority of the paper-based sets were excluded from the study, 
with the exception of select AMI and CHF sets initiated from outpatient facilities that did 
a good job providing order entry information to Clinical Informatics department for 
documentation purposes. These exceptions are noted where applicable in the 
Methodology chapter of this report. The organization where this dissertation research was 
conducted has made headway in pushing higher utilization of CPOE among its affiliated 
physicians, leading to much higher order placements in electronic format relative to 
paper-based ones. This means that the majority (90% - 95%) of the most recent orders 
were captured through database queries, reducing the impact of eliminating paper forms 
from the study. 
     A general concern was that the organization where the research was planned is not a 
research organization by culture. Persuading people to assist took time and patience. 
Some of the tasks were not high on the data owners’, project managers’, and application 
analysts’ to-do lists, so additional time had to be allocated for data extraction projects. 
Despite this lack of academic research support, all data owners took interest in the study 
that was well outside the realm of their normal day-to-day responsibilities and cooperated 
in the most collaborative manner during most stages of this study. The study was 
sponsored at the executive level (Chief Information Officer and Vice President of 
Clinical Informatics) in the organization. These leaders were interested in addressing 
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some of the major concerns, such as quality of care, health outcomes, and key result areas 
established by the executive management team. 
     While not a serious concern relative to outcomes of the study, it is noted that some 
references required for the literature review are rare and may come from sources that are 
over a decade old. However, the quality of literature used for this study is high, because 
longitudinal studies associated with adverse drug effects (representing the vast majority 
of the outdated references selected for the dissertation) have been conducted for some 
time with good outcomes, except for lack of solutions to the problems. Taken from high-
quality professionally regarded journals, these studies satisfy the need for justifying 
existing problems with medication errors and potential role of the medication order sets 
in standardization of care. A majority of the literature associated with CPOE and order 
sets came from recent publications, yet ADE-related studies can be obtained from older 
sources without compromise in terms of quality or relevancy. 
     The sources of references utilized for the literature review also require an explanation, 
as most come from medical or clinical IT journals, as opposed to the more traditional 
choices in the field of information systems. This is due to the fact that majority of the 
clinical IT research is sponsored and/or performed under medical leadership in both 
academic and industry/community organizations, where technology functions report to 
executives with clinical focus. The latter group prefers reading and publishing in 
clinically oriented journals. One particular publication, the Journal of the American 
Medical Informatics Association frequently cited in this paper, happens to be a well-
established authority in the field of clinical IT, despite being just a little over a decade 
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old. The newness of the field calls for exploration and the use of journal titles that 
appeared relatively recently and is an outgrowth of a new research area. 
Assumptions, Limitations, Delimitations 
Assumptions 
     As far as VTE cases are concerned, the main focus of this study was prevention rather 
than treatment. In general, only minority of the VTE cases are chronic and require 
treatment, while majority are expected negative clinical outcomes from many surgical 
and non-surgical procedures routinely performed at hospitals. Among non-chronic VTE 
cases where order sets are applied, there are treatment cases when a patient experienced 
VTE condition and required VTE medications and non-treatment (preventive) cases, 
when a patient received VTE medications aimed at preventing a potential VTE condition. 
The focus of this VTE study was on the latter cases. It was assumed that setting a limit on 
the query of VTE medications ordered within 48 hours of admission would, in a majority 
of cases, indicate that the order was placed for preventive reasons to address a potential 
VTE problem rather than treat an existing condition. No documented borderline exists for 
the method of differentiating between treatment and prophylaxis order sets, so the 
researcher made an assumption for the purposes of this dissertation study, after 
discussing with clinicians and specialists who analyze clinical data at Advocate. 
However, as a second line of defense from error, all chronic VTE cases were excluded 
from the study, as another way to ensure patients who require VTE treatment were not 
mixed in with prophylaxis population. This exclusion is listed in the detailed VTE 
methodology in Chapter 3. 
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     The researcher conducting this study skipped running queries against disparate CPOE, 
billing, and other systems containing necessary data in favor of utilizing the Enterprise 
Data Warehouse that maintains daily data interfaces with all necessary data sources. It 
was assumed, based on actual verification and meetings with data owners, that there is no 
missing data that arrives to EDW through the numerous data interfaces. 
     The study assumed that entire order set was utilized in case where order set = 1 (yes). 
The Limitations section below contains additional information on the physician ability to 
deselect certain items in the set – without a record indicating what was altered.  
     Charlson Comorbidity Index was assumed to be a good indicator of the overall patient 
complications score that is widely accepted in the healthcare industry. The Index contains 
a number of serious conditions indicative of the patients’ outcomes and/or pre-existing 
health issues. There is a number of ongoing initiatives in clinical informatics to design 
better complications measures, but none is currently available to utilize for the purposes 
of this study. Literature confirms that the Charlson Comorbidity Index is the current 
standard for measuring complications and comorbidities as part of similar quantitative 
studies utilizing health data from clinical information systems. 
Limitations 
     The study used data available in CPOE at the time of running database queries and 
could not investigate finer detail, such as all reasons that led to patient complications, 
mortality, or increased length of stay. This means that reasons other than order sets and 
existence of the documented patient condition are likely in play, but it will take years 
before CPOE systems become sufficiently mature to offer a level of detail necessary to 
enhance this research study with additional data. 
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     The study aimed to analyze several descriptive variables beyond order set utilization 
in terms of their impact on patient conditions and health outcomes. However, other 
factors not readily available in CPOE are likely at play that could not be made part of this 
study due to lack of data. 
     The study could only delineate use or lack of use of the order sets among physicians, 
assigning binary indicators to each case. In reality, physicians have an ability to deselect 
certain medications or procedures from the sets. However, CPOE does not currently keep 
track of records of the customized orders made via sets, so only two assumptions could 
be made: order set was utilized and order set was not utilized. Logs of all orders are, in 
fact, maintained in CPOE for the audit and history purposes, yet there is no reliable way 
to match them to other order set utilization documentation and health outcomes in order 
to reliably draw parallels between disparate pieces of information supplied to the EDW 
from various data sources. This problem is related to one of the barriers mentioned in the 
study – availability of a wealth of data contained in multiple repositories that do not link 
and are not verified against each other. 
     While a majority of physicians affiliated with the healthcare system that serves as the 
site for study shifted to utilization of CPOE, there is a small number of medication orders 
still placed via paper. These orders are difficult and time consuming to analyze, 
representing a 5%-10% fraction of all medication orders. Majority of these paper-based 
orders were excluded from the study, with the exception of some CHF and AMI records 
that have been documented by outpatient offices and entered into the database by Clinical 
Informatics departments. These select orders are documented where appropriate in 
Chapter 3. 
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Delimitations 
     The study utilized industry-standard definitions of patient conditions, surgical status, 
discharges, principal and secondary diagnosis, along with other variables. Therefore, 
results of this study are generalizable to other US hospitals. Researchers in international 
locations will need to pay attention to the AHRQ codes listed within the text and as part 
of the appendices and compare methodology utilized in this study to the one commonly 
used within their clinical settings. 
Definition of Terms 
ADE: Adverse Drug Effect 
AHRQ: Agency for Healthcare Research and Quality, a federal government agency 
charged with definitions of health-related standards, codes, and methods of treatment 
AMI: Acute Myocardial Infarction, one of the patient conditions selected for this study 
CHF: Congestive Heart Failure, one of the patient conditions selected for this study 
CCI: Charlson Comorbidity Index of patient complications 
CPOE: Computerized Physician Order Entry System, used interchangeably with EMR in 
this study. Advocate Health Care has gone through several stages of EMR and CPOE 
adoption, adding new modules and capabilities with each implementation phase. At this 
time application combines documentation and order entry features, bringing together 
EMR and CPOE as part of one software solution from Cerner, Inc. While EMR and 
CPOE are not the same, data extracted for the purposes of this study came from a 
universal source. In order to avoid confusion and maintain consistency throughout the 
document, the CPOE term is used in situations that specifically refer to physician order 
entry, such as when order sets are utilized to prescribe medications. In all other instances, 
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EMR serves the purpose of identifying software application that electronically maintains 
medical records and other clinical documentation. 
DRG: Diagnosis Related Group, frequently used with preceding letters appended for 
identification of principal and secondary diagnoses 
DVT: Deep Vein Thrombosis, used interchangeably with VTE in this study, older 
definition of the same/similar patient condition relative to VTE 
EDW: Enterprise Data Warehouse, a data repository that receives feeds from multiple 
sources, eliminating the need for many queries against several disparate databases. 
EMR: Electronic Medical Record, used interchangeably with CPOE in this study. 
Explanation and delineation of the two terms is available under the CPOE paragraph.  
HL7: Health Level 7, international standard for clinical interfaces used to ensure 
interoperability of software used for storage and maintenance of patient information. 
Programming in HL7 ensures that data can be exchanged between any of the clinical 
systems and is one of the very few data standards in existence that enable integration of 
clinical software applications. 
ICD: International Classification of Diseases, an industry standard identification of 
patient conditions governed by alpha-numeric codes 
LOS: Length of Stay 
Medication Order Set: collection of medications and order aimed at treating one common 
patient condition 
MSDRG: Medicare Diagnosis Related Group, a group defined for Medicare medical 
billing purposes 
OB: Obstetrics 
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GYN: Gynecology 
PSI: Patient Safety Indicator, used by AHRQ to define categories of patient conditions 
Psych: psychiatric/psychiatry 
SQL: Structured Query Language 
VTE: Venous Thromboembolism, one of the patient conditions selected for this study 
Summary 
     CPOE/EMR computer applications remain in the early stages of development and 
implementation, along with documentation of medical procedures that goes through its 
own development cycle managed by federal healthcare governing agencies. It is currently 
difficult to perform quantitative studies that involve health outcomes and quality of 
patient care using history data from electronic medical records. Many of the data sources 
lack consistency, integration, and frequently suffer from tendency by healthcare IT 
organization to computerize everything by implementing poorly communicating 
applications addressing varieties of clinical needs and specialties. The lack of standards 
for healthcare data, outside of the Health Level 7 (HL7) programming interface that is 
typically desired but not required of software vendors, forces hospitals to either take 
charge of their own integration efforts or enter local alliances complicated by competitive 
and political differences – effectively contributing to even greater disarray when it comes 
to data driven clinical research. Due to newness of the field, many assumptions not 
backed by documentation and literature must be made by researchers in order to move 
their efforts along.  
     As the following literature review reveals, there is interest among researchers to begin 
mining the data in the growing medical records systems. The latter includes the potential 
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ability to examine effects of evidence-based medicine and standardization of medication 
prescribing methods on patient health outcomes. Despite issues and barriers associated 
with lack of detailed data and requirements to make certain assumptions about patients 
and treatment, the research outlined in this dissertation study is the next big step in 
quantifying the benefits of standardization of care and setting a new baseline for health 
outcomes analysis utilizing statistics and clinical information systems within this 
knowledge management domain.  
     The study aimed at some of the most frequently researched patient conditions that are 
tracked from quality perspective by the majority of hospitals and healthcare systems 
across the United States. These conditions – VTE, CHF, AMI, and pneumonia – affect 
millions of patients annually and contribute to population health overall, as well as 
national healthcare expense. Prescribing medications via order sets is one of the myriad 
options available in modern CPOE applications that have not been tested for outcomes 
due to newness, lack of data and resources to perform studies, as well as ever-changing 
priorities in clinical research. Yet, there are opportunities to prove validity of existing 
practices and to encourage increased adoption, discontinue current practices, or make 
changes – based on results of a study that utilizes quantitative data to analyze patient 
outcomes as part of a longitudinal ex post facto study utilizing existing historical patient 
data. The introduction, literature review, and quantitative methods outlined below were 
aimed at answering several important questions with the potential to improve lives of 
thousands of patients who may receive more consistent health outcomes as results of their 
treatment in hospitals worldwide. 
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Chapter 2 
Review of the Literature 
 
Context 
     The literature review addresses two major research areas closely related to a study of 
order sets: (1) effectiveness of CPOE applications in a clinical setting and (2) impact of 
adverse drug effects (ADE) on quality of care. The review concludes with a summary of 
the latest research related to evidence-based medicine, medication order sets, and their 
effects on patient care. As previously stated, due to lack of research on effects of the 
evidence-based medicine on quality of care, the latter review includes a strong foundation 
supporting the existence of a potential problem due to the lack of analysis rather than 
coverage of related studies that offer a wealth of qualitative analysis to support the cause. 
CPOE Literature 
     Several research studies point out advantages and disadvantages of CPOE. Bates and 
Gawande (2003) highlighted standardization of care and records, along with instant 
verification against possible adverse drug effects as advantages, while pointing to cultural 
mismatches between programming logic and clinical decision making. Bates and 
Gawande warned of the lack of standards among CPOE software applications, leading to 
recent challenges in the processes of clinical systems integration and information 
exchange. Such standards prevent easy identification and comparison of data between 
26 
 
 
 
individual modules of the same EMR application, as well as data exchange between 
various applications utilizing medical records. A typical large healthcare system uses 
more than one application, taking advantage of the data contained in an EMR. In cases 
when the lack of standards prevents data owners from effectively exchanging and 
identifying records between systems, any research that involves a variety of disparate 
sources of information becomes difficult and costly to conduct. In addition, few 
organizations in the process of EMR development and expansion have a population of 
sufficient size to support quantitative research. This may be the primary reason for a lack 
of published research on effects of evidence-based medicine on health outcomes and 
patient care. 
     Ash et al. (2003) discussed CPOE in light of organizational effects that promote 
teamwork, responsibility, and accountability, while also introducing more effective and 
formal ways of communication to reduce chances for errors in verbal and written orders. 
Yet, Ash et al. also noted difficulty in adapting large CPOE rollouts to divergent local 
practices that vary by department and physician, and the mismatch between restrictive 
programming logic of CPOE applications and broader thinking patterns of physicians. 
Part of the problem is the programming of CPOE applications that uses the logic of 
central application management and universal standards. This makes adaptations to 
varied local practices difficult. Another problem is a lack of effective human intelligence 
mechanisms built into CPOE applications, calling for inclusion of the latest artificial 
intelligence breakthroughs with future versions of the CPOE software. However, such 
research may significantly increase already high software development costs, driving 
27 
 
 
 
major CPOE application vendors away from practice/content localization efforts aimed to 
incorporate individual physician preferences as a way to increase usability and adoption. 
     In a follow-up study of the unintentional consequences of information technology in 
healthcare, Ash, Berg, and Coiera (2004) revealed productivity loss among physicians 
and nurses resulting from additional cognitive overhead as a result of numerous order 
entry menus in CPOE applications, errors in keyboard data entry, ineffective graphical 
user interfaces delivered by some of the application vendors, and modification of the 
workflow established through years of practice and experience. Linearizing complex 
medical decisions has been highlighted as the single greatest dissatisfaction and 
productivity loss factor, causing some physicians to oppose further computerization of 
clinical settings (Ash et al., 2003).  
     Chan (2002) blamed low CPOE adoption rates on the failure of project managers in 
charge of vendor selection and project rollout to account for cultural, contextual, and 
cognitive factors as part of the social reengineering effort that must be included in the 
process of CPOE planning in addition to typical technology challenges. Such factors may 
range from small interface issues to entire, improperly designed modules of the 
application. For example, a number of recently interviewed physicians indicated that 
electronic patient charts should come up with a general status/condition screen rather than 
medication orders and vitals that need to be documented and reviewed later. While 
seemingly a minor issue, physicians believe that such wrong sequences  of screens/events 
programmed into CPOE applications erase physician logic by modifying a typical clinical 
workflow. Another example is the absence of a copy/paste feature for chart updates, 
which was designed as an additional safety measure by requiring an update on patients 
28 
 
 
 
every time the chart is opened. However, a typical patient’s condition does not change 
drastically between two chart reviews, thus requiring physicians to reenter almost 
everything recorded previously. In paper-based records, physicians have to enter notes on 
the patient’s condition but not go through the entire logic of reviewing a patient file. 
Some physicians view such software performance as an invasion into their workflow, 
leading to decreased utilization of CPOE at facilities where business cultures still allow 
using paper. Examples like these are many.  
     Han et al. (2005) presented evidence of the negative effect CPOE can have on clinical 
outcomes by measuring mortality rate increases from 2.8% to 6.57% after CPOE 
implementation at one healthcare facility. While Han et al. (2005) admitted that many 
factors likely played a role in this mortality rate increase, the lesson to measure more than 
just ADE as an outcome of CPOE implementation is clear. Longhurst et al. (2010) 
quantified the impact of CPOE on patient mortality in a historical data study performed at 
a 303-bed freestanding quaternary care academic children’s hospital, with a total of 
80,063 discharges analyzed before intervention on November 1, 2007 and 17,432 
discharges after implementation of CPOE. In the latter case, the mean monthly adjusted 
mortality rate decreased by 20% (1.008 – 0.716 deaths per 100 discharges/month, 0.8% 
& 40%, p = 0.03).  
     Poissant, Pereira, Tamblyn, and Kawasumi (2005) quantitatively explained 
productivity loss by physicians, measuring clinical case documentation efficiency among 
nurses (24% time reduction) and physicians (17.5% time increase). Returning the focus 
of this review to qualitative, Sittig, Krall, Kaalaas-Sittig, and Ash (2005) interviewed 
physicians to study the emotional side of CPOE implementations and found that the 
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majority of positive emotions were related to rewards through system alerts, acceptance 
of correct order entries, and instant access to vast knowledge databases behind order 
entry applications. A majority of the negative emotions were associated with doubts over 
physicians’ ability to make correct decisions as primary reasons for bringing CPOE to the 
clinical setting. A more recent study by McAlearney, Chisolm, Veneris, Rich, and 
Kelleher (2007) encompassed interviews with 10 focus groups and 71 physicians. This 
study discovered additional application design concerns (people serving technology 
rather than the opposite) and the cost of implementation in terms of modification of 
responsibilities and the workflow (physicians taking on data entry responsibilities that 
were previously shared among nurses and clerks in the past).  
     Concluding the study of CPOE advantages and disadvantages, Gross and Bates (2007) 
summarized success factors in implementation into 10 commandments: (1) speed, (2) real 
time information delivery, (3) fit to the workflow, (4) attention to details in usability 
studies, (5) recognition of resistance and the reasons behind this resistance, as well as 
remedial actions, (6) flexibility to change direction as a result of resistance study, (7) 
having simple guidelines and effective help available to users, (8) asking for additional 
data entry and tasks only when absolutely necessary, (9) monitoring impact and feedback 
as part of a continuous quality improvement process, and (10) managing and maintaining 
currency of the knowledge systems. Looking to the future, Rothschild and Lehmann 
(2005) proposed building problem-specific CPOE pick-lists from a database of explicitly 
linked orders and problems taken from actual clinical cases. The latter study explains the 
link between CPOE success and taking next steps in clinical knowledge management and 
integration as leading in two directions: (1) standardization of care through evidence 
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based medicine in the form of hundreds of ready-to-order sets of medications and (2) 
packaging entire clinical cases as bases for decision making by utilizing vast data and 
knowledge resources entered in CPOE over the years. Both future directions rest upon 
successful implementation of CPOE to build electronic databases of knowledge to be 
converted into multiple forms and shapes for further enhancement of health outcomes. 
ADE Literature 
     While CPOE establishes a base for enhanced electronic order set implementation, 
there is a need to describe the influence of adverse drug effects on quality and cost of 
care in order to discover the need for evidence-based care standardization as part of the 
health outcomes improvement effort. Walsh et al. (2006) described negative CPOE 
effects in the ADE language. In a study of 6,916 medication orders among 352 randomly 
selected pediatric admissions over 1,930 patient days, Walsh et al. discovered 104 
medication errors, 71 of them serious, with 19% computer data entry related. While the 
latter is a small rate of 3.6 errors per 1,000 orders compared to reasons unrelated to 
computers of 10 errors per 1,000 orders, it is important to remember that while CPOE 
helps reduce medication error rate, it is unable to eliminate it. A majority of the articles 
on ADE and CPOE published in the past several years are more upbeat about the future 
of CPOE and standardized care helping to reduce error rates. In an early study by 
Chertow et al. (2001), the researchers compared differences between “basic” CPOE 
(control group) and CPOE enhanced with decision-making capability (experimental 
group) over a period of four consecutive two-month intervals in 1997 and 1998. A total 
of 7,490 patients, 97,151 orders, and 14,440 orders modified by the decision support 
program (15% of the total) were evaluated, resulting in a 4.5 patient days mean stay in 
31 
 
 
 
intervention versus 4.8 days in control group hospital stays, pointing to a slight 
improvement in quality and cost of care in cases modified by the decision support 
system. This particular study does not account for other factors beyond decision support 
that might have influenced the outcome, yet points to a possibility of the computer-
enhanced workflow positively affecting health outcomes. 
     Teich et al. (2000) found that CPOE utilization resulted in an increase in use of 
nizatidine from 15.6% of all histamine blocker orders to 81.3%, with a decrease in the SD 
of drug doses by 11%. Increased use of nizatidine, if prescribed properly, leads to more 
effective treatment of the gastroesophageal reflux disease (GERD), as well as duodenal 
and gastric ulcers. In the same study, display of a recommended frequency for 
ondansetron hydrochloride administration resulted in an increase in use of approved 
frequency from 6% of all ondansetron orders to 75%. Finally, use of subcutaneous 
heparin sodium to prevent thrombosis increased from 24% to 47%. These changes 
persisted throughout the 1-2 years of the analysis.  
     Bates et al. (1997) analyzed 4108 admissions to a stratified random sample of 11 
medical and surgical units in two tertiary care hospitals over a six-month period. Post-
event length of stay and total costs of ADE were measured using chart and billing records 
review methods. There were 190 ADE, 60 of them preventable, from 207 admissions. An 
average additional length of stay was 2.2 days at an average cost of $3244. Among 
preventable ADE, there was a 4.6 average additional length of stay that resulted in $5857 
total cost. After sampling adjustment, the cost comparison between all ADE and 
preventable ones was $2595 vs. $4685, leading to the conclusion that preventable ADE 
carried extra cost and represented a good cause for investment into research with a goal 
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of reduction and elimination. Due to its primary focus on cost rather than quality of care, 
this study encompassed multiple departments and categories of illnesses without 
classification by disease.  
     Classen, Pestotnik, Evans, Lloyd, and Burke (1997) performed a study to determine 
excess length of stay, extra costs, and mortality from ADE at the Latter-Day Saints (LDS) 
hospital in Salt Lake City, Utah. ADE affected 2.43 of every 100 admissions resulting in 
extra stay of 1.74 days for an extra cost of $2,013. The data also revealed a roughly two-
fold increase in probability of death from ADE compared to non-ADE cases. King, Paice, 
Rangrej, Forestell, and Swarz (2003) conducted a study at a tertiary care pediatric 
hospital with patients in three medical and two surgery wards. Six years of data, 804 
medication errors with 18 ADE among 36,103 discharges and 179,183 patient days were 
analyzed. Before CPOE implementation, the error rate was 4.49 per 1,000 patient days, 
with the after-CPOE rate down 40%. This pointed to a huge health benefit from the 
CPOE rollout. In yet another study, Bates et al. (1999) determined a rate of 1 per 100 
medication errors resulting in ADE. Their study consisted of patients admitted to three 
medical units over a period of seven to ten weeks and over four different years, split 
between pre-CPOE (control group) and post-CPOE (experimental group) categories. The 
error rate fell 81% from 142 per 1,000 to 26.6 per 1,000 patient days – another health 
benefit of CPOE relative to ADE. 
     Kaushal et al. (2001) performed an ADE effects study with 1120 patients at two 
academic institutions during six weeks in 1999. Researchers analyzed 10,778 orders, with 
616 (5.7%) medication errors, 115 (1.1%) potential ADE cases, 26 (0.24%) actual ADE 
cases, with 19% of the cases preventable based on detailed review by pharmacists and 
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availability of standard medication practices to replace custom orders. ADE rates were 
significantly higher in neonatal and neonatal intensive care units. Most cases (79%) 
occurred at the stage of ordering and involved incorrect dosing (34%), anti-infective 
drugs (28%), and intravenous (IV) medications (54%). Physician reviewers, asked to 
comment on retrieved data, judged CPOE could prevent 93% of errors, and pharmacy 
reviewers came up with a 94% figure, ultimately agreeing that most ADE are preventable 
cases. 
Evidence-Based Medicine and Order Set Literature 
     Standardization of care through ADE prevention by using evidence-based medicine 
methods appears that it can help further reduce error rates and improve health outcomes. 
Only a handful of studies have been conducted using actual data analysis, and all these 
studies were based on isolated configurations such as alerts or decision support 
applications built for the purposes of conducting research, as opposed to standard CPOE-
based order sets routinely utilized in thousands of patient care cases for a period of 
several years - as proposed for this dissertation. The review also revealed that evidence-
based medicine is still in its initial discovery phases, with numerous challenges 
remaining. 
     Medication allergy checking, dose calculations, and drug interactions are some of the 
most common actions physicians perform when ordering medications, and these also 
happen to be some of the most common ordering stages when errors are made, especially 
in fast-paced community hospital environments (Del Fiol, Rocha, Bradshaw, Hulse, & 
Roemer, 2005). Implementation of CPOE-based electronic order sets at the 21 hospitals 
of Intermountain Health Care have had positive effects through simplification of the 
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thought process for some of the standard patient cases, but challenges identified as part of 
the study by Del Fiol et al. include the need for consistent change management 
exacerbated by the cost of maintaining a permanent panel of professionals representing 
multiple disciplines and a hierarchical structure of maintenance by different professionals 
utilizing CPOE. Yet, many medical professionals are interested in utilizing standardized 
sets, based on a study of early paper-based forms posted on an Intranet site for printing, 
when the utilization rate increased from 0 to 6400 hits for the form per month over the 
24-month period (Heffner, Brower, Ellis, & Brown, 2004). Early decision support-based 
programs administered at the end of the 1980s and in the mid-1990s at the 520-bed LDS 
hospital in Salt Lake City, Utah, used an antibiotic management program based on local 
clinician derived guidelines embedded in the software application. This helped decrease 
the cost of drug administration per patient from $122.66 in 1988 to $78.37 in 1994, 
despite an overall increase in antibiotic drug administration during the same period 
(Pestotnik, Classen, Evans, & Burke, 1996).  
     Brigham and Women’s hospital in Boston performed a more sophisticated study based 
on computer alerts in CPOE. The program encouraged prophylaxis as a way to reduce 
frequency of deep-vein thrombosis (DVT) among high-risk hospitalized patients (Kucher, 
Koo, Quiroz, Cooper, Paterno, Soukonnikov, & Goldhaber, 2005). There were 1,255 
patients in the intervention group and 1,251 in the control group. Acute DVT occurred in 
4.9% of patients in the intervention and 8.2% in control groups. This constituted a 41% 
reduction in the deep-vein thrombosis or pulmonary embolism rates at 90 days. In the 
most recent cluster-randomized controlled trial of 179 diabetes mellitus and inpatient 
hyperglycemia patients at an academic hospital, primary mean percent of the glucose 
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readings per patient were reduced to 60-180 mg/dL (Schnipper, Liang, Ndumele, & 
Pendergrass, 2010). The result of this experimentally categorized study, based on a 
custom medication order (control group) and a CPOE admission order set (intervention 
group), indicated a positive outcome from use of the standard medication order sets.  
     Payne, Hoey, Nichol, and Lovis (2003) performed a study at the Veterans 
Administration (VA) Puget Sound hospital in Washington with two medical centers, 
500,000 annual outpatient visits, and 10,000 discharges. While admitting a painful and 
time-consuming process of creating order sets, the study recorded order set utilization 
rates of 50% for order dialogs, 57% for quick orders, and 13% for full order sets used 
within six months of implementation. There was also a further 26% increase in use 
recorded over two years following the initial study. McAlearney, Chisolm, Veneris, Rich, 
and Kelleher (2006) analyzed rates of utilization of order sets by physicians among 529 
asthma patients (88.1% use), 277 appendectomy patients (79.4% use), and 210 CAP 
patients (21.1% use) between November 2001 and November 2003. The study indicates 
generally high, but variable, use among various types of order sets.  
     Dinning, Branowicki, O’Neill, Marino, and Billett (2005) found that 48,000 cancer-
diagnosed patients can expect ADE, 20% of them drug-related, but two-thirds of the 
cases should be preventable. Such improvement may come from utilization of order sets 
with the benefits of improved order legibility, time savings, standardization, and low 
percent of necessary adjustment in template set (given the quality of an order set). In the 
study, the use of templated sets increased from 1% in 1998 to 70% in 2005, with a 0% 
physician adjustment rate for CPOE sets and 5% to handwritten ones (Dinning et al., 
2005). Cowden, Barbacioru, Kahwash, and Saltz (2003) published an order set quality 
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improvement study with the goal of combining two orders and evaluating a combined 
chi-squared to predict order set correspondence to an ordering pattern. The study was 
performed using 3.06 million records from the Ohio State University (OSU) Medical 
Center with statistically significant patterns identified in 9762 records, corresponding to 
904 orders – a number leading to the conclusion that a large portion of medication orders 
qualifies for an order set. Chisolm et al. (2006) performed a quantitative study with 790 
pediatric asthma patients at Columbus Children’s Hospital, dividing patients into three 
groups: pre-set, set, and no set. Set patients were more likely to receive SCS and PulseOx 
than pre-set and no set patients, resulting in better health outcomes. There were no 
statistically significant differences found between no set and pre-set patients.  
     A number of qualitative studies have been performed to assess effects of evidence-
based medicine on patient care. Bobb, Payne, and Gross (2007) identified several 
controversies with order sets, while confirming excellent decision support opportunities 
from electronic CPOE-based implementations: (1) voluntary use by physicians creating 
variability in ADE and utilization rates, (2) typical CPOE sets versus locally used ones 
produced significant variability, (3) modification of some drugs in a set proved to be 
difficult despite the available option, and (4) order sets tend to go quickly out of date, 
requiring costly change and knowledge management efforts. Zafar and Dixon (2009) 
confirmed costly collaboration of multidisciplinary teams. However, they described as an 
advantage enhanced teamwork and collaboration among professionals who may 
otherwise be acting on their own, advancing quality of care and promoting more effective 
knowledge management practices in healthcare organizations. Zafar and Dixon saw 40% 
to 50% mortality rate reduction through such collaboration and higher utilization and 
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buy-in through participation among medical professionals. Yet, they identified time 
constraints as barriers to participation (typical order set creation project requires six to 
eight weeks of physician participation).  
     Rosenal et al. (2009) performed a comprehensive study on utilizing blood culture 
order sets among 2000 patients and 2000 physicians, encompassing 61,000 orders. They 
found mixed results due to communication and collaboration, as well as training, issues – 
concluding the report with quantitative data to back the claim that collaboration and 
knowledge management efforts to maintain currency of information in CPOE are keys to 
getting results described in the studies of evidence-based approaches to medical 
treatment. Lee, Teich, Spurr, and Bates (1996) found one satisfaction factor for 
physicians – ability to customize order sets – turn into a disadvantage by taking a toll on 
patient safety due to variable error rates after customization and confusion among 
technicians charged with following physician orders. Yet, Peitzman (2009) highlighted 
automation benefits of the order sets as the ones solving communication problems and 
helping to avoid errors in ordering under situations when multiple priorities may alter an 
otherwise standard procedure set.  
     Ahmad et al. (2002) documented a tendency of physicians to request custom sets, 
which increased availability and variability among order sets in CPOE, thus negatively 
affecting safety rates through lack of focus and effective communication with people in 
charge of execution. Ozdas et al. (2006) described another tendency of physicians to 
ignore medication sets even in cases perfectly matching established standards, with 
physician independence and different decision-making, potentially affecting quality of 
care. Rules to require consideration of order sets would represent a culture change that 
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many healthcare facilities are not ready to undertake. Adventist Health System in Florida 
undertook such transformation and cited physician engagement as the biggest reason for 
success of a 2.5-year project to address 80% of the diagnosis-related cases with an order 
set approach (Herring, 2009). Resistance to change was listed as the biggest challenge on 
an eventually successful initiative that led to quality of care improvement through 
reduction of the ADE rates. Hulse et al. (2005) summarized strategic advantages of 
evidence-based medicine as (1) support for clinical knowledge management, (2) frequent 
updates to the best drug practices, (3) true evidence-based medicine supported by review 
of the latest medical and pharmaceutical advances, and (4) health outcomes 
improvement. Yet, there is at least one argument against evidence-based medicine 
published in the scholarly literature by Maynard (2009), who argues that prevention of 
the deep vein thrombosis through implementation of standardized drug sets is a measure 
of mediocrity that should not replace physician analysis. However, this study is not of a 
quantitative nature and represents an expert opinion. In fact, Giuse, Williams, and Giuse 
(2010) recently published an article describing effectiveness of the Vanderbilt University 
Eskind Biomedical Library’s knowledge management team in utilizing multidisciplinary 
approach to evidence-based medicine to construct 225 evidence packets since 2004, 
many of which have been implemented electronically as part of CPOE and were well 
received by members of the clinical staff. The library team utilizes its data for more than 
just building medication sets and provides input for several quality management and 
standardization initiatives at the university medical center. 
     Interest in evidence-based medicine has been on the rise over the past couple of years, 
as insurance, government agencies, and healthcare organizations have renewed focus on 
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safety and quality in patient care. Due to this renewed interest, several research studies on 
medication order sets were conducted under various conditions, including experimental 
setups, with some just recently published. Afessa, Mullon, Badley, and Gajic (2007) 
conducted a study of the paper order set effects among 168 severe sepsis and 373 septic 
shock ICU patients. Health outcomes were selected using Acute Physiology and Chronic 
Health Evaluation (APACHE) III guidelines that require compliance with the following 
six elements of early goal-directed therapy and hospital mortality: (1) use of central 
venous pressure, (2) central venous oxygen saturation measurement, (3) adequate fluid 
resuscitation, (4) appropriate use of vasopressors, (5) inotropes, and (6) transfusion of red 
blood cells. The order set was utilized in 61.9% of the patient cases, with no statistically 
different outcomes relative to the non-set patients, but compliance with standards has 
increased from 24.8% to 39.6% of the patient cases. In a smaller, experimental study of 
120 patients with septic shock diagnosis performed at the Emergency Department (ED) 
of a 1,200-bed academic medical center, 60 patients in the experimental group were more 
likely to receive intravenous fluids while in the emergency department (ED) than patients 
in the control group (2825 +/- 1624 mL vs. 3789 +/- 1730 mL, p = 0.002), more likely to 
receive fluids of >20 mL/kg body weight before vasopressor administration (58.3% vs. 
88.3%, p < 0.001), and more likely to be treated with an appropriate initial antimicrobial 
regimen (71.7% vs. 86.7%, p = 0.043) (Micek, Roubinian, Heuring, Bode, Williams, 
Harrison, Murphy, Prentice, Ruoff, & Kollef, 2006). Overall, using order sets for 
administering drugs in treating septic patients was associated with statistically more 
rigorous fluid resuscitation of patients, more effective use of appropriate antibiotics, and 
lower 30-day mortality.  
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     Thiel, Asghar, Micek, Reichley, Doherty, and Kollef (2009) performed a follow-up 
severe sepsis study at the 1,200-bed academic Jewish-Barnes Hospital, this time among 
200 bacteremic patients with severe sepsis for 18 months prior to the order set 
implementation and 200 in the 18 months after. As with the earlier study, patients in the 
experimental group received more intravenous fluids in the first 12 hours after onset of 
the hypotension (1627 +/- 1862 mL vs. 2054 +/- 2237 mL; p = 0.04) and were more 
likely to receive an appropriate dose of the antibiotic therapy (53% vs. 65.5%, p = 0.01). 
Mortality has statistically decreased in the experimental group (55% vs. 39.5%, p < 0.01), 
along with the hospital stay (28.7 +/- 30.1 days vs. 22.4 +/- 20.9 days, p = 0.02). The 
experimental group also experienced other positive effects through reduction in 
complications, as follows: renal failure (70.5% vs. 57%, p < 0.01), cardiovascular failure 
(70.5% vs. 57%, p<0.01), and less likelihood of the vasopressor administration after fluid 
resuscitation (68.5% vs. 52.5%, p<0.01). In their own study of severe sepsis order set 
implementation, Rivers, Coba, and Rudis (2009) showed relative risk reduction of 0.34 
and absolute risk reduction of 16% with a corresponding cost reduction in results of an 
experiment performed at the Emergency Department (ED) of a university medical center. 
This translates into the saved life of one out of every six severe sepsis patients – a strong 
case for insisting on evidence-based medicine implementation in both academic and 
community hospital settings.1 
                                                 
     1 While there are many types of hospital designations depending on their purpose, 
scope, outreach, access to research, residency slots, etc – this study delineates between 
teaching and community hospitals as these relate to the dissertation subject. There are 
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     Bekmezian, Chung, and Yazdami (2009) quantitatively measured perceived benefits 
of the pediatric admission order sets (PAOS) among 97 medical residents at the 
University of California Los Angeles Children’s Hospital using a 5-point Likert scale. 
Eighty-nine percent of residents approved PAOS and 58% admitted using it all the time. 
Eighty-eight percent reported that PAOS saved time, 93% thought it was convenient, and 
most reported less need for communication and clarification with nurses and secretaries. 
Broussard, Bass, and Arnold (2007) conducted a pediatric sedation drug dosing study at 
Louisiana State University Health Sciences Center in Shreveport using paper order sets to 
compare the 26 patient intervention group to the control group of 42 sedations. The 
average age of patients in the groups was 45 and 71 months respectively. One hundred 
percent of documentation compliance cases increased from 32% in the control group to 
69% in the experimental one. Ordering of resuscitation equipment, American Society of 
Anesthesiologists (ASA) class, listing of allergies, and post-sedation orders all increased 
(93% to 100%, 0% to 81%, 64% to 100%, and 43% to 100% respectively). Medication 
dosages for Versed, Fentanyl, and Ketamine that fell within the recommended dosage 
range per Lexis-Comp’s Pediatric Dosage Handbook (+/- 10%) varied between control 
                                                                                                                                                 
expected differences between teaching hospitals, where students and residents enter 
medication orders in addition to physicians, and community hospitals where minimal 
research is performed and all medication orders are entered by attending physicians. 
These are also the only two types of hospitals managed by Advocate Health Care where 
this study is conducted.  Other types of hospitals may include academic, regional, tertiary 
care, etc. 
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and intervention groups as follows: 68% versus 100%, 100% versus 95%, 71% versus 
100%, and 67% versus 100%. Reversal agents ordered, using mg/kg, were 56% in the 
control group and 100% in the experimental one. Overall, and with a few exceptions, 
preprinted orders made a dramatic difference in the quality of pediatric sedation care. 
     Ballard, Ogola, Fleming, Heck, Gunderson, Mehta, Khetan, and Kerr (2008) 
conducted an observational study to examine order set use by hospital, discharge month, 
severity of illness, and risk of mortality for pneumonia patients between March 2006 and 
September 2007. They assessed the impact on in-hospital mortality and 30-day 
readmission rates using the following four measures: (1) Cox proportional hazards 
regression, (2) Joint Commission Core Measures compliance using logistic regression, 
(3) length of stay, and (4) financial indicators using robust regression methods for highly 
skewed data. Among 3,301 patient cases, order set use increased by 55 percent and 
significantly improved in-hospital mortality [95 percent confidence interval: 0.66 (0.45; 
0.97) or 0.67 (0.46; 0.98)] and Core Measures compliance [95 percent confidence 
interval: 1.24 (1.04; 1.48) or 1.22 (1.02; 1.45)], without affecting 30-day readmission 
rate.  
     Wright et al. (2010) analyzed order sets adoption and utilization among seven 
hospitals in a mix of community and academic type settings: Brigham and Women’s in 
Boston, Faulkner Hospital in Boston, Kaiser Permanente Northwest in 
Oregon/Washington, Massachusetts General Hospital in Boston, Sugar Land Hospital in 
Sugar Land, Texas, NSMC Union Hospital in Lynn, Massachusetts, and Providence 
Portlar Medical Center in Portland, Oregon. There was no commonality among these 
hospitals in terms of the CPOE systems they use, size (number of beds ranged from 77 to 
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750), and scope. The researchers searched for common trends in utilization of the order 
sets. They found a general increase in utilization, but no patterns in the types of sets. The 
most common ones among the top 10 at every site were emergency department admission 
sets, stroke admission orders, pediatric admission sets, general detoxication, and pre/post 
surgery sets. Other sets included patient controlled analgesia, post-cardiac catheterization, 
labor admission, insulin, dialysis, blood transfusion, neonatal circumcision, obstetrics 
admission, expedited admission, zosyn advisor (medication set used to treat or prevent 
drug-resistant infections, recommended by clinical decision support systems under 
certain medical conditions), rehabilitation orders, peripheral nerve block, chest pain 
nursing orders, intensive care unit admission, and psychiatry admission sets. Total 
availability of the order sets in CPOE ranged between 35 at Faulkner Hospital and 535 at 
Kaiser Permanente Northwest. Percentage of utilization was higher among health systems 
and academic hospitals versus smaller community centers. Overall, a growing trend 
towards utilization of the sets to standardize care practices and to improve efficiencies 
was identified, but no specific patterns of utilization were revealed. 
     Another indirect study around order sets that was intended to reveal health outcomes 
benefits was performed by Khajouei, Peek, Wierenga, Kersten, and Jaspers (2010). They 
researched efficiency of ordering medications via sets versus custom selection methods in 
CPOE and found the median excess number of mouse clicks and keystrokes needed by 
physicians in order to complete medication prescribing tasks was 6.2 times lower in the 
method with predefined order sets (P < 0.01). The excess number of mouse clicks and 
keystrokes was increased by erroneous messages with a factor of 2.62 (2.24 & 3.07 at 
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95% CI), use of unfamiliar terminology by a factor of 1.28 (1.14 & 1.43 at 95% CI), and 
non-informative system feedback by 1.15 (1.03 & 1.29 at 95% CI).  
     Fleming, Ogola, and Ballard (2009) measured utilization and health outcomes after an 
implementation of community-acquired pneumonia order set at the Baylor Health Care 
System, with 4,454 patients meeting the Joint Commission’s definition of pneumonia 
selected for the study between March 2006 and August 2008. After risk adjustment, 
analysis showed significant reduction in the following areas: in-hospital stay, 30-day 
mortality, and direct cost, with a 75% increase in compliance. The difference in core 
measure compliance was statistically significant at 1.08. Mortality reductions approached 
significance at 0.73 for in-hospital measures and 0.79 for 30-day mortality. The mean 
benefits of order set use in in-hospital mortality and costs were 1.67. The incremental 
cost-effectiveness ratio point estimate was -$22,882 per life saved, with an upper 95% 
confidence limit of $1,278 per life saved. 2 
     Braxton, Gerstenberger, and Cox (2010) demonstrated that use of medication order 
sets can improve compliance with Surgical Care Improvement Project (SCIP) guidelines 
developed by the US National Institute of Medicine. They utilized a tailored antibiotic 
                                                 
     2 Amount per life saved is a standard clinical case terminology, when savings from 
clinical quality initiatives are calculated. Terminology refers to savings per patient or 
patient case, relative to healthcare expenses for treating this same patient without the 
mentioned clinical innovation. In other words, it is a financial expression/measure of 
clinical success. 
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prophylaxis form to help standardize perioperative antimicrobial use, with 90% 
compliance and an estimated $8,500 annual pharmacy savings through standardization. 
Wren, Martin, Yoon, and Beck (2010) demonstrated through EMR data mining that 
electronic orders sets, coupled with education for medical professionals utilizing EMR, 
can decrease risk of the post-surgery hospital-acquired pneumonia. In their study 
conducted at the Veterans Administration Palo Alto Health Care System, 13 out of 1,668 
patients were admitted with post-operative pneumonia in the pre-intervention period, 
while only 3 of 1,651 patients were admitted after intervention. 
     Seattle Children’s Hospital implemented a number of quality improvement measures 
to establish governance over peripherally inserted central catheters, medication order sets 
included (Migita, Postetter, Heath, Hagan, & Beccaro, 2009). After implementation, 
insertion volume of the devices decreased by 33.4% and physician satisfaction with the 
ordering process increased from 2.68 to 3.55 based on a 5-point Likert scale. 
Improvements were sustained over 19 months, when observation for the purposes of the 
study concluded. Results were achieved through standardization of practices using 
evidence-based approaches to treat patients. O’Connor, Adhikari, DeCaire, and Friedrich 
(2009) conducted a deep venous thrombosis (DVT) prophylaxis quality improvement 
study at the 750-bed community hospital in Mississauga, Ontario using paper medication 
order sets for voluntary use by internists without prior education on benefits of the 
evidence-based approaches to medicine. Order sets were used to prescribe admission 
medications to 10.9% of the patients, who were 23.4% more likely to receive DVT 
prophylaxis than patients in the control group. Follow-up experiments showed 
improvements in other areas where medication order sets were made available, including 
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allied health consultations (62.8% vs. 12.7%), application of the standardized diabetic 
diet (17% vs. 5.1%), insulin sliding scale (19.1% vs. 7.6%), potassium replacement 
protocol (63.8% vs. 0.51%), documentation of allergies (54.3% vs. 9.6%), and 
resuscitation status (57.4% vs. 10.2%). This study repeated success of the earlier one 
performed at the same hospital, when results were tracked based on Heparin SC usage for 
DVT prophylaxis. The number of patients receiving this medication order increased from 
10.2% to 22.3% at that time, leading to improved DVT prevention results (O’Connor, 
DeCaire, & Friedrich, 2005). 
     Albert, Sherman, and Backus (2010) performed a comprehensive Six Sigma based 
experiment using a combination of medication order sets, standardization of practice 
methods, and prioritization for left-ventricular congestive heart failure (CHF) patients to 
determine impact of evidence-based practices on the length of hospital stay among CHF 
patients. Turnaround time was reduced from a mean of 2.2 days to a mean of 0.78 days 
for the left-ventricular CHF patients, while the length of stay was reduced from 7 days to 
4 days (P < 0.05), and utilization of the order sets by physicians rose from 25% to 72.6%. 
The study was performed at a medium-sized 265-bed community hospital and points to 
benefit of the order sets to treat CHF patients but stops short of providing quantitative 
evidence for the sets outside of the overall array of measures that, in addition to 
introduction of the sets, included factors such as a new rounding policy, safety checks, 
and prioritization of patients. However, the study does point out growing interest among 
researchers to investigate impact of clinical process standardization on CHF health 
outcomes. 
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     While few recently published studies attempted to link utilization of electronic order 
sets to quality indicators and patient care directly, a few came close to suggesting such a 
link without quantitative evidence to support the claim. For example, Ahmad et al. (2002) 
and Payne, Hoey, Nichol, and Lovis (2003) agreed that the measure of CPOE success is 
represented by (1) the percentage of orders entered into CPOE directly by providers and 
(2) the overall utilization of the order sets. Peshek, Cubera, and Gleespan (2010) 
measured the impact of CPOE implementation on order set utilization and compared the 
percentage of orders placed using paper sets versus electronic ones at Summa Health 
System in Ohio. The difference was an astonishing 46%, between 37% prior to CPOE 
(paper version) and 83% after CPOE (electronic version). Payne et al. (2003) supported 
the CPOE success measures and their close relationship to order sets and health outcomes 
by referring to the report by Mehta et al. (2002), which credited evidence-based medicine 
as a proven quality improvement measure resulting in better health outcomes for patients 
with acute myocardial infarction – without a direct reference to the order sets that happen 
to be the core element of the evidence-based medicine implementation as part of the 
CPOE. When studies of ADE, CPOE, and evidence-based medicine are reviewed and 
summarized, it is apparent that authors emphasized the positive impact of a CPOE and 
medication order set as its core element on health outcomes, with references to past 
studies of the evidence-based medicine that were not performed at healthcare facilities 
with strong CPOE culture. Moreover, the success of CPOE implementation was widely 
linked to utilization of its core elements, including medication order sets constructed by 
teams of clinicians. The missing piece is a quantitative study with the potential to claim a 
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direct effect of evidence-based medicine on quality of care, using order set data from 
EMR as a basis to form experimental groups of patients. 
     The Mayo Clinic introduced a comprehensive order set review process that includes 
formal committee evaluation, approval process, and mid-term progress checks on 
utilization and patient outcomes (Formea, Picha, Griffin, Schaller, & Lee, 2010). The 
only quantitative data provided in the study cites convenience surveys distributed among 
physicians, with 105 staff members surveyed, 56% responses returned, 65% reporting 
positive impact on hospital intrateam communications, 71% citing improvement in 
participant safety, 65% more satisfied with new process compared to the old one (more 
sporadic introduction of the order sets without formal committee review and progress 
checks), and 19% indicating no difference in efficiency. The study primarily took on 
process improvement benefits of the sets rather than direct impact on care, or at least no 
statistics is provided for the claims of patient safety improvements.  
     A couple of promising studies on direct medication order set benefits have been 
recently published. One is on congestive heart failure medication order set that closely 
resembles an attempt to explore quantitatively the relationship between evidence-based 
medicine and health outcomes. Another one is on impact of order sets to treat adult 
febrile neutropenia by antibiotics (not subject of this dissertation).  
     Ballard, Ogola, Fleming, Stauffer, Leonard, Khetan, and Yancy (2010) performed an 
observational study on the effects of a standardized heart failure order set on mortality, 
readmission, and cost of care. Patient population was adults (>18 years old) discharged 
between December 2007 and March 2009, with a length of stay shorter than 120 days, 
who had not undergone heart transplant and who did not have a left ventricular assistance 
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device. Order set utilization reached 73.1% by March 2009 and resulted in increased 
compliance with core measures (1.51 & 1.08; 2.12 at the 95% confidence level) and 
reduced in-patient mortality (0.49 & 0.28; 0.88 at the 95% confidence level). Reductions 
in 30-day readmissions and mortality approached significance. The study also analyzed 
factors influencing the physician’s decision to utilize order sets for prescribing 
medications. While this observational study is smaller, relative to the proposed study 
(fewer medication sets, conditions, illnesses, and variables), it represents a serious step 
forward in identifying quantitative support for evidence-based medicine and indicates 
documented significance of the dissertation topic.  
     Best et al. (2011) evaluated the impact of standardized medication order sets on the 
time interval in initiation of antibiotic therapy for adult patients with cancer and febrile 
neutropenia at the oncology unit of an urban community hospital in the southeastern 
United States. A small population sample of 53 cancer patients included a control group 
of 30 patients admitted in the six months prior to implementation of the order set and 23 
patients in the experimental group admitted in the three months after implementation. 
Order set use was the independent variable, and initial antibiotic times and length of stay 
were the dependent variables, analyzed in SPSS using One-Way ANOVA and logistic 
regression methods. An overall reduction of time intervals for initiation of antibiotic 
therapy was observed among the experimental group of patients – presentation (t = 2.25, 
df = 37, p = 0.031) and antibiotic administration (t = 2.67, df = 40.17, p = 0.012). Order 
set usage was 31% in the inpatient unit and 71% in the emergency department.  
     It is noteworthy that Khanna, Vittinghoff, Maselli, and Auerbach (2011) performed a 
quantitative study of the unintended consequences of a standard prophylaxis venous 
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thromboembolism (VTE) admission order set on patient outcomes, thus opening a new 
chapter in the evidence-based practices research. They argued that administration of 
prophylaxis sets may worsen outcomes among some patients who should not have 
received medications, even while improving outcomes among a majority of others who 
may have benefitted from evidence-based practices. The setting of their experiment was 
University of California at San Francisco Medical Center, a 790-bed academic hospital. 
The experiment was based on analysis of data from the pharmacy charge database 
between July 1, 2005 and December 31, 2008. The primary outcome was use of the VTE 
order sets among patients with likely benefit, unclear benefit, and potential harm. The 
sample size was 8429 control and 17635 experimental patients prior to and after 
implementation of the VTE order set. There was an overall rise in VTE cases after 
implementation at 58% after versus 51% before, p < 0.001, while patients with potential 
harm from the sets exhibited larger increase in VTE – odds ratio = 1.58 (1.12 & 2.22 at 
95% CI). While the overall increase in VTE was small, the higher odds ratio among 
patients with potential harm from the sets is of concern. Investigation of the harm from 
administration of the medication order sets to some groups of patients is outside of the 
scope of this study, but in case it reveals that majority of the patients could benefit from 
prophylaxis medications ordered via sets, a follow-up study for smaller groups of 
potentially harmed patients would be warranted before adjusting hospital policy on 
utilization of the sets and promoting them for all patients.  
     In their qualitative study on designing and implementing VTE protocols aimed at 
improving effectiveness of the prophylaxis methods, Maynard and Stein (2010) 
confirmed that failure to revise and manage order sets, including revisions based on 
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impact on certain groups of patients, may lead to unintended consequences of 
standardization. Among other influencing factors, complexity, no guidance for 
application of sets, failure to adjust risk levels, and lack of situational awareness are listed 
as contributors to higher VTE rates and failures of the evidence-based sets to increase 
compliance and reduce acute VTE occurrences. The latter factor has to do with building 
another line of defense in identification of patients eligible for prophylaxis sets who have 
not received them by building CPOE alerts recommending use of the sets and leading to 
potentially higher utilization by physicians.  
Summary 
     Based on this literature review, interest in evidence-based medicine, in general, and 
utilization of the medication order sets, specifically, to improve quality of care and 
increase compliance is likely to grow. Coupled with regulatory and industry focus on 
standardization and outcomes, evidence-based medicine appears poised to be the next big 
step to raise the quality bar. While few hospitals may have the resources available for 
implementation at this time, there is interest in exploring the subject among researchers 
and practitioners alike. 
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Chapter 3 
Methodology 
 
Overview of the Research Methodology 
     Analysis of the effectiveness of medication order sets measured by health outcomes 
was a quantitative ex post facto research study using a simple design and purposive 
sampling methodology. It was based on data extracted from a combination of 
computerized physician order entry (CPOE), patient accounting, and care quality sources. 
Full data sets were available beginning in 2007 for most hospitals but Trinity that went 
live with CPOE in April, 2010. Therefore, a majority of the data contained over four 
years of patient history. This translated into over 126,000 applicable venous 
thromboembolism (VTE) records, 5,000 pneumonia encounters, 11,000 congestive heart 
failure (CHF) cases, and 1,300 acute myocardial infarction (AMI) ones. The VTE study 
allowed for greater flexibility in terms of splitting patients into groups to perform 
additional discoveries, such as studying patient sex differences on outcomes and 
examining data on surgical and non-surgical patients separately. Hospital splits were 
attempted in VTE and pneumonia studies, while samples were too small to perform any 
categorizations and hospital splits for AMI and CHF – due to lower utilization of the 
order sets system-wide. In the pneumonia case, hospital splits could not produce 
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statistically significant results, but data was collected due to initial expectation that 
results had the potential to be significant. 
     Literature, national health problem prevention, cost of care, and actual Advocate 
Health Care key result areas comprised the basis for selection of the four patient 
conditions that affect millions of patients. Ultimately, effectiveness of any and all 
medication order sets must be explored as part of several quantitative studies. Due to lack 
of such data overall, some of the most common and serious patient conditions were 
selected for this particular study. Researchers have a chance to review input, content, and 
methodology behind this study, which is determined to be generalizable to any US-based 
hospital and, after adjustments to foreign standards of quality measures, any hospital 
worldwide. 
     Most of the data sources have existing inbound interfaces into the enterprise data 
warehouse (EDW), so a series of queries against one database reduced time and 
complexity necessary to extract data. Every patient encounter contains one principal 
diagnosis and up to 30 secondary ones. All were pulled and searched for the four patient 
conditions identified for this study. VTE represents secondary diagnosis only due to the 
prophylaxis focus of the study that explicitly excluded chronic VTE patients with a 
principal diagnosis of VTE. The latter category is too small to include as part of extensive 
study, at least until larger population samples are explored. All of the VTE patients would 
acquire or have the potential to acquire VTE as part of another treatment, making the 
diagnosis secondary. In contrast, a majority of the pneumonia patients have their 
diagnosis listed as principal for community acquired cases, with a minority acquired as 
hospital-born (nosocomial). A majority of the AMI patients were admitted with AMI as a 
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principal diagnosis, while CHF can be discovered both as part of the admission process 
or as part of treatment for a different chief complaint.  
     The patient encounter number was a unique patient identifier that made it possible to 
run complex queries against multiple computer applications, ensure proper comparisons 
between multiple spreadsheets and summary tables, and eliminate patient identity from 
the study, streamlining the IRB approval procedure. Due to disparity in records, lack of 
unique identifier for medication order sets, and differences in content among sets with 
similar titles, manual order set selection was performed on a spreadsheet broken down by 
hospital, with matching order set content for verification purposes, implementation date, 
statistical utilization average to ensure acceptable data sample size, and matching health 
outcomes to ensure validity of complex data queries. Each methodology case below 
contains detailed information on the order sets selected for the study, as well as lists 
utilization statistics. The high-level summary of the order sets is presented in Table 15, 
Appendix A.  
     There are ten hospitals within Advocate Health Care’s network, seven of which will 
appear as part of this dissertation study. Others are not included, as newer members of the 
network have not accumulated sufficient electronic patient data under the same computer 
databases utilized for this study. Table 1 lists all hospitals that participated in the study, 
along with abbreviated codes that are referenced in the methodology and results sections 
of this report. 
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Table 1. Advocate Health Care Hospital Reference Codes 
 
Hospital Code Description 
CMC Christ Medical Center, Chicago, IL 
GSAM Good Samaritan Hospital, Downers Grove, IL 
GSHP Good Shepherd Hospital, Barrington, IL 
IMMC Illinois Masonic Medical Center, Chicago, IL 
LGH Lutheran General Hospital, Park Ridge, IL 
SSUB South Suburban Hospital, Hazel Crest, IL 
TRIN Trinity Hospital, Chicago, IL 
 
     The paragraphs below explain sources and basic nature of the dependent variables in 
the study. These variables represent health outcomes as measurement instruments for 
quantitative evaluation of effectiveness of the order sets. Further information on specific 
criteria for these instruments is provided under specific case methodology sections of this 
chapter, under each patient condition.  
     Readmission rate stored in EDW came from Thomson-Reuters. It is available in the 
form of a yes/no binary value, with an added benefit of a reason for readmission that was 
linked to one or more of the diagnoses in patient encounter records to validate that 
readmission was a follow-up to a previous hospital stay. 
     Complications stored in the EDW are represented by the Charlson Comorbidity Index. 
It is a calculated score based on a list of complications that produce an 
expected/statistical complications index when added up. While seemingly not the most 
reliable method of calculating complications, it is the only industry standard widely 
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accepted by researchers who utilize medical records for historical data studies. Thomson 
Reuters is in the process of developing a new methodology, but it was not available in 
time to be utilized for the purposes of this research. Future use would also depend on the 
degree of acceptance of the new methodology among researchers, as it is best to refer to 
the most trusted sources in cases when no fully reliable research methods have been 
developed to analyze complications.   
     Mortality stored in the EDW was initially represented as a discharge code with 
matching description. It was converted to a yes/no binary format, based on selection 
methodology that is detailed within each study that uses mortality as a dependent 
variable. While projections based on diagnoses are available in the EDW, such data was 
irrelevant to this study. 
     Length of stay is stored in the EDW in actual and projected variants. Actual variant is 
the most relevant use for this variable, as it can tell researchers how long exactly the 
patient stayed and how medications were prescribed to result in this length of stay, rather 
than rely on predicted value that would be useful for other kinds of studies not involving 
historical data.  
     Overall, the study was split into four independent cases based on specific patient 
conditions. Results are reported independently as well, but with an overall summary 
linking all patient conditions to goals of this research study, culminating in 
recommendations for follow-up quantitative and (potentially) qualitative investigations. 
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Case I: VTE Methodology 
Overview 
     The study encompassed creation of several cases, split by hospitals chosen from 
among the heaviest users of the order sets based on EMR utilization statistics, marked by 
common factors delineating VTE, constrained by timing of the medication orders to filter 
out treatment sets, and linked to applicable health outcomes as follows: 
1. Reviewed one of the monthly medication order set utilization statistics reports to 
determine applicable sets for the VTE study and to choose hospitals offering the 
largest data samples. A summary of the August 2010 VTE statistics is presented 
in Table 130, Appendix B. 
2. Reviewed content of each order set in order to verify its validity to use for VTE 
prevention purposes and to make sure it actually contained medications and not 
just non-medication orders such as nurse communications or medical devices. The 
latter two comprised a different study but did not apply to the one examining 
medication order sets. The complete listing of each set selected for this study is 
presented in Table 134, Appendix B. 
3. Extracted patient encounters with VTE coded as diagnosis, where physicians 
utilized pre-defined EMR sets to order medications, to form experimental groups. 
The Enterprise Data Warehouse contains all patient data interfaced by the EMR, 
billing, and financial systems – necessary to perform extracts and conduct the 
study, eliminating the need for querying several systems. Data interfaces into the 
EDW were created as part of a different business need unrelated to this study. 
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4. Formed control groups of comparable patients who were eligible to receive VTE 
order sets based on their history expressed as ICD codes. Split cases by hospital 
(IMMC and LGH only), surgical/non-surgical patient status, and sex. 
5. Queried the length of stay and complications for both experimental and control 
groups. 
6. Accounted for factors outlined in the Inclusions and Exclusions sections of this 
document. 
7. Produced a spreadsheet with “raw” data extracted from the EDW.  
8. Analyzed the spreadsheet and further excluded unnecessary items that did not 
conform to requirements of the study, i.e. all chronic VTE encounters, orders 
placed outside of the 48-hour window from the time of admission, etc. 
9. Loaded the resulting “clean” data set into SPSS v. 19 for detailed statistical 
analysis. 
10. Performed case analysis, employing such methods as “if” case definition; group 
definition; crosstabs; chi-squared Fisher’s Exact; Pearson Chi-Squared tests to 
determine statistical significance of the results; One-Way ANOVA with 
Bonferroni, Tukey, Dunnett post hoc tests to compare means among independent 
variable groups and effect on the dependent variables; Mann-Whitney Non-
Parametric test of independent samples to test null hypotheses and compare 
means; and binary logistic regression to calculate the odds ratio among 
independent variables and between independent and dependent variables in the 
study. 
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Goal 
     The goal was to develop methodology for a causal comparative study analyzing the 
differences between health outcomes among groups of patients whose VTE medications 
were ordered via sets and using the “traditional” custom order method. Results indicate 
the effects of standardization of the medication ordering on quality of care. More 
specifically, the study was aimed at determining effectiveness of the VTE/DVT order sets 
in preventing occurrence of acute VTE among surgical and non-surgical inpatients at 
Advocate Lutheran General Hospital (LGH) and Advocate Illinois Masonic Medical 
Center (IMMC), as well as to establish any statistical relationships between utilization of 
the order sets, cases of diagnosed VTE, and two dependent variables most applicable to 
this illness: patient complications index and length of hospital stay. 
Research Questions and Hypotheses 
     Question 1: Do VTE/DVT medication order sets help prevent occurrence of acute 
VTE among adult non-surgical patients? 
     Hypothesis 1 (null): VTE/DVT medication order sets do not help prevent occurrence 
of acute VTE among adult non-surgical patients. 
     Question 2: Do VTE/DVT medication order sets help prevent occurrence of acute 
VTE among adult surgical patients? 
     Hypothesis 2 (null): VTE/DVT medication order sets do not help prevent occurrence 
of acute VTE among adult surgical patients. 
     Question 3: Does patient sex play a role in this study and alter answers to Questions 1 
and 2? 
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     Hypothesis 3 (null): Patient sex does not make a difference in the relationship between 
utilization of the medication order sets to prevent VTE and occurrence of acute VTE. 
     Question 4: What effect does utilization of the VTE medication order sets have on 
surgical patient complications index expressed as a calculated Charlson Comorbidity 
Index? 
     Hypothesis 4 (null): VTE medication order sets have no effect on surgical patient 
complications as expressed by the Charlson Comorbidity Index.  
     Question 5: What effect does utilization of the VTE medication order sets have on 
non-surgical patient complications index expressed as a calculated Charlson Comorbidity 
Index? 
     Hypothesis 5 (null): VTE medication order sets have no effect on non-surgical patient 
complications as expressed by the Charlson Comorbidity Index. 
     Question 6: What effect does utilization of the VTE medication order sets have on the 
length of surgical patients’ hospital stays? 
     Hypothesis 6 (null): Utilization of the VTE medication order sets has no effect on the 
length of surgical patients’ hospital stay. 
     Question 7: What effect does utilization of the VTE medication order sets have on the 
length of non-surgical patients’ hospital stays? 
     Hypothesis 7 (null): Utilization of the VTE medication order sets has no effect on the 
length of non-surgical patients’ hospital stay. 
     Question 8: Which among independent variables of order set utilization, patient age, 
patient sex, patient race, and surgery status has most influence on the independent 
variable of acute VTE? 
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     Hypothesis 8 (null): None of the independent variables of order set utilization, patient 
age, patient sex, patient race, and surgery status has any effect on acute VTE, or all of 
these variables have equal influence on acute VTE. 
High Level Overview of Elements and Outcomes of the Study 
     The study aimed to compare between identical groups of patients that received and did 
not receive medication order sets as prophylaxis for VTE. In order to ensure the 
prophylaxis purpose of the medications, as opposed to treatment, the study was limited to 
medications ordered within 48 hours of patients’ admission. Chronic VTE cases that were 
listed under a different ICD code were filtered out to ensure further compliance with the 
prophylaxis requirement. Due to potential differences in characteristics of the VTE 
conditions among groups differentiated by treatment facility, surgical status, and sex, the 
final report is split into eight major categories, as follows: 
1. Relationship between utilization of the order sets and acute VTE – 
split by hospital and surgery categories, a total of 4 cases as follows: 
a. IMMC Surgical Calculations 
b. IMMC Non-Surgical Calculations 
c. LGH Surgical Calculations 
d. LGH Non-Surgical Calculations 
2. Relationship between utilization of the order sets and acute VTE – 
split by hospital, surgery, and sex of the patients categories, a total of 
8 cases as follows:      
a. IMMC Surgical Calculations – Female 
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b. IMMC Surgical Calculations – Male 
c. IMMC Non-Surgical Calculations – Female 
d. IMMC Non-Surgical Calculations – Male 
e. LGH Surgical Calculations – Female 
f. LGH Surgical Calculations – Male 
g. LGH Non-Surgical Calculations – Female 
h. LGH Non-Surgical Calculations – Male 
3. Relationship between utilization of the order sets, acute VTE, and 
Charlson Comorbidity Index as follows: 
a. IMMC Surgical Calculations 
b. IMMC Non-Surgical Calculations 
c. LGH Surgical Calculations 
d. LGH Non-Surgical Calculations 
4. Relationship between utilization of the order sets, acute VTE, and 
length of stay, as follows: 
a. IMMC Surgical Calculations 
b. IMMC Non-Surgical Calculations 
c. LGH Surgical Calculations 
d. LGH Non-Surgical Calculations 
5. Direct relationship between utilization of the order sets and length of 
stay, as follows: 
a. IMMC Surgical Calculations 
b. IMMC Non-Surgical Calculations 
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c. LGH Surgical Calculations 
d. LGH Non-Surgical Calculations 
6. Direct relationship between utilization of the order sets and Charlson 
Comorbidity Index, as follows: 
a. IMMC Surgical Calculations 
b. IMMC Non-Surgical Calculations 
c. LGH Surgical Calculations 
d. LGH Non-Surgical Calculations 
7. Analysis of statistical significance of several independent variables on   
occurrence of acute VTE, as follows: 
a. Acute VTE as affected by utilization of the order sets, patient 
age, patient sex, patient race, and surgical/non-surgical status – 
LGH and IMMC combined. 
b. Acute VTE as affected by utilization of the order sets, patient 
age, patient sex, patient race, and surgical/non-surgical status –
IMMC. 
c. Acute VTE as affected by utilization of the order sets, patient 
age, patient sex, patient race, and surgical/non-surgical status – 
LGH. 
8. Descriptive statistics, as follows: 
a. Patient Sex, by order set utilization - IMMC 
b. Patient Sex, by order set utilization - LGH 
c. Patient Race, by order set utilization - IMMC 
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d. Patient Race, by order set utilization – LGH 
e. Study Race Codes 
     The surgical vs. non-surgical distinction was made via the Agency for Healthcare 
Research and Quality (AHRQ) industry standard, commonly available as PSI-12 
Postoperative Pulmonary Embolism or Deep Vein Thrombosis. 
Study Inclusions 
a. Acute VTE patients. 
b. Adult patients 18 years of age or older. 
c. VTE order sets available via EMR at LGH and IMMC hospitals. 
d. Surgical and Non-Surgical cases delineated (AHRQ ICD-9, PSI-12). 
e. Encounters with use of the order set and none (experimental vs. control groups). 
f. Sex of the patients. 
g. Age of the patients. 
h. Race of the patients. 
i. Length of stay (dependent variable). 
j. Charlson Comorbidity Index as rate of complications (Table 132, Appendix B). 
k. Full list of inclusions is presented in Table 2. Some elements are for the follow-up 
study use but included as part of the extract for efficiency purposes. 
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Table 2. Data Elements for Inclusion in the VTE Study 
 
Data Elements (Set 1) Data Elements (Set 2) 
Encounter number Discharge disposition code 
Patient key Length of stay 
Site Observed complications 
VTE (yes or no) Expected complications 
Order set (yes or no) Charlson Comorbidity Index score 
Order set (title) Patient age 
Order set catalog number Patient sex 
Surgery (yes or no), AHRQ ICD-9 basis 
PSI-12 table 
Patient race 
Admit date VTE Type (acute vs. chronic) 
Discharge date Attending physician name 
 
Study Exclusions 
a. OB patients. 
b. Psych patients. 
c. Pediatric patients under the age of 18.  
d. Medication sets ordered after 48 hours from the time of admission. 
e. Chronic VTE encounters to focus on prophylaxis only. 
Initial Data Processing Steps 
     The steps outlined in this section were required in order to get the raw data properly 
organized in Excel and loaded into SPSS, in accordance with inclusions and exclusions of 
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the study. First, it was necessary to extract data from the EDW database to receive a raw 
file suitable for analysis and data categorization. For this purpose, a query had to be built 
against EDW SQL Server database for all patient encounters available since inception of 
the data repository in 2007, so over four years of data within the 2007 – 2011 date range, 
using the list of variables provided in Table 2. Results of the query were converted to 
Excel format in order to be useful for statistical manipulations, including loading into 
SPSS. Table 131, Appendix B lists values assigned to variables in this study. The Excel 
file had variables listed as columns and patient encounters corresponding to these 
variables listed as rows. The query excluded patients under 18 years of age, obstetrics 
patients, and psych patients – as indicated by the list of exclusions produced for the VTE 
study. Other exclusions were taken care of via SPSS groups and filtering. 
     The “raw” file extracted out of the EDW database and saved in Excel produced a large 
listing with over 126,000 patient encounters, based on the monthly medication order set 
utilization statistics provided in Table 130, Appendix B. For encounters where 
medication order sets were utilized, a special column that displays time in days between 
admission and physician order set timestamp was necessary in order to comply with the 
policy of adhering to prophylaxis sets ordered within 48 hours of admission. Both 
variables were available via data extract. The valid time to include in the study was an 
integer that varied between negative range (pre-admitted patients from nursing homes or 
other outpatient facilities) and positive number not exceeding 1 (within 48 hours of 
admission). Zero is a valid value in the range, because days within admission is a 
calculated field where number of days is converted from hours, so if a medication order 
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was placed shortly before or after admission, it would have a non-zero value in hours but 
might have a zero-value in days when rounded. 
     A table of race codes was necessary in order to turn string format of the race 
description data coming from the warehouse into numerical field suitable for quantitative 
analysis of the race’s influence as an independent variable on the dependent variables in 
the study. This conversion of format was accomplished using “Search” function in Excel, 
building a table of race codes utilized in the data file, and assigning random numbers in 
logical order to each race type. The race codes for the VTE study are summarized in 
Table 133, Appendix B. The “Replace” function in Excel was utilized to assign numeric 
codes in the race column, replacing corresponding string values that cannot be used for 
statistical purposes.  
     Any unnecessary fields that arrived from raw data as results of extensive data entry for 
the study had to be removed, leaving only the following columns: 
• VTE Order Set Used 
• Facility Key (Table 1) 
• Admit Date 
• Patient Sex 
• Age 
• Race 
• Length of Stay 
• VTE Order Set Date 
• Days Admit to VTE Order Set (calculated in Excel) 
68 
 
 
 
• MAXDX (unnecessary field but required to load surgery status) 
• PSI 12 Denominator – categorical delineation between surgical and 
non-surgical patients based on AHRQ PSI-12, Appendix A standards, 
Operating Room Procedure Codes - listed in Table 135, Appendix B. 
Value of 0 is displayed when procedure code for the patient does not 
produce a match in the PSI table, otherwise a value of 1 is displayed 
indicating surgery – true. AHRQ codes are healthcare industry 
standards that providers and insurers refer to when reviewing services 
delivered to patients 
• Acute VTE 
• Chronic VTE 
• Charlson Comorbidity Index. 
     The resulting Excel file was ready for shifting work into SPSS and contained only 
data identified as required for the study. The initial full data set before cleanup can be 
utilized for follow-up studies that are proposed in Chapter 5. It was also important to 
account for any remaining study exclusions by deleting corresponding rows with patient 
encounters in SPSS using the Data Split File function for sorting, as follows: 
• Delete all cases with Chronic VTE = 1 
• Delete any rows containing encounters with the Days Admit variable 
value > 1. 
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Variable Setup for CCI and LOS cases 
     The One-Way ANOVA test was applied to examine complex relationship between 
utilization of the order sets, acute VTE (both independent variables), and length of stay or 
Charlson Comorbidity Index (both dependent variables). In this setup, it was important to 
not only account for the experimental factor of application of the order sets but also for 
the known fact of occurrence of the VTE before examining the overall effect of the VTE 
order set on health outcomes. In other words, whether the order set was applied and 
whether acute VTE occurred were facts known from medical records, creating four 
possible combinations that could influence LOS and CCI in four different ways. 
However, One-Way ANOVA is only effective in comparing categories of variables 
selected for experimental study but not examining complex relationships within this 
structure. Therefore, additional assumptions were necessary to simplify structure for 
ANOVA, with relationships between independent variables documented for analysis of 
the results. In order to properly configure One-Way ANOVA, a new field in SPSS, called 
VTE_Category, served the purpose of comparison of means between two independent 
variables of VTEOrderSetUsed and AcuteVTE, and the dependent variables of the length 
of stay and CharlsonComorbidityIndex. This was accomplished in SPSS in the following 
order: 
• Ensured that VTEOrderSet Used and AcuteVTE columns appeared 
next to each other for convenience 
• Inserted a new field called VTE_Combination next to AcuteVTE 
• Sorted VTEOrderSetUsed column in descending order 
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• Called the first combination of 1/1 
(VTEOrderSetUsed=1/AcuteVTE=1) as 1 and entered the value on the 
first row in the VTE_Combination column 
• Formatted the new field to integer with no decimal places 
• Copied and pasted the number for all rows next to the 1/1 combination 
rows 
• Labeled and documented all cases in the same fashion, as follows: 
a. 1->1 = 1 
b. 1->0 = 2 
c. 0->1 = 3 
d. 0->0 = 4 
     The above cases served as input for the One-Way ANOVA analysis of the relationship 
between independent and dependent variables (LOS and CCI).  
Case Separation by Hospital, Sex, and Surgical Status – Repetitive Process 
     The High Level Overview of Elements and Outcomes of the Study section outlined 
several cases split by hospital and surgical status that must be run separately in SPSS. 
This was accomplished using Data -> Select Cases functionality in SPSS. Examples are 
as follows: 
• IMMC Surgical calculations case: “Facility Code = 7 AND 
PSI12DENOM = 1” 
• LGH Non-Surgical Female calculations case: “Facility Code = 10 
AND PSI12DENOM = 0 AND Sex = 1” 
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• IMMC Surgical Male calculations case: “Facility Code = 7 AND 
PSI12DENOM = 1 AND Sex = 0” 
     Conditions for the first studies in the list can be defined as a single setup per case with 
resetting all conditions back to original state and defining conditions again, capturing 
data for each scenario. Repeating data select and reset operations helped in running all 
statistical manipulations on all identified hospital, surgical status, and sex condition 
combinations. 
Relationship Between Order Set Utilization and Acute VTE Independent Variables 
     For each of the cases, Analyze -> Descriptive Statistics -> Crosstab SPSS function 
was utilized to display VTE Order Set Used and Acute VTE columns with corresponding 
statistics in a table. Additionally, Statistics sub-menu contained the option to request chi-
squared data for each case. Statistics for the first two cases were obtained in the following 
format: 
Table 3. Format for Displaying Relationships Between Order Set Utilization and Acute 
VTE Independent Variables 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression 
VTE = yes       
VTE = no       
Percent 
(VTE=yes) 
/ total 
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     VTE outcomes, coupled with Control Group and Experimental Group patient 
encounters, represented four scenarios with VTE outcomes equal 0 or 1 and utilization of 
order sets equals 0 (control group) or 1 (experimental group). For each of the four groups, 
a within group ratio of acute VTE cases relative to the group total was reported, together 
with applicable statistics for the entire scenario that included Pearson Chi-Squared, 2-
sided Fisher’s Exact, 1-sided Fisher’s Exact, and the odds ratio from the binary logistic 
regression calculations. Lower percent of patients who acquired VTE always indicated 
the benefit for whatever group such lower ratio was recorded for, i.e. if lower percentage 
of VTE = yes was reported for the experimental group, the result indicated the benefit of 
ordering VTE medications via sets.    
     It made no sense to perform Pearson correlation testing for dichotomous variables 
expected to display low correlation values. Smaller ratio on the right side of the statistics 
reporting format above suggested that fewer cases when order sets were applied led to 
VTE, compared to cases when physicians did not utilize sets. This scenario indicated a 
benefit of the VTE order sets. Smaller ratio on the left of the statistics reporting format 
above suggested that fewer cases when order sets were not applied led to VTE, indicating 
negative impact of the sets. However, the best conclusion from this statistic was that 
factors other than medications were involved.  
     Two-sided Fisher’s Exact was used to measure significance in each case. Standard 
expectation is for p =< 0.05 in order for differences to be significant. These steps 
concluded studies (a) and (b). The 1-sided Fisher’s Exact, if significantly different from 
the 2-sided number, might indicate a larger spread of values within distribution or smaller 
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data samples. It was not used in the study as an indicator of significance but had the 
potential to contribute to summary and analysis. 
     Binary logistic regression was employed to define the relationship between two 
independent categorical variables, AcuteVTE and VTEOrderSetUsed. The binary 
regression formula is specifically designed in SPSS in order to compare two variables 
with dichotomous rather than continuous values. The following steps were followed in 
SPSS in order to run binary logistic regression and derive the value of the odds ratio 
(EXP(B)). For each case, Analyze -> Regression -> Binary Logistic function of SPSS 
was utilized. Setup was as follows: 
• Dependent: AcuteVTE 
• Covariate: VTEOrderSetUSed (categorical) 
• Methods: Enter and Backward LR 
• Options: CI for EXP(B) 
     Two of the following results are reported: odds ratio EXP(B) and the lower/upper 
boundaries at the 95% confidence level, followed by summary of the relationship 
between independent variables for all cases. 
Relationship Between Order Set Utilization and LOS/CCI 
     For the studies of establishing relationships between independent variables and 
dependent variables of length of stay and complications (LOS and CCI), the same case 
selection as in the earlier studies applied, but crosstabs listed the number of patient 
encounters corresponding to these variables – resulting in the following table templates 
that were filled with data when it became available as part of the Final Report stage of the 
dissertation process: 
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Table 4. Relationship Between Charlson Comorbidity Index (CCI), Order Set Utilization, 
and Acute VTE 
CCI Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
0       
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
 
Table 5. Relationship Between Length of Stay, Order Set Utilization, and Acute VTE 
 
Length Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
1 - 5       
6 - 10       
11 - 15       
16 - 20       
21 - 25       
26 - 30       
31 - 35       
36 - 40        
41 - 45         
 
     The length of stay was grouped due to excessive number of categories, with values 
above 45 days dropped due to small data samples and extreme statistically insignificant 
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ratios produced as a result. Smaller ratios on the right side of the template tables 4 and 5 
indicated fewer patients with VTE in cases where medication order sets were utilized, 
indicating statistical benefit of the sets. Larger number on the right side of the template 
tables 4 and 5 led to the opposite conclusion. 
     Each one of the 16 Charlson Comorbidity categories were analyzed for surgical and 
non-surgical patients at each of the two hospitals selected for the study. Each one of the 
length of stay groups were analyzed for surgical and non-surgical patients at each of the 
two hospitals selected for the study. Same categories from each study were compared to 
determine consistency. 
     The categorical column created at the outset of the SPSS manipulations process for the 
purposes of setting up the One-Way ANOVA study was then put in use. The test was 
executed in SPSS in the following fashion: 
• Analyze -> Compare Means -> One-Way ANOVA 
• LOS and CCI for dependent variables in two separate runs 
• VTE_Category as Factor 
• Options -> Descriptive 
• Post Hoc: Bonferroni, Tukey, Dunnett (Control Category = Last) 
     For all cases, the value of F, degrees of freedom, and significance were reported as 
basic One-Way ANOVA outcomes. Additionally, tables of means, standard deviation, 
significance, and 95% confidence intervals were reported for all cases. Group comparison 
tables for Bonferroni and Tukey post hoc tests have shed more light on relationships 
between experimental categories. Comparisons of means were performed between groups 
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of 1:2 (application of sets) and 3:4 (no application of sets). In order to qualify, SPSS must 
mark results statistically significant. For all significant results, means were compared to 
determine longer/shorter hospital stay for patients under all categories and higher/fewer 
number of complications.  
     Dunnett t-test is an alternative post-hoc method to Bonferroni and Tukey. It analyzes 
results for all groups against the control group. Dunnett results were reported for each of 
the cases. Control group was 4 (no order set and no VTE), and experimental group was 2 
(order set and no VTE). Other groups were disregarded as irrelevant for the study. This 
test revealed the relationship between utilization of the order sets and CCI/LOS, 
comparing experimental group with order sets applied and no VTE against control group 
with no order sets applied and no VTE. 
     Examining the direct relationship between utilization of the order sets and length of 
stay was accomplished by running the Mann-Whitney Independent Samples comparison 
of means aimed at testing the null hypotheses and comparing mean ranks among values 
for the categorical variable of VTEOrderSetUsed. Independent samples were utilized due 
to a mix of categorical and continuous variables. SPSS steps to run this test were as 
follows:  
• Analyze -> Nonparametric Tests -> Independent Samples 
• Test Field: LOS 
• Groups: VTEOrderSetUsed 
• Settings -> Customize Tests -> Mann-Whitney U (2) 
• Run 
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     The following was reported in order to document Mann-Whitney results: N for each 
category of the VTEOrderSetUsed variable, Total N, Mean Ranks, Mann-Whitney U, 
Wilcoxon W, Test Statistic, Standard Error, Standardized Test Statistic, and Significance. 
Final Mann-Whitney test results were reported as simply accepting/rejecting null 
hypothesis and outlining the differences between mean ranks for the VTEOrderSetUsed 
variable. 
     Similar setup is applicable for examining the relationship between utilization of the 
order sets and Charlson Comorbidity Index. SPSS setup steps were as follows: 
• Analyze -> Nonparametric Tests -> Independent Samples 
• Test Field: CharlsonComorbidityIndex 
• Groups: VTEOrderSetUsed 
• Settings -> Customize Tests -> Mann-Whitney U (2) 
• Run 
     At this point, cases were summarized and conclusions were drawn based on data 
provided in all tables used for the dependent variable studies. One-Way ANOVA and 
Mann-Whitney tests are two alternative methods for testing the same relationships 
between variables. Differences and similarities shed light on results of the study: same 
outcomes served as verification of validity of the results and differences indicated 
discrepancies that were analyzed before jumping to conclusions.  
Relationship Between Independent Variables of Order Set Utilization, Age, Sex, Race, 
and Surgical Status 
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     This last VTE study examined significance/effect of several independent variables on 
the value of independent variable Acute VTE. The test was accomplished using binary 
logistic regression function of SPSS, invoked by selecting Analyze -> Regression -> 
Binary Logistic, and utilizing the following setup: 
• Dependent: AcuteVTE 
• Covariates: Patient Sex (categorical), Patient Age, Race_Code, 
PSI12DENOM (categorical), VTEOrderSetUsed (categorical) 
• Method: Enter 
     Results for all hospitals and by hospital separately were reported in the following table 
template: 
Table 6. Acute VTE as Affected by Utilization of the Order Sets, Patient Age, Patient 
Sex, Patient Race, Surgical/Non-Surgical Status 
Independent Variable Significance, 95% conf. 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
  
Patient Age   
Patient Sex   
Patient Race   
Surgery Status   
Constant   
Descriptive Statistics and Patient Demographics 
     It was helpful to conclude the VTE study by reporting descriptive statistics for all 
cases. This was accomplished by invoking the Crosstabs functionality of SPSS and 
selecting various cases, as described earlier in the methodology. Totals broken down by 
patient sex, race, order set utilization, and acute VTE occurrence were reported. The 
complete list is as follows: 
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• Patient Sex, Order Sets – IMMC 
• Patient Sex, Order Sets – LGH 
• Patient Sex, Acute VTE – IMMC 
• Patient Sex, Acute VTE – LGH 
• Patient Race - IMMC 
• Patient Race – LGH 
     The final step in the VTE study was bringing together all statistics to answer the 
research questions and test hypotheses outlined for each of the questions. 
Case II: Pneumonia Methodology 
Overview 
     The study involved statistical comparison between experimental groups of patients 
who received medications via order sets available in EMR and control groups of patients 
who received medications via “traditional” custom electronic physician orders. Building 
the case, obtaining data, and performing analysis processes included the following high-
level steps: 
1. Reviewed one of the recent monthly mediation order set utilization reports to 
compile to determine applicable Pneumonia sets for this study and choose 
hospitals offering the best utilization with the largest samples. Summary of the 
August 2010 statistics is presented in Table 137, Appendix C. Pneumonia order 
set content is listed in Table 138, Appendix C. 
2. Due to relatively low utilization of Pneumonia order sets at many Advocate 
facilities, considered inclusion of all facilities in case individual ones did not 
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produce statistically significant results due to small populations. This was actually 
the case, but due to availability of data all results were reported: the combination 
of facilities and each facility individually. 
3. Formed experimental and control groups of patients by extracting from EDW all 
patient data with Pneumonia as principal diagnosis. Patient encounters without 
medication orders placed via sets constituted a control group, and those 
encounters where medications were ordered via sets constituted an experimental 
group. Given small utilization of the sets, control group was significantly larger 
than experimental group. 
4. Ensured that dependent variables of mortality, 30-day readmission, length of stay, 
and comorbidity appeared on the spreadsheet, along with other independent 
variables of age, sex, and race that will also serve for the purposes of listing 
descriptive statistics for control and experimental groups. 
5. Accounted for factors outlined in the Inclusions and Exclusions sections of this 
document. 
6. Reviewed the spreadsheet, cleaned up cases that did not appear to meet criteria for 
the study, and loaded into SPSS v. 19 for statistical analysis. 
7. Performed case analysis in SPSS, including methods such as Pearson Chi-
Squared, Fisher’s Exact significance, binary logistic regression to determine odds 
ratios for the relationships between independent and dependent variables, and 
Mann-Whitney independent samples test to reject/accept null hypothesis to 
determine the relationship between utilization of the order sets and length of stay 
and complications. 
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Goal 
     The goal was to develop methodology for a causal comparative study analyzing the 
differences in health outcomes among groups of patients whose medications were 
ordered via sets and using the “traditional” custom order method. Results indicated the 
effects of standardization of the medication ordering on quality of care. More 
specifically, the study was aimed at determining effectiveness of the pneumonia 
medication order sets in treating this illness, as evidenced by mortality, 30-day 
readmission, length of stay, and patient complications health outcomes data collected at 
Advocate Good Samaritan, Illinois Masonic, and South Suburban, and Trinity hospitals.  
Research Questions and Hypotheses  
     Question 1: Do pneumonia medication order sets help decrease mortality among 
pneumonia patients? 
     Hypothesis 1 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and in-hospital mortality among 
pneumonia patients. 
     Question 2: Is there a difference in the relationship between utilization of the 
pneumonia medication order sets and in-hospital mortality when patients with hospice 
discharge code are excluded from the study? 
     Hypothesis 2 (null): There is no statistical difference in mortality health outcomes 
relative to utilization of the pneumonia medication order sets when hospice patients are 
excluded from the study. 
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     Question 3: Do pneumonia medication order sets help prevent and/or decrease 30-day 
readmission rate among pneumonia patients? 
     Hypothesis 3 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and 30-day readmission rates among 
pneumonia patients. 
     Question 4: Is there a statistical relationship between utilization of the pneumonia 
medication order sets and in-hospital length of stay? 
     Hypothesis 4 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and length of stay among pneumonia 
patients. 
     Question 5: Is there a statistical relationship between utilization of the pneumonia 
medication order sets and patient complications represented by Charlson Comorbidity 
Index? 
     Hypothesis 5 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and patient complications. 
     Question 6: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
30-day hospital readmission among pneumonia patients? 
     Hypothesis 6 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict 30-day hospital readmission among 
pneumonia patients.  
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     Question 7: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
in-hospital mortality among pneumonia patients? 
     Hypothesis 7 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict in-hospital mortality among pneumonia 
patients. 
High Level Overview of Elements and Outcomes of the Study 
     The study aimed at comparison between identical groups of patients who received and 
did not receive medication order sets as treatment for pneumonia. It resulted into seven 
different reports, as follows: 
a. Relationship between utilization of the order sets and mortality, with 
discharge codes for hospice patients excluded for the purposes of this study. 
b. Relationship between utilization of the order sets and mortality, with only 
Expired discharge codes marked as mortality = yes. The differences between 
these cases with different classification of mortality were analyzed and 
reported.  
c. Relationship between utilization of the order sets and 30-day readmission. 
d. Relationship between utilization of the order sets and length hospital stay. 
e. Relationship between utilization of the order sets and patient complications 
represented by Charlson Comorbidity Index (CCI). 
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f. Analysis of significance among independent variables of utilization of the 
order sets, patient sex, patient race, and patient age in predicting the value of 
the dependent variables of readmissions and mortality. 
g. Descriptive statistics on patients reported in the study, including race and sex 
of patients distributed across control and experimental groups. 
     Cases of mortality from pneumonia, in addition to discharge codes appearing in the 
discharge summary in EMR, are governed by table of ICD-9-CM Diagnosis codes, listed 
as part of the industry-standard AHRQ IQI-20 Pneumonia Mortality Definitions. In other 
words, all cases with Expired and/or Hospice discharge codes must also match entries on 
the table of diagnosis codes in order to be mortality from pneumonia specifically. The 
ICD-9 codes pertaining to pneumonia cases are listed in Table 136, Appendix C. 
Study Inclusions 
a. Patients with primary diagnosis of pneumonia (community acquired, chief 
complaint on admission) and secondary diagnosis of pneumonia (nosocomial 
infection, hospital acquired, not chief complaint on admission). 
b. Adults over 18 years of age. 
c. Full list of variables pulled from EDW is provided in Table 7: 
Table 7: Data Elements Pulled as Part of the “Raw” Pneumonia EDW File 
Data Elements (Set 1) Data Elements (Set 2) 
Encounter Key MSDRG Description 
Encounter Number MSDRGMDC 
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Medical Record Number Discharge Location Code 
Facility Abbreviation Name Principal Diagnosis Code 
Admit Date Principal Diagnosis Description 
Discharge Date Principal Diagnosis POA 
Discharge Fiscal Year PN Order Set Indicator 
Discharge Fiscal Period Order Key 
Patient Age Year Catalog Code 
Patient Race Code Catalog Synonym Code 
Patient Race Description Final Order Status Description 
Patient Sex Code Order Original Date 
Financial Class Code Facility Key 
Financial Class Description Readmits Encounter Key 
Discharge Disposition Code Readmits Encounter Number 
Discharge Disposition Description Readmits Discharge Location Code 
Admit Source Date Readmits Financial Class Code 
Admit Source Description Has Readmit Indicator 
Length of Stay (LOS) Midas Readmit Index 
MSDRG Readmit Encounter Key 
Charlson Comorbidity Index  
 
d. Final list of variables loaded into SPSS for the purposes of this dissertation 
study (Table 8). Other variables can be utilized for follow-up studies, such as 
investigation of why patients without use of the order sets were readmitted 
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within 30 days and their corresponding discharge codes, financial impact of 
readmissions and longer length of stay, advanced effects of complications and 
how the influence the overall future state of the patient’s health outcomes 
beyond pneumonia case treatment, etc. 
Table 8. Final List of Variables Selected for the Pneumonia Study 
Data Elements  Notes and Values 
Facility Abbreviation Name GSAM = 4 
IMMC = 7 
SSUB = 9 
TRIN = 8 
Facility Key See codes above 
PN Order Set Indicator Order Set = no = 0 
Order Set = yes = 1 
Has Readmit Indicator Readmission = no = 0 
Readmission = yes = 1 
Length of Stay (LOS) Number of days 
Discharge Disposition Code Converted field, final form as 
follows: 
No Mortality = 0 
Mortality = 1 
Discharge Disposition Description FYI field for discharge disposition 
code 
Patient Age Year Age in years 
Patient Sex Code Male = 0 
Female = 1 
Patient Race Code Converted field, final form as follows 
See Table 139, Appendix C 
Patient Race Description FYI field for patient race code 
MSDRG (admit code) Values not used in calculations, but 
can be reviewed to confirm all 
patients are pneumonia patients 
MSDRG Description FYI field for MSDRG 
Principal Diagnosis Code Values not used in calculations, but 
can be reviewed to confirm all 
patients are pneumonia patients 
Principal Diagnosis Description FYI field for Principal Diagnosis 
Code 
Principal Diagnosis POA Easy verification for pneumonia 
patients: 
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Pneumonia = Y 
Other = N 
Charlson Comorbidity Index Calculated Total Index 
Values 0 - 16 
 
e. Patient discharge code 20 for the study that assumed mortality as Expired 
patient only. For mortality study that excludes hospice patients, excluded 
discharge codes were 50 (hospice/facility) and 51 (hospice/home). 
f. Admit and Diagnosis values that appear in the spreadsheet were already 
filtered for inclusion of pneumonia patients only – reason why these codes are 
displayed FYI for verification only. 
g. Order sets selected for each hospital, along with their detailed content, appear 
in Table 138, Appendix C. 
Study Exclusions 
a. Psych and OB patients. 
b. Pediatric patients (under 18 years of age). 
c. Trinity hospital discharges before April 2010 – these came from paper records 
before EMR was implemented, so no order set patients in the experimental 
group would match, thus forming invalid control group prior to that date. 
Detailed Review of the Steps and Elements of the Study 
     As with the VTE case, the data obtained from the EDW database was saved in Excel 
and cleaned up, leaving only columns/elements outlined in Table 8. The resulting Excel 
file was used for performing further numerical manipulations in SPSS. 
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Initial Data Processing Steps 
     Every discharge reason has corresponding code. This variety of codes is unnecessary 
for the study. The preference is to leave dichotomous values in the discharge code field. 
For the first of the two mortality studies, “Find” and “Replace” functions of Excel were 
utilized to convert all codes to 0 (no mortality), except the following: 20 (Expired), 50 
(Hospice/Facility), and 51 (Hospice/Home). The Expired values (20) were replaced with 
1. The other two values were left for later cleanup in SPSS. Result was a binary 
representation of mortality suitable for quantitative analysis. Other mortality differences 
had no value for this study. The new Excel file was saved separately for the study that 
assumed exclusion of the hospice patients as a way to examine differences between 
variables as related to the hospice cases specifically. The descriptive file name chosen for 
filing of these intermediate results was ‘Required + Mortality + Hospice Excluded” to 
indicate which study the file covered. For the study that only listed Expired patients as 
mortality = yes, another file was saved with a discharge code of 20 converted to 1 and 
other values converted to 0.  
     Using “Find” and “Replace” functions of Excel, the string race code values were 
converted to randomly assigned codes listed in Table 139, Appendix C. These numeric 
codes were more suitable for a quantitative study. 
     Excel files only contained required data at this point and were loaded into SPSS for 
further analysis. It was only required to work with two files for the purposes of 
conducting research on the dependent variable of mortality. For other variables, there was 
no difference, and any of the two SPSS/Excel files could be used. For study that excludes 
hospice patients from mortality, the Split File function of SPSS was utilized to sort the 
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DischargeDisposition field and delete all rows with values of 50 and 51. These rows were 
at the bottom.  
Relationship Between Order Set Utilization and Mortality 
     The Descriptive Statistics -> Crosstabs function of SPSS was invoked with 
PNOrderSetIndicator and DischargeDisposition fields and Pearson Chi-Squared 
calculation as the sole option. Pearson Chi-Squared and Fisher’s Exact values were used 
to determine significance of statistical relationship between the independent variable of 
order set utilization and the dependent variable of mortality. The number of entries for 
experimental and control group formed the following report: 
0 -> 1: X   1 -> 1: X 
0 -> 0: Y    1 -> 0: Y 
% (X/(X+Y))   % (X/(X+Y)) 
     These values represented percentage of orders with no medication order sets that 
resulted in mortality as a ratio of all orders with no medication order sets – left side. On 
the right side, there was comparison of orders where medication sets were utilized and 
resulted in mortality as a ratio of all orders with utilization of sets. Smaller number on the 
right means that fewer orders with medication sets led to mortality, while smaller number 
on the left skewed results towards benefit of the custom orders without utilization of the 
sets. The number above could and was also obtained as the odds ratio via binary logistic 
regression, as follows:  
• Analyze -> Regression -> Binary Logistic 
• Dependent: DischargeDispositionCode 
• Covariate: PNOrderSetIndicator (categorical) 
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• Option: CI for EXP(B) 
     The odds ratio was obtained via both Enter and Backward LR methods in order to 
determine whether differences in methods exist. Ratios over 1 indicated benefit of the 
sets (as represented by smaller percentage on the right side); ratios smaller than 1 
indicated the benefit of custom medication orders versus sets. It is also necessary to 
report lower and upper boundaries of the odds ratio, at the 95% confidence level. 
Relationship Between Order Set Utilization and Readmissions 
     All of the above SPSS steps were repeated using PNOrderSetIndicator as independent 
(covariate) variable and HasReadmit_Indicator variable as dependent to define 
relationship between these variables. So two tests were performed: (1) crosstabs with 
Pearson Chi-Squared and Fisher’s Exact and (2) binary logistic regression with odds ratio 
and upper/lower boundaries at the 95% confidence level. 
     All SPSS manipulations were repeatedly performed for all cases, split by hospital and 
sex using Select Cases functionality of the application. In all individual cases, the 
population size was too small to produce statistically significant results, but the data was 
reported for the combined and individual facility cases – without testing the split by 
patient sex that was obviously destined to produce statistically insignificant results. 
     All calculations were repeated for the separate data file representing scenario where 
hospice patients were not excluded and instead accounted for as mortality = no. Any 
differences and corresponding conclusions were reported, along with summary of the 
benefits of medication order sets based on the health outcomes of mortality and 
readmission. 
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Relationship Between Order Set Utilization and LOS/CCI 
     Due to a mix of continuous values for the LOS and CCI variables and dichotomous 
ones for the PNOrderSetIndicator variables, the best test for the LOS and CCI 
relationships was a Non-Parametric one designed for independent samples. It helped with 
testing the null hypothesis and determining which way results were skewed in case the 
null hypothesis was rejected.  
     The Non-Parametric tests were performed using the Analyze -> Nonparametric Tests -
> Independent Samples function of SPSS. In the Variable View, both variables were set 
to the Scale type. Other options were as follows: 
• Automatically Compare  
• Fields Tab -> LOS variable for the Test field  
• PNOrderSetIndicator will be a group variable with binary values of 
1 and 0 
• Settings -> Customize Fields, and select Mann-Whitney U (2 
samples) tests – the most appropriate comparison of the two 
samples with one dependent variable. This test can use categorical 
and continuous variables to produce results. 
     Results were summarized to make a verdict on acceptance or rejection of the null 
hypothesis – based on which direction results on the distribution were skewed in. The 
Non-Parametric tests were also repeated using Charlson Comorbidity Index as a 
dependent variable. Due to a relatively small data sample size, it only made sense to 
perform calculations for all hospitals selected for the study and skip individual 
calculations that were unlikely to produce statistically significant outcomes.  
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     A One-Way ANOVA helped double-checking results of the Non-Parametric tests 
from the comparison of means perspective, comparing the means for the two order set 
utilization binary values and testing for statistical significance. The following steps were 
necessary in order to run One-Way ANOVA tests in SPSS:  
a. Analyze -> Compare Means -> One-Way ANOVA 
b. Chose LOS as a dependent variable 
c. Chose PNOrderSetIndicator as a Factor 
d. Requested Descriptive from the Options list 
e. Ran the test 
f. Reported the F value, degrees of freedom, and the P value 
g. Repeated the same steps using CharlsonComorbidityIndex as a 
dependent variable. 
     Conclusions regarding relationship between utilization of the order sets and LOS, and 
utilization of the order sets and CCI were ready for documentation at this point, noting 
any discrepancies between One-Way ANOVA and Non-Parametric Mann-Whitney tests. 
The latter did not produce any significant differences, leading to sound conclusions 
proven by two different statistical methods. 
Relationship Between Independent Variables of Order Set Utilization, Age, Sex, & Race 
and Dependent Variables of LOS/CCI  
     The last study proposed for the pneumonia case was an explanation of the dependent 
variables of mortality and readmission by several independent variables of order set 
indicator, race code, sex, and age. Binary logistic regression was the most suitable 
method of running this study, because this statistical method used significance as a way 
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to indicate strength of the relationship and influence of the independent variables on 
health outcomes represented by the dependent variables of readmissions and mortality. 
This method also uses odds ratio to quantify the relationship between variables, leading 
to conclusions regarding significance of the independent variables in analysis of the 
outcomes and comparison between those variables hospitals/researchers cannot control 
(age, sex, race) and the ones they can (application of the order sets to request 
medications). Two tests, for the DischargeDispositionCode and HasReadmit_Indicator 
dependent variables, were reported separately. The PatientSexCode variable was defined 
as categorical. Table 9 represents format for the results of this test. 
Table 9. Pneumonia <Readmissions or Mortality> as Affected by Order Set Indicator, 
Patient Age, Patient Sex, and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
  
Patient Age   
Patient Sex   
Patient Race   
Constant   
     It was determined by analyzing results reported in Table 9 which independent 
variables best and better predict dependent ones, and which independent variables were 
statistically insignificant. 
Summary 
     The final report incorporates overall analysis and recommendations regarding 
utilization of the medication order sets to treat pneumonia, and how these sets 
influence/predict the health outcomes of length of stay, mortality, 30-day readmission, 
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and comorbidity. The report provides grounds for answering the research questions 
outlined in the pneumonia study and accepting/rejecting the research hypotheses. 
Case III: Congestive Heart Failure (CHF) Methodology 
Overview 
     The study involved statistical comparison between experimental groups of patients 
who received medications via order sets available in EMR or on paper and control groups 
of patients who received medications via “traditional” custom electronic or paper 
physician orders. Building the case, obtaining data, and performing analysis processes 
included the following high-level steps: 
1. Reviewed one of the recent monthly mediation order set utilization reports to 
determine applicable CHF sets for this study and choose hospitals offering the 
best utilization with the largest samples. Summary of the August 2010 statistics is 
presented in Table 141, Appendix D. 
2. Due to very low utilization of CHF order sets at many Advocate facilities, 
considered inclusion of all facilities in case individual ones did not produce 
statistically significant results due to small populations. This was actually the 
case, so it only made sense to work with the totals for all facilities participating in 
the CHF study. 
3. CHF is unique among other patient conditions in terms of the prescription 
medium: many physicians still utilize paper forms, in part because some sets are 
ordered ahead of time from outpatient offices or are used for outpatient treatment 
of CHF by doctors who have no direct access to in-hospital EMR. Due to 
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significant number of CHF sets ordered via paper and tracking of these sets in 
EDW, paper sets were included for the purposes of CHF study only.  
4. CHF study was also unique because outpatient and inpatient treatments were 
mixed: CHF can be treated both ways depending on circumstances of the case and 
its severity. Splitting the two and reporting separately was not possible due to 
small data samples leading to lack of statistical significance, although once 
utilization increases separate reporting would represent a nice follow-up study.  
5. Formed experimental and control groups of patients by extracting from EDW all 
patient data with CHF as principal diagnosis. Patient encounters without 
medication orders placed via sets constituted a control group, and those 
encounters where medications were ordered via sets constituted an experimental 
group. Given small utilization of the sets, control group was expected to be 
significantly larger than experimental group. 
6. Ensured that dependent variables of mortality, 30-day readmission, length of stay, 
and Charlson Comorbidity Index appeared on the spreadsheet, along with other 
independent variables of age, sex, and race that also served the purposes of listing 
descriptive statistics for control and experimental groups. 
7. Accounted for factors outlined in the Inclusions and Exclusions sections of this 
document. 
8. Reviewed the spreadsheet, cleaned up any cases that did not appear to meet 
criteria for the study, and loaded into SPSS v. 19 for statistical analysis. 
9. Performed case analysis in SPSS, including methods such as Pearson Chi-
Squared; Fisher’s Exact significance; binary logistic regression to determine odds 
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ratios for the relationships between independent and dependent variables; Mann-
Whitney independent samples test to reject/accept null hypothesis to determine 
the relationship between utilization of the order sets and length of stay, and 
between utilization of the order sets and complications; and One-Way ANOVA 
test to confirm Mann-Whitney test results. 
10. Some fields contained null values for the readmissions and CCI variables, so 
complete data samples were small, and consequently not all studies produced 
statistically significant results. 
Goal 
     The goal was to develop methodology for a causal comparative study analyzing the 
differences between health outcomes among groups of patients whose medications were 
ordered via sets and using the “traditional” custom order method. Results indicated 
effects of standardization of the medication ordering on quality of care. More 
specifically, the study was aimed at determining effectiveness of the congestive heart 
failure medication order sets in treating this condition, as evidenced by mortality, 30-day 
readmission, length of stay, and complications health outcomes data collected at 
Advocate Christ, Illinois Masonic, South Suburban, Good Shepherd, and Lutheran 
General hospitals.  
Research Questions and Hypotheses  
     Question 1: Do CHF medication order sets help decrease mortality among CHF 
patients? 
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     Hypothesis 1 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and in-hospital mortality among CHF patients. 
     Question 2: Is there a difference in the relationship between utilization of the CHF 
medication order sets and in-hospital mortality when patients with hospice discharge 
code are excluded from the study? 
     Hypothesis 2 (null): There is no statistical difference in mortality health outcomes 
relative to utilization of the CHF medication order sets when hospice patients are 
excluded from the study. 
     Question 3: Do CHF medication order sets help prevent and/or decrease 30-day 
readmission rate among CHF patients? 
     Hypothesis 3 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and 30-day readmission rates among CHF 
patients. 
     Question 4: Is there a statistical relationship between utilization of the CHF 
medication order sets and in-hospital length of stay? 
     Hypothesis 4 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and length of stay among CHF patients. 
     Question 5: Is there a statistical relationship between utilization of the CHF 
medication order sets and complications quantified via Charlson Comorbidity Index? 
     Hypothesis 5 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and complications among CHF patients. 
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     Question 6: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
30-day hospital readmission among CHF patients? 
     Hypothesis 6 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict 30-day hospital readmission among CHF 
patients.  
     Question 7: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
in-hospital mortality among CHF patients? 
     Hypothesis 7 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict in-hospital mortality among CHF patients.  
High Level Overview of Elements and Outcomes of the Study 
1. The study aimed at comparison between identical groups of patients who received 
and did not receive medication order sets as treatment for CHF. 
2. The study resulted into 7 different reports, as follows: 
a. Relationship between utilization of the order sets and mortality, with 
discharge codes for hospice patients excluded for the purposes of this study. 
b. Relationship between utilization of the order sets and mortality, with only 
Expired discharge codes marked as mortality = yes. The differences between 
these cases with different classification of mortality will be analyzed and 
reported.  
c. Relationship between utilization of the order sets and 30-day readmission. 
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d. Relationship between utilization of the order sets and length hospital stay. 
e. Relationship between utilization of the order sets and complications 
f. Analysis of significance among independent variables of utilization of the 
order sets, patient sex, patient race, and patient age in predicting the value of 
the dependent variables of readmissions and mortality. 
g. Descriptive statistics on patients reported in the study, including race and sex 
of patients distributed across control and experimental groups. 
3. Cases of mortality from CHF, in addition to discharge codes appearing in the 
discharge summary in EMR, are governed by table of ICD-9-CM Diagnosis 
codes, listed as part of the industry-standard AHRQ IQI-16 CHF Mortality 
Definitions. In other words, all cases with Expired and/or Hospice discharge 
codes must also match entries on the table of diagnosis codes in order to be 
mortality from CHF specifically. The ICD-9 codes pertaining to CHF cases are 
listed in Table 140, Appendix D. 
Study Inclusions 
a. Patients with primary and secondary diagnosis of CHF. 
b. Adults over 18 years of age. 
c. CPOE and Written CHF order sets (content provided in Table 142, Appendix 
D).  
d. Full list of variables pulled from EDW is provided in Table 10. 
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Table 10. Data Elements Pulled as Part of the “Raw” CHF EDW File 
Data Elements (Set 1) Data Elements (Set 2) 
Encounter Key MSDRG Description 
Encounter Number MSDRGMDC 
Medical Record Number Discharge Location Code 
Facility Abbreviation Name Principal Diagnosis Code 
Admit Date Principal Diagnosis Description 
Admit Time Admit Type Description 
Admit Source Admit Source Description 
Admitting Diagnosis Code Admitting Diagnosis Proof 
Discharge Date Principal Diagnosis POA 
Discharge Fiscal Year Has Order Set 
Discharge Fiscal Period Order Key 
Order Method Order Method Description 
Order Date Order Time 
Patient Age Year Catalog Code 
Patient Race Code Catalog Synonym Code 
Patient Race Description Final Order Status Description 
Patient Sex Code Order Original Date 
Financial Class Code Facility Key 
Financial Class Description Readmits Encounter Key 
Discharge Disposition Code Readmits Encounter Number 
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Discharge Location Code Discharge Location Description 
Discharge Disposition Description Readmits Discharge Location Code 
Admit Source Date Readmits Financial Class Code 
Admit Source Description Has Readmit Indicator 
Readmit Type Readmit Encounter Number 
Length of Stay (LOS) Midas Readmit Index 
MSDRG Readmit Encounter Key 
Secondary Diagnosis Charlson Comorbidity Index 
Attending Physician Last Name Attending Physician First Name 
Attending Physician Key Attending Physician Specialty Key 
 
e. Final list of variables loaded into SPSS for the purposes of this dissertation 
study. Other variables can be utilized for follow-up studies, such as 
investigation of why patients without use of the order sets were readmitted 
within 30 days and their corresponding discharge codes, financial impact of 
readmissions and longer length of stay, ratio of handwritten orders versus 
electronic, etc. 
Table 11. Final List of Variables Selected for the CHF Study 
Data Elements  
 
Notes and Values 
Facility Abbreviation Name LGH = 10 
IMMC = 7 
SSUB = 9 
CMC = 3 
GSHP=5 
Facility Key See codes above 
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Has Order Set Order Set = no = 0 
Order Set = yes = 1 
Catalog Code FYI field for the order set catalog 
number 
Order Method Description FYI field for descriptive statistics, 
values: 
WRITTEN 
CPOE 
Has Readmit Readmission = no = 0 
Readmission = yes = 1 
Length of Stay (LOS) Number of days 
Discharge Disposition Code Converted field, final form as 
follows: 
No Mortality = 0 
Mortality = 1 
Hospice: 50, 51 
Discharge Disposition Description FYI field for discharge disposition 
code 
Patient Age Year Age in years 
Patient Sex Code Converted field, final values below: 
Male = 0 
Female = 1 
Patient Race Code Converted field, final form as follows 
See Table 143, Appendix D 
Patient Race Description FYI field for patient race code 
MSDRG (admit code) Values not used in calculations, but 
can be reviewed to confirm all 
patients are CHF patients 
MSDRG Description FYI field for MSDRG 
Principal Diagnosis Code Values not used in calculations, but 
can be reviewed to confirm all 
patients are CHF patients 
Principal Diagnosis Description FYI field for Principal Diagnosis 
Code 
Principal Diagnosis POA Easy verification for CHF patients: 
CHF = Y 
Other = N 
Principal Diagnosis POA Int Converted integer field for numeric 
representation of the values above: 
CHF = 1 
Other = 0 
Admit Type Description FYI field to verify inpatient 
admission fact 
Charlson Comorbidity Index Calculated field, values 0 - 16 
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f. Patient discharge code 20 for the study that assumed mortality as Expired 
patient only. For mortality study that excluded hospice patients, excluded 
discharge codes were 50 (hospice/facility) and 51 (hospice/home). 
g. Admit and Diagnosis values that appeared in the spreadsheet were already 
filtered for inclusion of CHF patients only – reason why these codes were 
displayed FYI for verification only. 
h. CMC, GSHP, IMMC, and SSUB orders for 2008, 2009, 2010, and 2011. LGH 
orders for 2009, 2010, and 2011. 
Exclusions 
a. Psych and OB patients. 
b. Pediatric patients (under 18 years of age). 
Detailed Review of the Steps and Elements of the Study 
     As with the VTE and pneumonia cases, the data obtained from the EDW database was 
saved in Excel and cleaned up, leaving only columns/elements outlined in Table 11. The 
resulting Excel file was used for performing further numerical manipulations in SPSS. 
Initial Data Processing Steps 
     Drawing similarity to the pneumonia study, discharge descriptions were replaced with 
discharge codes suitable for quantitative analysis in SPSS, producing two Excel files with 
(1) hospice patients excluded from the study and (2) hospice patients accounted for with 
mortality set to 0 (no). Using “Find” and “Replace” functions of Excel, the string race 
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code values were converted to randomly assigned codes listed in Table 143, Appendix D. 
These numeric codes were more suitable for a quantitative study. 
     Excel files only contained required data at this point and could be loaded into SPSS 
for further analysis. It was only required to work with two files for the purposes of 
conducting research on the dependent variable of mortality. For other variables, there is 
no difference, and any of the two SPSS/Excel files can be used. For the study that 
excludes hospice patients from mortality, the Split File function of SPSS was utilized to 
sort the DischargeDisposition field and delete all rows with values of 50 and 51. These 
rows were at the bottom.  
Relationship Between Utilization of Order Sets and Mortality 
     The Descriptive Statistics -> Crosstabs function of SPSS was invoked with 
HasOrderSet and DischargeDisposition fields and Pearson Chi-Squared calculation as the 
sole option. Pearson Chi-Squared and Fisher’s Exact values were used to determine 
significance of statistical relationship between the independent variable of order set 
utilization and the dependent variable of mortality. The number of entries for 
experimental and control group formed the following report: 
0 -> 1: X   1 -> 1: X 
0 -> 0: Y    1 -> 0: Y 
% (X/(X+Y))   % (X/(X+Y)) 
     These values represented percentage of orders with no medication order sets that 
resulted in mortality as a ratio of all orders with no medication order sets – left side. On 
the right side, there was a comparison of orders where medication sets were utilized and 
resulted in mortality as a ratio of all orders with utilization of sets. Smaller number on the 
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right meant that fewer orders with medication sets led to mortality, while smaller number 
on the left skewed results towards benefit of the custom orders without utilization of the 
sets. The number above was also obtained as the odds ratio via binary logistic regression, 
as follows:  
• Analyze -> Regression -> Binary Logistic 
• Dependent: DischargeDispositionCode 
• Covariate: HasOrderSet (categorical) 
• Option: CI for EXP(B).  
     The odds ratio was obtained via both Enter and Backward LR methods in order to 
determine whether differences in methods exist. Ratios over 1 indicated benefit of the 
sets (as represented by smaller percentage on the right side); ratios smaller than 1 
indicated the benefit of custom medication orders versus sets. It was also necessary to 
report lower and upper boundaries of the odds ratio, at the 95% confidence level. 
Relationship Between Utilization of Order Sets and Readmissions 
     All of the above SPSS steps were repeated using HasOrderSet as independent 
(covariate) variable and HasReadmit variable as dependent to define relationship between 
these variables. So two tests were performed: (1) crosstabs with Pearson Chi-Squared and 
Fisher’s Exact and (2) binary logistic regression with odds ratio and upper/lower 
boundaries at the 95% confidence level. 
     All SPSS manipulations were repeatedly performed for all cases, split by hospital and 
sex using Select Cases functionality of the application. In all cases, the population size 
was too small to produce statistically significant results, so the odds ratio EXP(B) was 
only be reported for the first case of all facilities combined. The latter scenario was more 
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likely for the CHF study compared to VTE and pneumonia, provided that most facilities 
utilize no more than a few hundred sets a year, resulting in a small overall sample when it 
is split by hospital. CHF utilization trends are evident from Table 141, Appendix D. 
     All calculations were repeated for the separate data file representing scenario where 
hospice patients were not excluded and instead accounted for as mortality = no. Any 
differences and corresponding conclusions should be reported, along with summary of 
the benefits of medication order sets based on the health outcomes of mortality and 
readmission. 
Relationship Between Utilization of Order Sets and LOS/CCI 
     Due to a mix of continuous values for the LOS and CCI variables and dichotomous 
ones for the HasOrderSet variable, the best test for the LOS and CCI relationships was a 
Non-Parametric one designed for independent samples. It helped with testing of the null 
hypothesis and determining which way results were skewed in case the null hypothesis 
was rejected.  
     The Non-Parametric tests were performed using Analyze -> Nonparametric Tests -> 
Independent Samples function of SPSS. In the Variable View, both variables were set to 
the Scale type. Other options were as follows: 
• Automatically Compare  
• Fields Tab -> LOS variable for the Test field  
• PNOrderSetIndicator was a group variable with binary values of 1 
and 0 
• Settings -> Customize Fields, and select Mann-Whitney U (2 
samples) tests – the most appropriate comparison of the two 
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samples with one dependent variable. This test can use categorical 
and continuous variables to produce results. 
     Results were summarized to make a verdict on acceptance or rejection of the null 
hypothesis – based on which direction results on the distribution were skewed in. The 
Non-Parametric tests were also repeated using Charlson Comorbidity Index as a 
dependent variable. Due to a relatively small expected data sample size, it only made 
sense to perform calculations for all hospitals selected for the study and skip individual 
calculations that were likely to produce statistically insignificant outcomes.  
     A One-Way ANOVA helped double-checking results of the Non-Parametric tests 
from the comparison of means perspective, comparing the means for the two order set 
utilization binary values and testing for statistical significance. The following steps were 
necessary in order to run One-Way ANOVA tests in SPSS:  
a. Analyze -> Compare Means -> One-Way ANOVA 
b. Chose LOS as a dependent variable 
c. Chose HasOrderSet as a Factor 
d. Requested Descriptive from the Options list 
e. Ran the test 
f. Reported the F value, degrees of freedom, and the P value 
g. Repeated the same steps using CharlsonComorbidityIndex as a 
dependent variable. 
     Conclusions regarding relationship between utilization of the order sets and LOS, and 
utilization of the order sets and CCI were ready for documentation at this point, noting 
any discrepancies between One-Way ANOVA and Non-Parametric Mann-Whitney tests. 
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The latter did not produce any significant differences, leading to sound conclusions 
proven by two different statistical methods. 
Relationship Between Independent Variables of Order Set Utilization, Age, Sex, & Race 
and Dependent Variables of LOS/CCI 
     The last study proposed for the CHF case was an explanation of the dependent 
variables of mortality and readmission by several independent variables of order set 
indicator, race code, sex, and age. Binary logistic regression was the most suitable 
method of running this study. Two tests, for the DischargeDispositionCode and 
HasReadmit dependent variables, were reported separately. The PatientSexCode variable 
was defined as categorical. Table 12 represents format for the results of this test. 
Table 12. CHF <Readmissions or Mortality> as Affected by Order Set Indicator, Patient 
Age, Patient Sex, and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
  
Patient Age   
Patient Sex   
Patient Race   
Constant   
 
     It was determined by analyzing results reported in Table 12 which independent 
variables best and better predicted dependent ones, and which independent variables were 
statistically insignificant. 
Summary 
     The final report incorporates overall analysis and recommendations regarding 
utilization of the medication order sets to treat CHF, and how these sets influence/predict 
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the health outcomes of length of stay, mortality, 30-day readmission, and comorbidity. 
The report provides grounds for answering the research questions outlined in the CHF 
study and accepting/rejecting the research hypotheses. 
Case IV: Acute Myocardial Infarction (AMI) Methodology 
Overview 
     The study involved statistical comparison between experimental groups of patients 
who received medications via order sets and control groups of patients who received 
medications via “traditional” custom electronic physician orders. Building the case, 
obtaining data, and performing analysis processes included the following high-level 
steps: 
1. Reviewed one of the recent monthly mediation order set utilization reports to 
determine applicable AMI sets for this study and choose hospitals offering the 
best utilization with the largest samples. Summary of the August 2010 statistics is 
presented in Table 145, Appendix E. 
2. Due to relatively low utilization of AMI order sets at many Advocate facilities, 
considered inclusion of all facilities in case individual ones did not produce 
statistically significant results due to small populations. As was already evident 
from earlier review of the order set content prepared for the preliminary work as 
part of the dissertation process, only two hospitals (GSHP and TRIN) qualified 
for the study, thus introducing the risk of low samples and statistically 
insignificant results. Low utilization, couple with missing data in some patient 
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encounters, made it clear that only one case with all participating facilities 
included could stand a chance to produce statistically significant results. 
3. Formed experimental and control groups of patients by extracting from EDW all 
patient data with AMI as principal diagnosis. Patient encounters without 
medication orders placed via sets constituted a control group, and those 
encounters where medications were ordered via sets constituted an experimental 
group. Given small utilization of the sets, control group was significantly larger 
than experimental group. 
4. Ensured that dependent variables of mortality, 30-day readmission, length of stay, 
and Charlson Comorbidity Index appeared on the spreadsheet, along with other 
independent variables of age, sex, and race that also served the purposes of listing 
descriptive statistics for control and experimental groups. 
5. Accounted for factors outlined in the Inclusions and Exclusions sections of this 
document. 
6. Reviewed the spreadsheet, cleaned up any cases that do not appear to meet criteria 
for the study, and loaded into SPSS v. 19 for statistical analysis. 
7. Performed case analysis in SPSS, including methods such as Pearson Chi-
Squared; Fisher’s Exact significance; binary logistic regression to determine odds 
ratios for the relationships between independent and dependent variables; Mann-
Whitney independent samples test to reject/accept null hypothesis to determine 
the relationship between utilization of the order sets and length of stay, and 
between utilization of the order sets and complications; and One-Way ANOVA 
test to confirm Mann-Whitney test results. 
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Goal 
     The goal was to develop methodology for a causal comparative study analyzing the 
differences between health outcomes among groups of patients whose medications were 
ordered via sets and using the “traditional” custom order method. Results indicated 
effects of standardization of the medication ordering on quality of care. More 
specifically, the study was aimed at determining effectiveness of the acute myocardial 
infarction (AMI) medication order sets in treating this condition, as evidenced by 
mortality, 30-day readmission, length of stay, and complications health outcomes data 
collected at Advocate Good Shepherd and Trinity hospitals.  
Research Questions and Hypotheses 
     Question 1: Do AMI medication order sets help decrease mortality among AMI 
patients? 
     Hypothesis 1 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and in-hospital mortality among AMI patients. 
     Question 2: Is there a difference in the relationship between utilization of the AMI 
medication order sets and in-hospital mortality when patients with hospice discharge 
code are excluded from the study? 
     Hypothesis 2 (null): There is no statistical difference in mortality health outcomes 
relative to utilization of the AMI medication order sets when hospice patients are 
excluded from the study. 
     Question 3: Do AMI medication order sets help prevent and/or decrease 30-day 
readmission rate among AMI patients? 
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     Hypothesis 3 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and 30-day readmission rates among AMI 
patients. 
     Question 4: Is there a statistical relationship between utilization of the AMI 
medication order sets and in-hospital length of stay? 
     Hypothesis 4 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and length of stay among AMI patients. 
     Question 5: Is there a statistical relationship between utilization of the AMI 
medication order sets and complications quantified via Charlson Comorbidity Index? 
     Hypothesis 5 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and complications among AMI patients. 
     Question 6: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
30-day hospital readmission among AMI patients? 
     Hypothesis 6 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict 30-day hospital readmission among AMI 
patients.  
     Question 7: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
in-hospital mortality among AMI patients? 
     Hypothesis 7 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict in-hospital mortality among AMI patients. 
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High Level Overview of Elements and Outcomes of the Study 
1. The study aimed at comparison between identical groups of patients who received 
and did not receive medication order sets as treatment for AMI. 
2. The study resulted into 7 different reports, as follows: 
a. Relationship between utilization of the order sets and mortality, with 
discharge codes for hospice patients excluded for the purposes of this study. 
b. Relationship between utilization of the order sets and mortality, with only 
Expired discharge codes marked as mortality = yes. The differences between 
these cases with different classification of mortality were analyzed and 
reported.  
c. Relationship between utilization of the order sets and 30-day readmission. 
d. Relationship between utilization of the order sets and length hospital stay. 
e. Relationship between utilization of the order sets and complications 
f. Analysis of significance among independent variables of utilization of the 
order sets, patient sex, patient race, and patient age in predicting the value of 
the dependent variables of readmissions and mortality. 
g. Descriptive statistics on patients reported in the study, including race and sex 
of patients distributed across control and experimental groups. 
3. Cases of mortality from AMI, in addition to discharge codes appearing in the 
discharge summary in EMR, are governed by table of ICD-9-CM Diagnosis 
codes, listed as part of the industry-standard AHRQ IQI-15 AMI Mortality 
Definitions. In other words, all cases with Expired and/or Hospice discharge 
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codes must also match entries on the table of diagnosis codes in order to be 
mortality from AMI specifically. The ICD-9 codes pertaining to AMI cases are 
listed in Table 144, Appendix E. 
Study Inclusions 
a. Patients with primary and secondary diagnosis of AMI. 
b. Adults over 18 years of age. 
c. AMI order sets (content provided in Table 146, Appendix E).  
d. Full list of variables pulled from EDW is provided in Table 13: 
Table 13. Data Elements Pulled as Part of the “Raw” AMI EDW file 
Data Elements (Set 1) Data Elements (Set 2) 
Encounter Key MSDRG Description 
Encounter Number MSDRGMDC 
Medical Record Number Discharge Location Code 
Facility Abbreviation Name Principal Diagnosis Code 
Admit Date Principal Diagnosis Description 
Admit Time Admit Type Description 
Admit Source Admit Source Description 
Admitting Diagnosis Code Admitting Diagnosis Proof 
Discharge Date Principal Diagnosis POA 
Discharge Fiscal Year Has Order Set 
Discharge Fiscal Period Order Key 
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Order Method Order Method Description 
Order Date Order Time 
Patient Age Year Catalog Code 
Patient Race Code Catalog Synonym Code 
Patient Race Description Final Order Status Description 
Patient Sex Code Order Original Date 
Financial Class Code Facility Key 
Financial Class Description Readmits Encounter Key 
Discharge Disposition Code Readmits Encounter Number 
Discharge Location Code Discharge Location Description 
Discharge Disposition Description Readmits Discharge Location Code 
Admit Source Date Readmits Financial Class Code 
Admit Source Description Has Readmit Indicator 
Readmit Type Readmit Encounter Number 
Length of Stay (LOS) Midas Readmit Index 
MSDRG Readmit Encounter Key 
Secondary Diagnosis Charlson Comorbidity Index 
Attending Physician Last Name Attending Physician First Name 
Attending Physician Key Attending Physician Specialty Key 
 
e. The final list of variables loaded into SPSS for the purposes of this 
dissertation study is outlined in Table 14. Other variables can be utilized for 
follow-up studies, such as investigation of why patients without use of the 
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order sets were readmitted within 30 days and their corresponding discharge 
codes, financial impact of readmissions and longer length of stay, ratio of 
handwritten orders versus electronic, etc. 
Table 14. Final List of Variables Selected for the AMI Study 
Data Elements  Notes and Values 
Facility Abbreviation Name TRIN=8 
GSHP=5 
Facility Key See codes above 
Has Order Set Order Set = no = 0 
Order Set = yes = 1 
Catalog Code FYI field for the order set catalog 
number 
Has Readmit Readmission = no = 0 
Readmission = yes = 1 
Length of Stay (LOS) Number of days 
Discharge Disposition Code Converted field, final form as 
follows: 
No Mortality = 0 
Mortality = 1 
Hospice: 50, 51 
Discharge Disposition Description FYI field for discharge disposition 
code 
Patient Age Year Age in years 
Patient Sex Code Converted field, final values below: 
Male = 0 
Female = 1 
Patient Race Code Converted field, final form as follows 
See Table 147, Appendix E 
Patient Race Description FYI field for patient race code 
MSDRG (admit code) Values not used in calculations, but 
can be reviewed to confirm all 
patients are AMI patients 
MSDRG Description FYI field for MSDRG 
Principal Diagnosis Code Values not used in calculations, but 
can be reviewed to confirm all 
patients are AMI patients 
Principal Diagnosis Description FYI field for Principal Diagnosis 
Code 
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Principal Diagnosis POA Easy verification for AMI patients: 
AMI = Y 
Other = N 
Principal Diagnosis POA Int Converted integer field for numeric 
representation of the values above: 
AMI = 1 
Other = 0 
Admit Type Description FYI field to verify inpatient 
admission fact 
Charlson Comorbidity Index Calculated field, values 0 - 16 
 
f. Patient discharge code 20 for the study that assumed mortality as Expired 
patient only. For mortality study that excluded hospice patients, excluded 
discharge codes were 50 (hospice/facility) and 51 (hospice/home). 
g. Admit and Diagnosis values that appear in the spreadsheet were already 
filtered for inclusion of AMI patients only – reason why these codes were 
displayed FYI for verification only. 
h. GSHP orders for 2008, 2009, 2010, and 2011. Trinity orders for (November, 
December) 2009, 2010, and 2011. Trinity orders are only available since 
CPOE application has gone live at this facility. 
Exclusions 
a. Psych and OB patients 
b. Pediatric patients (under 18 years of age). 
Detailed Review of the Steps and Elements of the Study 
     There are many similarities between CHF and AMI cases, with main differences being 
in the variables, exclusions, and inclusions in the study outlined at the outset of the case 
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methodology descriptions. Many of the quantitative analysis steps below are applicable to 
both CHF and AMI studies.  
Initial Data Processing Steps 
     As with VTE, pneumonia, and CHF cases, the data obtained from the EDW database 
was saved in Excel and cleaned up, leaving only columns/elements outlined in Table 14. 
The resulting Excel file was used for performing further numerical manipulations in 
SPSS. Discharge descriptions were replaced with discharge codes suitable for 
quantitative analysis in SPSS, producing two Excel files with (1) hospice patients 
excluded from the study and (2) hospice patients accounted for with mortality set to 0 
(no). Using “Find” and “Replace” functions of Excel, the string race code values were 
converted to randomly assigned codes listed in Table 147, Appendix E. These numeric 
codes were more suitable for a quantitative study. 
     Excel files only contained required data at this point and were loaded into SPSS for 
further analysis. It was only required to work with two files for the purposes of 
conducting research on the dependent variable of mortality. For other variables, there was 
no difference, and any of the two SPSS/Excel files could be used. For the study that 
excluded hospice patients from mortality, the Split File function of SPSS was utilized to 
sort the DischargeDisposition field and delete all rows with values of 50 and 51. These 
rows were expected to be on the bottom.  
Relationship Between Utilization of Order Sets and Mortality 
     The Descriptive Statistics -> Crosstabs function of SPSS was invoked with 
HasOrderSet and DischargeDisposition fields and Pearson Chi-Squared calculation as the 
sole option. Pearson Chi-Squared and Fisher’s Exact values were used to determine 
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significance of statistical relationship between the independent variable of order set 
utilization and the dependent variable of mortality. The number of entries for 
experimental and control group formed the following report: 
0 -> 1: X   1 -> 1: X 
0 -> 0: Y    1 -> 0: Y 
% (X/(X+Y))   % (X/(X+Y)) 
     These values represented percentage of orders with no medication order sets that 
resulted in mortality as a ratio of all orders with no medication order sets – left side. On 
the right side, there was comparison of orders where medication sets were utilized and 
resulted in mortality as a ratio of all orders with utilization of sets. Smaller number on the 
right meant that fewer orders with medication sets led to mortality, while smaller number 
on the left skewed results towards benefit of the custom orders without utilization of the 
sets. The number above was also obtained as the odds ratio via binary logistic regression, 
as follows:  
• Analyze -> Regression -> Binary Logistic 
• Dependent: DischargeDispositionCode 
• Covariate: HasOrderSet (categorical) 
• Option: CI for EXP(B) 
     The odds ratio was obtained via both Enter and Backward LR methods in order to 
determine whether differences in methods exist. Ratios over 1 indicated benefit of the 
sets (as represented by smaller percentage on the right side); ratios smaller than 1 
indicated the benefit of custom medication orders versus sets. It is also necessary to 
report lower and upper boundaries of the odds ratio, at the 95% confidence level. 
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Relationship Between Utilization of Order Sets and LOS/CCI 
     All of the above SPSS steps were repeated using HasOrderSet as independent 
(covariate) variable and HasReadmit variable as dependent to define relationship between 
these variables. So, two tests were performed: (1) crosstabs with Pearson Chi-Squared 
and Fisher’s Exact and (2) binary logistic regression with odds ratio and upper/lower 
boundaries at the 95% confidence level. 
     All SPSS manipulations were repeatedly performed for all cases, split by hospital and 
sex using Select Cases functionality of the application. In all individual  hospital cases, 
the population size was too small to produce statistically significant results, so the odds 
ratio EXP(B) was only reported for the first cases of all facilities combined. The latter 
scenario was more likely for the AMI and CHF studies compared to VTE and 
pneumonia, provided that most facilities utilize no more than a few hundred sets a year, 
resulting in a small overall sample when it is split by hospital. AMI utilization trends are 
evident from Table 145, Appendix E. 
     All calculations were repeated for the separate data file representing scenario where 
hospice patients were not excluded and instead accounted for as mortality = no. Any 
differences and corresponding conclusions were reported, along with summary of the 
benefits of medication order sets based on the health outcomes of mortality and 
readmission. 
     Due to a mix of continuous values for the LOS and CCI variables and dichotomous 
ones for the HasOrderSet variables, the best test for the LOS and CCI relationships was a 
Non-Parametric one designed for independent samples. It helped with testing the null 
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hypothesis and determining which way results were skewed in case the null hypothesis 
was rejected.  
     The Non-Parametric tests were performed using Analyze -> Nonparametric Tests -> 
Independent Samples function of SPSS. In the Variable View, both variables must be set 
to the Scale type. Other options were as follows: 
• Automatically Compare  
• Fields Tab -> LOS variable for the Test field  
• PNOrderSetIndicator was a group variable with binary values of 1 
and 0 
• Settings -> Customize Fields, and selected Mann-Whitney U (2 
samples) tests – the most appropriate comparison of the two 
samples with one dependent variable. This test can use categorical 
and continuous variables to produce results. 
     Results were summarized to make a verdict on acceptance or rejection of the null 
hypothesis – based on which direction results on the distribution are skewed in. The Non-
Parametric tests were also repeated using Charlson Comorbidity Index as a dependent 
variable. Due to a very small data sample size, it only made sense to perform calculations 
for the total of all hospitals selected for the study and skip individual calculations that 
were unlikely to produce statistically significant outcomes.  
     A One-Way ANOVA helped double-checking results of the Non-Parametric tests 
from the comparison of means perspective, comparing the means for the two order set 
utilization binary values and testing for statistical significance. The following steps were 
necessary in order to run One-Way ANOVA tests in SPSS:  
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a. Analyze -> Compare Means -> One-Way ANOVA 
b. Chose LOS as a dependent variable 
c. Chose HasOrderSet as a Factor 
d. Requested Descriptive from the Options list 
e. Ran the test 
f. Reported the F value, degrees of freedom, and the P value 
g. Repeated steps “a” through “f” using 
CharlsonComorbidityIndex as a dependent variable. 
     Conclusions regarding relationship between utilization of the order sets and LOS, and 
utilization of the order sets and CCI were ready for documentation at this point, noting 
any discrepancies between One-Way ANOVA and Non-Parametric Mann-Whitney tests. 
The latter did not produce any significant differences, leading to sound conclusions 
proven by two different statistical methods. 
Relationship Between Independent Variables of Order Set Utilization, Age, Sex, & Race 
and Dependent Variables of LOS/CCI 
     The last study proposed for the AMI case was an explanation of the dependent 
variables of mortality and readmission by several independent variables of order set 
indicator, race code, sex, and age. Binary logistic regression was the most suitable 
method of running this study. Two tests, for the DischargeDispositionCode and 
HasReadmit dependent variables, were reported separately. The PatientSexCode variable 
was defined as categorical. Table 15 represents format for the results of this test. 
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Table 15. AMI <Readmissions or Mortality> as Affected by Order Set Indicator, Patient 
Age, Patient Sex, and Patient Race 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
  
Patient Age   
Patient Sex   
Patient Race   
Constant   
 
     It was determined by analyzing results reported in Table 15 which independent 
variables best and better predicted dependent ones, and which of the independent 
variables were statistically insignificant. 
Summary 
     The final report will incorporates overall analysis and recommendations regarding 
utilization of the medication order sets to treat AMI, and how these sets influence/predict 
the health outcomes of length of stay, mortality, 30-day readmission, and comorbidity. 
The report provides grounds for answering the research questions outlined in the CHF 
study and accepting/rejecting the research hypotheses. 
Resource Requirements 
     Since all of the data needed for this research is interfaced with EDW database, it is the 
only data source required to complete data queries. The data comes to EDW from 
multiple sources: CareConnection EMR/CPOE, Allegra patient accounting, TSI decision 
support, Thompson Reuters research, MIDAS quality (falls/incidents), AHRQ 
government healthcare standards, and NDNQI nursing quality applications. The latter 
two are government sources referenced in the healthcare industry. The CareConnection 
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EMR/CPOE team, led by Laurie Gift, Director of Clinical Applications at Advocate, was 
initially involved with supplying data to build the case and compile an idea paper. Their 
spreadsheets were invaluable in identifying current state of order set utilization at 
Advocate, content of the sets, running comparisons between the sets, and identifying data 
gaps and initial barriers to conducting the research. Beyond Research Proposal stage, 
only data from EDW was utilized to perform database queries, followed by statistical 
analysis in Excel (initial) and SPSS (advanced). 
     The Executive Sponsor for this research at Advocate, Dr. Joel Shoolin, provided 
clinical expertise to analyze outcomes of the research for each proposed patient 
condition. Dr. Shoolin also helped identify ways to implement recommendations from 
Final Report in the organization. He also helped identify the research problem, formulate 
the goals, select measurement criteria for outcomes, and identify resources available for 
the project. Mary Gagen from the EDW team assisted in performing initial extracts from 
the database before data is available for analysis based on methodology proposed for the 
study. Her help was also necessary to understand the content of raw data, agency sources 
governing healthcare data and quality standards, and methodologies behind clinical data 
analysis. Due to data security restrictions, only members of the EDW team can have 
direct access to raw data.  
     Executive support for the project was also ensured via Chief Information Officer, who 
signed IRB paperwork for the Advocate IRB office and received periodic updates on 
progress of the project. The Information Systems Leadership Team (ISLT), comprised of 
five Vice Presidents over several Information Systems organizations, also received 
periodic updates and presentations but was ultimately interested in final outcomes of the 
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study. Records of interactions with these individuals were maintained by the student 
researcher working on this dissertation.  
     NSU required following its own IRB process. The IRB paperwork for NSU was filed 
prior to the data collection phase of the research project, with Advocate’s IRB approvals 
attached, as the site where collection of the patient information took place. Advocate 
required for the IRB paperwork to be filed at the outset of the project in the idea stage 
before the overall project could be approved, while NSU required filing of the IRB forms 
prior to collecting data and with assumption that the hospital network had necessary 
signatures in place.  
Summary 
     Research methodology outlined in this chapter was aimed at analyzing effectiveness 
of evidence-based medication order sets on health outcomes, based on theoretical 
assumption that standardization of care for certain patient conditions could lead to 
improved quality, greater safety, and better health of the patients. The following 
statistical methods were utilized in the study: Pearson Chi-Squared, Fisher’s Exact, cross-
tabs, binary logistic regression, One-Way ANOVA comparison of means with 
Bonferroni, Tukey, and Dunnett add-ons, and Mann-Whitney non-parametric test of 
independent samples.  
     Due to differences in the unique setup of each case and circumstances of each patient 
condition, there were differences in health outcomes considered for examination in each 
case and research methods selected to analyze corresponding data. There were two 
distinct categories of cases: (1) VTE and (2) pneumonia, CHF, and AMI. The latter three 
were similar in the kinds of available data, setup, statistical analysis methods, and 
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variables. All three cases were analyzed using all four health outcomes: mortality, length 
of stay, readmissions, and complications. All three cases emphasized treatment of the 
conditions. VTE case emphasized prevention, used constraints to identify cases of 
prevention, and utilized two health outcomes from the general list of four – length of stay 
and complications. Mortality and readmissions were not applicable, as those were likely 
results of the chief and/or secondary complaints that patients are admitted to the hospital 
with. VTE case was also unique because it tracked patient progress from chief complaint 
to medical procedure to potential VTE suspicion to actual VTE outcome. This 
combination introduced one extra independent variable of acute VTE, enabling analysis 
of the relationship between two independent variables of order set utilization and acute 
VTE. There were further possibilities of both examining direct relationship between these 
variables, as well as more complex relationships controlled by the dependent variables of 
length of stay and complications/comorbidity – resulting in series of One-Way ANOVA 
setups.  
     Despite assumptions and barriers listed for the study, it represents a major leap in the 
analysis of order set effectiveness and the overall case of evidence-based medicine in the 
inpatient settings. The study utilized a wealth of data from large samples that few 
institutions possess in electronic EMR/CPOE format(s), thus making serious case for the 
first comprehensive review of the medication order set impact in clinical settings. Table 
16 is aimed at avoiding confusion regarding content and goals of each of the four studies. 
It lists each patient condition and corresponding measurements. The variables of sex, age, 
and race do not appear below, as the study of their influence is common and applicable to 
all patient conditions.  
127 
 
 
 
Table 16. Summary of Patient Conditions, Variables, and Health Outcomes 
Condition Mortality Readmission Length of 
Stay 
Complications Acute 
VTE 
VTE N/A N/A Analyze Analyze Analyze 
Pneumonia Analyze Analyze Analyze Analyze N/A 
CHF Analyze Analyze Analyze Analyze N/A 
AMI Analyze Analyze Analyze Analyze N/A 
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Chapter 4 
Results 
 
Introduction 
     Similar to Chapter 3, results sections are split into four categories by patient condition 
examined as part of this dissertation study: VTE, pneumonia, CHF, and AMI. 
Subsequently, there are several sub-sections under each section describing independent 
and dependent variables. Each quantitative summary outlined as part of these subsections 
is followed by a discussion of the findings before moving on to the next variable 
relationship analysis. The overall summary is provided at the end of this chapter in 
response to the research questions and hypotheses.  
VTE Study Results 
Case 1: Relationship Between Utilization of VTE Order Sets and Acute VTE (Independent 
vs. Independent Variables) – Split by Hospital and Surgery Categories 
Table 17. IMMC Hospital Surgical Calculations – VTE, by Hospital 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression 
VTE = yes 85 35     
VTE = no 7884 2200     
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Percent 
(VTE=yes) 
/ total 
 
 
1.07% 
 
 
1.57% 
 
3.745 
(p=0.044) 
 
 
0.045 
 
 
0.028 
0.670 
[0.452 & 
0.992] 
 
 
Table 18. IMMC Hospital Non-Surgical Calculations – VTE, by Hospital 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
VTE = yes 488 299     
VTE = no 13980 13456     
Percent 
(VTE=yes) 
/ total 
 
 
3.37% 
 
 
2.17% 
 
37.483 
(p<0.01) 
 
0.000 
(p<0.01) 
 
0.000 
(p<0.01) 
1.566 
[1.354 & 
1.812] 
 
 
Table 19. LGH Hospital Surgical Calculations – VTE, by Hospital 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
VTE = yes 262 60     
VTE = no 14878 1932     
Percent 
(VTE=yes) 
/ total 
 
 
1.73% 
 
 
3.1% 
 
16.817 
(p<0.01) 
 
0.000 
(p<0.01) 
 
0.000 
(p<0.01) 
0.497 
[0.383 & 
0.645] 
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Table 20. LGH Hospital Non-Surgical Calculations – VTE, by Hospital 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
VTE = yes 967 208     
VTE = no 29093 8248     
Percent 
(VTE=yes) 
/ total 
 
 
3.22% 
 
 
2.46% 
 
12.915  
(p=0.011) 
 
 
0.012 
 
 
0.006 
1.205 
[1.043 & 
1.393] 
 
 
VTE Case 1 Findings 
     The VTE study begins with a case that represents the most basic but quite powerful 
view of the collected data. The case provides comparative data for the control and 
experimental groups, listing VTE cases for each of the groups and percentages of VTE 
cases relative to the group totals. The smallest percentage of positive acute VTE cases 
indicates the benefit of one of the medication prescribing methods utilized in the 
research. Comparative data is strengthened with more advanced statistical views 
represented by significance at the 95% confidence level and logistic regression. 
     Details outlined above are subdivided by hospital and surgical status of the patients. 
Results presented in the tables show comparisons between percentages of patients who 
acquired VTE within control and experimental groups, relative to the total patient 
population in each group. The smaller percentage of patients who acquired VTE indicates 
the benefit of VTE medications administered via order sets. Person and Fisher’s Exact 
chi-squared tests indicate statistical significance in each table. Binary logistic regression 
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is another measure of the relationship between control and experimental groups that was 
employed.  
     The differences between the control and experimental groups must be statistically 
significant in order to ascertain valid conclusions from the study (Pearson Chi-Squared p 
=< 0.05). Fisher’s Exact statistic is provided as confirmation of significance indicated by 
Pearson Chi-Squared. While a 2-sided Fisher’s Exact is necessary to report on testing 
two-tailed null hypotheses utilized in this case, the 1-sided number is provided to indicate 
highly skewed results in cases where there is significant difference between the 2-sided 
and 1-sided numbers. The EXP(B) binary logistic regression odds ratio indicates the odds 
of acute VTE occurrence for every application of the order set. The binary logistic 
regression odds ratio is presented as a number followed by upper and lower bounds at the 
95% confidence level. All odds ratios indicative of the benefits of the order sets in 
preventing VTE are greater than 1. Higher numbers indicate higher odds of preventing 
VTE using medication order sets, while lower numbers indicate lower odds, with all 
ratios below 1 indicating lack of the medication order set benefit. Ultimately, all results 
provided as part of this sub-case are aimed at identifying cases where medication order 
sets were effective in preventing acute VTE. 
     Based on results presented in Tables 17 through 20, it is clear that non-surgical 
patients at both LGH and IMMC hospitals benefited from application of the order sets, 
while surgical patients did not benefit. Given the number of patients analyzed as part of 
this case, even a 0.5% difference indicates that many patients’ health outcomes could be 
improved through utilization of evidence-based medicine practices. In healthcare, small 
percentages and differences matter because of the impact on human lives and well being; 
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every gain in quality, health outcomes, and ability to save lives counts as positive impact, 
one human life at a time. All results were statistically significant. In all cases, binary 
logistic regression was obtained by using Enter and Backward LR methods in SPSS. Both 
methods returned identical results. 
Case 2: Relationship Between Utilization of VTE Order Sets and Acute VTE (Independent 
vs. Independent Variables) – Split by Hospital, Surgery, and Sex of the Patients 
Categories 
Table 21. IMMC Hospital Surgical Calculations – VTE, by Hospital and Sex 
 
Sex Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Fe-
male 
VTE = yes 29 17     
 VTE = no 4048 1042     
 Percent 
(VTE=yes) 
/ total 
 
 
0.71% 
 
 
1.6% 
 
7.569  
(p=0.006) 
 
 
0.010 
 
 
0.008 
0.439 
[0.240 & 
0.802] 
Male VTE = yes 56 18     
 VTE = no 3836 1158     
 Percent 
(VTE=yes)  
/ total 
 
 
1.49% 
 
 
1.53% 
 
0.053  
(p=0.818) 
 
 
0.783 
 
 
0.454 
0.939 
[0.550 & 
1.604] 
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Table 22. IMMC Hospital Non-Surgical Calculations – VTE, by Hospital and Sex 
 
Sex Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Fe-
male 
VTE = yes 242 159     
 VTE = no 7009 6784     
 Percent 
(VTE=yes) 
/ total 
 
 
3.34% 
 
 
2.29% 
 
14.173 
(p<0.01) 
 
0.000 
(p<0.01) 
 
0.000 
(p<0.01) 
1.473 
[1.203 & 
1.804] 
Male VTE = yes 246 140     
 VTE = no 6971 6678     
 Percent 
(VTE=yes) 
/ total 
 
 
3.4% 
 
 
2.05% 
 
24.075  
(p<0.01) 
 
0.000 
(p<0.01) 
 
0.000 
(p<0.01) 
1.683 
[1.364 & 
2.077] 
 
Table 23. LGH Hospital Surgical Calculations – VTE, by Hospital and Sex 
 
Sex Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Fe-
male 
VTE = yes 129 25     
 VTE = no 8202 1002     
 Percent 
(VTE=yes) 
/ total 
 
 
1.55% 
 
 
2.43% 
 
4.433 
(p=0.005) 
 
 
0.005 
 
 
0.029 
0.630 
[0.409 & 
0.972] 
Male VTE = yes 133 36     
 VTE = no 6676 931     
 Percent 
(VTE=yes) 
/ total 
 
 
1.99% 
 
 
3.72% 
 
12.471 
(p<0.01) 
 
0.000 
(p<0.01) 
 
0.000 
(p<0.01) 
0.515 
[0.354 & 
0.749] 
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Table 24. LGH Hospital Non-Surgical Calculations – VTE, by Hospital and Sex 
 
Sex Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Fe-
male 
VTE = yes 538 121     
` VTE = no 16173 4381     
 Percent 
(VTE=yes) 
/ total 
 
 
3.22% 
 
 
2.69% 
 
3.331 
(p=0.068) 
 
 
0.075 
 
 
0.038 
1.204 
[0.986 & 
1.471] 
Male VTE = yes 429 87     
 VTE = no 12920 3878     
 Percent 
(VTE=yes) 
/ total 
 
 
3.21% 
 
 
2.19% 
 
10.989 
(p=0.001) 
 
 
0.001 
 
 
0.001 
1.480 
[1.172 & 
1.869] 
 
VTE Case 2 Findings 
     This case was set up in the same way as VTE Case 1 but was further categorized by 
sex of the surgical and non-surgical patients reported for each of the two hospitals. In a 
few instances, results were not statistically significant, as indicated by Pearson and 
Fisher’s outcomes greater than p = 0.05. VTE Case 2 confirmed all of the findings made 
in VTE Case 1. The conclusion from VTE Case 2 is that sex of the patients does not 
make a difference in clinical outcomes from utilization of the order sets to prescribe VTE 
prophylaxis medications. Non-surgical patients benefit from the order sets and surgical 
patients do not benefit, regardless of sex of the patients. 
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Case 3: Relationship Between Utilization of VTE Order Sets, Acute VTE, and Charlson 
Comorbidity Index (Independent vs. Dependent Variables) 
     The following are categorical comparisons broken down by each of the 0-16 CCI 
values. Smaller ratios of VTE occurrences relative to the total number of patients in the 
experimental group represent the benefit of the VTE medication order sets. Smaller ratios 
in the control group indicate lack of the VTE order set benefit. Tables 25 through 28 are 
intended as introductory visual data representations, with no firm conclusions. The latter 
ones will be made in subsequent statistical tests following this introductory data view. 
Table 25. Charlson Comorbidy VTE Case Details – IMMC Surgical Patients  
CCI Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
0 41 4363 0.93% 6 882 0.68% 
1 11 1098 0.99% 3 303 0.98% 
2 14 1004 1.38% 13 296 4.21% 
3 6 558 1.06% 4 244 1.61% 
4 1 329 0.30% 3 157 1.88% 
5 4 139 2.80% 2 79 2.47% 
6 1 108 0.92%  65   
7 1 40 2.44%  45   
8 2 151 1.31% 1 78 1.27% 
9 1 50 1.96%  25   
10 2 22 8.33% 1 11 8.33% 
11 1 8 11.11% 1 8 11.11% 
12  10    4   
13  2   1 1 50.00% 
14         
15  2    2   
16         
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Table 26. Charlson Comorbidity VTE Case Details – IMMC Non-Surgical Patients 
CCI Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
0 152 6770 2.20% 84 5394 1.53% 
1 50 1765 2.75% 36 1843 1.92% 
2 74 1677 4.23% 48 1849 2.53% 
3 61 1307 4.46% 37 1569 2.30% 
4 37 937 3.80% 27 1036 2.54% 
5 23 494 4.45% 19 595 3.09% 
6 19 399 4.55% 9 448 1.97% 
7 9 147 5.77% 4 164 2.38% 
8 31 276 10.10% 22 308 6.67% 
9 6 97 5.83% 2 94 2.08% 
10 9 42 17.65% 3 61 4.69% 
11 9 36 20.00% 5 54 8.47% 
12 4 20 16.67% 2 19 9.52% 
13 1 8 11.11% 1 14 6.67% 
14 3 3 50.00%  3   
15  1    5   
16  1       
 
Table 27. Charlson Comorbidity VTE Case Details – LGH Surgical Patients 
CCI Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
0 148 8055 1.80% 23 827 2.71% 
1 35 1995 1.72% 13 277 4.48% 
2 30 2049 1.44% 7 280 2.44% 
3 18 1208 1.47% 5 211 2.31% 
4 10 443 2.21% 5 96 4.95% 
5 4 229 1.72% 2 70 2.78% 
6 3 125 2.34% 2 38 5.00% 
7  44 0.00%  14  
8 8 513 1.54% 2 75 2.60% 
9 5 121 3.97%  22  
10 1 44 2.22%  10  
11  26  1 5 16.67% 
12  14   7  
13  7     
14  3     
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15  2     
16       
 
Table 28. Charlson Comorbidity VTE Case Details – LGH Non-Surgical Patients 
CCI Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
0 439 11870 3.57% 66 2787 2.31% 
1 84 3632 2.26% 20 1005 1.95% 
2 137 4484 2.96% 41 1438 2.77% 
3 96 3441 2.71% 25 1088 2.25% 
4 35 1663 2.06% 16 547 2.84% 
5 29 1035 2.73% 8 386 2.03% 
6 10 600 1.64% 2 216 0.92% 
7 9 243 3.57% 3 71 4.05% 
8 74 1440 4.89% 11 423 2.53% 
9 24 296 7.50% 7 103 6.36% 
10 16 158 9.20% 2 74 2.63% 
11 8 110 6.78% 4 60 6.25% 
12 5 69 6.76% 3 33 8.33% 
13 1 34 2.86%  9   
14  10    3   
15  7    3   
16  1    2   
 
     Next, the experimental and control groups were labeled in SPSS for the purpose of 
examining complex relationships between application of the order sets, occurrence of 
acute VTE, and CCI. The One-Way ANOVA test with Bonferroni and Tukey post hoc 
tests selected for this exercise cannot track such complex relationship, because this test is 
designed to examine the relationship between two variables rather than deal with multiple 
ones. However, a One-Way ANOVA test can be utilized when each combination of order 
set utilization is paired with acute VTE outcome and labeled in sequential order, thus 
integrating two (order set application and occurrence of acute VTE) of three categories 
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set up for the One-Way ANOVA. Once all combinations of order set utilization and 
occurrence of acute VTE are paired and labeled, One-Way ANOVA can be applied to 
examine the relationship between these labeled pairs and CCI. The labels assigned in 
SPSS were as follows: 
Order_Set_Use =1 + Acute_VTE = 1: 1 
Order_Set_Use =1 + Acute_VTE = 0: 2 
Order_Set_Use =0 + Acute_VTE = 1: 3 
Order_Set_Use =0 + Acute_VTE = 0: 4 
     Therefore, labels 1 and 2 represent the experimental group (order sets used to place 
medication orders) and labels 3 and 4 represent the control group (sets not used to order 
medications). Detailed One-Way ANOVA results obtained in SPSS are outlined in 
Appendix F. In summary, standard means and statistical significance at the 95% 
confidence level were as follows: 
Table 29. One-Way ANOVA Bonferroni/Tukey Results for CCI – VTE Case 
Category Means Significant at 95%  
(p =< 0.05)? 
IMMC Surgical 1 : 2 = 0.870 
3 : 4 = 0.514 
Yes 
No 
LGH Surgical 1 : 2 = 0.221 
3 : 4 = (-) 0.020 
Yes 
No 
IMMC Non-Surgical 1 : 2 = 0.861 
3 : 4 = 1.255 
Yes 
Yes 
LGH Non-Surgical 1 : 2 = 0.462 
3 : 4 = 0.245 
Yes 
Yes 
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     The Dunnett post-hoc One-Way ANOVA t-test requires labels but is only capable of 
comparing one experimental group against one defined control group. Among groups 
outlined  in Table 29 for the One-Way ANOVA test, the following were used for the 
Dunnett post-hoc exercise. This is a test of CCI in the case of absence of the acute VTE 
factor. 
Order_Set_Use =1 + Acute_VTE = 0: 2 (experimental group) 
Order_Set_Use =0 + Acute_VTE = 0: 4 (control group) 
    Results of the Dunnett t-test are summarized in Table 30. Details from SPSS are 
provided as part of Appendix F. 
Table 30. One-Way ANOVA Dunnett Results for CCI – VTE Case 
Category Means Significant at 95%  
(p =< 0.05)? 
IMMC Surgical 2 : 4 = 0.796 Yes 
LGH Surgical 2 : 4 = 0.308 Yes 
IMMC Non-Surgical 2 : 4 = 0.612 Yes 
LGH Non-Surgical 2 : 4 = 0.368 Yes 
 
VTE Case 3 Findings 
     By visually reviewing descriptive CCI statistics and calculated ratios by hospital and 
patient category, many of the CCI sections appeared to show significant differences 
between control and experimental groups. However, One-Way ANOVA with three post-
hoc tests that followed descriptive statistics shed more light into relationships between 
groups. The Dunnett t-tests confirmed statistical significance between control and 
experimental groups as related to CCI, leading to the conclusion that VTE medication 
order sets made a difference in patient outcomes expressed by the CCI complications 
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index. The more detailed Bonferroni and Tukey (displayed same results using different 
methods) tests revealed the exact influence of medication order sets on CCI. 
     There was a significant difference between Charlson Comorbidity Indexes for the 
IMMC non-surgical groups of patients who received medications via orders sets and CCI 
for those who received custom orders, F (3,28271) = 94.297, P < 0.05. Patients in the 
experimental group had fewer comorbidities compared to those in the control group – 
indicating benefit of the order sets.  
     There was a significant difference between Charlson Comorbidity Indexes for the 
LGH non-surgical groups of patients who received medications via orders sets and CCI 
for those who received custom orders, F (3,38813) = 410.373, P < 0.05. Patients in the 
experimental group had more comorbidities compared to those in the control group, 
indicating lack of benefit of the order sets. However, more comorbidities may indicate 
other health concerns were in play, leading to a longer length of hospital stay due to 
issues unrelated to VTE. More discussion of this topic will be presented in Chapter 5. 
     There was no significant difference between VTE groups for IMMC and LGH 
surgical patients, using Charlson Comorbidity Index as a dependent variable. Due to 
conflicting results among the two hospitals for the non-surgical patients and lack of 
statistical significance of results among surgical patients, the CCI case results remain 
inconclusive, leaving discussion of the benefits of medication order sets to reduce 
complications from acute VTE open for future studies. 
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Case 4: Relationship Between Utilization of VTE Order Sets, Acute VTE, and Length of 
Stay (Independent vs. Dependent Variables) 
     The following are categorical comparisons broken down by groups of patient days. 
Due to a long list of values, a table broken down by each LOS value would show no 
statistically significant results and display unrealistically high ratio percentages. Smaller 
ratios in the experimental group indicate the benefit of the VTE medication order sets. 
Smaller ratios in the control group indicate lack of the VTE order set benefit. Tables 31 
through 34 are intended as introductory visual data representations, with no firm 
conclusions. The latter ones will be made in subsequent statistical tests under this data 
view. It would also be difficult to draw conclusions by reviewing the groups of patient 
days, as smaller or larger numbers on any side of the table leave too many questions 
open, such as the criteria for explaining fewer days within each group and what other 
factors could contribute to the length of stay outside of the VTE or prescribing 
medications to treat one. 
Table 31. Length of Stay VTE Case Details – IMMC Surgical Patients  
Length Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
1 - 5 14 5716 0.24% 3 1180 0.25% 
6 - 10 19 1193 1.57% 8 578 1.37% 
11 - 15 12 400 2.91% 7 241 2.82% 
16 - 20 17 181 8.59% 5 87 5.43% 
21 - 25 7 87 7.45% 5 41 10.87% 
26 - 30 10 63 13.70% 1 21 4.55% 
31 - 35 2 37 5.13% 3 11 21.43% 
36 - 40  23   2 4 33.33% 
41 - 45  18    6   
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Table 32. Length of Stay VTE Case Details – IMMC Non-Surgical Patients 
Length Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
1 - 5 265 10960 2.36% 162 10723 1.49% 
6 - 10 122 1612 7.04% 58 1580 3.54% 
11 - 15 36 365 8.98% 36 372 8.82% 
16 - 20 25 152 14.12% 15 115 11.54% 
21 - 25 16 59 21.33% 8 29 21.62% 
26 - 30 5 29 14.71% 1 26 3.70% 
31 - 35  8 0.00% 1 13 7.14% 
36 - 40 2 7 22.22% 2 5 28.57% 
41 - 45 3 6 33.33% 2 4 33.33% 
 
Table 33. Length of Stay VTE Case Details – LGH Surgical Patients 
Length Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
1 - 5 37 10905 0.34% 3 969 0.31% 
6 - 10 81 2587 3.04% 11 587 1.84% 
11 - 15 48 678 6.61% 14 191 6.83% 
16 - 20 27 272 9.03% 5 88 5.38% 
21 - 25 14 121 10.37% 9 30 23.08% 
26 - 30 13 64 16.88% 5 29 14.71% 
31 - 35 9 38 19.15% 5 12 29.41% 
36 - 40 10 23 30.30% 4 4 50.00% 
41 - 45 14 15 48.28% 1 2 33.33% 
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Table 34. Length of Stay VTE Case Details – LGH Non-Surgical Patients 
Length Control Group Experimental Group 
 VTE=yes VTE=no Ratio VTE=yes VTE=no Ratio 
1 - 5 563 22314 2.46% 74 5833 1.25% 
6 - 10 252 4453 5.36% 66 1594 3.98% 
11 - 15 75 912 7.60% 27 406 6.24% 
16 - 20 27 265 9.25% 15 128 10.49% 
21 - 25 12 103 10.43% 7 50 12.28% 
26 - 30 11 39 22.00% 7 31 18.42% 
31 - 35 7 27 20.59% 5 9 35.71% 
36 - 40 3 17 15.00% 1 8 11.11% 
41 - 45 2 10 16.67% 1 3 25.00% 
 
     Next, experimental and control groups were labeled in SPSS to examine complex 
relationships between application of the order sets, occurrence of acute VTE, and LOS. 
The One-Way ANOVA test with Bonferroni and Tukey post hoc tests selected for this 
analysis cannot track such complex relationship with multiple variables and require 
examination of one direct relationship between an independent and dependent variable. In 
order to prepare for such simple relationship setup, control and experimental VTE cases 
and outcomes were assigned four labels, thus building four cases of the order set 
application that resulted or did not result in acute VTE. The direct relationship between 
these cases and LOS will then met the setup requirements for a One-Way ANOVA test. 
The labels used in SPSS were as follows: 
Order_Set_Use =1 + Acute_VTE = 1: 1 
Order_Set_Use =1 + Acute_VTE = 0: 2 
Order_Set_Use =0 + Acute_VTE = 1: 3 
Order_Set_Use =0 + Acute_VTE = 0: 4 
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     Therefore, labels 1 and 2 represented the experimental group and labels 3 and 4 
represented the control group. Detailed One-Way ANOVA results obtained in SPSS are 
outlined in Appendix F. In summary, standard means and statistical significance at the 
95% confidence level were as follows: 
Table 35. One-Way ANOVA Bonferroni/Tukey Results for LOS – VTE Case 
Category Means Significant at 95%  
(p =< 0.05)? 
IMMC Surgical 1 : 2 = 11.370 
3 : 4 = 11.307 
Yes 
Yes 
LGH Surgical 1 : 2 = 12.321 
3 : 4 = 11.941 
Yes 
Yes 
IMMC Non-Surgical 1 : 2 = 3.707 
3 : 4 = 3.321 
Yes 
Yes 
LGH Non-Surgical 1 : 2 = 7.071 
3 : 4 = 2.488 
Yes 
Yes 
 
     The Dunnett post-hoc One-Way ANOVA t-test requires labels but compares any one 
experimental group against a defined control group. Among groups outlined for the One-
Way ANOVA test in Table 35, the following were used for the Dunnett post-hoc 
exercise. This is a test of LOS in the case of absence of acute VTE.  
 Order_Set_Use =1 + Acute_VTE = 0: 2 (experimental group) 
Order_Set_Use =0 + Acute_VTE = 0: 4 (control group) 
    Results of the Dunnett t-test are summarized in Table 36. Details from SPSS are 
provided as part of Appendix F. 
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Table 36. One-Way ANOVA Dunnett Results for LOS – VTE Case 
Category Means Significant at 95%  
(p =< 0.05)? 
IMMC Surgical 2 : 4 = 2.085 Yes 
LGH Surgical 2 : 4 = 0.030 No 
IMMC Non-Surgical 2 : 4 = 3.192 Yes 
LGH Non-Surgical 2 : 4 = 0.941 Yes 
      
VTE Case 4 Findings 
     The Dunnett t-tests confirmed that VTE medication order sets influenced the length of 
hospital stay among most patients eligible for this study, except LGH surgical patients, 
leaving this category without certain results despite availability and statistical 
significance of the IMMC surgical data. Yet, all of the Bonferroni relationships between 
groups were statistically significant, leading to the following statements derived from 
results. 
     There was a significant difference between Length of Stay for the IMMC non-surgical 
groups of patients who received medications via orders sets and LOS for those who 
received custom orders, F (3,28271) = 172.499, P < 0.05. Patients in the experimental 
group had slightly longer lengths of stay compared to those in the control group. 
     There was a significant difference between Length of Stay for the LGH non-surgical 
groups of patients who received medications via orders sets and LOS for those who 
received custom orders, F (3,38813) = 410.373, P < 0.05. Patients in the experimental 
group had slightly longer lengths of stay compared to those in the control group. 
     There was a significant difference between Length of Stay for the IMMC surgical 
groups of patients who received medications via orders sets and LOS for those who 
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received custom orders, F (3,10237) = 101.509, P < 0.05. Patients in the experimental 
group had slightly longer lengths of stay compared to those in the control group. 
     There was a significant difference between Length of Stay for the LGH surgical 
groups of patients who received medications via orders sets and LOS for those who 
received custom orders, F (3,17329) = 686.291, P < 0.05. Patients in the experimental 
group had longer lengths of stay compared to those in the control group. 
     Despite being statistically significant, the mean length of stay produced for the 
experimental group patients was higher compared to the control group, indicating a lack 
of benefit for the order sets relative to LOS. Further discussion of this outcome appears in 
Chapter 5. 
Case 5: Analysis of the Direct Relationship Between Utilization of the Order Sets and 
Length of Hospital Stay (LOS) 
     The following are results of the non-parametric independent samples tests suitable for 
examining relationships between dichotomous and continuous values assigned to 
utilization of the order sets (categorical) and LOS (continuous) variables. The plots 
graphically representing these results are available in Appendix F. Mann-Whitney test 
results are presented in pairs of tables: one containing basic statistics and another 
displaying the outcomes of frequency distribution and hypothesis testing.  
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IMMC surgical calculations 
Table 37. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Basic Statistics – IMMC Surgical 
 
Mann-Whitney Parameter Results 
Total N 10,259 
Mann-Whitney U 11,755,933.500 
Wilcoxcon W 14,369,974.500 
Test Statistic 11,755,933.500 
Standard Error 123,750.007 
Standard Test Statistic 21.356 
Pearson Chi-Squared Significance p < 0.01 
 
Table 38. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Outcomes – IMMC Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 7973 4798.53  
Experimental 2286 6286.08  
 
Decision from the test of hypothesis: Reject null hypothesis 
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IMMC non-surgical calculations 
Table 39. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Basic Statistics – IMMC Non-Surgical 
 
Mann-Whitney Parameter Results 
Total N 40,950 
Mann-Whitney U 189,937,128.500 
Wilcoxcon W 297,960,079.500 
Test Statistic 189,937,128.500 
Standard Error 1,131,645.853 
Standard Test Statistic -2.641 
Pearson Chi-Squared Significance p < 0.008 
 
Table 40. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Outcomes – IMMC Non-Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group Rank Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 26252 20589.35  
Experimental 14698 20272.15  
 
Decision from the test of hypothesis: Reject null hypothesis 
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LGH surgical calculations 
Table 41. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Basic Statistics – LGH Surgical 
 
Mann-Whitney Parameter Results 
Total N 17,359 
Mann-Whitney U 22,970,959.500 
Wilcoxcon W 25,394,260.500 
Test Statistic 22,970,959.500 
Standard Error 217,959.212 
Standard Test Statistic 28.857 
Pearson Chi-Squared Significance p < 0.01 
 
Table 42. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Outcomes – LGH Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group Rank Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 15158 8265.07  
Experimental 2201 11537.60  
 
Decision from the test of hypothesis: Reject null hypothesis 
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LGH non-surgical calculations 
Table 43. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Basic Statistics – LGH Non-Surgical 
 
Mann-Whitney Parameter Results 
Total N 56,799 
Mann-Whitney U 245,247,010.500 
Wilcoxcon W 287,296,045.500 
Test Statistic 245,247,010.500 
Standard Error 1,421,074.854 
Standard Test Statistic 18.907 
Pearson Chi-Squared Significance p < 0.01 
 
Table 44. Direct Relationship Between Utilization of VTE Order Sets and LOS, Mann-
Whitney Outcomes – LGH Non-Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group Rank Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 47629 27835.89  
Experimental 9170 31329.99  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
VTE Case 5 Findings 
     The Mann-Whitney tests confirm earlier One-Way ANOVA results, displaying strong 
statistical significance by rejection of the null hypotheses (indicating no relationship 
between variables), with a mix mean ranks – leading to inconclusive outcomes relative to 
the actual benefit of the order sets as represented by the length of stay health outcome. 
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Case 6: Analysis of Direct Relationship Between Utilization of the Order Sets and 
Charlson Comorbidity Index (CCI) 
     The following are results of the non-parametric independent samples tests suitable for 
examining relationship between dichotomous and continuous values assigned to 
utilization of the order sets (categorical) and CCI (continuous) variables. The plots 
graphically representing these results are available in Appendix F. 
IMMC surgical calculations 
Table 45. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Basic Statistics – IMMC Surgical 
 
Mann-Whitney Parameter Results 
Total N 10,241 
Mann-Whitney U 10,860,731.500 
Wilcoxcon W 13,442,859.500 
Test Statistic 10,860,731.500 
Standard Error 114,972.223 
Standard Test Statistic 15.725 
Pearson Chi-Squared Significance p < 0.01 
 
Table 46. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Outcomes – IMMC Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 7969 4893.13  
Experimental 2272 5916.75  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
 
152 
 
 
 
IMMC non-surgical calculations 
Table 47. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Basic Statistics – IMMC Non-Surgical 
 
Mann-Whitney Parameter Results 
Total N 28,275 
Mann-Whitney U 108,401,386.500 
Wilcoxcon W 203,724,914.500 
Test Statistic 108,401,386.500 
Standard Error 654,218.049 
Standard Test Statistic 13.026 
Pearson Chi-Squared Significance p < 0.01 
 
Table 48. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Outcomes – IMMC Non-Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group Rank Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 14468 13549.01  
Experimental 13807 14755.19  
 
Decision from the test of hypothesis: Reject null hypothesis 
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LGH surgical calculations 
Table 49. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Basic Statistics – LGH Surgical 
 
Mann-Whitney Parameter Results 
Total N 17,333 
Mann-Whitney U 19,295,760.00 
Wilcoxcon W 21,701,481 
Test Statistic 19,295,760.00 
Standard Error 201,827.472 
Standard Test Statistic 13.352 
Pearson Chi-Squared Significance p < 0.01 
 
Table 50. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Outcomes – LGH Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 15140 8489.01  
Experimental 2193 9895.80  
 
Decision from the test of hypothesis: Reject null hypothesis 
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LGH non-surgical calculations 
Table 51. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Basic Statistics – LGH Non-Surgical 
 
Mann-Whitney Parameter Results 
Total N 38,817 
Mann-Whitney U 143,818,946.500 
Wilcoxcon W 182,165,849.500 
Test Statistic 143,818,946.500 
Standard Error 890,680.524 
Standard Test Statistic 13.699 
Pearson Chi-Squared Significance p < 0.01 
 
Table 52. Direct Relationship Between Utilization of VTE Order Sets and CCI, Mann-
Whitney Outcomes – LGH Non-Surgical 
 
Patient Group Total Group 
Population (N) 
Mean Group Rank Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 30060 19003.10  
Experimental 8757 20802.31  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
VTE Case 6 Findings 
     The Mann-Whitney tests confirm earlier One-Way ANOVA results for non-surgical 
patients, displaying strong statistical significance by rejection of the null hypotheses 
(indicating strong relationships between variables). The Mann-Whitney test results for 
surgical patients contradict the One-Way ANOVA test, displaying statistical significance 
between utilization of the order sets and CCI by rejecting the null hypothesis. However, 
all mean ranks indicate higher comorbidities for those patients who received VTE 
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prevention medications via order sets, leading to the conclusion that VTE order sets do 
not benefit patients in terms of the complications health outcome. In fact, VTE 
prevention order sets may cause additional complications, although this outcome may 
depend on other variables that are discussed in Chapter 5. It is also important to note that 
Mann-Whitney and One-Way ANOVA tests differed in scope, with the former examining 
a direct relationship between order sets and CCI, and the latter examining the more 
complex relationship controlled by VTE occurrence. The final outcome remains 
inconclusive for CCI, due to a mixed bag of outcomes from all tests that either produced 
contradicting results (for surgical patients) or agreed on outcomes but showed higher rate 
of complications/comorbidities among experimental group patients.  
Case 7: Analysis of Statistical Significance of Several Independent Variables on 
Occurrence of Acute VTE 
     This case uses binary logistic regression method to measure and contrast the influence 
of several independent variables on occurrence of acute VTE, as well as to provide the 
odds ratios for each scenario.  
Table 53. Acute VTE as Affected by Utilization of the Order Sets, Patient Age, Patient 
Sex, Patient Race, and Surgical/Non-Surgical Status – IMMC and LGH Together 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.000 1.305 
Patient Age 0.000 1.007 
Patient Sex 0.223 1.052 
Patient Race 0.000 0.953 
Surgery Status 0.000 1.862 
Constant 0.000 0.016 
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Table 54. Acute VTE as Affected by Utilization of the Order Sets, Patient Age, Patient 
Sex, Patient Race, and Surgical/Non-Surgical Status – IMMC 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.000 1.534 
Patient Age 0.000 1.014 
Patient Sex 0.253 1.080 
Patient Race 0.000 0.944 
Surgery Status 0.000 2.552 
Constant 0.000 0.008 
 
 
Table 55. Acute VTE as Affected by Utilization of the Order Sets, Patient Age, Patient 
Sex, Patient Race, and Surgical/Non-Surgical Status – LGH 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.060 1.138 
Patient Age 0.058 1.003 
Patient Sex 0.480 1.038 
Patient Race 0.701 0.991 
Surgery Status 0.000 1.636 
Constant 0.000 0.016 
 
VTE Case 7 Results 
     For both hospitals as a whole, all variables but patient sex are significant in predicting 
the value of Acute VTE. However, the odds ratios are highest for surgery status and order 
set utilization. When considered separately, IMMC had the same outcomes as the two 
hospitals combined, while LGH had order set utilization and patient age approaching 
significance, with patient race being insignificant. Therefore, overall age is the strongest 
influencing factor for acute VTE, followed by surgery status and utilization of the order 
sets. Among these outcomes, it would be most obvious to clinicians that surgical status 
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and age have strong influence on VTE. However, clinicians would not expect medication 
order set utilization to have similar influence on VTE outcomes.  
     The odds ratios are also high for the order sets, supporting strong case for influence on 
VTE. High surgery odds ratios are expected due to nature of the problem. 
VTE Study Descriptive Statistics 
     The number of participants broken down by race, sex, and utilization of the order sets 
appears in Appendix F. 
Pneumonia Study Results 
Case 1: Relationship Between Utilization of Order Sets and Mortality (Independent vs. 
Dependent Variables) – Total and Split by Hospital, Hospice Patients Excluded from 
Study 
Table 56. Pneumonia Mortality: Total for GSAM, IMMC, SSUB, TRIN Combined – 
Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 338 11     
Mortality = no 4193 158     
Percent 
(Mortality=yes) 
/ total 
 
 
7.5% 
 
 
6.5% 
 
3.736 
(p=0.053) 
 
 
0.060 
 
 
0.029 
 
1.822 [0.983 
& 3.380] 
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Table 57. Pneumonia Mortality: GSAM Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 73 1     
Mortality = no 1756 112     
Percent 
(Mortality=yes) 
/ total 
 
 
4% 
 
 
0.9% 
 
2.804 (p= 
0.094) 
 
 
0.124 
 
 
0.062 
 
4.656 [0.641 
& 33.809] 
 
Table 58. Pneumonia Mortality: IMMC Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 26 6     
Mortality = no 846 327     
Percent 
(Mortality=yes) 
/ total 
 
 
3% 
 
 
1.8% 
 
1.298 (p= 
0.255) 
 
 
0.017 
 
 
0.010 
 
1.675 [0.683 
& 4.107] 
 
Table 59. Pneumonia Mortality: SSUB Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 47 1     
Mortality = no 1184 59     
Percent 
(Mortality=yes) 
/ total 
 
 
3.8% 
 
 
1.7% 
 
0.740 (p= 
0.39) 
 
 
0.723 
 
 
0.335 
 
2.342 [0.318 
& 17.269] 
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Table 60. Pneumonia Mortality: TRIN Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 12 3     
Mortality = no 407 34     
Percent 
(Mortality=yes) 
/ total 
 
 
2.9% 
 
 
8.1% 
 
2.939 (p= 
0.086) 
 
 
0.113 
 
 
0.113 
 
0.334 [0.090 
& 1.242] 
 
Pneumonia Case 1 Findings 
     This first study of the effects of administering pneumonia medication order sets on 
health outcomes was aimed at calculating basic percentages of patients who died from 
pneumonia relative to the total population. It might be the best, easiest, and most 
representative study of the mortality health outcome of order sets utilization, supported 
by statistical calculations of significance at the 95% confidence interval and binary 
logistic regression.   
     Details outlined in Tables 56 through 60 are broken down by hospital, starting with 
the total of all four facilities participating in the study. Only the latter study produced 
results that numerically approached significance by Pearson Chi-Squared and 2-sided 
Fisher’s Exact calculations (P approached 0.05). While the odds ratio was calculated for 
all cases using binary logistic regression, only results for all hospitals, taken as a whole, 
were valid, based on statistical significance. Both Enter and Backward LR methods of 
running binary logistic regression equation produced identical results. The reason for lack 
of statistical significance in each of the individual hospital cases is an insufficient 
160 
 
 
 
population sample that gets smaller with each attempt to conduct a more 
categorized/focused study. The pneumonia study is much smaller compared to VTE by 
the overall population (total admissions) of pneumonia patients available in EMR history, 
although this pneumonia data set is much larger than what the majority of the other 
hospitals with EMR ownership can offer today.  
     Mortality = yes is represented by the sole discharge disposition code of Expired (=20), 
while Mortality = no is a combination of many codes that were converted to 0 values for 
the purposes of this pneumonia study, so Mortality is a calculated field in SPSS. In this 
case, hospice patients (discharge disposition codes of 50 and 51) were excluded, as this 
group of patients makes a statistical difference on outcomes due to uncertain survival 
characteristics, with their outcomes difficult to track at this time (internal and external 
hospice facilities recording results in their own EMR applications that are not linked). 
Excluding hospice patients from the study was not a viable option, since these patients 
were, in fact, treated at the hospitals. So the more valid study was the one that followed 
it, with all patients accounted for. Yet it was important to show both sets of results, given 
that hospice patients affect outcome results. 
     Smaller ratios in the experimental group indicate the benefit of the order sets leading 
to reduced mortality, while smaller ratios for the control group mean lack of the order set 
benefit and the possibility of side effects from pneumonia medication order sets. As 
evidenced from SPSS crosstabs calculations, mortality was 1% lower for patients who 
received medications and orders via sets – a significant outcome given a total patient 
population of roughly 5,000. The odds ratio was also high at 1.822 – so the odds of dying 
from pneumonia while treated with medication order set are much lower compared to 
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custom physician orders. Patients’ health outcomes are more favorable when evidence-
based methods are utilized to treat pneumonia.  
Case 2: Relationship Between Utilization of Order Sets and Mortality (Independent vs. 
Dependent Variables) – Total and Split by Hospital, Hospice Patients as Mortality=0 
(no) 
Table 61. Pneumonia Mortality: Total for GSAM, IMMC, SSUB, TRIN – Hospice 
Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 545 11     
Mortality = no 4373 158     
Percent 
(Mortality=yes) 
/ total 
 
 
11% 
 
 
6.5% 
 
3.509 (p= 
0.061 
 
 
0.060 
 
 
0.034 
 
1.790 [0.965 
and 3.320] 
 
Table 62. Pneumonia Mortality: GSAM Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 119 1     
Mortality = no 1842 73     
Percent 
(Mortality=yes) 
/ total 
 
 
6% 
 
 
1.4% 
 
2.859 (p= 
0.091) 
 
 
0.126 
 
 
0.060 
 
4.716 [0.650 
and 34.227] 
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Table 63. Pneumonia Mortality: IMMC Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 333 6     
Mortality = no 885 26     
% 
(Mortality=yes) 
/ total 
 
 
27.3% 
 
 
23% 
 
1.164 (p= 
0.281) 
 
 
0.321 
 
 
0.192 
 
1.631 [0.685 
and 3.997] 
 
Table 64. Pneumonia Mortality: SSUB Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 59 1     
Mortality = no 1234 47     
Percent 
(Mortality=yes) 
/ total 
 
 
4.6% 
 
 
2.1% 
 
0.666 (p= 
0.415) 
 
 
0.720 
 
 
0.336 
 
2.247 [0.305 
and 16.569] 
 
Table 65. Pneumonia Mortality: TRIN Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 34 3     
Mortality = no 412 12     
Percent 
(Mortality=yes) 
/ total 
 
 
7.6% 
 
 
20% 
 
3.011 (p= 
0.083) 
 
 
0.111 
 
 
0.111 
 
0.33 [0.089 
and 1.227] 
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Pneumonia Case 2 Findings 
     Case 2 was performed in the same way as Case 1, with the only difference being that 
hospice patients were included in calculations with the mortality setting of 0 (mortality = 
no). Statistical significance was slightly smaller at p = 0.06 (approached significance), 
but percentage difference between control and experimental group ratios widened to 
4.5%, indicating that “borderline” hospice patients make a significant difference in the 
results of pneumonia mortality case of the medication order sets. The odds ratio was 
similar to the one identified in Case 1. As expected, none of the individual hospital cases 
produced statistically significant results. As evidenced from this case, pneumonia patients 
who receive medications and physician orders via sets have much higher chances of 
surviving compared to the experimental group of patients who received orders and 
medications via custom physician orders.  
Case 3: Relationship Between Utilization of Order Sets and Readmission (Independent 
vs. Dependent Variables) – Total and Split by Hospital 
Table 66. Pneumonia Readmissions: Total for GSAM, IMMC, SSUB, TRIN Combined 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Readmission 
= yes 
579 54     
Readmission 
= no 
3952 502     
Percent 
(Readmission 
=yes) / total 
 
 
14.7% 
 
 
10.8% 
 
 
4.274 (p= 
0.039) 
 
 
0.041 
 
 
0.020 
 
 
1.362 [1.015 
and 1.827] 
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Table 67. Pneumonia Readmissions: GSAM Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 237 15    
Readmission = no 1678 105    
Percent 
(Readmission 
=yes) / total 
 
 
12.4% 
 
 
12.5% 
 
 
0.002 (p= 
0.968) 
 
 
1.000 
 
 
 
0.528 
 
Table 68. Pneumonia Readmissions: IMMC Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 123 32    
Readmission = no 788 307    
Percent 
(Readmission 
=yes) / total 
 
 
13.5% 
 
 
9.4% 
 
 
3.753 (p= 
0.053) 
 
 
0.054 
 
 
0.031 
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Table 69. Pneumonia Readmissions: SSUB Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 167 2    
Readmission = no 1114 58    
Percent 
(Readmission 
=yes) / total 
 
 
13% 
 
 
3.3% 
 
 
4.9 (p= 
0.027 
 
 
0.026 
 
 
0.013 
 
 
Table 70. Pneumonia Readmissions: TRIN Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 52 5    
Readmission = no 372 32    
Percent 
(Readmission 
=yes) / total 
 
 
12.3% 
 
 
13.5% 
 
 
0.049 (p= 
0.825) 
 
 
0.795 
 
 
0.493 
 
Pneumonia Case 3 Findings 
     The pneumonia case 3 setup in SPSS was similar to both cases 1 and 2, but instead of 
mortality the dependent variable examined for health outcomes was 30-day readmission 
passed from EDW as categorical with 0 (no) and 1 (yes) values. As the first case for all 
hospitals indicates, the difference between readmitted patients for the experimental and 
control groups was almost 4%, indicating a significantly lower chance of being 
readmitted after being treated for pneumonia using evidence-based medicine techniques. 
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Results for this case were statistically significant. The odds ratio was relatively strong at 
1.362, indicating a lower chance of readmission after application of the order sets to treat 
pneumonia. Among individual hospitals in this case, calculations for the SSUB hospital 
were statistically significant and Pearson Chi-Squared for IMMC approached 
significance at the 95% confidence level. Binary logistic regression calculations for 
individual hospitals were omitted due to small experimental group samples that were 
expected to lead to statistically insignificant results. 
     It is clear from reading results of this case that patients’ chance of being readmitted is 
lower when order sets are applied to treat pneumonia. Therefore, pneumonia case 3 adds 
to cases 1 and 2 in statistically proving the point that patients are better off when 
physicians utilize sets to order treatment and medications for pneumonia, compared to 
custom orders.  
Case 4: Relationship Between Utilization of Order Sets and Length of Stay (Independent 
vs. Dependent Variables) 
     This case utilized the Mann-Whitney non-parametric analysis of independent samples 
to test the null hypothesis for the length of hospital stay for pneumonia patients. It was 
followed by basic One-Way ANOVA (without post-hoc tests) to compare means between 
control and experimental groups. Both tests produced means, the former as mean rank 
and the latter as a mathematical mean. The two tests were set up differently, hence it 
made sense to apply both for verification purposes. SPSS also provided a nice graphical 
representation of the null hypothesis test as part of the Mann-Whitney results. The 
detailed results and figure for Mann-Whitney are available in Appendix G. The overview 
of Mann-Whitney test results in this chapter are presented in pairs of tables: one 
167 
 
 
 
containing basic statistics and another displaying the outcomes of frequency distribution 
and hypothesis testing. 
Total for all hospitals 
Table 71. Relationship Between Utilization of Pneumonia Order Sets and LOS, Mann-
Whitney Basic Statistics – All Hospitals 
 
Mann-Whitney Parameter Results 
Total N 5087 
Mann-Whitney U 1,148,309 
Wilcoxcon W 1,303,155 
Test Statistic 1,148,309 
Standard Error 32,420.610 
Pearson Chi-Squared Significance p = 0.001 
 
Table 72. Relationship Between Utilization of Pneumonia Order Sets and LOS, Mann-
Whitney Outcomes – All Hospitals 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 4531 2568.57  
Experimental 556 2343.80  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
Table 73. One-Way ANOVA for Pneumonia LOS Case – Description View 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
0 4531 4.84 4.143 .062 4.72 4.96 0 40 
1 556 4.43 4.028 .171 4.10 4.77 0 43 
Total 5087 4.80 4.132 .058 4.68 4.91 0 43 
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Table 74. One-Way ANOVA for Pneumonia LOS Case – Basic View 
 
 Sum of 
Squares df 
Mean  
Square F Sig. 
 
Between Groups 
 
           81.848 
 
1 
 
81.848 
 
4.798 
 
0.029 
Within Groups      86749.531 5085 17.060   
Total      86831.380 5086    
 
Pneumonia Case 4 Findings 
     The Mann-Whitney test rejected the null hypothesis for the length of hospital stay, 
indicating that there is a statistically significant difference between control and 
experimental groups of pneumonia patients, signaling potential benefit of the order sets in 
yet another health outcomes category. However, rejection of the null hypothesis does not 
provide the level of detail necessary to determine whether length of stay was longer or 
shorter for patients in the experimental groups. Comparison of means within Mann-
Whitney test results revealed a higher mean rank for the control group of patients. This 
indicates that patients who received treatment orders via sets had a shorter hospital stay.  
     The same results were confirmed by the One-Way ANOVA test that uses 
mathematical means for each category of patients, with higher mean for the control 
group. Results of the ANOVA test were as follows: there was significant difference 
between LOS for pneumonia patients who received medications via order sets and those 
who had them prescribed via custom orders, F (1, 5085) = 4.798, P < 0.05; the mean 
length of stay was lower for patients who received medications via order sets. Case 4 
statistically proved the overall benefit of evidence based medicine to treat pneumonia in 
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terms of the length of hospital stay health outcome. This benefit also indicates lower cost 
for each case. 
Case 5: Relationship Between Utilization of Order Sets and Patient Complications 
Represented by Charlson Comorbidity Index (Independent vs. Dependent Variables) 
     This case was set up in the same way as pneumonia case 4 to test the null hypothesis 
and compare the actual complications indexes between control and experimental groups 
using mean ranks reported by the Mann-Whitney analysis. Results were subsequently 
verified using an alternative One-Way ANOVA test of comorbidities. The outcomes from 
both Mann-Whitney and One-Way ANOVA tests should match to the results.  
Total for All Hospitals 
Table 75. Relationship Between Utilization of Pneumonia Order Sets and CCI, Mann-
Whitney Basic Statistics – All Hospitals 
 
Mann-Whitney Parameter Results 
Total N 4983 
Mann-Whitney U 1,153,767.500 
Wilcoxcon W 1,153,767.500 
Test Statistic 1,153,767.500 
Standard Error 31,293.357 
Pearson Chi-Squared Significance p = 0.014 
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Table 76. Relationship Between Utilization of Pneumonia Order Sets and CCI, Mann-
Whitney Outcomes – All Hospitals 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 4427 2509.38  
Experimental 556 2353.62  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
Table 77. One-Way ANOVA for Pneumonia CCI Case – Description View 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
0 4427 2.40 2.424 .036 2.33 2.47 0 15 
1 556 2.13 2.289 .097 1.94 2.33 0 11 
Total 4983 2.37 2.410 .034 2.30 2.44 0 15 
 
Table 78. One-Way ANOVA for Pneumonia CCI Case – Basic View 
 
 Sum of     
 Squares df 
Mean  
Square F Sig. 
 
Between Groups 
 
34.551 
 
1 
 
34.551 
 
5.954 
 
0.015 
Within Groups 28904.801 4981 5.803   
Total 28939.353 4982    
 
Pneumonia Case 5 Findings 
     The Mann-Whitney test of independent samples rejected the null hypothesis and 
proved that a relationship between utilization of the order sets to treat pneumonia and 
patient complications exists. The mean rank for the control group of patients was higher 
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compared to the experimental group, indicating that experimental patients developed 
fewer complications when order sets were applied to prescribe clinical tests and 
medications, or these patients had fewer pre-existing conditions that made them appear as 
less sick for the purposes of the pneumonia order set study. The One-Way ANOVA test 
confirmed these results using simple mathematical means on a per-patient complications 
basis. Therefore, patients in the experimental group benefited from application of the 
order sets and had better health outcomes, in terms of complications. Detailed results and 
graphs and available in Appendix G. Additional discussion of differences between 
complications, comorbidities, and length of hospital stay will appear in Chapter 5. 
     Overall, Case 5 results can be summarized as follows: there was significant difference 
between CCI for pneumonia patients who received medications via order sets and those 
who had them prescribed via custom orders, F (1, 4981) = 5.954, P < 0.05. The mean 
complications index score was lower for patients who received medications via order 
sets.  
Case 6: Study of Several Independent Variables Affecting Dependent Variables 
     This case utilized binary logistic regression to examine the influence of several 
independent variables on the dependent variables of readmissions and mortality. 
Statistical significance is the primary test in this case, with the odds ratios providing clues 
into strength of the variable influence.  
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Table 79. Pneumonia Readmissions as Affected by Order Set Indicator, Patient Age, 
Patient Sex, and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ration EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.079 1.304 
Patient Age 0.000 1.006 
Patient Sex 0.003 0.778 
Patient Race 0.003 0.937 
Constant 0.000 0.199 
 
Table 80. Pneumonia Mortality as Affected by Order Set Indicator, Patient Age, Patient 
Sex, and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ration EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.028 1.618 
Patient Age 0.000 1.024 
Patient Sex 0.460 0.086 
Patient Race 0.056 0.053 
Constant 0.000 0.005 
 
Pneumonia Case 6 Findings 
     A patient’s age, race, and sex played a greater role in predicting readmission than use 
of the order set, which in this particular linear regression exercise approached 
significance. It is important to note that significance numbers are relative within this 
particular group of independent variables. 
     Patient age had the most influence on mortality, followed by use of the order set. 
Patient’s race was next and approached significance, while patient sex was statistically 
insignificant. 
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Pneumonia Study Descriptive Statistics 
     The number of participants by race, sex, and utilization of the order sets is available in 
Appendix G. 
CHF Study Results 
Case 1: Relationship Between Utilization of Order Sets and Mortality (Independent vs. 
Dependent variables) – Total and Split by Hospital, Hospice Patients Excluded from 
Study 
Table 81. CHF Mortality: Total for CMC, GSHP, SSUB, IMMC, LGH – Hospice 
Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 331 13     
Mortality = no 9505 692     
Percent 
(Mortality=yes) 
/ total 
 
 
3.4% 
 
 
1.9% 
 
11.128 (p= 
0.028) 
 
 
0.032 
 
 
0.018 
 
1.854 [1.059 
& 3.244] 
 
Table 82. CHF Mortality: CMC Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 130 1     
Mortality = no 4120 68     
Percent 
(Mortality=yes) 
/ total 
 
 
3% 
 
 
1.4% 
 
1.255 (p= 
0.439) 
 
 
0.724 
 
 
0.375 
 
2.146 [0.296 
& 15.572] 
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Table 83. CHF Mortality: IMMC Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 23 9     
Mortality = no 890 468     
Percent 
(Mortality=yes) 
/ total 
 
 
2.5% 
 
 
1.9% 
 
0.616 (p= 
0.455) 
 
 
0.573 
 
 
0.293 
 
1.344 [0.617 
& 2.928] 
 
Table 84. CHF Mortality: SSUB Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 57 0     
Mortality = no 1811 39     
Percent 
(Mortality=yes) 
/ total 
 
 
3% 
 
 
N/A 
 
2.903 (p= 
0.268) 
 
 
0.629 
 
 
0.303 
 
50845977.60 
[0 & N/A] 
 
Table 85. CHF Mortality: GSHP Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 48 0     
Mortality = no 1248 18     
Percent 
(Mortality=yes) 
/ total 
 
 
3.7% 
 
 
N/A 
 
4.157 (p= 
0.406) 
 
 
1.000 
 
 
0.510 
 
62133639.57 
[0 & N/A] 
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Table 86. CHF Mortality: LGH Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 73 3     
Mortality = no 1436 99     
Percent 
(Mortality=yes) 
/ total 
 
 
4.8% 
 
 
2.9% 
 
3.507 (p= 
0.382) 
 
 
0.626 
 
 
0.277 
 
1.678 [0.519 
and 5.418] 
 
CHF Case 1 Findings 
     Case parameters for pneumonia, CHF, and AMI are similar due to the same health 
outcomes targets and examination of relationships between one independent and three or 
four dependent variables. However, population and consequently data sample sizes 
decline from VTE to pneumonia to CHF to AMI. A greater number of more focused 
studies categorized by extra variables such as patient sex or treatment facility fails to 
produce statistically significant results. Only more time and encouragement for 
physicians to utilize medication order sets would help enrich these studies by increasing 
population sizes for experimental groups – outside of a controlled experiment where 
physicians are explicitly asked to prescribe via sets and give up their decision making 
independence. As a result, for the CHF study, only the total of all participating hospitals 
will be discussed.  
     As in the pneumonia study, the lower percentages in the experimental group indicate a 
benefit of the order set with a lower mortality ratio compared to the total of all cases 
where order sets were applied. The lower percentage in the control group indicates a lack 
176 
 
 
 
of an order set benefit and/or adverse effects. Binary logistic regression was run using 
Enter and Backward LR specifications in SPSS – both produced identical results. Due to 
small sample sizes in experimental groups, binary logistic regression results for 
individual hospital cases were omitted. 
       As evident from Tables 81 through 86, the mortality rate among experimental group 
patients was significantly lower than among control group patients, indicating clear 
benefit of CHF medication order sets in terms of mortality health outcomes. Hospice 
patients were excluded from Case 1. Including hospice patients would produce a study of 
greater validity, but due to the differences in outcomes that hospice patients generate, it is 
important to show both sets of numbers.  
Case 2: Relationship Between Utilization of Order Sets and Mortality (Independent vs. 
Dependent Variables) – Total and Split by Hospital, Hospice Patients as Mortality=0 
(no) 
Table 87. CHF Mortality: Total for CMC, GSHP, SSUB, IMMC, LGH – Hospice 
Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 331 13     
Mortality = no 9888 706     
Percent 
(Mortality=yes) 
/ total 
 
 
3.2% 
 
 
1.8% 
 
4.516 (p= 
0.034) 
 
 
0.040 
 
 
0.022 
 
1.818 [1.039 
& 3.181] 
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Table 88. CHF Mortality: CMC Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 130 1    
Mortality = no 4256 69    
Percent 
(Mortality=yes) / 
total 
 
 
3% 
 
 
1.4% 
 
0.569 (p= 
0.451) 
 
 
0.724 
 
 
0.384 
 
Table 89. CHF Mortality: IMMC Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 23 9    
Mortality = no 907 476    
Percent 
(Mortality=yes) / 
total 
 
 
2.5% 
 
 
1.9% 
 
0.550 (p= 
0.458) 
 
 
0.573 
 
 
0.295 
 
Table 90. CHF Mortality: SSUB Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 57 0    
Mortality = no 1889 39    
% (Mortality=yes) 
/ total 
 
 
2.9% 
 
 
N/A 
 
1.176 (p= 
0.278) 
 
 
0.627 
 
 
0.317 
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Table 91. CHF Mortality: GSHP Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 48 0    
Mortality = no 1286 20    
Percent 
(Mortality=yes) / 
total 
 
 
3.6% 
 
 
N/A 
 
0.746 (p= 
0.388) 
 
 
1.000 
 
 
0.483 
 
Table 92. CHF Mortality: LGH Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 73 3    
Mortality = no 1550 102    
Percent 
(Mortality=yes) / 
total 
 
 
4.5% 
 
 
2.9% 
 
0.631 (p= 
0.427) 
 
 
0.622 
 
 
0.309 
 
CHF Case 2 Findings 
     The only difference between this case and CHF Case 1 is treatment of the hospice 
patients by discharge disposition code: Case 1 excluded them and Case 2 included with 
mortality = no (actual known outcome). Only the case when all hospitals are included 
was statistically significant and revealed similar results in terms of mortality and benefit 
for the experimental group patients, thus re-confirming results for mortality. 
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Case 3: Relationship Between Utilization of Order Sets and Readmission (Independent 
vs. Dependent variables) – Total and Split by Hospital 
Table 93. CHF Readmissions: Total for CMC, IMMC, SSUB, GSHP, LGH Combined 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Readmission 
= yes 
1415 108     
Readmission 
= no 
6168 430     
Percent 
(Readmission 
=yes) / total 
 
 
19% 
 
 
20% 
 
0.659 (p= 
0.417) 
 
 
0.424 
 
 
0.224 
 
0.913 [0.734 
& 1.137] 
 
Table 94. CHF Readmissions: CMC Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 555 7    
Readmission = no 2513 34    
Percent 
(Readmission 
=yes) / total 
 
 
18% 
 
 
17% 
 
0.028 (p= 
0.867) 
 
 
1.000 
 
 
0.532 
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Table 95. CHF Readmissions: IMMC Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 138 74    
Readmission = no 543 270    
Percent 
(Readmission 
=yes) / total 
 
 
20.2% 
 
 
21.5% 
 
0.217 (p= 
0.642) 
 
 
0.683 
 
 
0.349 
 
Table 96. CHF Readmissions: SSUB Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 239 4    
Readmission = no 1089 26    
Percent 
(Readmission 
=yes) / total 
 
 
18% 
 
 
13.3% 
 
0.434 (p= 
0.510) 
 
 
0.635 
 
 
0.354 
 
Table 97. CHF Readmissions: GSHP Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 193 3    
Readmission = no 768 15    
Percent 
(Readmission 
=yes) / total 
 
 
20% 
 
 
16.7% 
 
0.129 (p= 
0.720) 
 
 
1.000 
 
 
0.499 
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Table 98. CHF Readmissions: LGH Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 290 20    
Readmission = no 1255 85    
Percent 
(Readmission 
=yes) / total 
 
 
18.8% 
 
 
19% 
 
0.005 (p= 
0.944) 
 
 
0.898 
 
 
0.514 
 
CHF Case 3 Findings 
     None of the Case 3 results were statistically significant due to insufficient 
readmissions data and missing fields on the spreadsheet received from EDW. While 
readmission rates for CHF could potentially be as high as indicated in the results, none of 
the data in Tables 93 through 98 should be trusted due to missing values in the data 
history and the small size of the experimental group data sample. 
Case 4: Relationship Between Utilization of Order Sets and Length of Stay (Independent 
vs. Dependent Variables) 
     The Mann-Whitney test of independent samples was aimed at testing the null 
hypothesis and comparing the mean ranks to contrast control and experimental groups in 
order to determine which patients had shorter stays. The Mann-Whitney test was 
followed by One-Way ANOVA to verify results using mathematical means. While 
numbers obtained from different comparisons of means methods were not expected to 
match, end results should. More detailed Mann-Whitney results, including a figure, are 
available in Appendix H. 
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Total for All Hospitals 
Table 99. Relationship Between Utilization of CHF Order Sets and LOS, Mann-Whitney 
Basic Statistics – All Hospitals 
 
Mann-Whitney Parameter Results 
Total N 10938 
Mann-Whitney U 3,472,652 
Wilcoxcon W 3,731,492 
Test Statistic 3,472,652 
Standard Error 81,223.765 
Pearson Chi-Squared Significance p = 0.013 
 
Table 100. Relationship Between Utilization of CHF Order Sets and LOS, Mann-
Whitney Outcomes – All Hospitals 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 10219 5489.18  
Experimental 719 5189.84  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
Table 101. One-Way ANOVA for CHF LOS Case – Description View 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
0 10219 5.46 6.473 .064 5.33 5.58 0 149 
1 719 4.75 4.827 .180 4.39 5.10 0 86 
Total 10938 5.41 6.380 .061 5.29 5.53 0 149 
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Table 102. One-Way ANOVA for CHF LOS Case – Basic View 
 
 Sum of 
Squares df 
Mean  
Square F Sig. 
 
Between Groups 
 
339.786 
 
1 
 
339.786 
 
8.352 
 
0.004 
Within Groups 444894.012 10936 40.682   
Total 445233.798 10937    
 
CHF Case 4 Findings 
     The Mann-Whitney and One-Way ANOVA tests both revealed that experimental 
group patients who received medications via order sets had shorter lengths of stay, with 
statistically significant results, rejecting the null hypothesis. Therefore, there is a clear 
benefit to utilization of the order sets to treat CHF, measuring in terms of the length of 
hospital stay health outcomes. This outcome would, in turn, lead to financial savings 
from lower expenses. Results from One-Way ANOVA included a significant difference 
between LOS for CHF patients who received medications via order sets and those who 
has them prescribed via custom orders, F (1,10936) = 8.352, P < 0.05; the mean length of 
stay was lower for patients who received medications via order sets. 
Case 5: Relationship Between Utilization of Order Sets and Patient Complications 
Represented by Charlson Comorbidity Index (Independent vs. Dependent Variables) 
     This case is similar to Case 4 in terms of statistical methods employed to perform 
calculations; the only difference was the dependent variable – CCI. More detailed Mann-
Whitney results, including a figure, are available in Appendix H. 
 
 
184 
 
 
 
Total for All Hospitals 
Table 103. Relationship Between Utilization of CHF Order Sets and CCI, Mann-Whitney 
Basic Statistics – All Hospitals 
 
Mann-Whitney Parameter Results 
Total N 7757 
Mann-Whitney U 1,840,535.500 
Wilcoxcon W 1,978,610.500 
Test Statistic 1,840,535.500 
Standard Error 48,189.915 
Pearson Chi-Squared Significance p = 0.23 
 
Table 104. Relationship Between Utilization of CHF Order Sets and CCI, Mann-Whitney 
Outcomes – All Hospitals 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 7232 3887  
Experimental 525 3768.78  
 
Decision from the test of hypothesis: Reject null hypothesis 
 
Table 105. One-Way ANOVA for CHF CCI Case – Description View 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
0 7232 3.68 1.795 .021 3.64 3.73 2 15 
1 525 3.64 1.885 .082 3.48 3.80 2 16 
Total 7757 3.68 1.801 .020 3.64 3.72 2 16 
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Table 106. One-Way ANOVA for CHF CCI Case – Basic View 
 
 Sum of 
Squares df 
Mean  
Square F Sig. 
 
Between Groups 
 
0.967 
 
1 
 
0.967 
 
0.298 
 
0.585 
Within Groups 25148.893 7755 3.243   
Total 25149.861 7756    
 
CHF Case 5 Findings 
     Due to missing values for CCI available in EDW, results are statistically insignificant 
and the null hypothesis is retained. This does not necessarily mean that CHF patients do 
not benefit from order sets in terms of complications. Results only indicate insufficient 
data to complete the study. 
Case 6: Study of Several Independent Variables Affecting Dependent Variables. 
Table 107. CHF Readmissions as Affected by Order Set Indicator, Patient Age, Patient 
Sex, and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.489 0.925 
Patient Age 0.560 0.999 
Patient Sex 0.125 0.914 
Patient Race 0.134 1.023 
Constant 0.000 0.215 
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Table 108. CHF Mortality as Affected by Order Set Indicator, Patient Age, Patient Sex, 
and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.030 1.866 
Patient Age 0.000 (p < 0.01) 1.037 
Patient Sex 0.410 1.098 
Patient Race 0.000 (p < 0.01) 1.137 
Constant 0.000 0.000 
 
CHF Case 6 Findings 
     None of the factors – patient age, sex, race, and order set utilization - showed 
statistical significance in influencing readmissions, as evident from the P > 0.05 
measurements under all categories in Table 107. This follows lack of statistical 
significance for all CHF cases involving readmissions. 
     Patient age and race had the most influence on mortality from CHF, followed by 
utilization of the order sets. All three factors were statistically significant. Utilization of 
the order sets had the highest odds ratio among all statistically significant factors, 
indicating a powerful effect on the outcome. Patient sex had no influence on mortality 
from CHF.  
CHF Study Descriptive Statistics 
     The number of participants broken down by race, sex, and utilization of the order sets 
is available in Appendix H. 
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AMI Study Results 
Case 1: Relationship Between Utilization of Order Sets and Mortality (Independent vs. 
Dependent variables) – Total and Split by Hospital, Hospice Patients Excluded from 
Study 
Table 109. AMI Mortality: Total for TRIN and GSHP – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 53 0     
Mortality = no 1183 32     
Percent 
(Mortality=yes) 
/ total 
 
 
4.4% 
 
 
N/A 
 
1.432 (p= 
0.231) 
 
 
0.641 
 
 
0.251 
 
72375466.14 
[0 and N/A] 
 
Table 110. AMI Mortality: TRIN Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 20 0    
Mortality = no 370 13    
Percent 
(Mortality=yes) / 
total 
 
 
5.1% 
 
 
N/A 
 
0.701 (p= 
0.402) 
 
 
1.000 
 
 
0.511 
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Table 111. AMI Mortality: GSHP Hospital Calculations – Hospice Excluded 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 33 0    
Mortality = no 813 19    
Percent 
(Mortality=yes) / 
total 
 
 
3.9% 
 
 
N/A 
 
0.771 (p= 
0.380) 
 
 
1.000 
 
 
0.474 
 
AMI Case 1 Findings 
     The AMI studies were conducted similarly to the pneumonia and CHF studies, starting 
with mortality and readmissions examinations, followed by length of stay and 
complications. Case 1 excluded hospice patients. N/A indicates lack of ratio calculation 
due to zero cases of mortality within the experimental group of patients.  
     Even when totals of the two qualified hospitals were utilized, no significant results 
were obtained due to small population size and, in some cases, lack of expired patients in 
the experimental group. The experimental group had no expired patients. This could 
indicate potential benefit of the order sets despite small samples, but because data is not 
available to produce statistically significant results, this statement cannot be 
quantitatively supported. Odds ratios are unusually high due to zero expired patients, and 
these results should be disregarded as invalid calculations. There is no mortality case 
available for AMI; larger data sets would be necessary to produce statistically significant 
results. 
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Case 2: Relationship Between Utilization of Order Sets and Mortality (Independent vs. 
Dependent Variables) – Total and Split by Hospital, Hospice Patients as Mortality=0 
(no) 
Table 112. AMI Mortality: Total for TRIN and GSHP – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Mortality = yes 53 0     
Mortality = no 1207 32     
Percent 
(Mortality=yes) 
/ total 
 
 
4.2% 
 
 
N/A 
 
1.404 (p= 
0.236 
 
 
0.639 
 
 
0.257 
 
70936340.51 
[0 and N/A] 
 
Table 113. AMI Mortality: TRIN Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 20 0    
Mortality = no 375 13    
Percent 
(Mortality=yes) / 
total 
 
 
5% 
 
 
N/A 
 
0.692 (p= 
0.405) 
 
 
1.000 
 
 
0.515 
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Table 114. AMI Mortality: GSHP Hospital Calculations – Hospice Mortality = 0 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Mortality = yes 33 0    
Mortality = no 832 19    
Percent 
(Mortality=yes) / 
total 
 
 
3.8% 
 
 
N/A 
 
0.753 (p= 
0.386) 
 
 
1.000 
 
 
0.482 
 
AMI Case 2 Findings 
     The only difference between Studies 1 and 2 is how hospice patients are counted. Case 
2 assumed including hospice patients with actual results reported – no expiration. This 
case still failed to produce statistically significant results, so there is no AMI mortality 
study that could be used to reach valid conclusions.  
Case 3: Relationship Between Utilization of Order Sets and Readmission (Independent 
vs. Dependent Variables) – Total and Split by Hospital 
Table 115. AMI Readmissions: Total for TRIN and GSHP Combined 
 
Outcomes 
and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
EXP (B) – 
Binary 
Logistic 
Regression  
Readmission 
= yes 
132 3     
Readmission 
= no 
893 28     
Percent 
(Readmission 
=yes) / total 
 
 
12.9% 
 
 
9.7% 
 
0.276 (p= 
0.599) 
 
 
0.788 
 
 
0.425 
 
70936340.51 
[0 and N/A] 
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Table 116. AMI Readmissions: TRIN Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 46 1    
Readmission = no 349 12    
Percent 
(Readmission 
=yes) / total 
 
 
11.6% 
 
 
7.7% 
 
0.193 (p= 
0.660) 
 
 
1.000 
 
 
0.546 
 
Table 117. AMI Readmissions: GSHP Hospital Calculations 
 
Outcomes and 
Measures 
Control 
Group 
Experi-
mental 
Group 
Pearson 
Chi-
Squared 
(χ2) 
2-sided 
Fisher’s 
Exact 
1-sided 
Fisher’s 
Exact 
Readmission = yes 86 2    
Readmission = no 544 16    
Percent 
(Readmission 
=yes) / total 
 
 
6% 
 
 
11.1% 
 
0.096 (p= 
0.756) 
 
 
1.000 
 
 
0.549 
 
AMI Case 3 Findings 
     While this case of readmissions data looks encouraging in terms of producing 
favorable results in support of the order sets and evidence based AMI treatment practices, 
the population size was too small to produce statistically significant results, so there is no 
study for AMI readmissions. Physicians should be encouraged to apply evidence-based 
practices to treat AMI patients more frequently, so valid results could be produced for 
AMI. 
192 
 
 
 
Case 4: Relationship Between Utilization of Order Sets and Length of Stay (Independent 
vs. Dependent Variables) 
     The Mann-Whitney test of independent samples examined the null hypothesis and 
produced results in the form of comparison of means, so the length of stay could be 
compared among control and experimental groups. The Mann-Whitney test was followed 
by the One-Way ANOVA test to confirm results through comparison of mathematical 
means among the two groups. Detailed data and a figure are available in Appendix I. 
Total for All Hospitals 
Table 118. Relationship Between Utilization of AMI Order Sets and LOS, Mann-
Whitney Basic Statistics – All Hospitals 
 
Mann-Whitney Parameter Results 
Total N 1292 
Mann-Whitney U 20,815.500 
Wilcoxcon W 21,343.500 
Test Statistic 20,815.500 
Standard Error 2,061.172 
Pearson Chi-Squared Significance p = 0.750 
 
Table 119. Relationship Between Utilization of AMI Order Sets and LOS, Mann-
Whitney Outcomes – All Hospitals 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 1260 645.98  
Experimental 32 666.98  
 
Decision from the test of hypothesis: Reject null hypothesis 
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Table 120. One-Way ANOVA for AMI LOS Case – Description View 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
0 1260 4.73 4.434 .125 4.48 4.97 0 46 
1 32 5.16 4.304 .761 3.60 6.71 0 15 
Total 1292 4.74 4.429 .123 4.50 4.98 0 46 
 
 
Table 121. One-Way ANOVA for AMI LOS Case – Basic View 
 
 Sum of 
Squares df 
Mean  
Square F Sig. 
 
Between Groups 
 
5.751 
 
1 
 
5.751 
 
0.293 
 
0.588 
Within Groups 25322.301 1290 19.630   
Total 25328.052 1291    
 
AMI Case 4 Findings 
     As with the previous three AMI studies, population sizes were too small to produce 
statistically significant results – the reason for confirming the null hypothesis. The mean 
length of stay for AMI patients was also longer when order sets were applied to prescribe 
medications – not a good sign, but any swings are possible when dealing with small 
population sizes. Further discussion would only be speculative based on insufficient data. 
Overall, there was no significant difference between LOS for the AMI patients who 
received medications via order sets and those who had them prescribed via custom orders 
in Case 4. 
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Case 5: Relationship Between Utilization of Order Sets and Patient Complications 
Represented by Charlson Comorbidity Index (Independent vs. Dependent Variables) 
     The relationship between utilization of the AMI order sets and patient complications 
were studied using the Mann-Whitney test of independent samples, followed by One-
Way ANOVA to confirm results using mathematical comparison of CCI means. Detailed 
data and a figure are available in Appendix I. 
Total for All Hospitals 
Table 122. Relationship Between Utilization of AMI Order Sets and CCI, Mann-Whitney 
Basic Statistics – All Hospitals 
 
Mann-Whitney Parameter Results 
Total N 1256 
Mann-Whitney U 17,708.500 
Wilcoxcon W 18,236.500 
Test Statistic 17,708.500 
Standard Error 1,960.795 
Pearson Chi-Squared Significance p = 0.339 
 
Table 123. Relationship Between Utilization of AMI Order Sets and CCI, Mann-Whitney 
Outcomes – All Hospitals 
 
Patient Group Total Group 
Population (N) 
Mean Group 
Rank 
Frequency 
Distribution Skew 
(Benefit Indicator) 
Control 1224 630.03  
Experimental 32 569.89  
 
Decision from the test of hypothesis: Reject null hypothesis 
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Table 124. One-Way ANOVA for AMI CCI Case – Description View 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
0 1224 2.78 1.957 .056 2.67 2.89 1 13 
1 32 2.34 1.494 .264 1.81 2.88 1 7 
Total 1256 2.76 1.947 .055 2.66 2.87 1 13 
 
Table 125. One-Way ANOVA for AMI CCI Case – Basic View 
 
 Sum of 
Squares df 
Mean  
Square F Sig. 
 
Between Groups 
 
5.808 
 
1 
 
5.808 
 
1.533 
 
0.216 
Within Groups 4752.434 1254 3.790   
Total 4758.242 1255    
 
AMI Case 5 Findings 
     While comparisons of means showed favorable results for the order sets, indicating 
fewer complications for the experimental group of patients, results lacked statistical 
significance due to small populations; hence the null hypothesis is sustained. More data is 
necessary to continue this investigation of the relationship between utilization of 
evidence based practices to treat AMI and patient complications. Overall, there was no 
significant difference between CCI for the AMI patients who received medications via 
order sets and those who had them prescribed via custom orders. 
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Case 6: Study of Several Independent Variables Affecting Dependent Variables 
Table 126. AMI Readmissions as Affected by Order Set Indicator, Patient Age, Patient 
Sex, and Patient Race 
 
Independent Variable Significance, 95% conf. 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.565 1.428 
Patient Age 0.001 1.023 
Patient Sex 0.293 0.814 
Patient Race 0.134 1.078 
Constant 0.000 0.009 
 
Table 127. AMI Mortality as Affected by Order Set Indicator, Patient Age, Patient Sex, 
and Patient Race 
 
Independent Variable Significance, 95% conf 
level 
Odds Ratio EXP(B) 
Order Set Indicator 
(categorical – yes/no) 
0.998 62163791.91 
Patient Age 0.000 (p < 0.01) 1.057 
Patient Sex 0.396 1.287 
Patient Race 0.795 1.022 
Constant 0.997 0.000 
 
AMI Case 6 Findings 
     Only patient age was statistically significant in predicting mortality and readmissions 
among AMI patients. However, there is possibility that other variables could have played 
greater roles if population size was greater. Therefore, results of this case are not 
statistically significant, just like the rest of AMI studies – due to insufficient population 
size.  
AMI Study Descriptive Statistics 
     The number of participants broken down by race, sex, and utilization of the order sets 
is available in Appendix I. 
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Answers to Research Questions 
VTE Order Sets 
     Question 1: Do VTE/DVT medication order sets help prevent occurrence of acute 
VTE among adult non-surgical patients? 
     Answer to Question 1: Yes, evidence based VTE/DVT medication order sets help 
prevent occurrence of VTE among adult non-surgical patients. Without accounting for 
patient sex, both study populations of IMMC and LGH teaching hospitals with significant 
utilization of VTE order sets showed reduced percentage of VTE rates among 
experimental group patients, with IMMC odds ratio of 1.566 [1.354 and 1.812 at 95% 
confidence level] and LGH odds ratio of 1.205 [1.043 and 1.393 at 95% confidence 
level].  
     Hypothesis 1 (null): VTE/DVT medication order sets do not help prevent occurrence 
of acute VTE among adult non-surgical patients. 
     Hypothesis 1 Statement: Hypothesis 1 was rejected by the study. 
     Question 2: Do VTE/DVT medication order sets help prevent occurrence of acute 
VTE among adult surgical patients? 
     Answer to Question 2: No, evidence based VTE/DVT medication order sets did not 
help prevent occurrence of VTE among adult non-surgical patients. Without accounting 
for patient sex, both IMMC and LGH teaching hospitals with significant utilization of 
VTE order sets showed an increased percentage of VTE rates among experimental group 
patients, with IMMC odds ratio of 0.670 [0.452 and 0.992 at 95% confidence level] and 
LGH odds ratio of 0.497 [0.383 and 0.645 at 95% confidence level]. The increase in VTE 
rates could be attributed to (1) factors unrelated to order sets, (2) danger of the VTE order 
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sets when administered to surgical patients, (3) higher comorbidity rate for these patients, 
as evidenced from other parts of the VTE/DVT study. 
     Hypothesis 2 (null): VTE/DVT medication order sets do not help to prevent 
occurrence of acute VTE among adult surgical patients. 
     Hypothesis 2 Statement: Hypothesis 2 was not rejected by the study. 
     Question 3: Does patient sex play a role in this study and alter answers to Questions 1 
and 2? 
     Answer to Question 3: No, patient sex does not introduce any variances to results of 
the study, with all surgical patients’ odds ratios held below 1 and all non-surgical 
patients’ odds ratios held above 1. 
     Hypothesis 3 (null): Patient sex does not make a difference in the relationship between 
utilization of the medication order sets to prevent VTE and occurrence of acute VTE. 
     Hypothesis 3 Statement: Hypothesis 3 was not rejected by the study. 
     Question 4: What effect does utilization of the VTE medication order sets have on the 
surgical patient complications index expressed as a calculated Charlson Comorbidity 
Index? 
     Answer to Question 4: VTE medication order sets had no significant effect on 
complications or did not show a strong relationship between ordering via sets and 
comorbidity. There was no significant difference in CCI between control and 
experimental surgical patients at both hospitals, as evident from ANOVA tests that took 
into account the complex relationship between order set utilization, VTE occurrence rate, 
and CCI. However, a Mann-Whitney evaluation of the direct relationship between order 
sets and CCI showed significant difference between the groups, with sicker patients in the 
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experimental group. The latter could explain longer lengths of stay for these patients. Due 
to these differences in results among various methods of research and outcomes, the best 
conclusion in this case is that ordering VTE medications via sets has no significant 
influence on CCI. 
     Hypothesis 4 (null): VTE medication order sets have no effect on surgical patient 
complications as expressed by the Charlson Comorbidity Index.  
     Hypothesis 4 Statement: Hypothesis 4 was not rejected by the ANOVA methods and 
rejected by the Mann-Whitney method. The former method took into account the more 
complex relationship between order sets, VTE occurrence rate, and CCI. Therefore, the 
conclusion is made based on the ANOVA outcomes. 
     Question 5: What effect does utilization of the VTE medication order sets have on 
non-surgical patient complications index expressed as a calculated Charlson Comorbidity 
Index? 
     Answer to Question 5: VTE medication order sets had no significant effect on 
complications or did not show a strong relationship between ordering via sets and 
comorbidity, according to the ANOVA tests that took into account the complex 
relationship between order sets, CCI, and VTE occurrence rates. There were significant 
differences in CCI for the IMMC and LGH non-surgical patients in the control and 
experimental groups (F (3,28271) = 94.297, P < 0.05 and F (3,38813) = 410.373, P < 
0.05 respectively for the two hospitals), but IMMC patients had fewer comorbidities, 
while LGH patients had greater comorbidities. Mixed ANOVA results failed to produce a 
clear outcome. The Mann-Whitney tests of the direct relationship between CCI and order 
sets, without control for the VTE occurrence rate, produced clear outcomes of higher 
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comorbidity among experimental group patients at both hospitals (mean rank of 14755 
for experimental group vs. mean rank of 13549 for the control group at IMMC and mean 
rank of 20802 for experimental group vs. a mean rank of 19003 for control group at 
LGH). Despite these clear Mann-Whitney results, there was a mix of outcomes between 
the two methods, so there was no significant effect of the VTE order sets on CCI overall 
among non-surgical patients. However, lower or higher comorbidity could serve as a side 
effect on length of stay and VTE occurrence, as sicker patients may have a tendency to 
remain in the hospital longer and acquire VTE at higher rates due to reasons unrelated to 
ordering medications via sets or in a custom way.  
     Hypothesis 5 (null): VTE medication order sets had no effect on non-surgical patient 
complications as expressed by the Charlson Comorbidity Index. 
     Hypothesis 5 Statement: Hypothesis 5 was not rejected by the ANOVA studies of the 
complex relationship between order sets, VTE rates, and CCI. Hypothesis 5 was rejected 
by the Mann-Whitney test of the direct relationship between VTE order sets and CCI. 
Since the ANOVA test was more comprehensive, the null hypothesis for CCI among 
non-surgical patients is not rejected.  
     Question 6: What effect does utilization of the VTE medication order sets have on the 
length of surgical patients’ hospital stays? 
     Answer to Question 6: There was a strong relationship between the medication 
ordering method and length of stay for surgical patients, but the length of stay was higher 
among experimental group patients, with P < 0.01. The outcome could be explained by 
(1) outside factors beyond the scope of this research, (2) higher comorbidity among 
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surgical patients, and (3) danger of applying order sets to administer VTE medications to 
surgical patients.  
     Hypothesis 6 (null): Utilization of the VTE medication order sets has no effect on the 
length of surgical patients’ hospital stays. 
     Hypothesis 6 Statement: Hypothesis 6 was rejected, but the mean length of stay was 
higher among experimental surgical patients (Mann-Whitney mean rank of 11537 for 
experimental group vs. 8265 for control group at LGH and mean rank of 6286 for 
experimental group vs. 4798 for control group at IMMC).  
     Question 7: What effect does utilization of the VTE medication order sets have on the 
length of non-surgical patients’ hospital stays? 
     Answer to Question 7: There was a strong relationship between the medication 
ordering method and length of stay for non-surgical patients, but results were mixed at P 
< 0.01. On average IMMC patients stayed longer, while LGH patients had shorter stays.  
     Hypothesis 7 (null): Utilization of the VTE medication order sets has no effect on the 
length of non-surgical patients’ hospital stays. 
     Hypothesis 7 Statement: Hypothesis 7 was rejected, but the mean length of stay was 
higher for experimental group non-surgical patients at LGH (Mann-Whitney mean rank 
of 31329 for experimental group vs. 27836 for control group) and lower for experimental 
group non-surgical patients at IMMC (mean rank of 20272 for experimental group vs. 
20589 for control group). Mixed results indicate failure to draw clear conclusions 
regarding benefits or disadvantages of ordering VTE medications via sets for non-
surgical patients, as evident by the length of stay health outcome.  
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     Question 8: Which among independent variables of order set utilization, patient age, 
patient sex, patient race, and surgery status has most influence on the independent 
variable of acute VTE? 
     Answer to Question 8: The variables of utilization of order sets, patient age, patient 
race, and surgery status had strong influence on the variable of acute VTE. The variable 
of patient sex had no significant effect on acute VTE. 
     Hypothesis 8 (null): None of the independent variables of order set utilization, patient 
age, patient sex, patient race, and surgery status has any effect on acute VTE, or all of 
these variables have equal influence on acute VTE. 
     Hypothesis 8 Statement: Hypothesis 8 was rejected by the study. 
Pneumonia Order Sets 
Question 1: Do pneumonia medication order sets help decrease mortality among 
pneumonia patients? 
     Answer to Question 1: Yes, utilization of the order sets for pneumonia medications 
produced lower mortality rates in both studies that excluded and included hospice 
patients, with the odds ratios of 1.79 [0.965 and 3.320 at 95% confidence level] in the 
latter study and 1.822 [0.983 and 3.380 at the 95% confidence level] in the former study. 
     Hypothesis 1 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and in-hospital mortality among 
pneumonia patients. 
     Hypothesis 1 Statement: Hypothesis 1 was rejected by the study. 
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     Question 2: Is there a difference in the relationship between utilization of the 
pneumonia medication order sets and in-hospital mortality when patients with a hospice 
discharge code are excluded from the study? 
     Answer to Question 2: No, there is no difference in the overall outcome. However, 
there are differences in mortality rates and odds ratios, which indicate that hospice 
patients have a tendency to influence results of the health outcomes.  
     Hypothesis 2 (null): There is no statistical difference in mortality health outcomes 
relative to utilization of the pneumonia medication order sets when hospice patients are 
excluded from the study. 
     Hypothesis 2 Statement: Hypothesis 2 was not rejected by the study.  
     Question 3: Do pneumonia medication order sets help prevent and/or decrease 30-day 
readmission rate among pneumonia patients? 
     Answer to Question 3: Yes, readmission rates among pneumonia patients in the 
experimental group were much lower, with the odds ratio of 1.362 [1.015 and 1.827at 
95% confidence level]. 
     Hypothesis 3 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and 30-day readmission rates among 
pneumonia patients. 
     Hypothesis 3 Statement: Hypothesis 3 was rejected by the study. 
     Question 4: Is there a statistical relationship between utilization of the pneumonia 
medication order sets and in-hospital length of stay? 
     Answer to Question 4: Yes, there is a statistical relationship between utilization of 
pneumonia order sets and length of stay, with the Mann-Whitney mean rank lower for 
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experimental group patients (2343 for experimental group vs. 2568 for control group), 
indicating the benefit of pneumonia order sets in reducing the length of hospital stay.  
     Hypothesis 4 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and length of stay among pneumonia 
patients. 
     Hypothesis 4 Statement: Hypothesis 4 was rejected by the study. 
     Question 5: Is there a statistical relationship between utilization of the pneumonia 
medication order sets and patient complications represented by the Charlson Comorbidity 
Index? 
     Answer to Question 5: Yes, there is a statistical relationship between utilization of 
pneumonia medication order sets and the rate of complications/comorbidity. The Mann-
Whitney rank for experimental group was lower (2353 vs. 2509), indicating potential 
benefit of the order sets as evident by the CCI health outcome. However, lower CCI 
could also mean that experimental group patients were not as sick as control group 
patients, leading to shorter hospital stays among the latter group. 
     Hypothesis 5 (null): There is no statistically significant relationship between 
utilization of pneumonia medication order sets and patient complications. 
     Hypothesis 5 Statement: Hypothesis 5 was rejected by the study. 
     Question 6: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
30-day hospital readmission among pneumonia patients? 
     Answer to Question 6: Patient age, sex, and race were more significant in predicting 
readmission rate among pneumonia patients than utilization of the order sets. 
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     Hypothesis 6 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict 30-day hospital readmission among 
pneumonia patients.  
     Hypothesis 6 Statement: Hypothesis 6 was rejected by the study. 
     Question 7: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
in-hospital mortality among pneumonia patients? 
     Answer to Question 7: Utilization of the order sets, patient age, and patient race were 
significant in predicting mortality among pneumonia patients. Patient sex was not 
significant. 
     Hypothesis 7 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict in-hospital mortality among pneumonia 
patients. 
     Hypothesis 7 Statement: Hypothesis 7 was rejected by the study. 
CHF Order Sets 
     Question 1: Do CHF medication order sets help decrease mortality among CHF 
patients? 
     Answer to Question 1: Yes, utilization of the order sets for CHF medications produced 
lower mortality rates in both studies that excluded and included hospice patients, with the 
odds ratios of 1.854 [1.059 and 3.244 at 95% confidence level] in the latter study and 
1.822 [0.983 and 3.380 at the 95% confidence level] in the former study. 
     Hypothesis 1 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and in-hospital mortality among CHF patients. 
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     Hypothesis 1 Statement: Hypothesis 1 was rejected by the study. 
     Question 2: Is there a difference in the relationship between utilization of the CHF 
medication order sets and in-hospital mortality when patients with a hospice discharge 
code are excluded from the study? 
     Answer to Question 2: No, the differences between mortality cases where hospice 
patients were included and excluded were subtle. 
     Hypothesis 2 (null): There is no statistical difference in mortality health outcomes 
relative to utilization of the CHF medication order sets when hospice patients are 
excluded from the study. 
     Hypothesis 2 Statement: Hypothesis 2 was not rejected by the study. 
     Question 3: Do CHF medication order sets help prevent and/or decrease 30-day 
readmission rate among CHF patients? 
     Answer to Question 3: There is insufficient data to answer this question (p = 0.417) 
for the total of all hospitals participating in the study. An increase in CHF order sets 
utilization is necessary in order to conduct this study. 
     Hypothesis 3 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and 30-day readmission rates among CHF 
patients. 
     Hypothesis 3 Statement: Hypothesis 3 was not rejected by the study.  
     Question 4: Is there a statistical relationship between utilization of the CHF 
medication order sets and in-hospital length of stay? 
     Answer to Question 4: Yes, there is a statistical relationship between application of 
the order sets to administer medications to CHF patients and hospital length of stay. The 
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Mann-Whitney mean rank for the experimental group is lower than the mean rank for the 
control group (5189 vs. 5489), indicating that patients who received CHF medications via 
sets had shorter hospital stays. This fact could be attributed to both application of the sets 
and lower comorbidity among experimental group patients, in terms of comorbidity 
serving as the rate of pre-existing health conditions.  
     Hypothesis 4 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and length of stay among CHF patients. 
     Hypothesis 4 Statement: Hypothesis 4 was rejected by the study. 
     Question 5: Is there a statistical relationship between utilization of the CHF 
medication order sets and complications quantified via Charlson Comorbidity Index? 
     Answer to Question 5: There is insufficient data to answer this question (p = 0.23). 
However, comorbidity was lower for the experimental group (3768 Mann-Whitney mean 
rank) compared to the control group (mean rank 3887). This outcome could partially 
explain shorter hospital stays by experimental group patients, if CCI is assumed to serve 
as the rate of pre-existing health conditions. 
     Hypothesis 5 (null): There is no statistically significant relationship between 
utilization of CHF medication order sets and complications among CHF patients. 
     Hypothesis 5 Statement: Hypothesis 5 was not rejected by the study. 
     Question 6: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
30-day hospital readmission among CHF patients? 
     Answer to Question 6: There was insufficient data to answer this question. 
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     Hypothesis 6 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict 30-day hospital readmission among CHF 
patients.  
     Hypothesis 6 Statement: Hypothesis 6 was not rejected by the study. 
     Question 7: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
in-hospital mortality among CHF patients? 
     Answer to Question 7: Order set utilization, patient age, and patient race had strong 
influence on mortality – with patient age and race being the strongest factors among the 
three. Patient sex made no difference on mortality. 
     Hypothesis 7 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict in-hospital mortality among CHF patients. 
     Hypothesis 7 Statement: Hypothesis 7 was rejected by the study. 
AMI Order Sets 
     Question 1: Do AMI medication order sets help decrease mortality among AMI 
patients? 
     Answer to Question 1: There was insufficient data to answer this question. Significant 
increase in AMI order set utilization is necessary in order to validate answers raised in 
the study. 
     Hypothesis 1 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and in-hospital mortality among AMI patients. 
     Hypothesis 1 Statement: Hypothesis 1 was not rejected by the study. 
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     Question 2: Is there a difference in the relationship between utilization of the AMI 
medication order sets and in-hospital mortality when patients with hospice discharge 
code are excluded from the study? 
     Answer to Question 2: There was insufficient data to answer this question. 
     Hypothesis 2 (null): There is no statistical difference in mortality health outcomes 
relative to utilization of the AMI medication order sets when hospice patients are 
excluded from the study. 
     Hypothesis 2 Statement: Hypothesis 2 was not rejected by the study. 
     Question 3: Do AMI medication order sets help prevent and/or decrease 30-day 
readmission rate among AMI patients? 
     Answer to Question 3: There was insufficient data to answer this question. 
     Hypothesis 3 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and 30-day readmission rates among AMI 
patients. 
     Hypothesis 3 Statement: Hypothesis 3 was not rejected by the study. 
     Question 4: Is there a statistical relationship between utilization of the AMI 
medication order sets and in-hospital length of stay? 
     Answer to Question 4: There was insufficient data to answer this question. 
     Hypothesis 4 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and length of stay among AMI patients. 
     Hypothesis 4 Statement: Hypothesis 4 was not rejected by the study. 
     Question 5: Is there a statistical relationship between utilization of the AMI 
medication order sets and complications quantified via Charlson Comorbidity Index? 
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     Answer to Question 5: There was insufficient data to answer this question. 
     Hypothesis 5 (null): There is no statistically significant relationship between 
utilization of AMI medication order sets and complications among AMI patients. 
     Hypothesis 5 Statement: Hypothesis 5 was not rejected by the study. 
     Question 6: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
30-day hospital readmission among AMI patients? 
     Answer to Question 6: There was insufficient data to answer this question. 
     Hypothesis 6 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict 30-day hospital readmission among AMI 
patients.  
     Hypothesis 6 Statement: Hypothesis 6 was not rejected by the study. 
     Question 7: Among independent variables of the order set utilization, patient age, 
patient sex, and patient race – which have the most influence on the dependent variable of 
in-hospital mortality among AMI patients? 
     Answer to Question 7: There was insufficient data to answer this question. 
     Hypothesis 7 (null): None of the independent variables of order set utilization, patient 
age, patient sex, and patient race can predict in-hospital mortality among AMI patients. 
     Hypothesis 7 Statement: Hypothesis 7 was not rejected by the study. 
Summary 
     All studies for the VTE, pneumonia, CHF, and AMI suffered from low utilization of 
order sets and subsequently low data samples within experimental groups. Among the 
four patient conditions, VTE case offered the best opportunity to conduct focused 
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categorized studies by hospital and patient sex. The latter studies revealed no significant 
differences, although a follow-up study of the male patients receiving treatment via VTE 
order sets was recommended. Lack of significant differences from the more focused 
studies benefitting from greater granularity of data points to the overall validity of results 
in all cases where statistical significance was achieved without categorization of data by 
patient sex, hospital procedure type, and treatment facility.  
     Among the four patient conditions, only three – VTE, pneumonia, and CHF – 
produced statistically significant results. Within VTE study, there was a clear benefit of 
the order sets in prevention of occurrence of acute VTE, while the length of hospital stay 
and readmissions cases were either inconclusive or pointed to potential negative effect(s) 
of using order sets to prescribe VTE medications. The latter effects could have multiple 
explanations, require narrower follow-up studies, and are further explained in Chapter 5. 
Pneumonia study was the most successful of all four, showing benefits of the order sets 
as measured by all four health outcomes: mortality, readmissions, complications, and 
length of stay. While CHF study failed to deliver conclusive results in the complications 
and readmissions categories, its positive mortality outcome alone has the potential of 
saving many lives. Discussion of the health outcomes continues in Chapter 5. 
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Chapter 5 
Conclusions, Implications, Recommendations, and Summary 
 
Conclusions 
Introduction 
     Despite numerous barriers and limitations to conducting this order set study, a number 
of positive outcomes not only provides clear conclusions leading to calls for increased 
utilization of the order sets in clinical settings but also builds foundational ground for 
follow-up investigations supported by physicians. The latter support could come from 
quantitative evidence behind conclusions made in this study. Such support could lead to 
more focused experimental clinical trials with higher percentages of order set utilization 
and subsequently larger data samples within experimental groups of patients. Therefore, 
results of this study are foundational in nature and expected to play a motivational role in 
encouraging follow-ups.  
     All studies employed complex and varied statistical methods to explore quantitatively 
benefits of the order sets as expressed by patient health outcomes. This complexity and 
barriers outlined in the Research Proposal led to a smaller than expected set of clear 
results indicating the benefit, or the lack of benefit, for order sets. One of the barriers was 
the small percentage of orders placed via pre-defined CPOE medication sets, leading to 
small data samples in the experimental patient groups and consequently to statistically 
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insignificant or somewhat inconclusive results. Another barrier was lack of the healthcare 
industry standard for measuring patient complications as outcome, as opposed to 
experimental study pre-qualification (pre-existing condition). This barrier led to selection 
of a controversial method of utilizing Charlson Comorbidity Index that can be interpreted 
in conflicting ways: as explanation of pre-existing health conditions of the patient prior to 
hospital admission or as a health outcome indicating complication as a result of current 
hospital stay. The ambiguity is due to comorbidity being measured and recorded once as 
a patient discharge task. Thus, no statistical method can derive the actual relationship 
between comorbidity recorded in CPOE and the actual studied patient condition. 
Therefore, conclusions of this study should account for the dual explanations of the 
results, taking on both possible outcomes from CCI measurements and calculations. 
     Another barrier was a lack of granularity of the data contained in CPOE, leading to an 
inability to explain cause and effect relationships for each patient condition, i.e. since 
chronic VTE patients were excluded from the study, none of the subjects was admitted 
with VTE condition, so procedures and medications unrelated to VTE were administered 
to the patient between the times of admission and discharge, hindering direct cause-effect 
relationship between application of the VTE medication order set and acute VTE. This 
information on events altering the relationship, while generally available in CPOE, 
cannot in any reliable way be correctly linked to the study. The reason is that CPOE 
application is programmed with the record-keeping and sharing purposes in mind, rather 
than to help researchers examine sequences of events and causal relationships between 
them. While it is possible to extract data on patients and their clinical treatments, it is 
difficult to track clinical progress and numerous variables that contribute to outcomes. 
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The audience for this research must make certain assumptions or follow up with a 
narrow, focused study to explore other dependencies. The latter would be performed in a 
manual way through detailed investigation of each patient case, since CPOE has no 
ability to link results when information is pulled from the database via scripts.  
     Overall, there is a mix of clear conclusions constrained by the possible existence of 
health factors not included in this study and speculative conclusions that warrant follow-
up studies, especially in the areas where order sets show promise of improved quality of 
care. Opportunities for follow-up studies are discussed in detail in the Recommendations 
section of this chapter.  
VTE Study Conclusions 
     There are two clear conclusions resulting from the VTE study. First, order sets lead to 
decreased rates of acute VTE among non-surgical patients, with possible lower rates of 
improvement for the male patients, although sex differences did not prove to be 
significant among any groups of patients considered for the study. Second, among 
independent variables of race, sex, order set utilization, and surgical status – only sex was 
an insignificant factor in determining the odds of a non-surgical patient acquiring acute 
VTE condition. While some of these independent variables were previously known to 
influence acute VTE rates, combining order set application with them in a single group to 
determine their statistical significance in preventing VTE was first attempted as part of 
this study. The promise of decreasing VTE rates among eligible non-surgical patients is 
alone a huge argument for further exploration of the role of standardized care and 
prescriptions in hospitals. Moreover, the differences in the rate of acute VTE were 
hovering around 1% of the total patient population that included thousands of patients. 
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This means that order sets have the potential of hundreds of patients avoiding VTE 
through application of standardized care methods. Such gain would be invaluable in the 
process of quality improvement and would also lead to financial savings. However, the 
financial and health benefits are problematic because VTE is a by-product of a procedure 
or another condition that served as a chief complaint for admission to the hospital. So 
implications of acquiring a VTE may or may not have direct impact on patient outcomes, 
although no one wants to have a VTE regardless of the explanation of the overall health 
and financial outcomes. This is the area where the study lacks confidence and data to 
explore exactly how patients and hospitals may benefit from the health and financial 
perspectives, other than not acquiring harmful VTE condition.  
     Despite success in achieving lower acute VTE rates among non-surgical patients, the 
study failed to reveal conclusive results in reducing the length of hospital stay among 
eligible VTE patients. Moreover, in some cases VTE stay was longer. Why did patients 
who avoided VTE due to application of standardized treatment sets stay longer? One 
explanation is another factor unaccounted for in the VTE study that led to longer stay, 
most likely factors related to the patient’s chief complaint on admission to the hospital, or 
a side condition, such as infection or complication that happened during his/her stay at 
the hospital. Only detailed manual review of the health record could help explain the 
exact factors, which were outside of the scope of this order set study. However, Charlson 
Comorbidity Index, another inconclusive outcome of the study, could help explain longer 
or shorter stays in some instances. For example, non-surgical patients who received 
medications via VTE order sets at LGH had both higher CCI and longer hospital stays, 
despite lower VTE rates. This is where CCI could be treated as a pre-existing condition 
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index rather than health outcomes and explain that experimental group patients at LGH 
were sicker prior to admission, so despite avoiding VTE during their LGH hospital stay, 
they ended up with other problems as results of their pre-existing conditions and needed 
to remain in the hospital longer. 
     Results above are also inconclusive, because IMMC patients had longer stays despite 
lower CCI and avoiding VTE, indicating that CCI cannot always be put forth as an 
explanatory factor, or other issues not part of the study are still in play. If CCI is treated 
as a complications health outcome, its results in relation to the VTE study are 
inconclusive, with variances among hospitals for every group of patients. It is also 
important to highlight that surgical patients did not only fail to benefit from VTE order 
sets, but their outcomes were worse when sets were utilized. This means that clinicians 
must avoid order sets applied to surgical patients’ CPOE orders, or other stronger factors 
are in play that overshadow any VTE results. Either way, what is clear is that surgical 
patients do not benefit from VTE order sets. As far as financial benefits go, while not 
included in the scope of this study, with complications and hospital stay outcomes 
showing inconclusive results, it would be difficult to use the VTE order set study to argue 
for cost of care savings.  
Pneumonia Study Conclusions 
     Unlike outcomes of the VTE study, the vast majority of the pneumonia cases showed 
clear results that encourage utilization of the order sets to treat pneumonia patients. First, 
application of the order sets led to lower mortality from pneumonia. Exactly how much 
mortality was lowered depended on the inclusion or exclusion of the patients discharged 
to hospice care. While outside of the scope of this study, factors about hospice patients in 
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relation to the pneumonia study affect results, although not to the degree of changing the 
overall mortality outcome. Pneumonia outcomes from utilizing order sets remain positive 
and indicative of the order sets benefit regardless of the inclusion of the hospice patients 
and resulting changes in numbers. With hospice patients excluded from the study, the 
difference in mortality between experimental and control groups was within the 1% to 
5% range. With hospice patients included as 0 mortality (since it was not known for how 
long these patients survived once they were transferred to hospice care, only that they 
were alive at the time of discharge), the mortality difference between control and 
experimental groups increased significantly for some hospitals, up to 12%. But, even if it 
were assumed in the 1% to 5% range, there was a survival benefit for dozens of patients 
across the system annually. If order sets were applied industry-wide, this evidence-based 
clinical innovation could result in thousands of saved lives. 
     The length of stay for experimental pneumonia patients was shorter, with a mean rank 
of roughly 0.5 days difference. This difference could lead to lower cost of care. However, 
the conclusive result for lower CCI among experimental patients could somewhat 
diminish results of the length of stay study, or support it depending on the exact 
interpretation of CCI. One interpretation states that pneumonia patients in the 
experimental group had a lower rate of pre-existing conditions, i.e. experimental group 
contained healthier patients, thus arguing that shorter length of stay resulted from fewer 
pre-existing health conditions and not application of pneumonia order sets. However, if 
CCI is treated as a complications index at the time of discharge, the argument changes to 
the dual benefit of pneumonia order sets expressed by both length of stay and 
complications outcomes. Reality is likely somewhere in between. This was not a 
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controlled study with assigned categories of patients by their pre-existing conditions, so 
the argument for selection of the healthier patients to join experimental group would be 
invalid. The groups contained a mix of patients with varied pre-existing conditions. 
     Results of the 30-day readmission quality study indicated a much lower rate of 
readmissions among experimental patients. The difference approached 30% (14.7% for 
the control group versus 10.8% for the experimental group). This could lead to dozens of 
patients across the system not having to go through another hospital experience, in 
addition to obvious financial savings for hospitals (readmissions with the same conditions 
within 30-day period are often not reimbursed by insurance companies). 
     Not having an answer to the CCI categorization question, conclusions must be drawn 
based on available statistics, as follows: application of pneumonia order sets to treat 
eligible patients leads to lower mortality, shorter length of stay, lower rate of 
complications, and fewer readmissions. The only problem with the data sample used for 
the study was its small size, which led to an inability to further categorize patients by sex, 
treatment facility, and pneumonia type (community acquired versus nosocomial) - due to 
risk of obtaining statistically insignificant results. 
     Comparison tests among independent variables influencing readmissions showed 
greatest significance by age, sex, and race and lower significance of the order sets when 
compared to the former three factors. However, order sets, age, and, to a lesser degree, 
approaching significance, race showed strong influence on mortality from pneumonia. In 
this case, sex showed no role, while the order set indicator was significant. The 
importance of this comparison study was that order sets were not part of any past study of 
the factors influencing mortality and readmissions among pneumonia patients. 
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CHF Study Conclusions 
     As with the pneumonia study, small data samples resulting from low utilization of the 
order sets at Advocate’s hospitals affected outcomes, including an inability to categorize 
patients by cause of CHF, sex, and treatment facility. In the CHF case, data samples were 
even smaller compared to pneumonia, and this small size disqualified readmissions, 
which resulted in a Pearson Chi-Squared over 0.05. For the remaining studies, mortality 
among experimental patients was roughly half compared to the control group, with no 
significant differences accounted for the discharge reason factor. Accounting for small 
data samples, the difference translates to about a dozen saved lives for the five-year span 
system-wide – a small difference that could gain momentum if achieved across all 
hospitals nationwide. Even with such small actual gains, healthcare’s aim is to save lives 
one life at a time, so mortality outcomes indicates a strong non-tangible influence on 
patients’ and their families’ lives.  
     The length of stay was shorter for experimental group and CCI was lower – both 
positive outcomes with dual interpretation. If treated as a pre-existing condition index, 
lower CCI could indicate that shorter length of stay among experimental patients was due 
to an overall healthier patient population. Yet, it would be difficult to make this argument 
given that the study did not incorporate control for a pre-existing conditions component. 
If treated as a health outcome, lower CCI means fewer complications and shorter hospital 
stay for patients who were prescribed medications via CPOE order sets. The mean 
difference in LOS approached 1 day, leading to a promise of lower cost of care for CHF 
patients.  
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     Comparison of influence on mortality among several independent variables led to 
disqualification of sex - with race, age, and order set utilization exhibiting strong 
influence. As with other studies performed as part of this research, this is the first time 
when order set utilization was tested against mortality in a group of other factors that 
have been explored in the past.  
AMI Study Conclusions 
     AMI order set utilization across Advocate was too low to produce statistically 
significant results, invalidating outcomes of all of the AMI cases performed as part of this 
study. Therefore, while statistical analysis for AMI was reported as part of Chapter 4, 
there is no basis for drawing conclusions in this chapter. 
Implications 
     There are several important implications from this study that suggest effectiveness of 
evidence based medicine and introduction of new treatment standardization techniques to 
regular hospital procedure and medication ordering routines. Despite relatively small data 
samples in nearly all experimental groups for the four patient conditions studied as part of 
this order set research, there is sufficient evidence that application of the order sets could 
lead to better health outcomes, with encouragement for further collaboration between 
clinicians and researchers to increase utilization of the order sets and subsequently to 
increase experimental group data sample sizes to produce stronger evidence of patient 
outcomes. The VTE study suggests that numerous patients could escape the fate of being 
treated for VTE following non-surgical procedures in hospitals, although their length of 
stay is unlikely to shorten. Yet even the same length of stay without one serious VTE 
complication would improve quality of care, patient satisfaction, and potentially lower 
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cost of care outside of the length of stay cost category (i.e. materials, procedures, 
personnel, medications, equipment, etc.). Thus application of the VTE order sets 
potentially leads to tangible and non-tangible benefits for hospitals, patients, and insurers, 
as well as increase core measures compliance.  
     The pneumonia study produced highly favorable results, indicating potential for lower 
mortality, shorter stay, decreased chance of readmission, and fewer complications. The 
latter category is less well-defined, as it could indicate lower rate and/or significance of 
pre-existing health conditions prior to hospital admission, partially explaining shorter 
hospital stay. Yet, even a remote chance that some of the patients had shorter stays and 
fewer complications as a result of standardized treatment practices has significance for 
everyone involved in the process of caring for patients and paying the bills for care. At 
the very least, the possibility of these two factors being the direct result of application of 
the order sets warrants further studies in the order set and evidence based practices 
domains. Lower mortality from pneumonia alone represents a strong outcome of the 
study and introduction of evidence based techniques to treat typical cases of community 
acquired pneumonia. 
     Even though the combination of lower comorbidity and shorter hospital stay for CHF 
patients casts doubt on outcomes of the CHF study (healthier patients could have shorter 
CHF stay), lower mortality represents a sound outcome in favor of the order set 
utilization to treat typical CHF cases. Overall, while all of the categories studied 
produced no or negative results, there is strong evidence in a number of categories under 
VTE, pneumonia, and CHF conditions to (1) suggest further studies outlined in the 
Recommendations section, (2) encourage higher utilization of the order sets in hospitals 
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in order to provide more sufficient data to support further evidence based clinical 
practices research, and (3) make direct connection between application of the order sets 
in CPOE and patient outcomes to suggest increased utilization and/or introduction of 
evidence based practices to treat well-defined patient conditions as a quality 
improvement mechanism with benefits to patients, care givers, and insurers. Table 128 
summarizes specific outcomes of the study as they apply to the four conditions covered in 
the order set research. 
Table 128. Cumulative Patient Benefit Summary by Patient Conditions 
 
Condition Mortality Readmission Length of 
Stay 
Complications Acute 
VTE 
VTE N/A N/A No No Yes – non-
surgical 
No –
surgical 
Pneumonia Yes Yes Yes Yes N/A 
CHF Yes No Data Yes No data N/A 
AMI No data No Data No data No data N/A 
 
Recommendations 
     A number of recommendations arise from results and observations recorded as part of 
the research on effectiveness of the order sets to improve patient health outcomes. The 
most obvious recommendation seen through analysis of the data and summary of the 
research implications is the need to partner with physicians to increase the number of 
CPOE orders placed via sets. More orders for experimental groups would produce higher 
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data samples, increase statistical significance of the results or turn some currently 
insignificant categories into significant ones, and make an AMI study more viable. It 
would also make other order studies involving more order sets a reality – those studies 
that have not been selected for the purposes of this study due to smaller patient 
population sizes and lower CPOE set utilization. Some of the encouraging results from 
this research should be sufficient to convince physicians to support further data collection 
through their ordering actions.  
     A longer-term outcome would be to design CPOE applications in a manner that 
enables more detailed research into causal relationships between different fields, so 
researchers could draw parallels between patient case details, outcomes, discharges, and 
other records on a case-by-case basis. Today, CPOE applications offer strong logging and 
documentation capabilities, but have little in the way of making sense of the data for 
research purposes. These applications have simply been designed with operations and 
basic reporting functions in mind, not research. The alternative is a growing clinical 
decision making domain of healthcare information technology, where applications are 
specifically designed to support physicians based on existing knowledge structurally 
available in computer databases. Yet, these applications must also be designed with 
powerful data retrieval and analysis functions in mind, not mere search capabilities.  
     A few smaller and more focused studies would be helpful as follow-ups to this 
research, which utilized massive amounts of data to reach significance in statistical 
analysis over an extended period of time. First, each individual patient case or a small set 
of representative cases could be analyzed to determine pre-existing health conditions, 
relationships between these conditions and outcomes, other factors and/or complications 
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that influenced outcomes and discharge description, and other case specifics. Such 
research could help shed more light into the exact status of Charlson Comorbidity Index 
as an either pre-existing or complications barometer in the study, as well as determine 
how this research could be altered to include more mediating variables to increase 
accuracy of reporting (assuming that corresponding data is available in the EMR). 
Second, a researcher might be interested in pulling groups of records from both 
experimental and control groups by physician to analyze ordering patterns associated 
with each physician, and then further analyzing physician factors such as age, experience, 
and professional style to determine success patterns in patient care as those relate to 
ordering medications and patient outcomes. Third, it would be interesting to study 
physician demographics in terms of tendency to choose order sets and evidence based 
treatment methods as opposed to custom ordering. Ballard, Ogola, Fleming, Stauffer, 
Leonard, Khetan, and Yancy (2010) have already attempted such basic research as part of 
their CHF order set effectiveness study at Baylor Health. Expanding such research to 
larger data sets, other clinical settings, and other patient conditions could further extend 
accuracy and outreach of such study with the goal of properly targeting individual groups 
of physicians when working with them to increase buy-in and/or compliance. 
     Other examples of diversifying the study of order sets into smaller focused chunks 
could include categorizing patients by treatment facilities, sex, and specific types of 
illnesses. For example, teaching and community hospitals could be studied separately to 
determine whether residents make a difference when it comes to medication orders and 
outcomes. Other than VTE, validation of results by sex was impossible due to small 
experimental group data samples. Introducing this constraint to the study could be 
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valuable. Furthermore, illnesses covered in this study have various types, i.e. pneumonia 
could be categorized as either community acquired (majority of the patients) or 
nosocomial (hospital acquired). All of these examples require larger data samples that 
would be impossible to produce without collaboration with physicians to increase order 
set utilization in CPOE. 
     This study of order sets has only brushed upon relationships between independent 
variables such as set utilization, sex, age, and race. Larger data sets could afford greater 
flexibility to afford exploration of various age categories that might have differing 
characteristics in responding to order placed via sets. An example of a contributing factor 
related to age difference would be the risk level of applying bundled orders, as it applies 
to certain age ranges. Race as a general factor is only a starting point in initiating a 
specific study into each race, as differences in response rates to order sets could be 
significant among various races listed in the tables appended to this study. A study 
focused on application of different sets by race has the potential of benefitting patients 
with more precise treatment options designed for them based on their existing body of 
knowledge. 
     Healthcare industry research analysts are already working to develop new methods of 
measuring complications and introducing more effective methods compared to 
comorbidity index that leaves results open to interpretation. Development of such 
methods could lead to greater accuracy of the research outcomes for the variables of 
length of stay and complications – both are parts of the core compliance and key result 
measurements for the majority of the US hospitals.  
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     A study of delineation between treatment and prophylaxis classifications for VTE 
would be helpful in the process of documenting a clinical basis for parameter selection in 
this order set study. The 48-hours from the time of admission to VTE order delineation 
was chosen based on interviews with physicians rather than published research – the 
issue outlined in the Research Proposal. Quantitative study on VTE prophylaxis versus 
treatment could change results of this order set study based on adjustment in the in-scope 
data criteria.  
     Completion and general availability of the proposed research above could lead to 
redesign of this study to achieve greater accuracy with a fewer number of issues and 
limitations compared to the ones outlined in this study. Consequently, a more accurate 
study will lead to convincing outcomes prompting hospitals to mandate standardization 
of ordering practices for certain patient conditions in an effort to increase core measures 
and quality compliance. Moreover, quality and compliance principles could change based 
on the industry shift to greater treatment standardization and new levels of expectations 
of the patient care outcomes. Such a shift in standards is likely to be publicized at the 
level of consumer comprehension and further drive competition among healthcare 
organizations to achieve better outcomes at a lower cost. The market shift of this 
magnitude is in line with national efforts to improve quality of care, lower cost, and 
increase affordability and access to care.  
     Publication of research based on the knowledge offered by EMR/CPOE systems could 
prompt IT healthcare vendors to invest into expansion of software functionality to 
support data analysis efforts in addition to offering documentation and record sharing 
capability. Entering the clinical research arena at a new level would essentially drive 
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profits by offering hospitals more reasons to invest into software upgrades and new 
applications. Current versions of EMR and CPOE applications are not designed with 
clinical research in mind, and hospital IT departments do not configure these systems for 
research even if such capabilities could be explored at a custom level. It takes significant 
research to show promise and return on such investments, and results positively affecting 
health outcomes are good reasons to justify a new wave in healthcare technology 
investment. 
Summary 
     Efforts to employ evidence based medicine to treat well-researched patient conditions, 
improve core clinical measures compliance, and increase quality through process 
standardization have been ongoing for the past three decades. A majority of the studies 
culminated in breakthrough publications on reductions in the rate of adverse drug effects 
(ADE) through application of quality and process standardization routines, further 
advanced by healthcare information technologies such as automated VTE alerts 
developed at Brigham Women’s Hospital in Boston and documented by Kucher, Koo, 
Quiroz, Cooper, Paterno, Soukonnikov, and Goldhaber (2005). But no other technology 
breakthroughs advanced effectiveness of the evidence based medicine as much as 
medication order sets available to physicians via Computerized Physician Order Entry 
(CPOE) applications. These sets enable treatment process standardization for certain 
patient conditions via pre-defined order sets approved by multi-disciplinary professional 
committees typically consisting of physicians, nurses, and pharmacists. A number of 
organizations with fully implemented EMR and CPOE computer applications rolled out 
hundreds of order sets that are widely utilized by physicians. However, few clinical 
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studies have been completed that empirically explore and justify utilization of the order 
sets to treat eligible patients. This study is aimed at closing this research gap and 
quantitatively exploring effectiveness of the order sets to improve health outcomes.  
     The methodology applied to conduct the study was based on empirical analysis of 
over four years of patient data between 2007 and 2012, with the goal of determining 
effectiveness of the order sets applied to experimental groups of patients based on the 
health outcomes of mortality, readmissions, length of stay, and 
complications/comorbidity. Patient conditions of venous thromboembolism (VTE), 
pneumonia, congestive heart failure (CHF), and acute myocardial infarction (AMI) were 
selected based on large patient volumes and inclusion in the set of current key results 
areas of focus for the research site, Oak Brook, Illinois based integrated healthcare 
delivery network – Advocate Health Care. 
     Zafar and Dixon (2009) defined the theoretical foundation of order sets and their 
potential effectiveness to standardize treatment in a study sponsored by the US 
Department of Health and Human Services. Since publication of their study, Ballard, 
Ogola, Fleming, Stauffer, Leonard, Khetan, and Yancy (2010) published results of their 
Congestive Heart Failure (CHF) order set study conducted at Baylor Health and 
concluded that evidence based prescription methods decrease mortality, hospital stay, and 
rate of readmissions. Best, Frith, Anderson, Rapp, Rioux, and Ciccarello (2011) found 
reduced interval rates in initiation of antibiotic therapy from the time of diagnosis in the 
process of treating febrile neutropenia, with potential for greater success in treating this 
condition as a result of swifter clinical response. Wright, Sitting, Carpenter, Krall, Pang, 
and Middleton (2010) analyzed patterns in the order set utilization among several leading 
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healthcare facilities in the Northeastern part of the United States. Khanna, Vittinghoff, 
Maselli, and Auerbach (2011) at University of California, San Francisco quantitatively 
proved that the application of VTE order sets to treat certain groups of patients can be 
dangerous, arguing that more detailed studies of order sets are necessary to determine 
their effectiveness, benefits, and risks of side effects from standardization. No broader 
studies analyzing the overall effectiveness of the order sets based on patient history have 
been published to date. 
     For VTE, the independent variables were utilization of the order sets and occurrence 
of acute VTE – with prophylaxis focus of the study delineated by exclusion of any VTE 
orders placed after 48 hours of admission and exclusion of chronic VTE patients with 
chief complaint of VTE. For all other conditions, the independent variable was utilization 
of the order sets. The list of dependent variables included four major health outcomes: 
mortality, 30-day readmissions, length of stay, and complications. Additionally, the study 
analyzed the influence of several other variables such as age, race, and sex, in 
conjunction with order set utilization, on health outcomes. Mortality was derived from 
analysis of the discharge codes, and complications were identified by employing 
Charlson Comorbidity Index (CCI) due to lack of the more effective methods to quantify 
complications. The latter led to dual meaning of the CCI that could identify post-
treatment complications rate or indicate severity of pre-existing health conditions prior to 
hospital admission. Other barriers included lack of information on other factors 
influencing health outcomes beyond those included in the study and the small size of 
experimental groups in the CHF, AMI, and pneumonia studies, leading to either 
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statistically insignificant results in some categories or an inability to categorize patients 
into more diverse groups by type of condition, sex, race, and other factors.  
     In the VTE category, results found lower acute VTE rates among non-surgical patients 
in the experimental group but higher length of stay and comorbidity. The latter two could 
be interdependent if higher comorbidity represented sicker patients with pre-existing 
health conditions prior to admission, ultimately leading to longer length of stay for these 
patients, caused by health factors independent from the VTE condition. Mortality and 
readmission were not important as VTE health outcomes and excluded from the study. 
The reason for exclusion of these factors is lack of clinical evidence that patients may die 
or return to a hospital within 30-days due to symptoms associated specifically with VTE. 
Such patients are likely to experience other issues causing death or readmission. Sex 
differences were insignificant, with a slightly lower benefit from order sets among male 
non-surgical patients. Surgical patients did not benefit from medication ordering via 
CPOE sets.  
     In the pneumonia category, patients in the experimental group had lower mortality, 
lower readmission rate, lower complications rate, and had shorter hospital stays – all 
benefits at least in part attributable to utilization of the order sets. These outcomes hold 
true even if some of the patients benefitted from smaller pre-existing condition rates if 
CCI is interpreted as comorbidity rate prior to admission. In the CHF category, 
experimental group patients had lower mortality, shorter hospital stays, and smaller CCI. 
Even with potential conflict among the latter two outcomes, mortality benefit was 
significant. In the AMI category, the experimental group was too small relative to the 
control group to produce statistically significant results. Among several independent 
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variables influencing various health outcomes, utilization of order sets resulted in 
significant outcomes or outcomes approaching significance in most categories, indicating 
significance of order sets as factors leading up to adjustment in health outcomes. This 
study of health outcomes influence was the first of its kind to include order sets among 
basic human factors of race, sex, and age.  
     Overall, the study was significant in the following ways. First, it quantified the benefit 
of order sets to treat three patient conditions and supplied data behind hospitals’ 
assumptions that ongoing utilization of CPOE medication sets was/is justified. Second, it 
proved the effectiveness of order sets to treat three of the four patient conditions studied, 
based on some of the attempted health outcomes. Third, it provided significant backing to 
the claim of effectiveness of evidence based medicine in improving quality and health 
outcomes, through quantitative support for one of the core elements of the method – 
medication order set. Fourth, despite identified barriers and limitations, the study serves 
to encourage further collaboration between researchers and physicians to increase 
utilization of the order sets necessary to produce larger experimental group data sets and 
consequently more convincing results of empirical order set effectiveness analysis. Fifth, 
it opened up new areas of future research, including (1) more detailed studies of each 
patient condition and ways to improve health outcomes based on more targeted utilization 
of order sets, (2) factors influencing physicians’ willingness to employ order sets in the 
treatment and ordering processes, (3) investigation of order set effectiveness as it applies 
to patients in various race, sex, and age categories in order to avoid unintended 
consequences, (4) data-driven encouragement for healthcare facilities to invest into 
healthcare information technology as a way to improve quality and drive down cost of 
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care, and (5) the potential to spur activity among healthcare software vendors to develop 
new generations of code that are more research-friendly and enable investigation of the 
relationships between many variables involved in the treatment process.  
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Appendix A 
Medication Order Set Listing 
 
Table 129. Medication Order Sets 
Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available 
Monthly 
Utilization 
Average 
(Aug 2010) 
Acute MI GSHP Acute Coronary 
Syndrome Order 
Set GSH 
 
49493862 
 
2005 4 
 SSUB Low Risk Chest 
Pain Evaluation 
Program Order Set 
SSH 
 
178578195 
 
2007 4 
 TRIN Chest Pain Orders 
Order Set TRI 
 
483944189 
 
2009 36 
CHF CMC CHF Unit 
Admission Order 
Set CMC 
 
13026418 
 
2004 3 
 GSHP Congestive Heart 
Failure Admission 
Order Set GSH 
 
49502942 
 
2005 2 
 IMMC Congestive Heart 
Failure Admission 
Order Set IMC 
 
24458894 
 
2005 26 
 LGH Heart Failure 
Management Order 
Set LGH 
 
369504735 
 
2008 6 
 SSUB Heart Failure 
Order Set SSH 
 
173004691 
 
2007 4 
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Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available 
Monthly 
Utilization 
Average 
(Aug 2010) 
Pneumonia CMC Community 
Acquired 
Pneumonia Adult 
Order Set CMC 
 
33166393 
 
2005 2 
 GSAM Pneumonia Adult 
Order Set GSA 
 
48577863 
 
2005 7 
 GSHP Pneumonia Order 
Set GSH 
 
49610362 
 
2005 2 
 IMMC Community 
Acquired 
Pneumonia (CAP) 
Order Set IMC 
 
32342226 
 
2005 20 
 SSUB Pneumonia 
Inpatient Adult 
Order Set SSH 
 
139008712 
 
2006 4 
 TRIN Community 
Acquired 
Pneumonia Order 
Set TRI 
 
483701535 
 
2007 6 
VTE CMC Venous 
Thromboembolism 
Prophylaxis Order 
Set CMC 
 
209906896 
 
2007 11 
 GSHP Deep Vein 
Thrombosis 
Prophylaxis Order 
Set GSH 
 
49503537 
 
2005 2 
 IMMC DVT Prophylaxis 
Order Set IMC 
 
13040866 
 
2004 624 
 LGH VTE Prophylaxis 
Order Set LGH 
 
254585783 
 
2008 458 
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Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available 
Monthly 
Utilization 
Average 
(Aug 2010) 
 SSUB DVT Prophylaxis 
Order Set SSH 
 
142677644 
 
2006 2 
 SSUB DVT Prophylaxis 
Order Set TRI 
483221836 
 
2009 5 
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Appendix B 
Supplemental VTE Methodology Tables 
 
Table 130. Monthly Utilization of the VTE Order Sets 
Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available 
Monthly 
Utilization 
Average 
(Aug 2010) 
VTE CMC Venous 
Thromboembolis 
Prophylaxis Order 
Set CMC 
 
209906896 
 
2007 11 
 GSHP Deep Vein 
Thrombosis 
Prophylaxis Order 
Set GSH 
 
49503537 
 
2005 2 
 IMMC DVT Prophylaxis 
Order Set IMC 
 
13040866 
 
2004 624 
 LGH VTE Prophylaxis 
Order Set LGH 
 
254585783 
 
2008 458 
 SSUB DVT Prophylaxis 
Order Set SSH 
 
142677644 
 
2006 2 
 SSUB DVT Prophylaxis 
Order Set TRI 
483221836 
 
2009 5 
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Table 131. Variables Used in the VTE Study 
Variable Source Type Definition Notes 
Encounter Number EDW Identifying/Continuous  Numeric  
Patient Key EDW Identifying/Continuous Numeric  
 
 
 
 
Order Set Title 
 
 
 
 
EDW 
 
 
 
 
Identifying/Continuous 
 
 
 
 
Text 
 
 
 
 
DVT 
Prophylaxis 
Order Set 
IMC, 
VTE 
Prophylaxis 
Order Set 
LGH 
Order Set Catalog 
Number 
EDW Identifying/Continuous Numeric 13040866 
(IMMC), 
254585783 
(LGH) 
Discharge Date EDW Identifying/Continuous Date  
Patient Sex EDW Identifying/Categorical 1=female 
0=male 
 
Discharge Disposition 
Code 
EDW Identifying/Continuous Text  
Race_Caucasian EDW Identifying/Categorical 1=yes 
0=no 
 
Race_Africal_American EDW Identifying/Categorical 1=yes 
0=no 
 
Race_Hispanic EDW Identifying/Categorical 1=yes 
0=no 
 
Attending Physician 
Name 
EDW Identifying/Continuous Text Future study 
VTE (yes or no) EDW Independent/Categorical 1=present 
0=not 
present 
ICD-9-CM 
codes: 
451.11, 
451.19, 
451.2, 
451.81, 
451.9, 
453.40, 
453.41, 
453.42, 
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Variable Source Type Definition Notes 
453.8, 
453.9, 
415.1, 
415.11, 
415.19 
Order Set (yes or no) EDW Independent/Categorical 1=present 
0=not 
present 
 
Facility Key EDW Intervening/Categorical Text  
Surgery (yes or no) EDW Intervening/Categorical 1=present 
0=not 
present 
See Table 
135 
Patient Age EDW Intervening/Continuous Numeric  
Length of Stay EDW Dependent/Continuous Numeric  
Charlson Comorbidity 
Index 
EDW Dependent/Continuous Numeric See Table 
132 
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Table 132. Charlson Comorbidity Index of Patient Complications 
Illness Point Count 
Myocardial infarction 1 
Peripheral vascular disease 1 
CVA 1 
Diabetes without complications 1 
Congestive heart failure  2 
COPD 2 
Mild liver disease 2 
Malignancy 2 
Dementia 3 
Connective tissue disease 3 
HIV 4 
Moderate to severe liver disease 4 
Metastatic cancer 6 
 
Table 133. Listing of Race Codes Utilized in the VTE Study 
Race Randomly Assigned 
Code 
African American / 
Black 
10 
American Indian / 
Alaska Native 
11 
Asian/Filipino 12 
Caucasian/White 13 
Declined 14 
Eastern Indian 15 
Hispanic 16 
Middle East 17 
Other 18 
Pacific Islander / 
Hawaiian  
19 
Unknown 20 
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Table 134. VTE Medication Order Sets Content, by Hospital 
Hospital Order Set Title (from EMR) Order Set Content 
IMMC DVT Prophylaxis Order Set 
IMC 
Activity Patient 
Coumadin 
Heparin 
INR/PT 
Lovenox 
Nursing Communication Order 
Platelet Count Blood (PLT) 
Pulsation Boot 
Sequential Compression Device 
LGH VTE Prophylaxis Order Set 
LGH 
Antiembolytic Hose 
CPD SCD Machine/Sleeve 
Enoxaparin 
Heparin 
Nursing Communication Order 
 
Table 135. AHRQ PSI-12 Appendix A: Operating Room Procedure Codes 
Code  Description 
50  IMPL CRT PACEMAKER SYS    
51  IMPL CRT DEFIBRILLAT SYS    
52  IMP/REP LEAD LF VEN SYS   
53  IMP/REP CRT PACEMAKR GEN    
54  IMP/REP CRT DEFIB GENAT    
56  INS/REP IMPL SENSOR LEAD OCT06-   
57  IMP/REP SUBCUE CARD DEV OCT06-   
61  PERC ANGIO PRECEREB VES (OCT 04)  
62  PERC ANGIO INTRACRAN VES (OCT 04)  
66  PTCA OR CORONARY ATHER OCT05-   
70  REV HIP REPL-ACETAB/FEM OCT05-    
71  REV HIP REPL-ACETAB COMP OCT05-   
72  REV HIP REPL-FEM COMP OCT05-   
73  REV HIP REPL-LINER/HEAD OCT05-    
80  REV KNEE REPLACEMT-TOTAL OCT05-    
81  REV KNEE REPL-TIBIA COMP OCT05-   
82  REV KNEE REPL-FEMUR COMP OCT05-   
83  REV KNEE REPLACE-PATELLA OCT05-    
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84  REV KNEE REPL-TIBIA LIN OCT05-   
85  RESRF HIPTOTAL-ACET/FEM OCT06-     
86  RESRF HIPPART-FEM HEAD OCT06-    
87  RESRF HIPPART-ACETABLUM OCT06-     
94  INTRA-OP NEURO PHYS MONTR OCT08-   
110  INTRACRAN PRESSURE MONTR OCT08-    
112  OPEN CEREB MENINGES BX    
114  OPEN BRAIN BIOPSY     
115  SKULL BIOPSY      
116  INTRACRANIAL 2 MONITOR OCT08-    
117  BRAIN TEMP MONITORING OCT08-    
118  OTHER BRAIN DX PROCEDURE    
119  OTHER SKULL DX PROCEDURE    
121  CRANIAL SINUS I & D   
122  REMOV INTRACRAN STIMULAT     
123  REOPEN CRANIOTOMY SITE     
124  OTHER CRANIOTOMY      
125  OTHER CRANIECTOMY      
128  INTRACEREB CTH-BURR HOLE OCT06-    
131  INCISE CEREBRAL MENINGES     
132  LOBOTOMY & TRACTOTOMY     
139  OTHER BRAIN INCISION     
141  THALAMUS OPERATIONS      
142  GLOBUS PALLIDUS OPS     
151  EX CEREB MENINGEAL LES    
152  HEMISPHERECTOMY       
153  BRAIN LOBECTOMY      
159  OTHER BRAIN EXCISION     
16  EXCISE SKULL LESION     
201  LINEAR CRANIECTOMY      
202  ELEVATE SKULL FX FRAGMNT    
203  SKULL FLAP FORMATION     
204  BONE GRAFT TO SKULL    
205  SKULL PLATE INSERTION     
206  CRANIAL OSTEOPLASTY NEC     
207  SKULL PLATE REMOVAL     
211  SIMPLE SUTURE OF DURA    
212  BRAIN MENINGE REPAIR NEC    
213  MENINGE VESSEL LIGATION     
214  CHOROID PLEXECTOMY      
22  VENTRICULOSTOMY       
231  VENTRICL SHUNT-HEAD/NECK      
232  VENTRI SHUNT-CIRCULA SYS     
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233  VENTRICL SHUNT-THORAX      
234  VENTRICL SHUNT-ABDOMEN      
235  VENTRI SHUNT-UNINARY SYS     
239  OTHER VENTRICULAR SHUNT     
242  REPLACE VENTRICLE SHUNT     
243  REMOVE VENTRICLE SHUNT     
291  LYSIS CORTICAL ADHESION     
292  BRAIN REPAIR      
293  IMPLANT BRAIN STIMULATOR     
294  INSERT/REPLAC SKULL TONG     
299  SKULL & BRAIN OP NEC   
301  REMOVAL FB SPINAL CANAL    
302  REOPEN LAMINECTOMY SITE     
309  SPINAL CANAL EXPLOR NEC    
31  INTRASPIN NERVE ROOT DIV    
321  PERCUTANEOUS CHORDOTOMY      
329  OTHER CHORDOTOMY      
332  SPINAL CORD/MENINGES BX     
339  OTHER SPINAL DX PROC    
34  EXCIS SPINAL CORD LESION    
351  SPINE MENINGOCELE REPAIR     
352  MYELOMENINGOCEL REPAIR      
353  VERTEBRAL FX REPAIR     
359  SPINAL STRUCT REPAIR NEC    
36  SPINAL CORD ADHESIOLYSIS     
371  SUBARACH-PERITON SHUNT      
372  SUBARACH-URETERAL SHUNT      
379  OTH SPINAL THECAL SHUNT    
393  INSERT SPINAL STIMULATOR     
394  REMOVE SPINAL STIMULATOR     
397  REVISE SPINE THECA SHUNT    
398  REMOVE SPINE THECA SHUNT    
399  SPINE CANAL STRUC OP NEC   
401  EXCISION ACOUSTC NEUROMA     
402  TRIGEMINAL NERV DIVISION     
403  PERIPH NERVE DIV NEC    
404  PERIPH NERVE INCIS NEC    
405  GASSERIAN GANGLIONECTOMY      
406  PERIPH GANGLIONECT NEC     
407  PERIPH NERV EXCISION NEC    
412  OPEN PERIPH NERVE BIOPSY    
419  PERIPH NERVE DX PROC NEC   
43  PERIPHERAL NERVE SUTURE     
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441  DECOMPRESS TRIGEM ROOT     
442  CRAN NERV ROOT DECOM NEC   
443  CARPAL TUNNEL RELEASE     
444  TARSAL TUNNEL RELEASE     
449  PER NERVE ADHESIOLYS NEC    
45  PERIPHERAL NERVE GRAFT     
46  PERIPH NERVE TRANSPOSIT     
471  HYPOGLOSS-FACIAL ANASTOM      
472  ACCESSORY-FACIAL ANASTOM      
473  ACCESS-HYPOGLOSS ANASTOM      
474  PERIPH NERV ANASTOM NEC    
475  POSTOP REVIS PER NERV OP   
476  LATE REPAIR PER NERV INJ   
479  OTHER NEUROPLASTY      
491  NEURECTASIS       
492  IMPLANT PERIPH STIMULAT     
493  REMOVE PERIPH STIMULATOR     
499  PERIPHERAL NERVE OPS NEC    
50  SYMPATH NERVE DIVISION     
511  SYMPATHETIC NERVE BIOPSY     
519  SYMPATH NRV DX PROC NEC   
521  SPHENOPALATIN GANGLIONEC      
522  CERVICAL SYMPATHECTOMY      
523  LUMBAR SYMPATHECTOMY      
524  PRESACRAL SYMPATHECTOMY      
525  PERIART SYMPATHECTOMY      
529  OTHER SYMPATHECTOMY      
581  SYMPATHETIC NERVE REPAIR     
589  SYMPATHETIC NERVE OP NEC    
59  OTHER NERVOUS SYSTEM OPS    
602  REOPEN THYROID FIELD WND    
609  INCIS THYROID FIELD NEC    
612  OPEN THYROID GLAND BX    
613  PARATHYROID BIOPSY      
619  THYR/PARATHY DX PROC NEC    
62  UNILAT THYROID LOBECTOMY     
631  EXCISION THYROID LESION     
639  PART THYROIDECTOMY NEC     
64  COMPLETE THYROIDECTOMY      
650  SUBSTERN THYROIDECT NOS     
651  PART SUBSTERN THYROIDECT     
652  TOT SUBSTERN THYROIDECT     
66  LINGUAL THYROID EXCISION     
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67  THYROGLOSS DUCT EXCISION     
681  TOTAL PARATHYROIDECTOMY      
689  OTHER PARATHYROIDECTOMY      
691  THYROID ISTHMUS DIVISION     
692  THYROID VESSEL LIGATION     
693  THYROID SUTURE      
694  THYROID REIMPLANTATION      
695  PARATHYROID REIMPLANT      
698  OTHER THYROID OPERATIONS     
699  OTHER PARATHYROID OPS     
700  ADRENAL EXPLORATION NOS     
701  UNILAT ADRENAL EXPLORAT     
702  BILAT ADRENAL EXPLORAT     
712  OPEN ADRENAL GLAND BX    
713  TRANSFRONT PITUITARY BX     
714  TRANSPHEN PITUITARY BX     
715  PITUITARY BIOPSY NOS     
716  THYMUS BIOPSY      
717  PINEAL BIOPSY      
719  ENDOCRINE DX PROC NEC    
721  ADRENAL LESION EXCISION     
722  UNILATERAL ADRENALECTOMY      
729  PART ADRENALECTOMY NEC     
73  BILATERAL ADRENALECTOMY      
741  ADRENAL INCISION      
742  ADRENAL NERVE DIVISION     
743  ADRENAL VESSEL LIGATION     
744  ADRENAL REPAIR      
745  ADRENAL REIMPLANTATION      
749  ADRENAL OPERATION NEC     
751  PINEAL FIELD EXPLORATION     
752  PINEAL GLAND INCISION     
753  PARTIAL PINEALECTOMY      
754  TOTAL PINEALECTOMY      
759  PINEAL OPERATION NEC     
761  EXC PITUIT LES-TRANSFRON     
762  EXC PITUIT LES-TRANSPHEN     
763  PART EXCIS PITUITARY NOS    
764  TOT EXC PITUIT-TRANSFRON     
765  TOT EXC PITUIT-TRANSPHEN     
768  TOTAL EXC PITUITARY NEC    
769  TOTAL EXC PITUITARY NOS    
771  PITUITARY FOSSA EXPLORAT     
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772  PITUITARY GLAND INCISION     
779  PITUITARY OPERATION NEC     
780  THYMECTOMY NOS      
781  PART EXCISION OF THYMUS    
782  TOTAL EXCISION OF THYMUS    
783  THORAC PART EXISN THYMUS OCT08-   
784  THORAC TOTAL EXC THYMUS OCT08-   
791  THYMUS FIELD EXPLORATION     
792  INCISION OF THYMUS     
793  REPAIR OF THYMUS     
794  THYMUS TRANSPLANTATION      
795  THORAC INCISION THYMUS OCT08-    
798  OTH THORAC OP THYMUS NOS OCT08-  
799  THYMUS OPERATION NEC     
811  EYELID BIOPSY      
820  REMOVE EYELID LESION NOS    
821  CHALAZION EXCISION      
822  EXCISE MINOR LES LID NEC   
823  EXC MAJ LES LID PRT-THIC   
824  EXC MAJ LES LID FUL-THIC   
825  DESTRUCTION LID LESION     
831  PTOSIS REP-FRONT MUS SUT    
832  PTOSIS REP-FRON MUS SLNG    
833  PTOSIS REP-LEVAT MUS ADV    
834  PTOSIS REP-LEVAT MUS NEC    
835  PTOS REP-TARSAL TECHNIQ     
836  BLEPHAROPTOS REPAIR NEC     
837  REDUC OVERCORRECT PTOSIS     
838  CORRECT LID RETRACTION     
841  THERMOCAUT/ENTROPION REP      
842  SUTURE ENTROPION REPAIR     
843  WEDG RESEC ENTROPION REP    
844  LID RECONS ENTROPION REP    
849  ENTROPION/ECTROP REP NEC     
851  CANTHOTOMY       
852  BLEPHARORRHAPHY       
859  ADJUST LID POSITION NEC    
861  LID RECONST W SKIN GRAFT   
862  LID RECONST W MUC GRAFT   
863  LID RECONST W HAIR GRAFT   
864  LID RECON-TARSOCONJ FLAP     
869  LID RECONSTR W GRAFT NEC   
870  LID RECONSTRUCTION NOS     
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871  LID MARG RECON-PART THIC    
872  LID RECONS-PART THIC NEC    
873  LID MARG RECONS FUL THIC   
874  LID RECONST-FUL THIC NEC    
891  ELECTROSURG LID EPILAT     
892  CRYOSURG LID EPILATION     
893  EYELID EPILATION NEC     
899  EYELID OPERATION NEC     
90  LACRIMAL GLAND INCISION     
911  LACRIMAL GLAND BIOPSY     
912  LACRIMAL SAC BIOPSY     
919  LACRIMAL SYS DX PROC NEC   
920  EXC LACRIMAL GLAND NOS    
921  EXCIS LES LACRIMAL GLAND    
922  PART DACRYOADENECT NEC     
923  TOTAL DACRYOADENECTOMY      
93  OTHER LACRIMAL GLAND OPS    
941  LACRIMAL PUNCTUM PROBE     
942  LAC CANALICULI PROBE     
943  NASOLACRIMAL DUCT PROBE     
944  NASOLAC DUCT INTUBAT     
949  LAC PASSAGE MANIP NEC    
951  LAC PUNCTUM INCISION     
952  LAC CANALICULI INCISION     
953  LACRIMAL SAC INCISION     
959  LACRIM PASSAGE INCIS NEC    
96  LACRIM SAC/PASSAGE EXCIS     
971  CORRECT EVERTED PUNCTUM     
972  PUNCTUM REPAIR NEC     
973  CANALICULUS REPAIR      
981  DACRYOCYSTORHINOSTOMY       
982  CONJUNCTIVOCYSTORHINOST       
983  CONJUNCTIVORHINOS W TUBE     
991  LAC PUNCTUM OBLITERATION     
999  LACRIMAL SYSTEM OP NEC    
100  INCISE/REMOV CONJUNCT FB     
101  CONJUNCTIVA INCISION NEC     
1021  CONJUNCTIVAL BIOPSY      
1029  CONJUNCTIVA DX PROC NEC    
1031  EXCISE CONJUNCTIV LESION     
1032  DESTRUCT CONJUNC LES NEC    
1033  OTH CONJUNC DESTRUC PROC    
1041  SYMBLEPH REP W FREE GRFT   
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1042  GRAFT CONJUNC CUL-DE-SAC     
1043  CONJUN CUL-DE-SAC RX NEC    
1044  CONJUNC FREE GRAFT NEC    
1049  CONJUNCTIVOPLASTY NEC      
105  CONJUNC/LID ADHESIOLYSIS      
106  REPAIR CONJUNCT LACERAT     
1091  SUBCONJUNCTIVAL INJECT      
1099  CONJUNCTIVAL OP NEC     
110  MAGNET REMOVAL CORNEA FB    
111  CORNEAL INCISION      
1121  CORNEAL SCRAPE FOR SMEAR    
1122  CORNEAL BIOPSY      
1129  CORNEAL DX PROC NEC    
1131  PTERYGIUM TRANSPOSITION      
1132  PTERYG EXC W CORNEA GRFT   
1139  PTERYGIUM EXCISION NEC     
1141  MECH REMOV CORNEA EPITH    
1142  THERMOCAUT CORNEA LESION     
1143  CRYOTHERAP CORNEA LESION     
1149  DESTRUCT CORNEA LES NEC    
1151  SUTURE CORNEA LACERATION     
1152  REP CORNEA POSTOP DEHISC    
1153  RX CORNEA LAC W CONJ FLP  
1159  CORNEAL REPAIR NEC     
1160  CORNEAL TRANSPLANT NOS     
1161  LAM KERATPLAST W AUTGRFT    
1162  LAMELLAR KERATOPLAST NEC     
1163  PERF KERATOPL W AUTOGRFT    
1164  PERFORAT KERATOPLAST NEC     
1169  CORNEAL TRANSPLANT NEC     
1171  KERATOMILEUSIS       
1172  KERATOPHAKIA       
1173  KERATOPROSTHESIS       
1174  THERMOKERATOPLASTY       
1175  RADIAL KERATOTOMY      
1176  EPIKERATOPHAKIA       
1179  CORNEA RECONSTRUCT NEC     
1191  CORNEAL TATTOOING      
1192  REMOVE CORNEAL IMPLANT     
1199  CORNEAL OPERATION NEC     
1200  REMOV ANT SEGMNT FB NOS   
1201  MAGNET REMOV ANT SEG FB   
1202  NONMAG REMOV ANT SEG FB   
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1211  IRIDOTOMY W TRANSFIXION     
1212  IRIDOTOMY NEC      
1213  PROLAPSED IRIS EXCISION     
1214  IRIDECTOMY NEC      
1221  DX ASPIRAT-ANT CHAMBER     
1222  IRIS BIOPSY      
1229  ANT SEGMENT DX PROC NEC   
1231  GONIOSYNECHIAE LYSIS      
1232  ANT SYNECHIA LYSIS NEC    
1233  POST SYNECHIAE LYSIS     
1234  CORNEOVITREAL ADHESIOLYS      
1235  COREOPLASTY       
1239  IRIDOPLASTY NEC      
1240  REMOV ANT SEGMNT LES NOS   
1241  NONEXC DESTRUC IRIS LES    
1242  EXCISION OF IRIS LESION    
1243  NONEXC DESTR CIL BOD LES   
1244  EXCISE CILIARY BODY LES    
1251  GONIOPUNCTURE       
1252  GONIOTOMY       
1253  GONIOTOMY W GONIOPUNCTUR     
1254  TRABECULOTOMY AB EXTERNO     
1255  CYCLODIALYSIS       
1259  FACILIT INTRAOC CIRC NEC    
1261  TREPHIN SCLERA W IRIDECT    
1262  THERMCAUT SCLER W IRIDEC    
1263  IRIDENCLEISIS/IRIDOTASIS       
1264  TRABECULECTOM AB EXTERNO     
1265  SCLER FISTULIZ W IRIDECT    
1266  POSTOP REVIS SCL FISTUL    
1269  SCLER FISTULIZING OP NEC    
1271  CYCLODIATHERMY       
1272  CYCLOCRYOTHERAPY       
1273  CYCLOPHOTOCOAGULATION       
1274  CIL BODY DIMINUTION NOS    
1279  GLAUCOMA PROCEDURE NEC     
1281  SUTURE SCLERAL LACER     
1282  SCLERAL FISTULA REPAIR     
1283  REVIS ANT SEG OP WND NEC  
1284  DESTRUCT SCLERAL LESION     
1285  REPAIR STAPHYLOM W GRAFT    
1286  REP SCLER STAPHYLOMA NEC    
1287  GRAFT REINFORCE SCLERA     
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1288  SCLERA REINFORCEMENT NEC     
1289  SCLERAL OPERATION NEC     
1291  THERAPEUT EVAC ANT CHAMB    
1292  ANTERIOR CHAMBER INJECT     
1293  REMOV EPITHEL DOWNGROWTH     
1297  IRIS OPERATION NEC     
1298  CILIARY BODY OP NEC    
1299  ANTERIOR CHAMBER OP NEC    
1300  REMOVE FB LENS NOS    
1301  MAGNET REMOVE FB LENS    
1302  NONMAGNET REMOVE FB LENS    
1311  TEMP-INF INTRCAP LENS EX    
1319  INTRACAPSUL LENS EXT NEC    
132  LINEAR EXTRACAP LENS EXT    
133  SIMPL ASPIR LENS EXTRACT    
1341  CATARAC PHACOEMULS/ASPIR      
1342  POST CATARAC FRAG/ASPIR     
1343  CATARACT FRAG/ASPIR NEC     
1351  TEMP-INF XTRACAP LENS EX    
1359  EXTRACAP LENS EXTRAC NEC    
1361  EXTRACAP LENS EXTRAC NEC    
1362  EXTRACAP LENS EXTRAC NEC    
1363  EXTRACAP LENS EXTRAC NEC    
1364  AFTER-CATAR DISCISSION      
1365  AFTER-CATARACT EXCISION      
1366  AFTER CATAR FRAGMNTATION     
1369  CATARACT EXTRACTION NEC     
1370  INSERT PSEUDOPHAKOS NOS     
1371  INSERT LENS AT CATAR EXT   
1372  SECONDARY INSERT LENS     
138  IMPLANTED LENS REMOVAL     
139  OTHER OPERATIONS ON LENS    
1390  OPERATION ON LENS NEC OCT06-   
1391  IMPL INTRAOC TELESC PROS OCT06-   
1400  REMOV POST SEGMNT FB NOS   
1401  MAGNET REMOV POST SEG FB   
1402  NONMAG REMOV POST SEG FB   
1411  DIAGNOST VITREOUS ASPIR     
1419  DX PROC POST SEG NEC   
1421  CHORIORET LES DIATHERMY     
1422  CHORIORETIN LES CRYOTHER     
1426  CHORIORET LES RADIOTHER     
1427  CHORIORET LES RAD IMPLAN    
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1429  CHORIORET LES DESTR NEC    
1431  RETINAL TEAR DIATHERMY     
1432  RETINAL TEAR CRYOTHERAPY     
1439  RETINAL TEAR REPAIR NEC    
1441  SCLERAL BUCKLE W IMPLANT    
1449  SCLERAL BUCKLING NEC     
1451  DETACH RETINA-DIATHERMY      
1452  DETACH RETINA-CRYOTHERAP      
1453  DETACH RETINA XENON COAG    
1454  DETACH RETINA LASER COAG    
1455  DETACH RET PHOTOCOAG NOS    
1459  REPAIR RETINA DETACH NEC    
146  REMOV PROS MAT POST SEG   
1471  ANTERIOR REMOV VITREOUS     
1472  VITREOUS REMOVAL NEC     
1473  ANTERIOR MECHAN VITRECT     
1474  MECH VITRECTOMY NEC     
1475  VITREOUS SUBSTITUT INJEC     
1479  VITREOUS OPERATION NEC     
149  OTHER POST SEGMENT OPS    
1501  EXTRAOC MUSC-TEND BIOPSY     
1509  EXTRAOC MUSC DX PROC NEC   
1511  ONE EXTRAOC MUS RECESS    
1512  1 EXTRAOC MUSCL ADVANCE    
1513  1 EXTRAOC MUSCL RESECT    
1519  XTRAOC MUS OP/DETACH NEC    
1521  LENGTHEN 1 EXTRAOC MUSC    
1522  SHORTEN 1 EXTRAOC MUSC    
1529  OP ON 1 EXTRAOC MUSC NEC  
153  TEMP DETACH >1 XTROC MUS   
154  OTH OP ON >L EXTRAOC MUS  
155  EXTRAOCUL MUS TRANSPOSIT     
156  REVIS EXTRAOC MUSC SURG    
157  EXTRAOC MUSC INJ REPAIR    
159  OTH EXTRAOC MUS-TEND OP    
1601  ORBITOTOMY W BONE FLAP    
1602  ORBITOTOMY W IMPLANT     
1609  ORBITOTOMY NEC      
161  REMOVE PENETRAT FB EYE    
1622  DIAGNOSTIC ASP OF ORBIT    
1623  EYEBALL & ORBIT BIOPSY    
1629  EYEBAL/ORBIT DX PROC NEC    
1631  EYE EVISC W SYNCH IMPLAN   
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1639  EYEBALL EVISCERATION NEC     
1641  EYE ENUC/IMPLAN/MUSC ATT     
1642  EYE ENUC W IMPLANT NEC   
1649  EYEBALL ENUCLEATION NEC     
1651  RADICAL ORBITOMAXILLECT      
1652  ORBIT EXENT W BONE REMOV   
1659  ORBITAL EXENTERATION NEC     
1661  2NDRY OCULAR IMP INSERT    
1662  REVIS/REINSERT OCUL IMP     
1663  REVIS ENUC SOCKET W GRFT   
1664  ENUC SOCKET REVIS NEC    
1665  2NDRY EXENT CAVITY GRAFT    
1666  REVIS EXENTER CAVITY NEC    
1669  2ND OP POST EYE REM NEC  
1671  REMOVE OCULAR IMPLANT     
1672  REMOVE ORBITAL IMPLANT     
1681  REPAIR OF ORBITAL WOUND    
1682  REPAIR EYEBALL RUPTURE     
1689  EYE/ORBIT INJ REPAIR NEC    
1692  EXCISION ORBITAL LESION     
1693  EXCISION EYE LESION NOS    
1698  OPERATION ON ORBIT NEC    
1699  OPERATION ON EYEBALL NEC    
1711  LAP DIR ING HERN-GRAFT OCT08-   
1712  LAP INDIR ING HERN-GRAFT OCT08-   
1713  LAP ING HERN-GRAFT NOS OCT08-   
1721  LAP BIL DIR ING HRN-GRFT OCT08-  
1722  LAP BI INDIR ING HRN-GRF OCT08-  
1723  LAP BI DR/IND ING HRN-GR OCT08-  
1724  LAP BIL ING HERN-GRF NOS OCT08-  
1731  LAP MUL SEG RES LG INTES OCT08- 
1732  LAPAROSCOPIC CECECTOMY OCT08-     
1733  LAP RIGHT HEMICOLECTOMY OCT08-    
1734  LAP RES TRANSVERSE COLON OCT08-   
1735  LAP LEFT HEMICOLECTOMY OCT08-    
1736  LAP SIGMOIDECTOMY OCT08-     
1739  LAP PT EX LRG INTEST NEC OCT08- 
1751  IMPLANT CCM, TOTAL SYSTEM OCT09-   
1752  IMPLANT CCM PULSE GENRTR OCT09-   
1761  LITT LESN BRAIN, GUIDANCE OCT09-   
1762  LITT LESN HD/NCK GUIDANCE OCT09-   
1763  LITT LESN LIVER, GUIDEANCE OCT09-   
1769  LITT LESN GUIDE OTH/NOS OCT09-   
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1821  PREAURICULAR SINUS EXCIS     
1831  RAD EXCIS EXT EAR LES   
1839  EXCIS EXTERNAL EAR NEC    
185  CORRECTION PROMINENT EAR     
186  EXT AUDIT CANAL RECONSTR    
1871  CONSTRUCTION EAR AURICLE     
1872  REATTACH AMPUTATED EAR     
1879  PLASTIC REP EXT EAR NEC   
189  OTHER EXT EAR OPERATIONS    
190  STAPES MOBILIZATION      
1911  STAPEDECT W REPLAC INCUS    
1919  STAPEDECTOMY NEC      
1921  REV STAPDEC W INCUS REPL   
1929  STAPEDECTOMY REVIS NEC     
193  OSSICULAR CHAIN OP NEC    
194  MYRINGOPLASTY       
1952  TYPE 2 TYMPANOPLASTY     
1953  TYPE 3 TYMPANOPLASTY     
1954  TYPE 4 TYMPANOPLASTY     
1955  TYPE 5 TYMPANOPLASTY     
196  TYMPANOPLASTY REVISION      
199  MIDDLE EAR REPAIR NEC    
2001  MYRINGOTOMY W INTUBATION     
2021  MASTOID INCISION      
2022  PETRUS PYRAM AIR CEL INC   
2023  MIDDLE EAR INCISION     
2032  MID & INNER EAR BIOPSY   
2039  MID/IN EAR DX PROC NEC   
2041  SIMPLE MASTOIDECTOMY      
2042  RADICAL MASTOIDECTOMY      
2049  MASTOIDECTOMY NEC      
2051  EXCISE MIDDLE EAR LESION    
2059  MIDDLE EAR EXCISION NEC    
2061  INNER EAR FENESTRATION     
2062  REVIS INNER EAR FENESTRA    
2071  ENDOLYMPHATIC SHUNT      
2072  INNER EAR INJECTION     
2079  INC/EXC/DESTR IN EAR NEC    
2091  TYMPANOSYMPATHECTOMY       
2092  MASTOIDECTOMY REVISION      
2093  REPAIR OVAL/ROUND WINDOW     
2095  ELECMAG HEAR DEV IMPLANT    
2096  IMPLT COCHLEAR PROST NOS    
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2097  IMP/REP SCHAN COCH PROS    
2098  IMP/REP MCHAN COCHL PROS    
2099  MID-INNER EAR OPS NEC    
2104  ETHMOID ART LIGAT-EPIST     
2105  MAX ART LIG FOR EPISTAX   
2106  EXT CAROT ART LIG-EPIST    
2107  NASAL SEPT GRFT-EPISTAX     
2109  EPISTAXIS CONTROL NEC     
214  RESECTION OF NOSE     
215  SUBMUC NASAL SEPT RESECT    
2161  DIATHER/CRYO TURBINECTOM      
2162  TURBINATE FRACTURE      
2169  TURBINECTOMY NEC      
2172  OPEN REDUCTION NASAL FX    
2182  NASAL FISTULA CLOSURE     
2183  TOT NASAL RECONSTRUCTION     
2184  REVISION RHINOPLASTY      
2185  AUGMENTATION RHINOPLASTY      
2186  LIMITED RHINOPLASTY      
2187  RHINOPLASTY NEC      
2188  SEPTOPLASTY NEC      
2189  NASAL REPAIR NEC     
2199  NASAL OPERATION NEC     
2212  OPEN BIOPSY NASAL SINUS    
2231  RADICAL MAXILLARY ANTROT     
2239  EXT MAXILLARY ANTROT NEC    
2241  FRONTAL SINUSOTOMY      
2242  FRONTAL SINUSECTOMY      
2250  SINUSOTOMY NOS      
2251  ETHMOIDOTOMY       
2252  SPHENOIDOTOMY       
2253  MULTIPLE SINUS INCISION     
2260  SINUSECTOMY NOS      
2261  C-LUC EXC MAX SINUS LES   
2262  EXC MAX SINUS LESION NEC   
2263  ETHMOIDECTOMY       
2264  SPHENOIDECTOMY       
2271  NASAL SINUS FISTULA CLOS    
2279  NASAL SINUS REPAIR NEC    
229  OTHER NASAL SINUS OPS    
242  GINGIVOPLASTY       
244  EXC OF DENTAL LES OF JAW  
245  ALVEOLOPLASTY       
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2502  OPEN BIOPSY OF TONGUE    
251  DESTRUCTION TONGUE LES     
252  PARTIAL GLOSSECTOMY      
253  COMPLETE GLOSSECTOMY      
254  RADICAL GLOSSECTOMY      
2559  REPAIR OF TONGUE NEC    
2594  OTHER GLOSSOTOMY      
2599  TONGUE OPERATION NEC     
2612  OPEN BX SALIV GLAND/DUCT    
2621  SALIVARY CYST MARSUPIAL     
2629  SALIV LESION EXCIS NEC    
2630  SIALOADENECTOMY NOS      
2631  PARTIAL SIALOADENECTOMY      
2632  COMPLETE SIALOADENECTOMY      
2641  SUTURE OF SALIV GLND LAC   
2642  SALIVARY FISTULA CLOSURE     
2649  SALIVARY REPAIR NEC     
2699  SALIVARY OPERATION NEC     
270  DRAIN FACE & MOUTH FLOOR   
271  INCISION OF PALATE     
2721  BONY PALATE BIOPSY     
2722  UVULA AND SOFT PALATE BX   
2731  LOC EXC BONY PALATE LES   
2732  WIDE EXC BONY PALATE LES   
2742  WIDE EXCISION OF LIP LES   
2743  EXCISION OF LIP LES NEC   
2749  EXCISION OF MOUTH NEC    
2753  CLOSURE OF MOUTH FISTULA    
2754  REPAIR OF CLEFT LIP    
2755  FULL-THICK GRFT TO MOUTH    
2756  SKIN GRAFT TO MOUTH NEC   
2757  PEDICLE ATTACH TO MOUTH    
2759  MOUTH REPAIR NEC     
2761  SUTURE OF PALATE LACERAT    
2762  CLEFT PALATE CORRECTION     
2763  REVIS CLEFT PALAT REPAIR    
2769  OTH PLASTIC REPAIR PALAT    
2771  INCISION OF UVULA     
2772  EXCISION OF UVULA     
2773  REPAIR OF UVULA     
2779  OTHER UVULA OPERATIONS     
2792  MOUTH INCISION NOS     
2799  ORAL CAVITY OPS NEC    
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280  PERITONSILLAR I & D    
2811  TONSIL&ADENOID BIOPSY      
2819  TONSIL&ADENOID DX OP NEC    
282  TONSILLECTOMY       
283  TONSILLECTOMY/ADENOIDEC       
284  EXCISION OF TONSIL TAG    
285  EXCISION LINGUAL TONSIL     
286  ADENOIDECTOMY       
287  HEMORR CONTRL POST T & A  
2891  INCIS TO REMOV TONSIL FB   
2892  EXCIS TONSIL/ADENOID LES     
2899  TONSIL/ADENOID OPS NEC     
290  PHARYNGOTOMY       
292  EXC BRANCHIAL CLEFT CYST    
293  EXC BRANCHIAL CLEFT CYST    
2931  CRICOPHARYNGEAL MYOTOMY      
2932  PHARYNGEAL DIVERTICULEC      
2933  PHARYNGECTOMY       
2939  EXCIS/DESTR LES PHAR NEC    
294  PLASTIC OP ON PHARYNX    
2951  SUTURE OF PHARYNGEAL LAC    
2952  CLOS BRANCH CLEFT FISTUL    
2953  CLOS PHARYNX FISTULA NEC    
2954  LYSIS PHARYNGEAL ADHES     
2959  PHARYNGEAL REPAIR NEC     
2992  DIVIS GLOSSOPHARYNG NERV     
2999  PHARYNGEAL OPERATION NEC     
3001  LARYNX CYST MARSUPIALIZ     
3009  DESTRUCT LARYNX LES NEC    
301  HEMILARYNGECTOMY       
3021  EPIGLOTTIDECTOMY       
3022  VOCAL CORDECTOMY      
3029  OTHER PART LARYNGECTOMY     
303  COMPLETE LARYNGECTOMY      
304  RADICAL LARYNGECTOMY      
3121  MEDIASTINAL TRACHEOSTOMY      
3129  OTHER PERM TRACHEOSTOMY     
313  INCIS LARYNX TRACHEA NEC    
3145  OPN BX LARYNX OR TRACHEA   
315  LOCAL DESTRUC TRACH LES    
3161  SUTURE OF LARYNGEAL LAC    
3162  LARYNGEAL FISTULA CLOS     
3163  LARYNGOSTOMY REVISION      
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3164  LARYNGEAL FX REPAIR     
3169  OTHER LARYNGEAL REPAIR     
3171  SUTURE OF TRACHEAL LACER    
3172  CLOSURE OF TRACHEOSTOMY     
3173  TRACHEA FISTULA CLOS NEC    
3174  REVISION OF TRACHEOSTOMY     
3175  TRACHEAL RECONSTRUCTION      
3179  OTHER TRACHEAL REPAIR     
3191  LARYNGEAL NERV DIVISION     
3192  LYSIS TRACH/LARYNX ADHES     
3198  OTH LARYNGEAL OPERATION     
3199  OTHER TRACHEAL OPERATION     
320  OTHER TRACHEAL OPERATION     
3209  OTHER DESTRUC BRONC LES    
321  OTHER BRONCHIAL EXCISION     
3220  THORAC EXC LUNG LESION OCT08-   
3221  EMPHYSEMA BLEB PLICATION     
3222  LUNG VOL REDUCTION SURG    
3223  OPEN ABLTN LUNG LES/TISS OCT06-   
3224  PERC ABLTN LUNG LES/TISS OCT06-   
3225  THOR ABLTN LUNG LES/TISS OCT06-   
3226  ABLTN LUNG TISS NEC/NOS OCT06-   
3229  DESTROY LOC LUNG LES NEC   
323  SEGMENTAL LUNG RESECTION     
3230  THORAC SEG LUNG RESECT OCT08-   
3239  OTH SEG LUNG RESECT NOS OCT08-  
324  LOBECTOMY OF LUNG     
3241  THORAC LOBECTOMY LUNG OCT08-    
3249  LOBECTOMY OF LUNG NEC OCT08-   
325  COMPLETE PNEUMONECTOMY      
3250  THORACOSPC PNEUMONECTOMY OCT08-     
3259  OTHER PNEUMONECTOMY NOS OCT08-    
326  RAD DISSEC THORAC STRUCT    
329  OTHER EXCISION OF LUNG    
330  INCISION OF BRONCHUS     
331  INCISION OF LUNG     
3320  THORACOSCOPC LUNG BIOPSY OCT08-    
3325  OPEN BRONCHIAL BIOPSY     
3327  CLOS ENDOSCOPIC LUNG BX    
3328  OPEN LUNG BIOPSY     
3329  BRONCH/LUNG DX PROC NEC    
3334  THORACOPLASTY       
3339  SURG COLLAPS OF LUNG NEC   
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3341  BRONCHIAL LACERAT SUTURE     
3342  BRONCHIAL FISTULA CLOS     
3343  LUNG LACERATION CLOSURE     
3348  BRONCHIAL REPAIR NEC     
3349  LUNG REPAIR NEC     
335  LUNG REPAIR NEC     
3350  LUNG TRANSPLANT NOS     
3351  UNILAT LUNG TRANSPLANT     
3352  BILAT LUNG TRANSPLANT     
336  COMB HEART/LUNG TRANSPLA     
3392  BRONCHIAL LIGATION      
3393  PUNCTURE OF LUNG     
3398  BRONCHIAL OPERATION NEC     
3399  LUNG OPERATION NEC     
3402  EXPLORATORY THORACOTOMY      
3403  REOPEN THORACOTOMY SITE     
3406  THORAC DRAIN PLEURL CAV OCT08-   
341  INCISION OF MEDIASTINUM     
3420  THORACOSCOPIC PLEURAL BX OCT08-    
3421  TRANSPLEURA THORACOSCOPY      
3422  MEDIASTINOSCOPY       
3426  OPEN MEDIASTINAL BIOPSY     
3427  BIOPSY OF DIAPHRAGM     
3428  DX PROCEDURE THORAX NEC    
3429  DX PROC MEDIASTINUM NEC    
343  DESTRUCT MEDIASTIN LES     
344  DESTRUCT CHEST WALL LES    
3451  DECORTICATION OF LUNG     
3452  THORACOSCOPC DECORT LUNG OCT08-    
3459  OTHER PLEURAL EXCISION     
346  SCARIFICATION OF PLEURA     
3473  CLOS THORACIC FISTUL NEC    
3474  PECTUS DEFORMITY REPAIR     
3479  OTHER CHEST WALL REPAIR    
3481  EXCISE DIAPHRAGM LESION     
3482  SUTURE DIAPHRAGM LACERAT     
3483  CLOSE DIAPHRAGM FISTULA     
3484  OTHER DIAPHRAGM REPAIR     
3485  IMPLANT DIAPHRA PACEMAKE     
3489  DIAPHRAGM OPERATION NEC     
3493  REPAIR OF PLEURA     
3499  THORACIC OPERATION NEC     
3500  CLOSED VALVOTOMY NOS     
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3501  CLOSED AORTIC VALVOTOMY     
3502  CLOSED MITRAL VALVOTOMY     
3503  CLOSED PULMON VALVOTOMY     
3504  CLOSED TRICUSP VALVOTOMY     
3510  OPEN VALVULOPLASTY NOS     
3511  OPN AORTIC VALVULOPLASTY     
3512  OPN MITRAL VALVULOPLASTY     
3513  OPN PULMON VALVULOPLASTY     
3514  OPN TRICUS VALVULOPLASTY     
3520  REPLACE HEART VALVE NOS    
3521  REPLACE AORT VALV-TISSUE     
3522  REPLACE AORTIC VALVE NEC    
3523  REPLACE MITR VALV-TISSUE     
3524  REPLACE MITRAL VALVE NEC    
3525  REPLACE PULM VALV-TISSUE     
3526  REPLACE PULMON VALVE NEC    
3527  REPLACE TRIC VALV-TISSUE     
3528  REPLACE TRICUSP VALV NEC    
3531  PAPILLARY MUSCLE OPS     
3532  CHORDAE TENDINEAE OPS     
3533  ANNULOPLASTY       
3534  INFUNDIBULECTOMY       
3535  TRABECUL CARNEAE CORD OP    
3539  TISS ADJ TO VALV OPS NEC  
3542  CREATE SEPTAL DEFECT     
3550  PROSTH REP HRT SEPTA NOS   
3551  PROS REP ATRIAL DEF-OPN    
3552  PROS REPAIR ATRIA DEF-CL    
3553  PROST REPAIR VENTRIC DEF    
3554  PROS REP ENDOCAR CUSHION    
3555  PROS REP VENTRC DEF-CLOS OCT06-   
3560  GRFT REPAIR HRT SEPT NOS   
3561  GRAFT REPAIR ATRIAL DEF    
3562  GRAFT REPAIR VENTRIC DEF    
3563  GRFT REP ENDOCAR CUSHION    
3570  HEART SEPTA REPAIR NOS    
3571  ATRIA SEPTA DEF REP NEC   
3572  VENTR SEPTA DEF REP NEC   
3573  ENDOCAR CUSHION REP NEC    
3581  TOT REPAIR TETRAL FALLOT    
3582  TOTAL REPAIR OF TAPVC    
3583  TOT REP TRUNCUS ARTERIOS    
3584  TOT COR TRANSPOS GRT VES   
259 
 
 
 
Code  Description 
3591  INTERAT VEN RETRN TRANSP    
3592  CONDUIT RT VENT-PUL ART    
3593  CONDUIT LEFT VENTR-AORTA     
3594  CONDUIT ARTIUM-PULM ART     
3595  HEART REPAIR REVISION     
3596  PERC HEART VALVULOPLASTY     
3598  OTHER HEART SEPTA OPS    
3599  OTHER HEART VALVE OPS    
3600  OTHER HEART VALVE OPS    
3601  PTCA-1 VES/ATH W/O AGENT    
3602  PTCA-1 VES/ATH W AGENT    
3603  OPEN CORONRY ANGIOPLASTY     
3605  PTCA-MULTIPLE VESSEL/ATH      
3609  REM OF COR ART OBSTR NEC  
3610  AORTOCORONARY BYPASS NOS     
3611  AORTOCOR BYPAS-1 COR ART    
3612  AORTOCOR BYPAS-2 COR ART    
3613  AORTOCOR BYPAS-3 COR ART    
3614  AORTCOR BYPAS-4+ COR ART    
3615  1 INT MAM-COR ART BYPASS   
3616  2 INT MAM-COR ART BYPASS   
3617  ABD-CORON ARTERY BYPASS     
3619  HRT REVAS BYPS ANAS NEC   
362  ARTERIAL IMPLANT REVASC     
363  ARTERIAL IMPLANT REVASC     
3631  OPEN CHEST TRANS REVASC    
3632  OTH TRANSMYO REVASCULAR     
3633  ENDO TRANSMYO REVASCULAR OCT06-    
3634  PERC TRANSMYO REVASCULAR OCT06-    
3639  OTH HEART REVASCULAR     
3691  CORON VESS ANEURYSM REP    
3699  HEART VESSEL OP NEC    
3710  INCISION OF HEART NOS    
3711  CARDIOTOMY       
3712  PERICARDIOTOMY       
3724  PERICARDIAL BIOPSY      
3731  PERICARDIECTOMY       
3732  HEART ANEURYSM EXCISION     
3733  EXC/DEST HRT LESION OPEN    
3734  EXC/DEST HRT LES OTHER    
3735  PARTIAL VENTRICULECTOMY      
374  HEART & PERICARD REPAIR    
3741  IMPL CARDIAC SUPPORT DEV OCT05-   
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3749  HEART/PERICARD REPR NEC OCT05-    
375  HEART & PERICARD REPAIR    
3751  HEART TRANSPLANTATION OCT03-     
3752  IMPLANT TOT REP HRT SYS   
3753  REPL/REP THORAC UNIT HRT    
3754  REPL/REP OTH TOT HRT SYS   
3755  REM INT BIVENT HRT SYS OCT08-  
3760  IMP BIVN EXT HRT AST SYS OCT08- 
3761  PULSATION BALLOON IMPLAN     
3762  IMPLANT HRT ASST SYS NEC   
3763  REPLACE HRT ASSIST SYST    
3764  REMOVE HEART ASSIST SYS    
3765  IMP EXT PUL HRT ASST SYS  
3766  IMP IMP PUL HRT ASST SYS  
3767  IMP CARDIOMYOSTIMUL SYS     
3768  PERCUTAN HRT ASSIST SYST    
3774  INT OR REPL LEAD EPICAR   
3775  REVISION OF LEAD     
3776  REPL TV ATRI-VENT LEAD    
3777  REMOVAL OF LEAD W/O REPL   
3779  REVIS OR RELOCATE POCKET    
3780  INT OR REPL PERM PACEMKR   
3785  REPL PACEM W 1-CHAM, NON   
3786  REPL PACEM 1-CHAM, RATE    
3787  REPL PACEM W DUAL-CHAM    
3789  REVISE OR REMOVE PACEMAK    
3791  OPN CHEST CARDIAC MASSAG    
3794  IMPLT/REPL CARDDEFIB TOT     
3795  IMPLT CARDIODEFIB LEADS     
3796  IMPLT CARDIODEFIB GENATR     
3797  REPL CARDIODEFIB LEADS     
3798  REPL CARDIODEFIB GENRATR     
3799  OTHER HEART/PERICARD OPS     
3800  INCISION OF VESSEL NOS    
3801  INTRACRAN VESSEL INCIS     
3802  HEAD/NECK VES INCIS NEC    
3803  UPPER LIMB VESSEL INCIS    
3804  INCISION OF AORTA     
3805  THORACIC VESSEL INC NEC    
3806  ABDOMEN ARTERY INCISION     
3807  ABDOMINAL VEIN INCISION     
3808  LOWER LIMB ARTERY INCIS    
3809  LOWER LIMB VEIN INCISION    
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3810  ENDARTERECTOMY NOS      
3811  INTRACRAN ENDARTERECTOMY      
3812  HEAD & NECK ENDARTER NEC   
3813  UPPER LIMB ENDARTERECTOM     
3814  ENDARTERECTOMY OF AORTA     
3815  THORACIC ENDARTERECTOMY      
3816  ABDOMINAL ENDARTERECTOMY      
3818  LOWER LIMB ENDARTERECT     
3821  BLOOD VESSEL BIOPSY     
3829  BLOOD VESSEL DX PROC NEC   
3830  VESSEL RESECT/ANAST NOS     
3831  INTRACRAN VES RESEC-ANAS     
3832  HEAD/NECK VES RESEC-ANAS     
3833  ARM VESSEL RESECT/ANAST     
3834  AORTA RESECTION & ANAST    
3835  THOR VESSEL RESECT/ANAST     
3836  ABD VESSEL RESECT/ANAST     
3837  ABD VEIN RESECT & ANAST   
3838  LEG ARTERY RESECT/ANAST     
3839  LEG VEIN RESECT/ANASTOM     
3840  VESSEL RESECT/REPLAC NOS     
3841  INTRACRAN VES RESEC-REPL     
3842  HEAD/NECK VES RESEC-REPL     
3843  ARM VES RESECT W REPLACE   
3844  RESECT ABDM AORTA W REPL   
3845  RESECT THORAC VES W REPL   
3846  ABD ARTERY RESEC W REPLA   
3847  ABD VEIN RESECT W REPLAC   
3848  LEG ARTERY RESEC W REPLA   
3849  LEG VEIN RESECT W REPLAC   
3850  VARICOSE V LIG-STRIP NOS    
3851  INTCRAN VAR V LIG-STRIP    
3852  HEAD/NECK VAR V LIG-STR    
3853  ARM VARICOSE V LIG-STRIP    
3855  THORAC VAR V LIG-STRIP    
3857  ABD VARICOS V LIGA-STRIP    
3859  LEG VARICOS V LIGA-STRIP    
3860  EXCISION OF VESSEL NOS    
3861  INTRACRAN VESSEL EXCIS     
3862  HEAD/NECK VESSEL EXCIS     
3863  ARM VESSEL EXCISION     
3864  EXCISION OF AORTA     
3865  THORACIC VESSEL EXCISION     
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3866  ABDOMINAL ARTERY EXCIS     
3867  ABDOMINAL VEIN EXCISION     
3868  LEG ARTERY EXCISION     
3869  LEG VEIN EXCISION     
3880  SURG VESSEL OCCLUS NEC    
3881  OCCLUS INTRACRAN VES NEC    
3882  OCCLUS HEAD/NECK VES NEC    
3883  OCCLUDE ARM VESSEL NEC    
3884  OCCLUDE AORTA NEC     
3885  OCCLUDE THORACIC VES NEC    
3886  OCCLUDE ABD ARTERY NEC    
3887  OCCLUDE ABD VEIN NEC    
3888  OCCLUDE LEG ARTERY NEC    
3889  OCCLUDE LEG VEIN NEC    
390  SYSTEMIC-PULM ART SHUNT     
391  INTRA-ABD VENOUS SHUNT     
398  CARTD BODY/SINUS/VASC OP OCT08-    
3921  CAVAL-PULMON ART ANASTOM     
3922  AORTA-SUBCLV-CAROT BYPAS      
3923  INTRATHORACIC SHUNT NEC     
3924  AORTA-RENAL BYPASS      
3925  AORTA-ILIAC-FEMOR BYPASS      
3926  INTRA-ABDOMIN SHUNT NEC     
3927  DIALYSIS ARTERIOVENOSTOM      
3928  EXTRACRAN-INTRACR BYPASS      
3929  VASC SHUNT & BYPASS NEC   
3930  SUTURE OF VESSEL NOS    
3931  SUTURE OF ARTERY     
3932  SUTURE OF VEIN     
3941  POSTOP VASC OP HEM CONTR   
3942  REVIS REN DIALYSIS SHUNT    
3943  REMOV REN DIALYSIS SHUNT    
3949  VASC PROC REVISION NEC    
3950  ANGIO/ATH NON-CORO VES     
3951  CLIPPING OF ANEURYSM     
3952  ANEURYSM REPAIR NEC     
3953  ARTERIOVEN FISTULA REP     
3954  RE-ENTRY OPERATION      
3955  REIMPLAN ABERR RENAL VES    
3956  REPAIR VESS W TIS PATCH   
3957  REP VESS W SYNTH PATCH   
3958  REPAIR VESS W PATCH NOS   
3959  REPAIR OF VESSEL NEC    
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397  PER CARDIOPULMON BYPASS     
3971  ENDO IMPL GRFT ABD AORTA   
3972  ENDOVASC REPAIR HEAD VES    
3973  ENDO IMP GRFT THOR AORTA OCT05-  
3974  ENDO REM OBS HD/NECK VES OCT06-  
3975  ENDO EM HD/NK, BARE COILD OCT09-  
3976  ENDO EM HD/NK, BIOAC COIL OCT09-  
3979  ENDO REPAIR OTHER VESSEL    
398  VASCULAR BODY OPERATIONS     
3991  FREEING OF VESSEL     
3992  VEIN INJECT-SCLEROS AGNT     
3993  INSERT VES-TO-VES CANNUL     
3994  REPLAC VES-TO-VES CANNUL     
3998  HEMORRHAGE CONTROL NOS     
3999  VESSEL OPERATION NEC     
400  INCIS LYMPHATIC STRUCTUR     
4011  LYMPHATIC STRUCT BIOPSY     
4019  LYMPHATIC DIAG PROC NEC    
4021  EXCIS DEEP CERVICAL NODE    
4022  EXCISE INT MAMMARY NODE    
4023  EXCISE AXILLARY NODE     
4024  EXCISE INGUINAL NODE     
4029  SIMP EXC LYMPH STRUC NEC   
403  REGIONAL LYMPH NODE EXC    
4040  RAD NECK DISSECTION NOS    
4041  UNILAT RAD NECK DISSECT    
4042  BILAT RAD NECK DISSECT    
4050  RAD NODE DISSECTION NOS    
4051  RAD DISSEC AXILLARY NODE    
4052  RAD DISSEC PERIAORT NODE    
4053  RAD DISSECT ILIAC NODES    
4054  RADICAL GROIN DISSECTION     
4059  RAD NODE DISSECTION NEC    
4061  THORAC DUCT CANNULATION     
4062  THORACIC DUCT FISTULIZAT     
4063  CLOSE THORACIC DUCT FIST    
4064  LIGATE THORACIC DUCT     
4069  THORACIC DUCT OP NEC    
409  LYMPH STRUCTURE OP NEC    
412  SPLENOTOMY       
4133  OPEN SPLEEN BIOPSY     
4141  SPLENIC CYST MARSUPIAL     
4142  EXC SPLENIC LESION/TISS     
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4143  PARTIAL SPLENECTOMY      
415  TOTAL SPLENECTOMY      
4193  EXC OF ACCESSORY SPLEEN    
4194  SPLEEN TRANSPLANTATION      
4195  REPAIR OF SPLEEN     
4199  SPLEEN OPERATION NEC     
4201  ESOPHAGEAL WEB INCISION     
4209  ESOPHAGEAL INCISION NEC     
4210  ESOPHAGOSTOMY NOS      
4211  CERVICAL ESOPHAGOSTOMY      
4212  ESOPH POUCH EXTERIORIZAT     
4219  EXT FISTULIZAT ESOPH NEC    
4221  ESOPHAGOSCOPY BY INCIS     
4225  OPEN BIOPSY OF ESOPHAGUS    
4231  LOC EXCIS ESOPH DIVERTIC    
4232  LOCAL EXCIS ESOPHAG NEC    
4239  DESTRUCT ESOPHAG LES NEC    
4240  ESOPHAGECTOMY NOS      
4241  PARTIAL ESOPHAGECTOMY      
4242  TOTAL ESOPHAGECTOMY      
4251  THORAC ESOPHAGOESOPHAGOS      
4252  THORAC ESOPHAGOGASTROST      
4253  THORAC SM BOWEL INTERPOS    
4254  THORAC ESOPHAGOENTER NEC     
4255  THORAC LG BOWEL INTERPOS    
4256  THORAC ESOPHAGOCOLOS NEC     
4258  THORAC INTERPOSITION NEC     
4259  THORAC ESOPHAG ANAST NEC    
4261  STERN ESOPHAGOESOPHAGOST      
4262  STERN ESOPHAGOGASTROSTOM      
4263  STERN SM BOWEL INTERPOS    
4264  STERN ESOPHAGOENTER NEC     
4265  STERN LG BOWEL INTERPOS    
4266  STERN ESOPHAGOCOLOS NEC     
4268  STERN INTERPOSITION NEC     
4269  STERN ESOPHAG ANAST NEC    
427  ESOPHAGOMYOTOMY       
4282  SUTURE ESOPHAGEAL LACER     
4283  ESOPHAGOSTOMY CLOSURE      
4284  ESOPH FISTULA REPAIR NEC    
4285  ESOPHAG STRICTURE REPAIR     
4286  PROD SUBQ TUNNEL NO ANAS   
4287  ESOPHAGEAL GRAFT NEC     
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4289  ESOPHAGEAL REPAIR NEC     
4291  LIGATION ESOPH VARIX     
430  GASTROTOMY       
431  GASTROTOMY       
432  OTHER GASTROSTOMY      
433  PYLOROMYOTOMY       
4342  LOCAL GASTR EXCISION NEC    
4349  LOCAL GASTR DESTRUCT NEC    
435  PROXIMAL GASTRECTOMY      
436  DISTAL GASTRECTOMY      
437  PART GASTREC W JEJ ANAST   
4381  PART GAST W JEJ TRANSPOS   
4389  PARTIAL GASTRECTOMY NEC     
4391  TOT GAST W INTES INTERPO   
4399  TOTAL GASTRECTOMY NEC     
4400  VAGOTOMY NOS      
4401  TRUNCAL VAGOTOMY      
4402  HIGHLY SELECT VAGOTOMY     
4403  SELECTIVE VAGOTOMY NEC     
4411  TRANSABDOMIN GASTROSCOPY      
4415  OPEN GASTRIC BIOPSY     
442  GASTRIC DIAGNOS PROC NEC    
4421  DILATE PYLORUS, INCISION     
4429  OTHER PYLOROPLASTY      
4431  HIGH GASTRIC BYPASS     
4432  PERCU GASTROJEJUNOSTOMY      
4438  LAP GASTROENTEROSTOMY (OCT 04)    
4439  GASTROENTEROSTOMY NEC      
4440  SUTURE PEPTIC ULCER NOS    
4441  SUT GASTRIC ULCER SITE    
4442  SUTURE DUODEN ULCER SITE    
445  REVISION GASTRIC ANASTOM     
4461  SUTURE GASTRIC LACERAT     
4463  CLOSE GASTRIC FISTUL NEC    
4464  GASTROPEXY       
4465  ESOPHAGOGASTROPLASTY       
4466  CREAT ESOPHAGASTR SPHINC     
4467  LAP CREAT ESOPH SPHINCT (OCT 04)  
4468  LAPAROSCOP GASTROPLSTY (OCT 04)    
4469  GASTRIC REPAIR NEC     
4491  LIGATE GASTRIC VARICES     
4492  INTRAOP GASTRIC MANIPUL     
4495  LAP GASTRIC RESTRIC PROC (OCT 04)  
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4496  LAP REV GAST RESTRI PROC (OCT 04) 
4497  LAP REM GAST RESTRIC DEV (OCT 04) 
4498  ADJUST GAST RESTRICT DEV (OCT 04)  
4499  GASTRIC OPERATION NEC     
4500  INTESTINAL INCISION NOS     
4501  DUODENAL INCISION      
4502  SMALL BOWEL INCISION NEC    
4503  LARGE BOWEL INCISION     
4511  TRANSAB SM BOWEL ENDOSC    
4515  OPEN SMALL BOWEL BIOPSY    
4521  TRANSAB LG BOWEL ENDOSC    
4526  OPEN LARGE BOWEL BIOPSY    
4531  OTH EXCISE DUODENUM LES    
4532  DESTRUCT DUODEN LES NEC    
4533  LOCAL EXCIS SM BOWEL NEC   
4534  DESTR SM BOWEL LES NEC   
4541  EXCISE LG INTESTINE LES    
4549  DESTRUC LG BOWEL LES NEC   
4550  INTEST SEG ISOLAT NOS    
4551  SM BOWEL SEGMENT ISOLAT    
4552  LG BOWEL SEGMENT ISOLAT    
4561  MULT SEG SM BOWEL EXCIS   
4562  PART SM BOWEL RESECT NEC   
4563  TOTAL REMOVAL SM BOWEL    
4571  MULT SEG LG BOWEL EXCIS   
4572  CECECTOMY       
4573  RIGHT HEMICOLECTOMY      
4574  TRANSVERSE COLON RESECT     
4575  LEFT HEMICOLECTOMY      
4576  SIGMOIDECTOMY       
4579  PART LG BOWEL EXCIS NEC   
458  TOT INTRA-ABD COLECTOMY     
4581  LAP TOT INTR-AB COLECTMY OCT08-   
4582  OP TOT INTR-ABD COLECTMY OCT08-   
4583  TOT ABD COLECTMY NEC/NOS OCT08-   
4590  INTESTINAL ANASTOM NOS     
4591  SM-TO-SM BOWEL ANASTOM     
4592  SM BOWEL-RECT STUMP ANAS    
4593  SMALL-TO-LARGE BOWEL NEC     
4594  LG-TO-LG BOWEL ANASTOM     
4595  ANAL ANASTOMOSIS      
4601  SM BOWEL EXTERIORIZATION     
4602  RESECT EXT SEG SM BOWEL   
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4603  LG BOWEL EXTERIORIZATION     
4604  RESECT EXT SEG LG BOWEL   
4610  COLOSTOMY NOS      
4611  TEMPORARY COLOSTOMY      
4612  TEMPORARY COLOSTOMY      
4613  PERMANENT COLOSTOMY      
4620  ILEOSTOMY NOS      
4621  TEMPORARY ILEOSTOMY      
4622  CONTINENT ILEOSTOMY      
4623  PERMANENT ILEOSTOMY NEC     
4640  INTEST STOMA REVIS NOS    
4641  SM BOWEL STOMA REVISION    
4642  PERICOLOST HERNIA REPAIR     
4643  LG BOWEL STOMA REVIS NEC   
4650  INTEST STOMA CLOSURE NOS    
4651  SM BOWEL STOMA CLOSURE    
4652  LG BOWEL STOMA CLOSURE    
4660  INTESTINAL FIXATION NOS     
4661  SM BOWEL-ABD WALL FIXAT    
4662  SMALL BOWEL FIXATION NEC    
4663  LG BOWEL-ABD WALL FIXAT    
4664  LARGE BOWEL FIXATION NEC    
4671  DUODENAL LACERAT SUTURE     
4672  DUODENAL FISTULA CLOSURE     
4673  SMALL BOWEL SUTURE NEC    
4674  CLOSE SM BOWEL FIST NEC   
4675  SUTURE LG BOWEL LACERAT    
4676  CLOSE LG BOWEL FISTULA    
4679  REPAIR OF INTESTINE NEC    
4680  INTRA-AB BOWEL MANIP NOS    
4681  INTRA-ABD SM BOWEL MANIP    
4682  INTRA-ABD LG BOWEL MANIP    
4691  MYOTOMY OF SIGMOID COLON    
4692  MYOTOMY OF COLON NEC    
4693  REVISE SM BOWEL ANASTOM    
4694  REVISE LG BOWEL ANASTOM    
4697  TRANSPLANT OF INTESTINE     
4699  INTESTINAL OP NEC     
470  INTESTINAL OP NEC     
4701  LAP APPENDECTOMY      
4709  OTHER APPENDECTOMY      
471  OTHER APPENDECTOMY      
4711  LAP INCID APPENDECTOMY     
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4719  OTHER INCID APPENDECTOMY     
472  DRAIN APPENDICEAL ABSC     
4791  APPENDICOSTOMY       
4792  CLOSE APPENDICEAL FISTUL     
4799  APPENDICEAL OPS NEC     
480  PROCTOTOMY       
481  PROCTOSTOMY       
4821  TRANSAB PROCTOSIGMOIDOSC      
4825  OPEN RECTAL BIOPSY     
4835  LOCAL EXCIS RECTAL LES    
4840  PULL-THRU RES RECTUM NOS OCT08-   
4841  SOAVE SUBMUC RECT RESECT    
4842  LAP PULL-THRU RES RECTUM OCT08-   
4843  OPN PULL-THRU RES RECTUM OCT08-   
4849  PULL-THRU RECT RESEC NEC    
485  ABD-PERINEAL RECT RESECT     
4850  ABDPERNEAL RES RECTM NOS 0CT09-   
4851  LAP ABDPERNEAL RESC REC OCT08-   
4852  OPN ABDPERNEAL RESC REC OCT08-   
4859  ABDPERNEAL RESC RECT NEC OCT08-   
4861  TRANSSAC RECTOSIGMOIDECT      
4862  ANT RECT RESECT W COLOST   
4863  ANTERIOR RECT RESECT NEC    
4864  POSTERIOR RECT RESECTION     
4865  DUHAMEL RECTAL RESECTION     
4866  DUHAMEL RECTAL RESECTION     
4869  RECTAL RESECTION NEC     
4871  SUTURE OF RECTAL LACER    
4872  CLOSURE OF PROCTOSTOMY     
4873  CLOSE RECTAL FIST NEC    
4874  RECTORECTOSTOMY       
4875  ABDOMINAL PROCTOPEXY      
4876  PROCTOPEXY NEC      
4879  REPAIR OF RECTUM NEC    
4881  PERIRECTAL INCISION      
4882  PERIRECTAL EXCISION      
4891  INCIS RECTAL STRICTURE     
4892  ANORECTAL MYOMECTOMY      
4893  REPAIR PERIRECT FISTULA     
4899  RECTAL PERIRECT OP NEC    
4901  INCIS PERIANAL ABSCESS     
4902  PERIANAL INCISION NEC     
4904  PERIANAL EXCISION NEC     
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4911  ANAL FISTULOTOMY      
4912  ANAL FISTULECTOMY      
493  ANAL/PERIAN DX PROC NEC    
4939  OTHER DESTRUC ANUS LES    
4944  HEMORRHOID CRYOTHERAPY      
4945  HEMORRHOID LIGATION      
4946  HEMORRHOIDECTOMY       
4949  HEMORRHOID PROCEDURE NEC     
4951  LEFT LAT SPHINCTEROTOMY     
4952  POST SPHINCTEROTOMY      
4959  ANAL SPHINCTEROTOMY NEC     
496  EXCISION OF ANUS     
4971  SUTURE ANAL LACERATION     
4972  ANAL CERCLAGE      
4973  CLOSURE OF ANAL FISTULA    
4974  GRACILIS MUSC TRANSPLAN     
4975  IMPL OR REV ART ANAL SPH  
4976  REMOV ART ANAL SPHINCTER    
4979  ANAL SPHINCT REPAIR NEC    
4991  INCISION OF ANAL SEPTUM    
4992  INSERT SUBQ ANAL STIMUL    
4993  ANAL INCISION NEC     
4994  REDUCTION ANAL PROLAPSE     
4995  CONTROL ANAL HEMORRHAGE     
4999  ANAL OPERATION NEC     
500  HEPATOTOMY       
5012  OPEN LIVER BIOPSY     
5013  TRANSJUGULAR LIVER BX OCT08-    
5014  LAPAROSCOPIC LIVER BX OCT08-    
5019  HEPATIC DX PROC NEC    
5021  MARSUPIALIZAT LIVER LES     
5022  PARTIAL HEPATECTOMY      
5023  OPN ABLTN LIVER LES/TISS OCT06-   
5024  PERC ABLTN LIVER LES/TIS OCT06-   
5025  LAP ABLTN LIVER LES/TISS OCT06-   
5026  ABLTN LIVER LES/TISS NEC OCT06-   
5029  DESTRUC HEPATIC LES NEC    
503  HEPATIC LOBECTOMY      
504  TOTAL HEPATECTOMY      
5013  TRANSJUGULAR LIVER BX OCT08-    
5014  LAPAROSCOPIC LIVER BX OCT08-    
5051  AUXILIARY LIVER TRANSPL     
5059  LIVER TRANSPLANT NEC     
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5061  CLOSURE LIVER LACERAT     
5069  LIVER REPAIR NEC     
5102  TROCAR CHOLECYSTOSTOMY      
5103  CHOLECYSTOSTOMY NEC      
5104  CHOLECYSTOTOMY NEC      
5113  OPEN BILIARY TRACT BX    
5119  BILIARY TR DX PROC NEC   
5121  OTH PART CHOLECYSTECTOMY     
5122  CHOLECYSTECTOMY       
5123  LAPAROSCOPIC CHOLECYSTEC      
5124  LAP PART CHOLECYSTECTOMY     
5131  GB-TO-HEPAT DUCT ANAST     
5132  GB-TO-INTESTINE ANASTOM      
5133  GB-TO-PANCREAS ANASTOM      
5134  GB-TO-STOMACH ANASTOMOS      
5135  GALLBLADDER ANASTOM NEC     
5136  CHOLEDOCHOENTEROSTOMY       
5137  HEPATIC DUCT-GI ANASTOM     
5139  BILE DUCT ANASTOMOS NEC    
5141  CDE FOR CALCULUS REMOV    
5142  CDE FOR OBSTRUCTION NEC    
5143  CHOLEDOCHOHEPAT INTUBAT      
5149  INCIS OBSTR BILE DUC NEC   
5151  COMMON DUCT EXPLORATION     
5159  BILE DUCT INCISION NEC    
5161  EXCIS CYST DUCT REMNANT    
5162  EXCIS AMPULLA OF VATER    
5163  COMMON DUCT EXCIS NEC    
5169  BILE DUCT EXCISION NEC    
5171  SIMPLE SUT-COMMON DUCT     
5172  CHOLEDOCHOPLASTY       
5179  BILE DUCT REPAIR NEC    
5181  SPHINCTER OF ODDI DILAT    
5182  PANCREAT SPHINCTEROTOM      
5183  PANCREAT SPHINCTEROPLAS      
5189  SPHINCT OF ODDI OP NEC   
5191  REPAIR GB LACERATION     
5192  CLOSURE CHOLECYSTOSTOMY      
5193  CLOS BILIARY FISTUL NEC    
5194  REVIS BILE TRACT ANASTOM    
5195  REMOVE BILE DUCT PROSTH    
5199  BILIARY TRACT OP NEC    
5201  CATH DRAIN-PANCREAT CYST     
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5209  PANCREATOTOMY NEC      
5212  OPEN PANCREATIC BIOPSY     
5219  PANCREATIC DX PROC NEC    
522  PANCREATIC DX PROC NEC    
5222  OTHER DESTRU PANCREA LES    
523  PANCREAT CYST MARSUPIALI     
524  INT DRAIN PANCREAT CYST    
5251  PROXIMAL PANCREATECTOMY      
5252  DISTAL PANCREATECTOMY      
5253  RAD SUBTOT PANCREATECTOM     
5259  PARTIAL PANCREATECT NEC     
526  TOTAL PANCREATECTOMY      
527  RAD PANCREATICODUODENECT      
5280  PANCREAT TRANSPLANT NOS     
5281  REIMPLANT PANCREATIC TIS     
5282  PANCREATIC HOMOTRANSPLAN      
5283  PANCREATIC HETEROTRANSPL      
5291  TRNSPLNT ISLETS LANG NOS    
5292  CANNULATION PANCREA DUC     
5295  PANCREATIC REPAIR NEC     
5296  PANCREATIC ANASTOMOSIS      
5299  PANCREATIC OPERATION NEC     
5300  UNILAT ING HERN REP NOS   
5301  REPAIR DIRECT ING HERNIA    
5302  REPAIR INDIR ING HERNIA    
5303  DIR ING HERNIA REP-GRAFT    
5304  IND ING HERNIA REP-GRAFT    
5305  ING HERNIA REP-GRAFT NOS    
5310  BILAT ING HERNIA REP NOS   
5311  BILAT DIR ING HERN REP   
5312  BILAT IND ING HERN REP   
5313  BIL DIR/IND ING HRN REP   
5314  BIL DIR ING HRN REP-GRFT   
5315  BIL IND ING HRN REP-GRFT   
5316  BIL DIR/IND ING HERN-PRO    
5317  BIL ING HRN REP-GRFT NOS   
5321  UNIL FEMOR HRN REP-GRFT    
5329  UNIL FEMOR HERN REP NEC   
5331  BIL FEM HERN REPAIR-GRFT    
5339  BIL FEM HERN REPAIR NEC   
5341  UMBIL HERNIA REPAIR-GRFT     
5342  LAP UMBIL HERNIA-GRAFT OCT08-    
5343  LAP UMBILICAL HERNIA NEC OCT08-   
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5349  UMBIL HERNIA REPAIR NEC    
5351  INCISIONAL HERNIA REPAIR     
5359  ABD WALL HERN REPAIR NEC   
5361  INCIS HERNIA REPAIR-GRFT     
5362  LAP INCIS HERN REPR-GRFT OCT08-   
5363  LAP HERN ANT ABD-GFT NEC OCT08-  
5369  ABD HERN REPAIR-GRFT NEC    
537  ABD REPAIR-DIAPHR HERNIA     
5371  LAP ABD REP-DIAPHR HERN OCT08-   
5372  OPN ABD DIAPHRM HERN NEC OCT08-  
5375  ABD REP-DIAPHR HERN NOS OCT08-   
5380  THOR REP-DIAPH HERN NOS    
5381  DIAPHRAGMATIC PLICATION      
5382  PARASTERN HERNIA REPAIR     
5383  LAP THORC APP-DIAPH HERN OCT08-   
5384  OPN THORC DIAPH HERN NEC OCT08-  
539  OTHER HERNIA REPAIR     
540  ABDOMINAL WALL INCISION     
5411  EXPLORATORY LAPAROTOMY      
5412  REOPEN RECENT LAP SITE    
5419  LAPAROTOMY NEC      
5421  LAPAROSCOPY       
5422  ABDOMINAL WALL BIOPSY     
5423  PERITONEAL BIOPSY      
5429  ABD REGION DX PROC NEC   
543  DESTRUCT ABD WALL LESION    
544  DESTRUCT PERITONEAL TISS     
545  DESTRUCT PERITONEAL TISS     
5451  LAP PERITON ADHESIOLYSIS     
5459  OTH PERITON ADHESIOLYSIS     
5461  RECLOSE POST OP DISRUPT    
5462  DELAYED CLOS ABD WOUND    
5463  ABD WALL SUTURE NEC    
5464  PERITONEAL SUTURE      
5471  REPAIR OF GASTROSCHISIS     
5472  ABDOMEN WALL REPAIR NEC    
5473  PERITONEAL REPAIR NEC     
5474  OMENTAL REPAIR NEC     
5475  MESENTERIC REPAIR NEC     
5492  REMOVE FB FROM PERITON    
5493  CREATE CUTANPERITON FIST     
5494  CREAT PERITONEOVAS SHUNT     
5495  PERITONEAL INCISION      
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5501  NEPHROTOMY       
5502  NEPHROSTOMY       
5503  PERCU NEPHROSTM W/O FRAG    
5504  PERCU NEPHROSTMY W FRAG    
5511  PYELOTOMY       
5512  PYELOSTOMY       
5524  OPEN RENAL BIOPSY     
5529  RENAL DIAGNOST PROC NEC    
5531  RENAL LES MARSUPIALIZAT     
5532  OPN ABLTN RENAL LES/TISS OCT06-   
5533  PERC ABLTN RENL LES/TISS OCT06-   
5534  LAP ABLTN RENAL LES/TISS OCT06-   
5535  ABLTN RENAL LES/TISS NEC OCT06-   
5539  LOC DESTR RENAL LES NEC   
554  PARTIAL NEPHRECTOMY      
5551  NEPHROURETERECTOMY       
5552  SOLITARY KIDNEY NEPHRECT     
5553  REJECTED KIDNEY NEPHRECT     
5554  BILATERAL NEPHRECTOMY      
5561  RENAL AUTOTRANSPLANT      
5569  KIDNEY TRANSPLANT NEC     
557  NEPHROPEXY       
5581  SUTURE KIDNEY LACERATION     
5582  CLOSE NEPHROST & PYELOST    
5583  CLOSE RENAL FISTULA NEC    
5584  REDUCE RENAL PEDICL TORS    
5585  SYMPHYSIOTOMY       
5586  RENAL ANASTOMOSIS      
5587  CORRECT URETEROPELV JUNC     
5589  RENAL REPAIR NEC     
5591  RENAL DECAPSULATION      
5597  IMPLANT MECHANIC KIDNEY     
5598  REMOV MECHANICAL KIDNEY     
5599  RENAL OPERATION NEC     
560  TU REMOV URETER OBSTRUCT    
561  URETERAL MEATOTOMY      
562  URETEROTOMY       
5634  OPEN URETERAL BIOPSY     
5639  URETERAL DX PROCEDUR NEC    
5640  URETERECTOMY NOS      
5641  PARTIAL URETERECTOMY      
5642  TOTAL URETERECTOMY      
5651  FORM CUTAN ILEOURETEROST     
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5652  REVIS CUTAN ILEOURETEROS     
5661  FORM CUTAN URETEROSTOMY     
5662  REVIS CUTAN URETEROS NEC    
5671  URIN DIVERSION TO BOWEL    
5672  REVIS URETEROENTEROSTOMY      
5673  NEPHROCYSTANASTOMOSI NOS      
5674  URETERONEOCYSTOSTOMY       
5675  TRANSURETEROURETEROSTOMY       
5679  URETERAL ANASTOMOSIS NEC     
5681  INTRALUM URETE ADHESIOLY     
5682  SUTURE URETERAL LACERAT     
5683  URETEROSTOMY CLOSURE      
5684  CLOSE URETER FISTULA NEC    
5685  URETEROPEXY       
5686  REMOVE URETERAL LIGATURE     
5689  REPAIR OF URETER NEC    
5692  IMPLANT URETERAL STIMUL     
5693  REPLACE URETERAL STIMUL     
5694  REMOVE URETERAL STIMULAT     
5695  LIGATION OF URETER     
5699  URETERAL OPERATION NEC     
5712  CYSTOTOMY & ADHESIOLYSIS     
5718  OTHER SUPRAPU CYSTOSTOMY     
5719  CYSTOTOMY NEC      
5721  VESICOSTOMY       
5722  REVISE CLO VESICOSTOMY     
5733  CLOS TRANSURETH BLADD BX    
5734  OPEN BLADDER BIOPSY     
5739  BLADDER DIAGNOS PROC NEC    
5741  TU ADHESIOLYSIS BLADDER     
5749  TU DESTRUC BLADD LES NEC   
5751  EXCISION OF URACHUS     
5759  BLADDER LES DESTRUCT NEC    
576  PARTIAL CYSTECTOMY      
5771  RADICAL CYSTECTOMY      
5779  TOTAL CYSTECTOMY NEC     
5781  SUTURE BLADDER LACERAT     
5782  CYSTOSTOMY CLOSURE      
5783  ENTEROVESICO FIST REPAIR     
5784  VESIC FISTULA REPAIR NEC    
5785  CYSTOURETHROPLASTY       
5786  BLADDER EXSTROPHY REPAIR     
5787  BLADDER RECONSTRUCTION      
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5788  BLADDER ANASTOMOSIS NEC     
5789  BLADDER REPAIR NEC     
5791  BLADDER SPHINCTEROTOMY      
5793  CONTROL BLADD HEMORRHAGE     
5796  IMPLANT BLADDER STIMULAT     
5797  REPLACE BLADDER STIMULAT     
5798  REMOVE BLADDER STIMULAT     
5799  BLADDER OPERATION NEC     
580  URETHROTOMY       
581  URETHRAL MEATOTOMY      
5841  SUTURE URETHRAL LACERAT     
5842  URETHROSTOMY CLOSURE      
5843  CLOSE URETH FISTULA NEC    
5844  URETHRAL REANASTOMOSIS      
5845  HYPO-EPISPADIUS REPAIR      
5846  URETH RECONSTRUCTION NEC     
5847  URETHRAL MEATOPLASTY      
5849  URETHRAL REPAIR NEC     
585  URETH STRICTURE RELEASE     
5891  PERIURETHRAL INCISION      
5892  PERIURETHRAL EXCISION      
5893  IMPLT ARTF URIN SPHINCT    
5899  URETH/PERIURETH OP NEC     
5900  RETROPERIT DISSECT NOS     
5901  RETROPERIT DISSECT NOS     
5902  PERIREN ADHESIOLYS NEC     
5903  LAP LYS PERIREN/URET ADH    
5909  PERIREN/URETER INCIS NEC     
5911  OTH LYS PERIVES ADHESIO    
5912  LAP LYS PERIVESURETH ADH    
5919  PERIVESICAL INCISION NEC     
5921  PERIREN/URETERAL BIOPSY      
5929  PERIREN/URET DX PROC NEC    
593  URETHROVES JUNCT PLICAT     
594  SUPRAPUBIC SLING OP     
595  RETROPUBIC URETH SUSPENS     
596  PARAURETHRAL SUSPENSION      
5971  LEVATOR MUSC SUSPENSION     
5979  URIN INCONTIN REPAIR NEC    
5991  PERIREN/VESICLE EXCISION      
5992  PERIREN/VESICLE OP NEC     
600  INCISION OF PROSTATE     
6012  OPEN PROSTATIC BIOPSY     
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6014  OPEN SEMINAL VESICLES BX    
6015  PERIPROSTATIC BIOPSY      
6018  PROSTATIC DX PROCED NEC    
6019  SEMIN VES DX PROCED NEC   
602  SEMIN VES DX PROCED NEC   
6021  TRANSURETH PROSTATECTOMY      
6029  OTH TRANSURETH PROSTATEC     
603  SUPRAPUBIC PROSTATECTOMY      
604  RETROPUBIC PROSTATECTOMY      
605  RADICAL PROSTATECTOMY      
6061  LOS EXCIS PROSTATIC LES    
6062  PERINEAL PROSTATECTOMY      
6069  PROSTATECTOMY NEC      
6072  SEMINAL VESICLE INCISION     
6073  SEMINAL VESICLE EXCISION     
6079  SEMINAL VESICLE OP NEC    
6081  PERIPROSTATIC INCISION      
6082  PERIPROSTATIC EXCISION      
6093  REPAIR OF PROSTATE     
6094  CONTROL PROSTATE HEMORR     
6095  TRANS BAL DIL PROS URETH   
6096  TU DESTR PROSTATE BY MT   
6097  OTH TU DESTR PROS - RT  
6099  PROSTATIC OPERATION NEC     
612  EXCISION OF HYDROCELE     
6142  SCROTAL FISTULA REPAIR     
6149  SCROTUM/TUNIC REPAIR NEC     
6192  EXCISION TUNICA LES NEC    
6199  SCROTUM & TUNICA OP NEC   
620  INCISION OF TESTES     
6212  OPEN TESTICULAR BIOPSY     
6219  TESTES DX PROCEDURE NEC    
622  TESTICULAR LES DESTRUCT     
623  UNILATERAL ORCHIECTOMY      
6241  REMOVE BOTH TESTES     
6242  REMOVE SOLITARY TESTIS     
625  ORCHIOPEXY       
6261  SUTURE TESTICULAR LACER     
6269  TESTICULAR REPAIR NEC     
627  INSERT TESTICULAR PROSTH     
6299  TESTICULAR OPERATION NEC     
6309  SPERMAT CORD/VAS DX NEC    
631  EXC SPERMATIC VARICOCELE     
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632  EXCISE EPIDIDYMIS CYST     
633  EXCISE CORD/EPID LES NEC    
634  EPIDIDYMECTOMY       
6351  SUTURE CORD & EPID LACER   
6353  TRANSPLANT SPERMAT CORD     
6359  CORD & EPIDID REPAIR NEC   
6381  SUTURE VAS & EPIDID LAC   
6382  POSTOP VAS RECONSTRUCT     
6383  EPIDIDYMOVASOSTOMY       
6385  REMOV VAS DEFERENS VALVE    
6389  VAS & EPIDIDY REPAIR NEC   
6392  EPIDIDYMOTOMY       
6393  SPERMATIC CORD INCISION     
6394  SPERM CORD ADHESIOLYSIS     
6395  INSERT VALVE IN VAS DEF   
6399  CORD/EPID/VAS OPS NEC     
640  CIRCUMCISION       
6411  PENILE BIOPSY      
642  LOCAL EXCIS PENILE LES    
643  AMPUTATION OF PENIS     
6441  SUTURE PENILE LACERATION     
6442  RELEASE OF CHORDEE     
6443  CONSTRUCTION OF PENIS     
6444  RECONSTRUCTION OF PENIS     
6445  REPLANTATION OF PENIS     
6449  PENILE REPAIR NEC     
645  SEX TRANSFORMAT OP NEC    
6492  INCISION OF PENIS     
6493  DIVISION OF PENILE ADHES    
6495  INS NONINFL PENIS PROSTH    
6496  REMOVE INT PENILE PROSTH    
6497  INS INFLATE PENIS PROSTH    
6498  PENILE OPERATION NEC     
6499  MALE GENITAL OP NEC    
650  MALE GENITAL OP NEC    
6501  LAPAROSCOPIC OOPHOROTOMY      
6509  OTHER OOPHOROTOMY      
6511  OVARIAN ASPIRAT BIOPSY     
6512  OVARIAN BIOPSY NEC     
6513  LAP BIOPSY OF OVARY    
6514  OTH LAP DX PROC OVARIES   
6519  OVARIAN DX PROCEDURE NEC    
6521  OVARIAN CYST MARSUPIALIZ     
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6522  OVARIAN WEDGE RESECTION     
6523  LAP MARSUP OVARIAN CYST    
6524  LAP WEDGE RESECT OVARY    
6525  OTH LAP LOC EXC DEST OVA  
6529  LOCAL DESTR OVA LES NEC   
653  LOCAL DESTR OVA LES NEC   
6531  LAP UNILAT OOPHORECTOMY     
6539  OTH UNILAT OOPHORECTOMY     
654  OTH UNILAT OOPHORECTOMY     
6541  LAP UNI SALPINGO-OOPHOR     
6549  OTH UNI SALPINGO-OOPHOR     
6551  OTH REMOVE BOTH OVARIES    
6552  OTH REMOVE REMAIN OVARY    
6553  LAP REMOVE BOTH OVARIES    
6554  LAP REMOVE REMAIN OVARY    
6561  OTH REMOVE OVARIES/TUBES     
6562  OTH REMOVE REM OVA/TUBE    
6563  LAP REMOVE OVARIES/TUBES     
6564  LAP REMOVE REM OVA/TUBE    
6571  OTH SIMPLE SUTURE OVARY    
6572  OTH REIMPLANT OF OVARY    
6573  OTH SALPINGO-OOPHOROPLAS      
6574  LAP SIMPLE SUTURE OVARY    
6575  LAP REIMPLANT OF OVARY    
6576  LAP SALPINGO-OOPHOROPLAS      
6579  REPAIR OF OVARY NEC    
658  REPAIR OF OVARY NEC    
6581  LAP ADHESIOLYS OVA/TUBE     
6589  ADHESIOLYSIS OVARY/TUBE      
6591  ASPIRATION OF OVARY     
6592  TRANSPLANTATION OF OVARY     
6593  MANUAL RUPT OVARIAN CYST    
6594  OVARIAN DENERVATION      
6595  OVARIAN TORSION RELEASE     
6599  OVARIAN OPERATION NEC     
660  OVARIAN OPERATION NEC     
6601  SALPINGOTOMY       
6602  SALPINGOSTOMY       
6611  FALLOPIAN TUBE BIOPSY     
6619  FALLOP TUBE DX PROC NEC   
6621  BILAT ENDOSC CRUSH TUBE    
6622  BILAT ENDOSC DIVIS TUBE    
6629  BILAT ENDOS OCC TUBE NEC   
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6631  BILAT TUBAL CRUSHING NEC    
6632  BILAT TUBAL DIVISION NEC    
6639  BILAT TUBAL DESTRUCT NEC    
664  TOTAL UNILAT SALPINGECT     
6651  REMOVE BOTH FALLOP TUBES    
6652  REMOVE SOLITARY FAL TUBE    
6661  DESTROY FALLOP TUBE LES    
6662  REMOV TUBE & ECTOP PREG   
6663  BILAT PART SALPINGEC NOS    
6669  PARTIAL SALPINGECTOM NEC     
6671  SIMPL SUTURE FALLOP TUBE    
6672  SALPINGO-OOPHOROSTOMY       
6673  SALPINGO-SALPINGOSTOMY       
6674  SALPINGO-UTEROSTOMY       
6679  FALLOP TUBE REPAIR NEC    
6692  UNILAT FALLOP TUBE DESTR    
6693  IMPL FALLOP TUBE PROSTH    
6694  REMOV FALLOP TUBE PROSTH    
6695  BLOW THERAPEUT INTO TUBE    
6696  FALLOPIAN TUBE DILATION     
6697  BURY FIMBRIAE IN UTERUS    
6699  FALLOPIAN TUBE OP NEC    
6711  ENDOCERVICAL BIOPSY      
6712  CERVICAL BIOPSY NEC     
6719  CERVICAL DX PROCEDUR NEC    
672  CONIZATION OF CERVIX     
6731  CERVICAL CYST MARSUPIAL     
6732  CERVICAL LES CAUTERIZAT     
6733  CERVICAL LES CRYOTHERAPY     
6739  CERVICAL LES DESTRUC NEC    
674  AMPUTATION OF CERVIX     
675  AMPUTATION OF CERVIX     
6751  TRANSAB CERCLAGE CERVIX     
6759  OTH REP INT CERVICAL OS   
6761  SUTURE CERVICAL LACERAT     
6762  CERVICAL FISTULA REPAIR     
6769  CERVICAL REPAIR NEC     
680  HYSTEROTOMY       
6813  OPEN UTERINE BIOPSY     
6814  OPEN UTERINE LIGAMENT BX    
6815  CLOS UTERINE LIGAMENT BX    
6816  CLOSED UTERINE BIOPSY     
6819  UTERUS/ADNEX DX PROC NEC    
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6821  ENDOMET SYNECHIAE DIVIS     
6822  INCISION UTERINE SEPTUM     
6823  ENDOMETRIAL ABLATION      
6829  UTERINE LES DESTRUCT NEC    
683  UTERINE LES DESTRUCT NEC    
6831  LAP SCERVIC HYSTERECTOMY     
6839  OTH SUBTOT ABD HYSTERECT OCT03-   
684  TOTAL ABD HYSTERECTOMY     
6841  LAP TOTAL ABDOMINAL HYST OCT06-   
6849  TOTAL ABD HYST NEC/NOS OCT06-   
685  VAGINAL HYSTERECTOMY      
6851  LAP AST VAG HYSTERECTOMY    
6859  VAG HYSTERECTOMY NEC/NOS     
686  RADICAL ABD HYSTERECTOMY     
6861  LAP RADICAL ABDOMNL HYST OCT06-   
6869  RADICAL ABD HYST NEC/NOS OCT06-   
687  RADICAL VAG HYSTERECTOMY     
6871  LAP RADICAL VAGINAL HYST OCT06-   
6879  RADICAL VAG HYST NEC/NOS OCT06-   
688  PELVIC EVISCERATION      
689  HYSTERECTOMY NEC/NOS      
6901  D & C FOR PREG TERMINAT  
6902  D & C POST DELIVERY   
6909  D & C NEC    
6911  D & C NEC    
6919  DESTRUC UTER SUPPORT NEC    
6921  INTERPOSIT OP UTERIN LIG    
6922  UTERINE SUSPENSION NEC     
6923  VAG REPAIR INVERS UTERUS    
6929  UTERUS/ADNEXA REPAIR NEC     
693  PARACERV UTERINE DENERV     
6941  SUTURE UTERINE LACERAT     
6942  CLOSURE UTERINE FISTULA     
6949  UTERINE REPAIR NEC     
6951  ASPIRAT CURET-PREG TERMI     
6952  ASPIRAT CURET-POST DELIV     
6995  INCISION OF CERVIX     
6997  REMOVE PENETRAT CERV FB    
6998  UTERINE SUPPORT OP NEC    
6999  UTERINE OPERATION NEC     
7012  CULDOTOMY       
7013  INTRALUM VAG ADHESIOLYS     
7014  VAGINOTOMY NEC      
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7023  CUL-DE-SAC BIOPSY      
7024  VAGINAL BIOPSY      
7029  VAGIN/CUL-DE-SAC DX NEC     
7031  HYMENECTOMY       
7032  EXCIS CUL-DE-SAC LESION     
7033  EXCISION VAGINAL LESION     
704  VAGINAL OBLITERATION      
7050  CYSTOCEL/RECTOCEL REPAIR      
7051  CYSTOCELE REPAIR      
7052  RECTOCELE REPAIR      
7053  CYSTO & RECTO W GRF/PROS OCT08-  
7054  REP CYSTOCEL W GRFT/PROS OCT08-   
7055  REP RECTOCELE W GRF/PROS    
7061  VAGINAL CONSTRUCTION      
7062  VAGINAL RECONSTRUCTION      
7063  VAGINAL CONST W GRF/PROS OCT08-   
7064  VAG RECONST W GRFT/PROS OCT08-   
7071  SUTURE VAGINA LACERATION     
7072  REPAIR COLOVAGIN FISTULA     
7073  REPAIR RECTOVAG FISTULA     
7074  REP VAGINOENT FISTUL NEC    
7075  REPAIR VAG FISTULA NEC    
7076  HYMENORRHAPHY       
7077  VAGINAL SUSPENS & FIXAT    
7078  VAG SUSP/FIX W GRFT/PROS OCT08-   
7079  VAGINAL REPAIR NEC     
708  VAGINAL VAULT OBLITERAT     
7091  VAGINAL OPERATION NEC     
7092  CUL-DE-SAC OPERATION NEC     
7093  CUL-DE-SAC GRF/PROS NEC OCT08-    
7101  VULVAR ADHESIOLYSIS      
7109  INCIS VULVA/PERINEUM NEC     
7111  VULVAR BIOPSY      
7119  VULVAR DIAGNOS PROC NEC    
7122  INCISE BARTHOLIN"S GLAND     
7123  BARTHOLIN GLAND MARSUP     
7124  DESTRUC BARTHOLIN GLAND     
7129  BARTHOLIN"S GLAND OP NEC    
713  LOCAL VULVAR EXCIS NEC    
714  OPERATIONS ON CLITORIS     
715  RADICAL VULVECTOMY      
7161  UNILATERAL VULVECTOMY      
7162  BILATERAL VULVECTOMY      
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7171  SUTURE VULVAR LACERATION     
7172  REPAIR VULVAR FISTULA     
7179  VULVAR/PERIN REPAIR NEC     
718  OTHER VULVAR OPERATIONS     
719  OTHER FEMALE GENITAL OPS    
7394  PUBIOTOMY TO ASSIST DEL    
7399  OPS ASSISTING DELIV NEC    
740  CLASSICAL C-SECTION      
741  LOW CERVICAL C-SECTION     
742  EXTRAPERITONEAL C-SECT      
743  REM EXTRATUB ECTOP PREG    
744  CESAREAN SECTION NEC     
7491  HYSTEROTOMY TO TERMIN PG    
7499  CESAREAN SECTION NOS     
7536  CORRECTION FETAL DEFECT     
7550  REPAIR OB LAC UTERUS NOS   
7551  REPAIR OB LACERAT CERVIX    
7552  REPAIR OB LAC CORP UTERI   
7561  REPAIR OB LAC BLAD/URETH    
7593  SURG CORR INVERT UTERUS    
7599  OBSTETRIC OPERATION NEC     
7601  FACIAL BONE SEQUESTRECT     
7609  FACIAL BONE INCISION NEC    
7611  FACIAL BONE BIOPSY     
7619  FACIAL BONE DX PROC NEC   
762  DESTRUCT FACIAL BONE LES    
7631  PARTIAL MANDIBULECTOMY      
7639  PART FACIAL OSTECTOM NEC    
7641  TOT MANDIBULEC W RECONST    
7642  TOTAL MANDIBULECTOMY NEC     
7643  MANDIBULAR RECONST NEC     
7644  TOT FACE OSTECT W RECONS   
7645  TOT FACE BONE OSTECT NEC   
7646  FACIAL BONE RECONSTR NEC    
765  TEMPOROMAND ARTHROPLASTY      
7661  CL OSTEOPLASTY MAND RAMI    
7662  OPEN OSTEOPLAS MAND RAMI    
7663  OSTEOPLASTY MANDIBLE BDY     
7664  MAND ORTHOGNATHIC OP NEC    
7665  SEG OSTEOPLASTY MAXILLA     
7666  TOT OSTEOPLASTY MAXILLA     
7667  REDUCTION GENIOPLASTY      
7668  AUGMENTATION GENIOPLASTY      
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7669  FACIAL BONE REPAIR NEC    
7670  REDUCTION FACIAL FX NOS    
7672  OPN REDUCT MALAR/ZYGO FX    
7674  OPEN REDUCT MAXILLARY FX    
7676  OPEN REDUCT MANDIBLE FX    
7677  OPEN REDUCT ALVEOLAR FX    
7679  OPEN REDUCT FACE FX NEC   
7691  BONE GRAFT TO FACE BONE   
7692  SYN IMPLANT TO FACE BONE   
7694  OPEN REDUCT TM DISLOCAT    
7697  REMOVE INT FIX FACE BONE   
7699  FACIAL BONE/JNT OP NEC    
7700  SEQUESTRECTOMY NOS      
7701  CHEST CAGE SEQUESTREC     
7702  HUMERUS SEQUESTRECTOMY      
7703  RADIUS & ULNA SEQUESTREC    
7704  METACARP/CARP SEQUESTREC      
7705  FEMORAL SEQUESTRECTOMY      
7706  PATELLAR SEQUESTRECTOMY      
7707  TIBIA/FIBULA SEQUESTREC      
7708  METATAR/TAR SEQUESTREC      
7709  SEQUESTRECTOMY NEC      
7710  OTHER BONE INCISION NOS    
7711  OTHER CHEST CAGE INCIS    
7712  OTHER HUMERUS INCISION     
7713  OTHER RADIUS/ULNA INCIS     
7714  OTH METACARP/CARP INCIS     
7715  OTHER FEMORAL INCISION     
7716  OTHER PATELLAR INCISION     
7717  OTHER TIBIA/FIBULA INCIS     
7718  OTH METATARS/TARS INCIS     
7719  BONE INCIS W/O DIV NEC   
7720  WEDGE OSTEOTOMY NOS     
7721  CHEST CAGE WEDG OSTEOTOM    
7722  HUMERUS WEDGE OSTEOTOMY     
7723  RADIUS/ULNA WEDG OSTEOTO     
7724  METACAR/CAR WEDG OSTEOTO     
7725  FEMORAL WEDGE OSTEOTOMY     
7726  PATELLAR WEDGE OSTEOTOMY     
7727  TIBIA/FIBUL WEDG OSTEOT     
7728  METATAR/TAR WEDG OSTEOT     
7729  WEDGE OSTEOTOMY NEC     
7730  OTHER BONE DIVISION NOS    
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7731  CHEST CAGE BONE DIV NEC   
7732  HUMERUS DIVISION NEC     
7733  RADIUS/ULNA DIVISION NEC     
7734  METACAR/CAR DIVISION NEC     
7735  FEMORAL DIVISION NEC     
7736  PATELLAR DIVISION NEC     
7737  TIBIA/FIBULA DIV NEC     
7738  METATAR/TAR DIVISION NEC     
7739  BONE DIVISION NEC     
7740  BONE BIOPSY NOS     
7741  CHEST CAGE BONE BIOPSY    
7742  HUMERUS BIOPSY      
7743  RADIUS & ULNA BIOPSY    
7744  METACARPAL/CARPAL BIOPSY      
7745  FEMORAL BIOPSY      
7746  PATELLAR BIOPSY      
7747  TIBIA & FIBULA BIOPSY    
7748  METATARSAL/TARSAL BIOPSY      
7749  BONE BIOPSY NEC     
7751  BUNIONECT/SFT/OSTEOTOMY       
7752  BUNIONECT/SFT/ARTHRODES       
7753  OTH BUNIONECT W SFT CORR   
7754  EXC CORRECT BUNIONETTE     
7756  REPAIR OF HAMMER TOE    
7757  REPAIR OF CLAW TOE    
7758  OTH EXC, FUS, REPAIR TOE   
7759  BUNIONECTOMY NEC      
7760  LOC EXC BONE LESION NOS   
7761  EXC CHEST CAGE BONE LES   
7762  LOC EXC BONE LES HUMERUS   
7763  LOC EXC LES RADIUS/ULNA    
7764  LOC EXC LES METACAR/CAR    
7765  LOC EXC BONE LES FEMUR   
7766  LOC EXC BONE LES PATELLA   
7767  LOC EXC LES TIBIA/FIBULA    
7768  LOC EXC LES METATAR/TAR    
7769  LOC EXC BONE LESION NEC   
7770  EXCISE BONE FOR GRFT NOS   
7771  EX CHEST CAGE BONE-GFT    
7772  EXCISE HUMERUS FOR GRAFT    
7773  EXCIS RADIUS/ULNA-GRAFT      
7774  EXCIS METACAR/CAR-GRAFT      
7775  EXCISE FEMUR FOR GRAFT    
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7776  EXCISE PATELLA FOR GRAFT    
7777  EXCISE TIB/FIB FOR GRAFT    
7778  EXCIS METATAR/TAR-GRAFT      
7779  EXCISE BONE FOR GFT NEC   
7780  OTH PART OSTECTOMY NOS    
7781  OTH CHEST CAGE OSTECTOMY    
7782  PARTIAL HUMERECTOMY NEC     
7783  PART OSTECT-RADIUS/ULNA      
7784  PART OSTECT-METACAR/CAR      
7785  PART OSTECTOMY-FEMUR      
7786  PARTIAL PATELLECTOMY      
7787  PART OSTECT-TIBIA/FIBULA      
7788  PART OSTECT-METATAR/TAR      
7789  PARTIAL OSTECTOMY NEC     
7790  TOTAL OSTECTOMY NOS     
7791  TOT CHEST CAGE OSTECTOMY    
7792  TOTAL OSTECTOMY-HUMERUS      
7793  TOT OSTECT-RADIUS/ULNA      
7794  TOT OSTECT-METACARP/CARP      
7795  TOT OSTECTOMY-FEMUR      
7796  TOTAL PATELLECTOMY      
7797  TOT OSTECT-TIBIA/FIBULA      
7798  TOT OSTECT-METATARS/TARS      
7799  TOTAL OSTECTOMY NEC     
7800  BONE GRAFT NOS     
7801  BONE GRAFT TO CHEST CAGE   
7802  BONE GRAFT TO HUMERUS    
7803  BONE GRAFT-RADIUS/ULNA      
7804  BONE GRFT TO METACAR/CAR    
7805  BONE GRAFT TO FEMUR    
7806  BONE GRAFT TO PATELLA    
7807  BONE GRAFT-TIBIA/FIBULA      
7808  BONE GRAFT-METATAR/TAR      
7809  BONE GRAFT NEC     
7810  APPLIC EXT FIX DEV NOS   
7811  APPL EXT FIX-CHEST CAGE    
7812  APPLIC EXT FIX-HUMERUS     
7813  APPL EXT FIX-RADIUS/ULNA     
7814  APPL EXT FIX-METACAR/CAR     
7815  APPLIC EXT FIX DEV-FEMUR    
7816  APPL EXT FIX DEV-PATELLA    
7817  APPL EXT FIX-TIB/FIBULA     
7818  APPL EXT FIX-METATAR/TAR     
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7819  APPLIC EXT FIX DEV NEC   
7820  LIMB SHORTEN PROC NOS    
7822  LIMB SHORT PROC-HUMERUS     
7823  LIMB SHORTEN-RADIUS/ULNA      
7824  LIMB SHORTEN-METACAR/CAR      
7825  LIMB SHORT PROC-FEMUR     
7827  LIMB SHORTEN-TIB/FIBULA      
7828  LIMB SHORTEN-METATAR/TAR      
7829  LIMB SHORTEN PROC NEC    
7830  LIMB LENGTHEN PROC NOS    
7831  LIMB LENGTHEN PROC NOS    
7832  LIMB LENGTH PROC-HUMERUS     
7833  LIMB LENGTH-RADIUS/ULNA      
7834  LIMB LENGTH-METACAR/CAR      
7835  LIMB LENGTH PROC-FEMUR     
7837  LIMB LENGTHEN-TIB/FIBULA      
7838  LIMB LENGTHN-METATAR/TAR      
7839  LIMB LENGTHEN PROC NEC    
7840  OTH BONE REPAIR/PLAST OP    
7841  OTH CHEST CAGE REP/PLAST    
7842  OTH HUMERUS REPAIR/PLAST     
7843  OTH RAD/ULN REPAIR/PLAST     
7844  OTH METAC/CARP REP/PLAST     
7845  OTH FEMUR REPAIR/PLASTIC     
7846  OTH PATELLA REPAIR/PLAST     
7847  OTH TIB/FIB REPAIR/PLAST     
7848  OTH META/TAR REPA/PLAST     
7849  OTH BONE REPA/PLAST NEC    
7850  INT FIX W/O FX REDUC NOS  
7851  INT FIXATION-CHEST CAGE     
7852  INT FIXATION-HUMERUS      
7853  INT FIXATION-RADIUS/ULNA      
7854  INT FIXATION-METACAR/CAR      
7855  INTERNAL FIXATION-FEMUR      
7856  INTERNAL FIX-PATELLA      
7857  INT FIXATION-TIBIA/FIBUL      
7858  INT FIXATION-METATAR/TAR      
7859  INT FIX-NO FX REDUCT NEC   
7860  REMOVE IMP DEVICE NOS    
7861  REMOV IMP DEV-CHEST CAGE    
7862  REMOVE IMPL DEV-HUMERUS     
7863  REMOV IMP DEV-RADIUS/ULN     
7864  REMOV IMP DEV-METAC/CARP     
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7865  REMOVE IMP DEVICE-FEMUR     
7866  REMOV IMP DEVICE-PATELLA     
7867  REMOV IMP DEV-TIB/FIBULA     
7868  REMOVE IMP DEV-METAT/TAR     
7869  REMOVE IMPL DEVICE NEC    
7870  OSTEOCLASIS NOS      
7871  OSTEOCLASIS-CHEST CAGE      
7872  OSTEOCLASIS-HUMERUS       
7873  OSTEOCLASIS-RADIUS/ULNA       
7874  OSTEOCLASIS-METACAR/CAR       
7875  OSTEOCLASIS-FEMUR       
7876  OSTEOCLASIS-PATELLA       
7877  OSTEOCLASIS-TIBIA/FIBULA       
7878  OSTEOCLASIS-METATAR/TAR       
7879  OSTEOCLASIS NEC      
7880  OTHER BONE DX PROC NOS   
7881  OTH DX PROCED-CHEST CAGE    
7882  OTH DX PROCED-HUMERUS     
7883  OTH DX PROC-RADIUS/ULNA     
7884  OTH DX PROC-METACAR/CAR     
7885  OTH DX PROCED-FEMUR     
7886  OTH DX PROCED-PATELLA     
7887  OTH DX PROC-TIBIA/FIBULA     
7888  OTH DX PROC-METATAR/TAR     
7889  OTHER BONE DX PROC NEC   
7890  INSERT BONE STIMUL NOS    
7891  INSERT BONE STIMUL-CHEST     
7892  INSERT BONE STIM-HUMERUS     
7893  INSER BONE STIM-RAD/ULNA     
7894  INSER BONE STIM-META/CAR     
7895  INSERT BONE STIM-FEMUR     
7896  INSERT BONE STIM-PATELLA     
7897  INSER BONE STIM-TIB/FIB     
7898  INSER BONE STIM-META/TAR     
7899  INSERT BONE STIMUL NEC    
7910  CL FX REDUC-INT FIX NOS   
7911  CLOS RED-INT FIX HUMERUS    
7912  CL RED-INT FIX RAD/ULNA    
7913  CL RED-INT FIX METAC/CAR    
7914  CLOSE RED-INT FIX FINGER    
7915  CLOSED RED-INT FIX FEMUR    
7916  CL RED-INT FIX TIB/FIBU    
7917  CL RED-INT FIX METAT/TAR    
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7918  CLOSE RED-INT FIX TOE FX   
7919  CL FX REDUC-INT FIX NEC   
7920  OPEN FX REDUCTION NOS    
7921  OPEN REDUC-HUMERUS FX     
7922  OPEN REDUC-RADIUS/ULN FX     
7923  OPEN REDUC-METAC/CAR FX     
7924  OPEN REDUCTION-FINGER FX     
7925  OPEN REDUCTION-FEMUR FX     
7926  OPEN REDUC-TIBIA/FIB FX     
7927  OPEN REDUC-METAT/TARS FX     
7928  OPEN REDUCTION-TOE FX     
7929  OPEN FX REDUCTION NEC    
7930  OPN FX RED W INT FIX NOS 
7931  OPEN RED-INT FIX HUMERUS    
7932  OP RED-INT FIX RAD/ULNA    
7933  OP RED-INT FIX METAC/CAR    
7934  OPEN RED-INT FIX FINGER    
7935  OPEN REDUC-INT FIX FEMUR    
7936  OP RED-INT FIX TIB/FIBUL    
7937  OP RED-INT FIX METAT/TAR    
7938  OPEN REDUCT-INT FIX TOE    
7939  OPN FX RED W INT FIX NEC 
7940  CLS REDUC-SEP EPIPHY NOS    
7941  CLOSE RED-HUMERUS EPIPHY     
7942  CLS RED-RADIUS/UL EPIPHY     
7945  CLOSE REDUC-FEMUR EPIPHY     
7946  CLS RED-TIBIA/FIB EPIPHY     
7949  CLS REDUC-SEP EPIPHY NEC    
7950  OPEN RED-SEP EPIPHY NOS    
7951  OPN RED-SEP EPIPHY-HUMER     
7952  OP RED-RADIUS/ULN EPIPHY     
7955  OPN RED-SEP EPIPHY-FEMUR     
7956  OP RED-TIBIA/FIB EPIPHYS     
7959  OPEN RED-SEP EPIPHY NEC    
7960  OPEN FX SITE DEBRIDE NOS   
7961  DEBRID OPEN FX-HUMERUS     
7962  DEBRID OPN FX-RADIUS/ULN     
7963  DEBRID OPN FX-METAC/CAR     
7964  DEBRID OPN FX-FINGER     
7965  DEBRID OPN FX-FEMUR     
7966  DEBRID OPN FX-TIBIA/FIB     
7967  DEBRID OPN FX-METAT/TAR     
7968  DEBRID OPN FX-TOE     
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7969  OPEN FX SITE DEBRIDE NEC   
7980  OPEN REDUC-DISLOCAT NOS     
7981  OPN REDUC DISLOC-SHOULDR     
7982  OPEN REDUC-ELBOW DISLOC     
7983  OPEN REDUC-WRIST DISLOC     
7984  OPN REDUC DISLOC-HAND     
7985  OPEN REDUC-HIP DISLOCAT     
7986  OPEN REDUC-KNEE DISLOCAT     
7987  OPEN REDUC-ANKLE DISLOC     
7988  OPN REDUC DISLOC-FT/TOE     
7989  OPEN REDUC-DISLOCAT NEC     
7990  UNSPEC OP BONE INJ NOS   
7991  HUMERUS INJURY OP NOS    
7992  RADIUS/ULNA INJ OP NOS    
7993  METACARP/CARP INJ OP NOS    
7994  FINGER INJURY OP NOS    
7995  FEMUR INJURY OP NOS    
7996  TIBIA/FIBULA INJ OP NOS    
7997  METATARS/TARS INJ OP NOS    
7998  TOE INJURY OPERATION NOS    
7999  UNSPEC OP-BONE INJ NEC    
8000  ARTHROT & PROS REMOV NOS   
8001  ARTHROT/PROS REMOV-SHLDR      
8002  ARTHROT/PROS REMOV-ELBOW      
8003  ARTHROT/PROS REMOV-WRIST      
8004  ARTHROT/PROS REMOV-HAND      
8005  ARTHROT/PROS REMOV-HIP      
8006  ARTHROT/PROS REMOV-KNEE      
8007  ARTHROT/PROS REMOV-ANKLE      
8008  ARTHROT/PROS REMOV-FOOT      
8009  ARTHROT & PROS REMOV NEC   
8010  OTHER ARTHROTOMY NOS     
8011  OTH ARTHROTOMY-SHOULDER      
8012  OTH ARTHROTOMY-ELBOW      
8013  OTH ARTHROTOMY-WRIST      
8014  OTH ARTHROTOMY-HAND/FNGR      
8015  OTH ARTHROTOMY-HIP      
8016  OTH ARTHROTOMY-KNEE      
8017  OTH ARTHROTOMY-ANKLE      
8018  OTH ARTHROTOMY-FOOT/TOE      
8019  OTHER ARTHROTOMY NEC     
8020  ARTHROSCOPY NOS      
8021  SHOULDER ARTHROSCOPY      
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8022  ELBOW ARTHROSCOPY      
8023  WRIST ARTHROSCOPY      
8024  HAND & FINGER ARTHROSCOP    
8025  HIP ARTHROSCOPY      
8026  KNEE ARTHROSCOPY      
8027  ANKLE ARTHROSCOPY      
8028  FOOT & TOE ARTHROSCOPY    
8029  ARTHROSCOPY NEC      
8040  JT STRUCTUR DIVISION NOS    
8041  SHOULDER STRUCT DIVISION     
8042  ELBOW STRUCTURE DIVISION     
8043  WRIST STRUCTURE DIVISION     
8044  HAND JOINT STRUCT DIVIS    
8045  HIP STRUCTURE DIVISION     
8046  KNEE STRUCTURE DIVISION     
8047  ANKLE STRUCTURE DIVISION     
8048  FOOT JOINT STRUCT DIVIS    
8049  JT STRUCTUR DIVISION NEC    
805  JT STRUCTUR DIVISION NEC    
8050  EXC/DEST INTVRT DISC NOS    
8051  EXCISION INTERVERT DISC     
8053  REP ANULUS FIBROSUS-GRFT OCT08-    
8054  REP ANULS FIBROS NEC/NOS OCT08-   
8059  OTH EXC/DEST INTVRT DISC    
806  EXCIS KNEE SEMILUN CARTL    
8070  SYNOVECTOMY-SITE NOS      
8071  SHOULDER SYNOVECTOMY      
8072  ELBOW SYNOVECTOMY      
8073  WRIST SYNOVECTOMY      
8074  HAND SYNOVECTOMY      
8075  HIP SYNOVECTOMY      
8076  KNEE SYNOVECTOMY      
8077  ANKLE SYNOVECTOMY      
8078  FOOT SYNOVECTOMY      
8079  SYNOVECTOMY-SITE NEC      
8080  DESTRUCT JOINT LES NOS    
8081  DESTRUC-SHOULDER LES NEC     
8082  DESTRUC-ELBOW LESION NEC     
8083  DESTRUC-WRIST LESION NEC     
8084  DESTRUC-HAND JT LES NEC    
8085  DESTRUCT-HIP LESION NEC     
8086  DESTRUCT-KNEE LESION NEC     
8087  DESTRUC-ANKLE LESION NEC     
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8088  DESTRUC-FOOT JT LES NEC    
8089  DESTRUCT JOINT LES NEC    
8090  EXCISION OF JOINT NOS    
8091  EXCISION OF SHOULDER NEC    
8092  EXCISION OF ELBOW NEC    
8093  EXCISION OF WRIST NEC    
8094  EXCISION HAND JOINT NEC    
8095  EXCISION OF HIP NEC    
8096  EXCISION OF KNEE NEC    
8097  EXCISION OF ANKLE NEC    
8098  EXCISION FOOT JOINT NEC    
8099  EXCISION OF JOINT NEC    
8100  SPINAL FUSION NOS     
8101  ATLAS-AXIS FUSION      
8102  OTHER CERVICAL FUS ANT    
8103  OTHER CERVICAL FUS POST    
8104  DORSAL/DORSOLUM FUS ANT     
8105  DORSAL/DORSOLUM FUS POST     
8106  LUMBAR/LUMBOSAC FUS ANT     
8107  LUMBAR/LUMBOSAC FUS LAT     
8108  LUMBAR/LUMBOSAC FUS POST     
8109  LUMBAR/LUMBOSAC FUS POST     
8111  ANKLE FUSION      
8112  TRIPLE ARTHRODESIS      
8113  SUBTALAR FUSION      
8114  MIDTARSAL FUSION      
8115  TARSOMETATARSAL FUSION      
8116  METATARSOPHALANGEAL FUS      
8117  OTHER FUSION OF FOOT    
8118  OTHER FUSION OF FOOT    
8120  ARTHRODESIS NOS      
8121  ARTHRODESIS OF HIP     
8122  ARTHRODESIS OF KNEE     
8123  ARTHRODESIS OF SHOULDER     
8124  ARTHRODESIS OF ELBOW     
8125  CARPORADIAL FUSION      
8126  METACARPOCARPAL FUSION      
8127  METACARPOPHALANGEAL FUS      
8128  INTERPHALANGEAL FUSION      
8129  ARTHRODESIS NEC    04)  
8130  SPINAL REFUSION NOS   04)  
8131  REFUSION OF ATLAS-AXIS     
8132  REFUSION OF OTH CERV ANT   
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8133  REFUS OF OTH CERV POST   
8134  REFUSION OF DORSAL ANT    
8135  REFUSION OF DORSAL POST    
8136  REFUSION OF LUMBAR ANT    
8137  REFUSION OF LUMBAR LAT    
8138  REFUSION OF LUMBAR POST    
8139  REFUSION OF SPINE NEC    
8140  REPAIR OF HIP, NEC    
8141  REPAIR OF HIP, NEC    
8142  FIVE-IN-ONE KNEE REPAIR     
8143  TRIAD KNEE REPAIR     
8144  PATELLAR STABILIZATION      
8145  CRUCIATE LIG REPAIR NEC    
8146  COLLATERL LIG REPAIR NEC    
8147  OTHER REPAIR OF KNEE    
8148  OTHER REPAIR OF KNEE    
8149  OTHER REPAIR OF ANKLE    
8151  TOTAL HIP REPLACEMENT     
8152  PARTIAL HIP REPLACEMENT     
8153  REVISE HIP REPLACEMENT     
8154  TOTAL KNEE REPLACEMENT     
8155  REVISE KNEE REPLACEMENT     
8156  TOTAL ANKLE REPLACEMENT     
8157  REPL JOINT OF FOOT, TOE   
8159  REV JT REPL LOW EXT   
8161  360 SPINAL FUSION     
8162  FUS/REFUS 40577 VERTEBRAE     
8163  FUS/REFUS 40641 VERTEBRAE     
8164  FUS/REFUS 9 VERTEBRAE     
8165  VERTEBROPLASTY (OCT 04)     
8166  KYPHOPLASTY (OCT 04)     
8169  OTH HIP REPAIR JAN80--SEP89 OCT05-   
8171  ARTHROPLAS METACARP WIT     
8172  ARTHROPLASTY METACAR W/O     
8173  TOTAL WRIST REPLACEMENT     
8174  ARTHROPLASTY CARPAL WIT     
8175  ARTHROPLASTY CARPAL W/O     
8179  OTH REPAIR HAN/FIN/WRIS     
8180  TOTAL SHOULDER REPLACE     
8181  PARTIAL SHOULDER REPLACE     
8182  REP RECUR SHLDER DISLOC    
8183  SHOULDER ARTHROPLAST NEC     
8184  TOTAL ELBOW REPLACEMENT     
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8185  ELBOW ARTHROPLASTY NEC     
8186  ELBOW ARTHROPLASTY NEC     
8187  ELBOW ARTHROPLASTY NEC     
8193  SUTUR CAPSUL/LIGAMEN ARM     
8194  SUTURE CAPSUL/LIG ANK/FT     
8195  SUTUR CAPSUL/LIG LEG NEC    
8196  OTHER REPAIR OF JOINT    
8197  REV JT REPL UPPER EXTREM   
8198  OTHER JOINT DX PROCEDURE    
8199  JOINT STRUCTURE OP NEC    
8201  EXPLOR TEND SHEATH-HAND     
8202  MYOTOMY OF HAND     
8203  BURSOTOMY OF HAND     
8209  INC SOFT TISSUE HAND NEC   
8211  TENOTOMY OF HAND     
8212  FASCIOTOMY OF HAND     
8219  DIV SOFT TISSUE HAND NEC   
8221  EXC LES TEND SHEATH HAND   
8222  EXCISION HAND MUSCLE LES    
8229  EXC LES SFT TISS HND   
8231  BURSECTOMY OF HAND     
8232  EXCIS HAND TEND FOR GRFT   
8233  HAND TENONECTOMY NEC     
8234  EXC HND MUS/FAS FOR GRFT   
8235  HAND FASCIECTOMY NEC     
8236  OTHER MYECTOMY OF HAND    
8239  HAND SOFT TISSUE EXC NEC   
8241  SUTURE TENDN SHEATH HAND    
8242  DELAY SUT FLEX TEND HAND   
8243  DELAY SUT HAND TEND NEC   
8244  SUTUR FLEX TEND HAND NEC   
8245  SUTURE HAND TENDON NEC    
8246  SUTURE HAND MUSCLE/FASC     
8251  HAND TENDON ADVANCEMENT     
8252  HAND TENDON RECESSION     
8253  HAND TENDON REATTACHMENT     
8254  HAND MUSCLE REATTACHMENT     
8255  CHNG HND MUS/TEN LNG NEC   
8256  TRANSPLANT HAND TEND NEC    
8257  TRANSPOSIT HAND TEND NEC    
8258  TRANSPLANT HAND MUSC NEC    
8259  TRANSPOSIT HAND MUSC NEC    
8261  POLLICIZATION OPERATION      
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8269  THUMB RECONSTRUCTION NEC     
8271  HAND TEND PULLEY RECONST    
8272  PLAST OP HND-MUS/FAS GRF    
8279  PLAST OP HAND W GRFT   
8281  TRANSFER OF FINGER     
8282  REPAIR OF CLEFT HAND    
8283  REPAIR OF MACRODACTYLY     
8284  REPAIR OF MALLET FINGER    
8285  OTHER TENODESIS OF HAND    
8286  OTHER TENOPLASTY OF HAND    
8289  HAND PLASTIC OP NEC    
8291  LYSIS OF HAND ADHESIONS    
8299  HAND MUS/TEN/FAS/OPS NEC     
8301  TENDON SHEATH EXPLORAT     
8302  MYOTOMY       
8303  BURSOTOMY       
8309  SOFT TISSUE INCISION NEC    
8311  ACHILLOTENOTOMY       
8312  ADDUCTOR TENOTOMY OF HIP    
8313  OTHER TENOTOMY      
8314  FASCIOTOMY       
8319  SOFT TISSUE DIVISION NEC    
8321  SOFT TISSUE BIOPSY     
8329  SOFT TISSUE DX PROC NEC   
8331  EXCIS LES TENDON SHEATH    
8332  EXCIS LESION OF MUSCLE    
8339  EXC LES SOFT TISSUE NEC   
8341  TENDON EXCISION FOR GRFT    
8342  OTHER TENONECTOMY      
8343  MUSC/FASC EXCIS FOR GRFT    
8344  OTHER FASCIECTOMY      
8345  OTHER MYECTOMY      
8349  OTHER SOFT TISSUE EXCIS    
835  BURSECTOMY       
8361  TENDON SHEATH SUTURE     
8362  DELAYED TENDON SUTURE     
8363  ROTATOR CUFF REPAIR     
8364  OTHER SUTURE OF TENDON    
8365  OTHER MUSCLE/FASC SUTURE     
8371  TENDON ADVANCEMENT      
8372  TENDON RECESSION      
8373  TENDON REATTACHMENT      
8374  MUSCLE REATTACHMENT      
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8375  TENDON TRNSFR/TRANSPLANT      
8376  OTHER TENDON TRANSPOSIT     
8377  MUSCLE TRNSFR/TRANSPLANT      
8379  OTHER MUSCLE TRANSPOSIT     
8381  TENDON GRAFT      
8382  MUSCLE OR FASCIA GRAFT    
8383  TENDON PULLEY RECONSTRUC     
8384  CLUBFOOT RELEASE NEC     
8385  MUSC/TEND LNG CHANGE NEC    
8386  QUADRICEPSPLASTY       
8387  OTHER PLASTIC OPS MUSCLE    
8388  OTHER PLASTIC OPS TENDON    
8389  OTHER PLASTIC OPS FASCIA    
8391  ADHESIOLYSIS MUS/TEN/FAS      
8392  INSERT SKEL MUSC STIMULA    
8393  REMOV SKEL MUSC STIMULAT    
8399  MUS/TEN/FAS/BUR OP NEC     
8400  UPPER LIMB AMPUTAT NOS    
8401  FINGER AMPUTATION      
8402  THUMB AMPUTATION      
8403  AMPUTATION THROUGH HAND     
8404  DISARTICULATION OF WRIST     
8405  AMPUTATION THRU FOREARM     
8406  DISARTICULATION OF ELBOW     
8407  AMPUTATION THRU HUMERUS     
8408  SHOULDER DISARTICULATION      
8409  FOREQUARTER AMPUTATION      
8410  LOWER LIMB AMPUTAT NOS    
8411  TOE AMPUTATION      
8412  AMPUTATION THROUGH FOOT     
8413  DISARTICULATION OF ANKLE     
8414  AMPUTAT THROUGH MALLEOLI     
8415  BELOW KNEE AMPUTAT NEC    
8416  DISARTICULATION OF KNEE     
8417  ABOVE KNEE AMPUTATION     
8418  DISARTICULATION OF HIP     
8419  HINDQUARTER AMPUTATION      
8421  THUMB REATTACHMENT      
8422  FINGER REATTACHMENT      
8423  FOREARM/WRIST/HAND REATT      
8424  UPPER ARM REATTACHMENT     
8425  TOE REATTACHMENT      
8426  FOOT REATTACHMENT      
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8427  LOWER LEG/ANKLE REATTACH     
8428  THIGH REATTACHMENT      
8429  REATTACHMENT NEC      
843  AMPUTATION STUMP REVIS     
8440  IMPLNT/FIT PROS LIMB NOS    
8444  IMPLANT ARM PROSTHESIS     
8448  IMPLANT LEG PROSTHESIS     
8458  IMP INTRSPINE DECOMP DEV OCT05-   
8459  INSERT OTH SPIN DEVICE    
8460  INSERT DISC PROS NOS (OCT   
8461  INS PART DISC PROS CERV   
8462  INS TOT DISC PROST CERV   
8463  INS SPIN DISC PROS THOR   
8464  INS PART DISC PROS LUMB   
8465  INS TOTL DISC PROS LUMB   
8466  REVISE DISC PROST CERV (OCT   
8467  REVISE DISC PROST THORA (OCT   
8468  REVISE DISC PROSTH LUMB (OCT   
8469  REVISE DISC PROSTH NOS (OCT   
8480  INS/REPL INTERSPINE DEV OCT08-  OCT08-  
8481  REV INTERSPINE DEVICE OCT08-    
8482  INS/REPL PDCL STABIL DEV OCT08-   
8483  REV PEDCL DYN STABIL DEV   
8484  INS/REPL FACET REPLC DEV OCT08-   
8485  REV FACET REPLACE DEVICE OCT08-   
8491  AMPUTATION NOS      
8492  SEPARAT EQUAL JOIN TWIN    
8493  SEPARAT UNEQUL JOIN TWIN    
8499  MUSCULOSKELETAL OP NEC     
8512  OPEN BREAST BIOPSY     
8520  BREAST TISSU DESTRUC NOS    
8521  LOCAL EXCIS BREAST LES    
8522  QUADRANT RESECT BREAST     
8523  SUBTOTAL MASTECTOMY      
8524  EXC ECTOPIC BREAST TISSU    
8525  EXCISION OF NIPPLE     
8531  UNILAT REDUCT MAMMOPLAST     
8532  BILAT REDUCT MAMMOPLASTY     
8533  UNIL SUBQ MAMMECT-IMPLNT     
8534  UNILAT SUBQ MAMMECT NEC    
8535  BIL SUBQ MAMMECT-IMPLANT     
8536  BILAT SUBQ MAMMECTOM NEC    
8541  UNILAT SIMPLE MASTECTOMY     
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8542  BILAT SIMPLE MASTECTOMY     
8543  UNILAT EXTEN SIMP MASTEC    
8544  BILAT EXTEND SIMP MASTEC    
8545  UNILAT RADICAL MASTECTOM     
8546  BILAT RADICAL MASTECTOMY     
8547  UNIL EXT RAD MASTECTOMY    
8548  BIL EXTEN RAD MASTECTOMY    
8550  AUGMENT MAMMOPLASTY NOS     
8553  UNILAT BREAST IMPLANT     
8554  BILATERAL BREAST IMPLANT     
856  MASTOPEXY       
857  TOTAL BREAST RECONSTRUCT     
8570  TOTL RECONSTC BREAST NOS OCT09-   
8571  LATISS DORSI MYOCUT FLAP OCT08-   
8572  TRAM FLAP, PEDICLED OCT08-    
8573  TRAM FLAP, FREE OCT08-    
8574  DIEP FLAP, FREE OCT08-    
8575  SIEA FLAP, FREE OCT08-    
8576  GAP FLAP, FREE OCT08-    
8579  TOTL RECONST BREAST NEC OCT08-   
8582  BREAST SPLIT-THICK GRAFT     
8583  BREAST FULL-THICK GRAFT     
8584  BREAST PEDICLE GRAFT     
8585  BREAST MUSCLE FLAP GRAFT    
8586  TRANSPOSITION OF NIPPLE     
8587  NIPPLE REPAIR NEC     
8589  MAMMOPLASTY NEC      
8593  BREAST IMPLANT REVISION     
8594  BREAST IMPLANT REMOVAL     
8595  INSER BREAST TISSU EXPAN    
8596  REMOV BREAST TISSU EXPAN    
8599  BREAST OPERATION NEC     
8606  INSERT INFUSION PUMP     
8621  EXCISION OF PILONID CYST    
8622  EXC WOUND DEBRIDEMENT     
8625  DERMABRASION       
864  RADICAL EXCIS SKIN LES    
8660  FREE SKIN GRAFT NOS    
8661  FULL-THICK HAND SKIN GRF    
8662  HAND SKIN GRAFT NEC    
8663  FULL-THICK SKIN GRFT NEC    
8665  HETEROGRAFT TO SKIN     
8666  HOMOGRAFT TO SKIN     
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8667  DERMAL REGENER GRAFT     
8669  FREE SKIN GRAFT NEC    
8670  PEDICLE GRAFT/FLAP NOS     
8671  CUT & PREP PEDICLE GRAFT   
8672  PEDICLE GRAFT ADVANCEMEN     
8673  ATTACH PEDICLE TO HAND    
8674  ATTACH PEDICLE GRAFT NEC    
8675  REVISION OF PEDICLE GRFT    
8681  REPAIR FACIAL WEAKNESS     
8682  FACIAL RHYTIDECTOMY      
8683  SIZE REDUCT PLASTIC OP    
8684  RELAXATION OF SCAR     
8685  SYNDACTYLY CORRECTION      
8686  ONYCHOPLASTY       
8689  SKIN REPAIR & PLASTY NEC   
8691  SKIN EXCISION FOR GRAFT    
8693  INSERT TISSUE EXPANDER     
8694  INS/REPL SINGLE PUL GEN (OCT   
8695  INS/REPL DUAL PULSE GEN (OCT   
8696  INSERT/REPL OTH NEUROST (OCT 04)   
8697  INS/REP 1 PUL GEN OCT05-   
8698  INS/REP 2 PUL GEN OCT05-   
8753  INTRAOPER CHOLANGIOGRAM      
9227  RADIOACTIVE ELEM IMPLANT OCT09-    
9504  ANESTHETIZED EYE EXAM     
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Appendix C 
Supplemental Pneumonia Methodology Tables 
 
Table 136. AHRQ IQI-20: Pneumonia Mortality Definitions, ICD-9-CM Diagnosis 
Codes 
 
Code  Description 
00322  SALMONELLA PNEUMONIA  
0212  PULMONARY TULAREMIA  
0391  PULMONARY ACTINOMYCOSIS  
0521  VARICELLA PNEUMONITIS  
0551  POSTMEASLES PNEUMONIA  
0730  ORNITHOSIS PNEUMONIA  
1124  CANDIDIASIS OF LUNG  
1140  PRIMARY COCCIDIOIDOMYCOS  
1144  CHRONIC 
PULMONCOCCIDIOIDOMYCOSIS  
1145  UNSPEC PULMON 
COCCIDIOIDOMYCOSIS  
11505  HISTOPLASM CAPS PNEUMON  
11515  HISTOPLASM DUB PNEUMONIA  
11595  HISTOPLASMOSIS PNEUMONIA  
1304  TOXOPLASMA PNEUMONITIS  
1363  PNEUMOCYSTOSIS  
4800  ADENOVIRAL PNEUMONIA  
4801  RESP SYNCYT VIRAL PNEUM  
4802  PARINFLUENZA VIRAL PNEUM  
4803  PNEUMONIA DUE TO SARS OCT03-  
4808  VIRAL PNEUMONIA NEC  
4809  VIRAL PNEUMONIA NOS  
481  PNEUMOCOCCAL PNEUMONIA  
4820  K. PNEUMONIAE PNEUMONIA  
4821  PSEUDOMONAL PNEUMONIA  
4822  H.INFLUENZAE PNEUMONIA  
4824  STAPHYLOCOCCAL PNEUMONIA  
4831  CHLAMYDIA PNEUMONIA OCT96-  
4838  OTH SPEC ORG PNEUMONIA  
4841  PNEUM W CYTOMEG INCL DIS 
4829  BACTERIAL PNEUMONIA NOS 
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4830  MYCOPLASMA PNEUMONIA 
4843  PNEUMONIA IN WHOOP COUGH  
4845  PNEUMONIA IN ANTHRAX 
4846  PNEUM IN ASPERGILLOSIS 
4847  PNEUM IN OTH SYS MYCOSES 
4848  PNEUM IN INFECT DIS NEC 
485  BRONCOPNEUMONIA ORG NOS 
486  PNEUMONIA, ORGANISM NOS 
48230  STREP PNEUMONIA, UNSPEC 
48231  GRP A STREP PNEUMONIA 
48232  GRP B STREP PNEUMONIA 
48239  OTH STREP PNEUMONIA 
48240  STAPH PNEUMONIA UNSP OCT98- 
48241  METICILLIN SUSCEPTIBLE PNEUMONIA 
DUE TO STAPHYLOCOCCUS AUREUS 
OCT08- 
48242  METHICILLIN RESISTANT PNEUMONIA 
DUE TO STAPHYLOCOCCUS AUREUS 
OCT08- 
42249  STAPH PNEUMON OTH OCT98- 
48281  ANAEROBIC PNEUMONIA 
48282  E COLI PNEUMONIA 
48283  OTH GRAM NEG PNEUMONIA 
48284  LEGIONNAIRES DX OCT97- 
48289  BACT PNEUMONIA NEC 
4870  INFLUENZA WITH PNEUMONIA 
 
Exclude cases:  
• Missing discharge disposition (DISP = missing), sex (SEX = missing), age (AGE = 
missing), quarter (DQTR = missing), year (YEAR = missing) or principal diagnosis 
(DX1 = missing)  
• Transferring to another short-term hospital (DISP = 2)  
• MDC 14 (pregnancy, childbirth, and puerperium). 
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Table 137. Monthly Utilization of Pneumonia Order Sets 
Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available 
Monthly 
Utilization 
Average 
(Aug 2010) 
Pneumonia CMC Community 
Acquired 
Pneumonia Adult 
Order Set CMC 
33166393 2007 
 
2 
Pneumonia GSAM Pneumonia Adult 
Order Set GSA 
48577863 2007 7 
Pneumonia IMMC Community 
Acquired 
Pneumonia (CAP) 
Order Set IMC 
32342226 2007 20 
Pneumonia SSUB Pneumonia 
Inpatient Adult 
Order Set SSH 
139008712 2007 4 
 TRIN Community 
Acquired 
Pneumonia Order 
Set TRI 
483701535 2010 6 
 
Table 138. Pneumonia Order Set Content 
Order Set 
Title 
Facility Catalog 
Number 
Content 
Community 
Acquired 
Pneumonia 
Adult Order 
Set CMC 
CMC 33166393 Activity Patient 
Admit Patient - full inpatient 
Azithromycin 
Blood Culture [BLC] 
Blood Gas 
Cardiac Diet 
CBC with differential [CBCA] 
Ceftriaxone 
Comprehensive Metabolic Panel [CPNL] 
Dextrose 5% - 0.45% NaCl 
Diabetic 1800 Cal diet 
Discharge planning Evaluation Adult 
Doxycycline 
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Order Set 
Title 
Facility Catalog 
Number 
Content 
General diet 
Gram smear [GRAS] 
Influenza Rapid AG [FLUAG] 
Influenza virus vaccine, inactivated 
Lactated ringers 
Legionella AG urine [LEGEIA] 
Mini BAL 
Moxifloxacin 
NPO 
Nursing Communication Order 
Oxygen 
Place in 23hr observation 
Pneumococcal 23-valent vaccine 
Pulse Ox spot check 
Saline Lock insertion 
Sodium Chloride 0.9% 
Sputum Culture/Smear 
Vancomycin 
Vital signs per unit routine 
XR Chest PA, Lateral 2V 
Zosyn 
 
Pneumonia 
Adult Order 
Set GSA 
GSAM 48577863 Azithromycin 
Aztreonam 
Blood Culture [BLC] 
Bronchodilator protocol 
CBC with Differential [CBCA] 
Cefepime 
Ceftriaxone 
Ciprofloxacin 
CMP 
Levofloxacin 
Medical/Surgical General Admission Order Set 
GSA 
Moxifloxacin 
O2 protocol 
Pharmacist to dose: Vancomycin (consult) 
Social work weferral adult 
XR chest PA, Lateral 2V 
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Order Set 
Title 
Facility Catalog 
Number 
Content 
Community 
Acquired 
Pneumonia 
(CAP) Order 
Set IMC 
IMMC 32342226 AFB culture/smear 
Blood Culture [BLC] 
CAP Standard Antibiotic Regimen Order Set 
IMC 
CAP suspected gram Neg/Aspiration/NH 
Admit Order Set IMC 
Gram smear [GRAS] 
HIV I/II AB SCR-ELISA [HIVABS] 
Isolation 
Legionella AG urine [LEGEIA] 
Nursing communication order 
Pulse Ox spot check 
S Pneumonia Antigen [USTREP] 
Sputum culture/smear 
 
Pneumonia 
Inpatient 
Adult Order 
Set SSH 
SSUB 139008712 Avelox 
Azactam 
Blood Culture [BLC] 
BMP 
CBC with differential [CBCA] 
Cleocin 
EKG 12 Lead SSH 
Maxipime 
MetroNIDAZOLE 
Oxygen 
Pulse Ox spot check 
Rocephin 
Saline (sodium chloride) IV lock flush 
injection 
Saline Lock Insertion 
UA complete W C/S IF IND 
Vancomycin - pharmacist to dose (consult) 
Vancomycin 
XR chest PA, Lateral 2V 
Zithromax 
Zosyn 
 
Community 
Acquired 
Pneumonia 
Order Set 
TRI 
TRIN 483701535 ABG 
Admit patient - full inpatient 
AFB culture/smear 
Azithromycin 
Aztreonam 
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Order Set 
Title 
Facility Catalog 
Number 
Content 
B Type Natriuretic Peptide [BNPEP] 
Basic metabolic panel [BPNL] 
Bedside swallow adult evaluation and TX 
Blood culture [BLC] 
CBC with differential [CBCA] 
Ceftriaxone 
Ciprofloxacin 
Consult physician 
CT chest high resolution WO consultation 
Discharge planning evaluation - adult 
HIV I/II AB SCR-ELISA [HIVABS] 
Influenza virus vaccine, inactivated 
Intake and output 
Isolation 
Legionella AB [LEGA] 
Linezolid 
Moxifloxacin 
Mycoplasma Pneumoniae IGG 
Mycoplasma Pneumoniae IGM 
NM Lung VQ scan 
Nursing communication order 
Patient activity 
Piperacillin-tazobactam 
Place in 23hr observation 
Pneumococcal 23-valent vaccine 
Pulse Ox spot check 
RBC SED rate [RESR] 
Respiratory assessment nursing 
Respiratory therapy communication order 
S Pneumoniae Antigen [USTREP] 
Saline lock insertion 
Smoking cessation education - nursing 
Sputum culture/smear 
Sputum induction 
Swallow adult evaluation and TX 
Vancomycin 
Vital signs 
XR chest PA, Lateral 2V 
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Table 139. Randomly Generated Patient Race Codes – Pneumonia Study 
Race Description Randomly 
Generated Code 
African American / 
Black 
10 
American Indian / 
Alaska Native 
11 
Asian/Filipino 12 
Caucasian/White 13 
Declined 14 
Eastern Indian 15 
Hispanic 16 
Middle East 17 
Other 18 
Pacific Islander / 
Hawaiian  
19 
Unknown 20 
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Appendix D 
Supplemental CHF Methodology Tables 
 
Table 140. AHRQ IQI-16: CHF Mortality Definitions, ICD-9-CM Diagnosis Codes 
Code  Description 
39891  RHEUMATIC HEART FAILURE  
40201  MAL HYPERT HRT DIS W CHF  
40211  BENIGN HYP HRT DIS W CHF  
40291  HYPERTEN HEART DIS W CHF  
40401  MAL HYPER HRT/REN W CHF  
40403  MAL HYP HRT/REN W CHF&RF  
40411  BEN HYPER HRT/REN W CHF  
40413  BEN HYP HRT/REN W CHF&RF  
40491  HYPER HRT/REN NOS W CHF  
40493  HYP HT/REN NOS W CHF&RF  
4280  CONGESTIVE HEART FAILURE  
4281  LEFT HEART FAILURE  
42820  SYSTOLIC HEART FAILURE NOS 
(OCT02)  
42821  AC SYSTOLIC HRT FAILURE (OCT02)  
42822  CHR SYSTOLIC HRT FAILURE (OCT02)  
42823  AC ON CHR SYST HRT FAIL (OCT02)  
4289  HEART FAILURE NOS  
42830  DIASTOLIC HRT FAILURE NOS (OCT02)  
42831  AC DIASTOLIC HRT FAILURE (OCT02)  
42832  CHR DIASTOLIC HRT FAIL (OCT02)  
42833  AC ON CHR DIAST HRT FAIL (OCT02)  
42840  SYST/DIAST HRT FAIL NOS (OCT02)  
42841  AC SYST/DIASTOL HRT FAIL (OCT02)  
42842  CHR SYST/DIASTL HRT FAIL (OCT02)  
42843  AC/CHR SYST/DIA HRT FAIL (OCT02)  
 
Exclude cases: 
• Transferring to another short-term hospital (Disposition=2)  
• MDC 14 (pregnancy, childbirth, and puerperium)  
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• With missing discharge disposition (Disposition=missing), sex (Sex=missing), 
age (Age=missing), quarter (DQTR=missing), year (Year=missing), or principal 
diagnosis (DX1=missing). 
Table 141. Monthly Utilization of CHF Order Sets 
 
Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available 
Monthly 
Utilization 
Average 
(Aug 2010) 
CHF CMC CHF Unit 
Admission Order 
Set CMC 
13026418 2004 
 
3 
CHF GSHP Congestive Heart 
Failure Order 
Admission Set 
GSH 
49502942 2005 2 
CHF IMMC Congestive Heart 
Failure Order 
Admission Set 
IMC 
24458894 2005 26 
CHF SSUB Heart Failure 
Order Set SSH 
173004691 2007 4 
CHF LGH Heart Failure 
Management 
Order Set LGH 
369504735 2008 6 
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Table 142. CHF Order Set Content 
 
Order Set 
Title 
Facility Catalog 
Number 
Content 
CHF Unit 
Admission 
Order Set 
CMC 
CMC 13026418 ACE Contraindications 
Activity Patient 
Admit Patient - Full Inpatient 
albuterol inhalation 0.083% 2.5 mg/3 mL 
solution. 
Altace 
Antiembolytic Hose 
ARB Contraindications 
Avapro 
B TYPE NATRIURETIC PEPTIDE [BNPEP] 
BASIC METABOLIC PANEL [BPNL] 
Bioimpedance Test 
BIPAP 
Capoten 
Cardiac Diet 
Cardiac Rehab Inpatient 
CBC WITH DIFFERENTIAL [CBCA] 
CD DOPPLER ECHOCARDIO; COMPLETE 
CD ECG 12 LEAD; TRACING ONLY 
CHF Nurse Consult 
CK-MB [MMB] 
Consult Physician 
Coreg 
Cozaar 
CPAP 
Demadex 
Diabetic 1800 Cal Diet 
Diabetic 2000 Cal Diet 
DIGOXIN LEVEL [DIG] 
Diovan 
Discharge Planning Evaluation Adult 
DOBUTamine 1,000 mg/250 mL D5W IV 
premix 
Ecotrin 
Furosemide 1,000 mg/250 mL D5W IV 
Heparin Weight Based Protocol Cardiac Order 
Set CMC 
heparin. 
hydrALAZINE. 
HydroDIURIL. 
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Imdur. 
influenza virus vaccine, inactivated 
Intake and Output 
K-Dur 20 
Lanoxin 
Lasix 
LIPID PANEL W/O REFLEX [LIPDPL] 
Lovenox. 
MAGNESIUM LEVEL [MG] 
Magnesium sulfate 
Mag-Ox 400 
Milrinone 20 mg/100 mL D5W IV premix 
Milrinone bolus 
Natrecor 0.75 mg/125 mL D5W IV 
Natrecor bolus 
NitroGLYCERIN 50 mg/250 mL D5W IV 
premix 
NitroGLYCERIN topical 2% ointment. 
Nitroglycerin Topical Patch Order Set 
Nitrostat 
NPO 
Nursing Communication Order 
Nutrition Consult Adult 
Oxygen 
Plavix 
Pneumococcal 23-valent vaccine 
Prinivil / Zestril 
PROTHROMBIN TIME [PTINR] 
Pulse Ox Spot check 
Saline (sodium chloride) IV lock flush injection. 
Saline Lock Insertion 
Sequential Compression Device 
Toprol XL 
TROPONIN I ULTRASENSITIVE [TROPI] 
TSH 
URINALYSIS SCREEN (USCR) 
Vasotec 
Vital Signs 
Vital Signs per Unit Routine 
Weigh Patient 
XR CHEST PA, LATERAL 2V 
Zaroxolyn. 
Zebeta 
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Congestive 
Heart Failure 
Order 
Admission 
Set GSH 
GSHP 49502942 Aldactone 
Altace 
Aspirin 
Atenolol 
Avapro 
B TYPE NATRIURETIC PEPTIDE [BNPEP] 
BASIC METABOLIC PANEL [BPNL] 
BIPAP 
Bumex 
Capoten 
Cardiac Monitoring 
Carvedilol 
Catheter Urinary Insertion 
CBC WITH DIFFERENTIAL [CBCA] 
CHF Nurse Consult 
CK-MB [MMB] 
Coreg 
Cozaar 
CPAP 
DIGOXIN LEVEL [DIG] 
Digoxin 
Diovan 
Discharge Planning Evaluation Adult 
DOBUTamine 500 mg/250 mL D5W IV 
premix 
DuoNeb inhalation 2.5-0.5 mg/3 mL solution 
DVT Prophylaxis Order Set GSH 
Echocardiogram 2D w Doppler Adult GSH 
EKG Adult - GSH 
Heparin 
Hydralazine 
Hydrodiuril 
Imdur 
Intake and Output 
Lanoxin 
Lasix 
LIPID PANEL W/O REFLEX [LIPDPL] 
Lisinopril 
Lopressor 
Lovenox - Pharmacist to Dose (consult) 
MAGNESIUM LEVEL [MG] 
Magnesium oxide 
Magnesium sulfate 
Milrinone 20 mg/100 mL D5W IV premix 
Milrinone bolus injection 
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Nesiritide - Pharmacist to Dose (consult) 
Nitro-Bid topical 2% ointment 
NitroGLYCERIN 50 mg/250 mL D5W IV 
premix 
Nitroglycerin Topical Patch Order Set 
Nitroglycerin 
Notify Physician 
Nursing Communication Order 
Nutrition Consult Adult 
Oxygen 
Pharmacist to Dose: Coumadin (consult) 
Pharmacist to Dose: Heparin (consult) 
Physical Therapy Adult Evaluation and 
Treatment 
Plavix 
Potassium CHLORIDE. 
Proventil inhalation 0.083% 2.5 mg/3 mL 
solution 
Respiratory Therapy Communication Order 
Sleep Apnea Risk Assessment 
Toprol XL 
TROPONIN I ULTRASENSITIVE [TROPI] 
TSH WITH REFLEX [THSR] 
Vasotec 
Vital Signs per Unit Routine 
Warfarin 
Weigh Patient 
XR CHEST 1V 
XR CHEST PA, LATERAL 2V 
Zaroxolyn 
 
Congestive 
Heart Failure 
Order 
Admission 
Set IMC 
IMMC 24458894 Admit Order IMC 
Albuterol inhalation 0.5% 2.5 mg/0.5 mL 
solution. 
Aldactone 
Antiembolytic Hose 
Aspirin 
Avapro. 
B TYPE NATRIURETIC PEPTIDE [BNPEP] 
BASIC METABOLIC PANEL [BPNL] 
BIPAP 
Capoten 
Cardiac Monitoring 
Catheter Urinary Insertion 
CBC WITH DIFFERENTIAL [CBCA] 
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CK-MB [MMB] 
Consult CHF Clinic Evaluation 
Coreg 
Cozaar 
CPAP 
Demadex 
DIGOXIN LEVEL [DIG] 
Diovan 
Echocardiogram 2D w Doppler Adult IMC 
EKG Adult IMC 
Furosemide 200 mg/100 mL D5W IV 
Hydrodiuril 
Intake and Output 
Isosorbide mononitrate 
Lanoxin. 
Lasix. 
LIPID PANEL W/O REFLEX [LIPDPL] 
Lopressor 
MAGNESIUM LEVEL [MG] 
Magnesium oxide 
Nitroglycerin sublingual. 
Nitroglycerin topical 2% ointment. 
Nursing Communication Order 
Nutrition Consult Adult 
Potassium chloride 
Prinivil / Zestril 
Toprol XL 
TROPONIN I ULTRASENSITIVE [TROPI] 
TSH WITH REFLEX [THSR] 
URINE COMPLETE [UCOM] 
Vasotec 
Vital Signs per Unit Routine 
Weigh Patient 
XR CHEST PA, LATERAL 2V 
Zaroxolyn 
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Heart Failure 
Order Set 
SSH 
SSUB 173004691 Activity Patient 
Admit Patient - Full Inpatient 
Admitting Diagnosis 
B TYPE NATRIURETIC PEPTIDE [BNPEP] 
BASIC METABOLIC PANEL [BPNL] 
BIPAP 
Cardiac Diet 
Cardiac Rehab Inpatient 
CBC WITH DIFFERENTIAL [CBCA] 
CHF Nurse Consult 
COMPREHENSIVE METABOLIC PANEL 
[CPNL] 
Consult Physician 
CPAP 
DIGOXIN LEVEL [DIG] 
Discharge Planning Evaluation Adult 
Echocardio 2D With Doppler SSH 
Intake and Output 
LIPID PANEL W/O REFLEX [LIPDPL] 
MAGNESIUM LEVEL [MG] 
Nursing Communication Order 
Nutrition Consult Adult 
Old Charts to Floor 
Oxygen 
PT/INR 
Pulse Ox Spot check 
Saline (sodium chloride) IV lock flush 
injection 
Saline Lock Insertion 
Telemetry PCU Protocol Order Set SSH 
TROPONIN I ULTRASENSITIVE [TROPI] 
TSH 
Vital Signs per Unit Routine 
Weigh Patient 
XR CHEST 1V 
XR CHEST PA, LATERAL 2V 
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Table 143. Randomly Generated Patient Race Codes – CHF Study 
Race Description Randomly 
Generated Code 
African American / 
Black 
10 
American Indian / 
Alaska Native 
11 
Asian/Filipino 12 
Caucasian/White 13 
Declined 14 
Eastern Indian 15 
Hispanic 16 
Middle East 17 
Other 18 
Pacific Islander / 
Hawaiian  
19 
Unknown 20 
Heart Failure 
Management 
Order Set 
LGH 
LGH 369504735 ACE Contraindications 
ALBUMIN LEVEL [ALB] 
ARB Contraindications 
BNP 
Cardiac Rehab Inpatient 
CBC WITH DIFFERENTIAL [CBCA] 
CD ECHO 2D COMPLETE-ADULT 
CHF Nurse Consult 
EKG - Adult LGH 
EKG STAT Adult LGH 
Heart Failure History 
HEPATIC FUNCTION PANEL [LIVPNL] 
HYPERAL PROFILE [HYPRL] 
Intake and Output 
LIPID PANEL W/O REFLEX [LIPDPL] 
Patient Education 
Sodium 2-3 GM Diet 
Sodium 4 GM Diet 
Telemetry 
TROPONIN I ULTRASENSITIVE [TROPI] 
TSH 
URINALYSIS SCREEN (USCR) 
Weigh Patient 
XR CHEST PORTABLE 1V 
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Appendix E 
Supplemental AMI Methodology Tables 
Table 144. AHRQ IQI-15: AMI Mortality Definitions, ICD-9-CM Diagnosis Codes 
 
Code  Description 
41000  AMI ANTEROLATERAL, UNSPECIFIED  
41001  AMI ANTEROLATERAL, INITIAL 
41010  AMI ANTERIOR WALL, UNSPECIFIED  
41011  AMI ANTERIOR WALL, INITIAL 
41020  AMI INFEROLATERAL, UNSPECIFIED  
41021  AMI INFEROLATERAL, INITIAL 
41030  AMI INFEROPOST, UNSPECIFIED  
41031  AMI INFEROPOST, INITIAL  
41040  AMI INFERIOR WALL, UNSPECIFIED  
41041  AMI INFERIOR WALL, INITIAL 
41050  AMI LATERAL NEC, UNSPECIFIED  
41051  AMI LATERAL NEC, INITIAL  
41060  TRUE POST INFARCT, UNSPECIFIED  
41061  TRUE POST INFARCT, INITIAL  
41070  SUBENDO INFARCT, UNSPECIFIED  
41071  SUBENDO INFARCT, INITIAL  
41080  AMI NEC, UNSPECIFIED  
41081  AMI NEC, INITIAL  
41090  AMI NOS, UNSPECIFIED  
41091  AMI NOS, INITIAL  
 
Exclude cases: 
• Transferring to another short-term hospital (Disposition=2)  
• MDC 14 (pregnancy, childbirth, and puerperium)  
• With missing discharge disposition (Disposition=missing), sex (Sex=missing), 
age (Age=missing), quarter (DQTR=missing), year (Year=missing), or principal 
diagnosis (DX1=missing)  
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Table 145. Monthly Utilization of AMI Order Sets 
 
Category Hospital 
Code 
Order Set Title Catalog ID Year 
Available  
Monthly 
Utilization 
Average 
(Aug 2010) 
AMI GSHP Acute Coronary 
Syndrome Order 
Set GSH 
49493862 2008 4 
AMI TRIN Chest Pain Orders 
Order Set TRI 
483944189 2009 36 
 
Table 146. AMI Order Set Content 
 
Order Set 
Title 
Facility Catalog 
Number 
Content 
Acute 
Coronary 
Syndrome 
Order Set 
GSH 
GSHP 49493862 Altace 
Aspirin 
CK-MB [MMB] 
DIGOXIN LEVEL [DIG] 
EKG Adult - GSH 
Eptifibatide 75 mg/100 mL IV premix 
Eptifibatide bolus 
GLYCOHEMOGLOBIN LEVEL [GLYH] 
Heparin - Pharmacist to Dose (consult) 
Integrilin - Pharmacist to Dose (consult) 
Lasix 
LIPID PANEL W/O REFLEX [LIPDPL] 
Lipitor 
Lopressor 
Lovenox 
Morphine 
Nitro-Bid topical 2% ointment 
NitroGLYCERIN 50 mg/250 mL D5W IV 
Premix 
nitroGLYCERIN sublingual 
Nitroglycerin Topical Patch Order Set 
Nursing Communication Order 
OCCULT BLOOD [STBLD] 
Physician Consult 
Plavix 
PT/INR 
PTT 
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Telemetry 
TROPONIN I ULTRASENSITIVE [TROPI] 
Vasotec 
 
Chest Pain 
Orders 
Order Set 
TRI 
TRIN 483944189 Admit Patient - Full Inpatient 
Admitting Diagnosis 
Aspirin 
Cardiac Rehab Inpatient 
CBC WITH DIFFERENTIAL [CBCA] 
CK-MB [MMB] 
Clear Liquid Diet 
Colace 
COMPREHENSIVE METABOLIC PANEL 
[CPNL] 
Coreg 
Diovan 
Discharge Planning Eval Adult 
EKG 12 Lead Routine-TRI 
EKG 12 Lead Stat-TRI 
Enoxaparin 
Fragmin 
Heparin 
Intake and Output 
Integrilin 200 mg/100 mL IV premix 
Isolation 
LIPID PANEL W/O REFLEX [LIPDPL] 
Lipitor 
Lisinopril 
Metoprolol 
Morphine 
Nitro-Bid topical 2% ointment. 
NitroGLYCERIN 50 mg/250 mL D5W IV 
Premix 
NitroGLYCERIN sublingual. 
Notify Physician If 
NPO 
Nursing Communication Order 
Nutrition Consult Adult 
Oxygen 
Patient Activity 
Physician Consult 
Place in 23hr Observation 
Plavix 
PROTHROMBIN TIME [PTINR] 
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Table 147. Randomly Generated Patient Race Codes – AMI Study 
 
Race Description Randomly 
Generated Code 
African American / 
Black 
10 
American Indian / 
Alaska Native 
11 
Asian/Filipino 12 
Caucasian/White 13 
Declined 14 
Eastern Indian 15 
Hispanic 16 
Middle East 17 
Other 18 
Pacific Islander / 
Hawaiian  
19 
Unknown 20 
Multi-Racial 21 
 
 
 
 
PTT 
Pulse Oximetry 
Saline Lock Insertion 
Smoking Cessation Education - Nursing 
Smoking Cessation Education - RT 
Sodium 2 GM Diet 
Sodium Chloride 0.45% 
Sodium Chloride 0.9% 
Telemetry 
temazepam. 
TROPONIN I ULTRASENSITIVE [TROPI] 
Tylenol 
Vital Signs per Unit Routine 
Weigh Patient 
Xanax 
Zocor 
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Appendix F 
Supplemental VTE Results 
 
Relationship Between Utilization of the VTE Order Sets, Acute VTE, and Charlson 
Comorbidity Index 
IMMC Surgical Calculations 
Table 148. One-Way ANOVA – Surgical IMMC VTE Patients, CCI 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
1192.029 3 397.343 87.429 .000 
Within Groups 46524.452 10237 4.545   
Total 47716.482 10240    
 
Table 149. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Surgical IMMC 
VTE Patients, CCI 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
tion 
Mean 
Differe
nce (I-
J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 .870 .358 .072 -.05 1.79 
3 1.152* .424 .033 .06 2.24 
4 1.666* .356 .000 .75 2.58 
2 1 -.870 .358 .072 -1.79 .05 
3 .282 .236 .629 -.32 .89 
4 .796* .051 .000 .66 .93 
3 1 -1.152* .424 .033 -2.24 -.06 
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2 -.282 .236 .629 -.89 .32 
4 .514 .232 .120 -.08 1.11 
4 1 -1.666* .356 .000 -2.58 -.75 
2 -.796* .051 .000 -.93 -.66 
3 -.514 .232 .120 -1.11 .08 
Bonferroni 1 2 .870 .358 .091 -.07 1.82 
3 1.152* .424 .040 .03 2.27 
4 1.666* .356 .000 .73 2.61 
2 1 -.870 .358 .091 -1.82 .07 
3 .282 .236 1.000 -.34 .90 
4 .796* .051 .000 .66 .93 
3 1 -1.152* .424 .040 -2.27 -.03 
2 -.282 .236 1.000 -.90 .34 
4 .514 .232 .162 -.10 1.13 
4 1 -1.666* .356 .000 -2.61 -.73 
2 -.796* .051 .000 -.93 -.66 
3 -.514 .232 .162 -1.13 .10 
*. The mean difference is significant at the 0.05 level. 
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Table 150. One-Way ANOVA Descriptive Statistics – Surgical IMMC VTE Patients, 
CCI 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 36 2.92 3.102 .517 1.87 3.97 0 13 
2 2236 2.05 2.512 .053 1.94 2.15 0 15 
3 85 1.76 2.644 .287 1.19 2.34 0 11 
4 7884 1.25 1.999 .023 1.21 1.29 0 15 
Total 10241 1.43 2.159 .021 1.39 1.48 0 15 
 
Table 151. One-Way ANOVA Post-Hoc Dunnett T-Tests – Surgical IMMC VTE 
Patients, CCI 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 1.666* .356 .000 .82 2.52 
2 4 .796* .051 .000 .67 .92 
3 4 .514 .232 .079 -.04 1.07 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 1. Mann-Whitney U Test of Independent Samples – Surgical IMMC VTE 
Patients, CCI 
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IMMC Non-Surgical Calculations 
Table 152. One-Way ANOVA – Non-Surgical IMMC VTE Patients, CCI 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
9248.485 3 3082.828 172.499 .000 
Within Groups 505247.753 28271 17.872   
Total 514496.238 28274    
 
Table 153. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Non-Surgical 
IMMC VTE Patients, CCI 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
nation 
Mean 
Differe
nce (I-
J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 3.707* .246 .000 3.07 4.34 
3 .415 .310 .537 -.38 1.21 
4 3.737* .246 .000 3.10 4.37 
2 1 -3.707* .246 .000 -4.34 -3.07 
3 -3.292* .195 .000 -3.79 -2.79 
4 .030 .051 .938 -.10 .16 
3 1 -.415 .310 .537 -1.21 .38 
2 3.292* .195 .000 2.79 3.79 
4 3.321* .195 .000 2.82 3.82 
4 1 -3.737* .246 .000 -4.37 -3.10 
2 -.030 .051 .938 -.16 .10 
3 -3.321* .195 .000 -3.82 -2.82 
Bonferr
oni 
1 2 3.707* .246 .000 3.06 4.36 
3 .415 .310 1.000 -.40 1.23 
4 3.737* .246 .000 3.09 4.39 
2 1 -3.707* .246 .000 -4.36 -3.06 
3 -3.292* .195 .000 -3.81 -2.78 
4 .030 .051 1.000 -.11 .16 
3 1 -.415 .310 1.000 -1.23 .40 
2 3.292* .195 .000 2.78 3.81 
4 3.321* .195 .000 2.81 3.84 
4 1 -3.737* .246 .000 -4.39 -3.09 
2 -.030 .051 1.000 -.16 .11 
3 -3.321* .195 .000 -3.84 -2.81 
*. The mean difference is significant at the 0.05 level. 
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Table 154. One-Way ANOVA Descriptive Statistics – Non-Surgical IMMC VTE 
Patients, CCI 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 301 7.17 8.288 .478 6.23 8.11 0 72 
2 13506 3.46 3.792 .033 3.40 3.53 0 82 
3 488 6.75 7.007 .317 6.13 7.38 0 47 
4 13980 3.43 4.367 .037 3.36 3.51 0 190 
Total 28275 3.54 4.266 .025 3.49 3.59 0 190 
 
Table 155. One-Way ANOVA Post-Hoc Dunnett T-Tests – Non-Surgical IMMC VTE 
Patients, CCI 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 3.737* .246 .000 3.15 4.32 
2 4 .030 .051 .915 -.09 .15 
3 4 3.321* .195 .000 2.86 3.79 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 2. Mann-Whitney U Test of Independent Samples – Non-Surgical IMMC VTE 
Patients, CCI 
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LGH Surgical Calculations 
Table 156. One-Way ANOVA – Surgical LGH VTE Patients, CCI 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
69932.001 3 23310.667 686.291 .000 
Within Groups 588599.537 17329 33.966   
Total 658531.539 17332    
 
Table 157. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Surgical LGH 
VTE Patients, CCI 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
nation 
Mean 
Differe
nce (I-
J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 12.321* .685 .000 10.56 14.08 
3 3.572* .763 .000 1.61 5.53 
4 15.512* .675 .000 13.78 17.25 
2 1 -12.321* .685 .000 -14.08 -10.56 
3 -8.749* .382 .000 -9.73 -7.77 
4 3.192* .135 .000 2.84 3.54 
3 1 -3.572* .763 .000 -5.53 -1.61 
2 8.749* .382 .000 7.77 9.73 
4 11.941* .363 .000 11.01 12.87 
4 1 -15.512* .675 .000 -17.25 -13.78 
2 -3.192* .135 .000 -3.54 -2.84 
3 -11.941* .363 .000 -12.87 -11.01 
Bonferr
oni 
1 2 12.321* .685 .000 10.51 14.13 
3 3.572* .763 .000 1.56 5.59 
4 15.512* .675 .000 13.73 17.29 
2 1 -12.321* .685 .000 -14.13 -10.51 
3 -8.749* .382 .000 -9.76 -7.74 
4 3.192* .135 .000 2.83 3.55 
3 1 -3.572* .763 .000 -5.59 -1.56 
2 8.749* .382 .000 7.74 9.76 
4 11.941* .363 .000 10.98 12.90 
4 1 -15.512* .675 .000 -17.29 -13.73 
2 -3.192* .135 .000 -3.55 -2.83 
3 -11.941* .363 .000 -12.90 -10.98 
*. The mean difference is significant at the 0.05 level. 
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Table 158. One-Way ANOVA Descriptive Statistics – Surgical LGH VTE Patients, CCI 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 75 20.35 12.520 1.446 17.47 23.23 2 63 
2 2118 8.03 7.437 .162 7.71 8.34 0 79 
3 262 16.77 13.658 .844 15.11 18.44 1 77 
4 14878 4.83 5.257 .043 4.75 4.92 0 101 
Total 17333 5.47 6.164 .047 5.38 5.56 0 101 
 
Table 159. One-Way ANOVA Post-Hoc Dunnett T-Tests – Surgical LGH VTE Patients, 
CCI 
 
(I) 
VTE_Combination 
(J) 
VTE_Com
bination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 15.512* .675 .000 13.90 17.12 
2 4 3.192* .135 .000 2.87 3.51 
3 4 11.941* .363 .000 11.07 12.81 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 3. Mann-Whitney U Test of Independent Samples – Surgical LGH VTE Patients, 
CCI 
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LGH Non-Surgical Calculations 
Table 160. One-Way ANOVA – Non-Surgical LGH VTE Patients, CCI 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
24710.266 3 8236.755 410.373 .000 
Within Groups 779029.917 38813 20.071   
Total 803740.184 38816    
 
Table 161. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Non-Surgical 
LGH VTE Patients, CCI 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
nation 
Mean 
Differe
nce (I-
J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 7.071* .296 .000 6.31 7.83 
3 5.524* .326 .000 4.69 6.36 
4 8.012* .293 .000 7.26 8.77 
2 1 -7.071* .296 .000 -7.83 -6.31 
3 -1.547* .152 .000 -1.94 -1.16 
4 .941* .055 .000 .80 1.08 
3 1 -5.524* .326 .000 -6.36 -4.69 
2 1.547* .152 .000 1.16 1.94 
4 2.488* .146 .000 2.11 2.86 
4 1 -8.012* .293 .000 -8.77 -7.26 
2 -.941* .055 .000 -1.08 -.80 
3 -2.488* .146 .000 -2.86 -2.11 
Bonferr
oni 
1 2 7.071* .296 .000 6.29 7.85 
3 5.524* .326 .000 4.66 6.38 
4 8.012* .293 .000 7.24 8.79 
2 1 -7.071* .296 .000 -7.85 -6.29 
3 -1.547* .152 .000 -1.95 -1.15 
4 .941* .055 .000 .80 1.09 
3 1 -5.524* .326 .000 -6.38 -4.66 
2 1.547* .152 .000 1.15 1.95 
4 2.488* .146 .000 2.10 2.87 
4 1 -8.012* .293 .000 -8.79 -7.24 
2 -.941* .055 .000 -1.09 -.80 
3 -2.488* .146 .000 -2.87 -2.10 
*. The mean difference is significant at the 0.05 level. 
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Table 162. One-Way ANOVA Descriptive Statistics – Non-Surgical LGH VTE Patients, 
CCI 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 235 12.01 15.474 1.009 10.02 14.00 0 183 
2 8522 4.94 4.825 .052 4.84 5.04 0 75 
3 967 6.49 6.841 .220 6.06 6.92 0 66 
4 29093 4.00 4.059 .024 3.95 4.05 0 295 
Total 38817 4.32 4.550 .023 4.27 4.36 0 295 
 
Table 163. One-Way ANOVA Post-Hoc Dunnett T-Tests – Non-Surgical LGH VTE 
Patients, CCI 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 8.012* .293 .000 7.31 8.71 
2 4 .941* .055 .000 .81 1.07 
3 4 2.488* .146 .000 2.14 2.84 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 4. Mann-Whitney U Test of Independent Samples – Non-Surgical LGH VTE 
Patients, CCI 
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Relationship Between Utilization of the VTE Order Sets, Acute VTE, and Length of 
Stay 
IMMC Surgical Calculations 
Table 164. One-Way ANOVA – Surgical IMMC VTE Patients, LOS 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
23466.811 3 7822.270 101.509 .000 
Within Groups 788860.010 10237 77.060   
Total 812326.821 10240    
 
Table 165. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Surgical IMMC 
VTE Patients, LOS 
 
 (J) 
VTE_
Combi
nation 
Mean 
Differe
nce (I-
J) 
Std. Error Sig.  
95% Confidence 
Interval 
      Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 11.370* 1.475 .000 7.58 15.16 
3 2.148 1.746 .607 -2.34 6.63 
4 13.455* 1.466 .000 9.69 17.22 
2 1 -11.370* 1.475 .000 -15.16 -7.58 
3 -9.222* .970 .000 -11.71 -6.73 
4 2.085* .210 .000 1.55 2.63 
3 1 -2.148 1.746 .607 -6.63 2.34 
2 9.222* .970 .000 6.73 11.71 
4 11.307* .957 .000 8.85 13.77 
4 1 -13.455* 1.466 .000 -17.22 -9.69 
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2 -2.085* .210 .000 -2.63 -1.55 
3 -11.307* .957 .000 -13.77 -8.85 
Bonferro
ni 
1 2 11.370* 1.475 .000 7.48 15.26 
3 2.148 1.746 1.000 -2.46 6.75 
4 13.455* 1.466 .000 9.59 17.32 
2 1 -11.370* 1.475 .000 -15.26 -7.48 
3 -9.222* .970 .000 -11.78 -6.66 
4 2.085* .210 .000 1.53 2.64 
3 1 -2.148 1.746 1.000 -6.75 2.46 
2 9.222* .970 .000 6.66 11.78 
4 11.307* .957 .000 8.78 13.83 
4 1 -13.455* 1.466 .000 -17.32 -9.59 
2 -2.085* .210 .000 -2.64 -1.53 
3 -11.307* .957 .000 -13.83 -8.78 
 
Table 166. One-Way ANOVA Descriptive Statistics – Surgical IMMC VTE Patients, 
LOS 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 36 18.58 12.749 2.125 14.27 22.90 2 59 
2 2236 7.21 7.916 .167 6.89 7.54 0 134 
3 85 16.44 11.911 1.292 13.87 19.00 1 59 
4 7884 5.13 8.948 .101 4.93 5.33 0 486 
Total 10241 5.72 8.907 .088 5.55 5.90 0 486 
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Table 167. One-Way ANOVA Post-Hoc Dunnett T-Tests – Surgical IMMC VTE 
Patients, LOS 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 13.455* 1.466 .000 9.95 16.96 
2 4 2.085* .210 .000 1.58 2.59 
3 4 11.307* .957 .000 9.02 13.59 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 5. Mann-Whitney U Test of Independent Samples – Surgical IMMC VTE 
Patients, LOS 
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IMMC Non-Surgical Calculations 
Table 168. One-Way ANOVA – Non-Surgical IMMC VTE Patients, LOS 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
9248.485 3 3082.828 172.499 .000 
Within Groups 505247.753 28271 17.872   
Total 514496.238 28274    
 
Table 169. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Non-Surgical 
IMMC VTE Patients, LOS 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
nation 
Mean 
Differe
nce (I-
J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 3.707* .246 .000 3.07 4.34 
3 .415 .310 .537 -.38 1.21 
4 3.737* .246 .000 3.10 4.37 
2 1 -3.707* .246 .000 -4.34 -3.07 
3 -3.292* .195 .000 -3.79 -2.79 
4 .030 .051 .938 -.10 .16 
3 1 -.415 .310 .537 -1.21 .38 
2 3.292* .195 .000 2.79 3.79 
4 3.321* .195 .000 2.82 3.82 
4 1 -3.737* .246 .000 -4.37 -3.10 
2 -.030 .051 .938 -.16 .10 
3 -3.321* .195 .000 -3.82 -2.82 
Bonferr
oni 
1 2 3.707* .246 .000 3.06 4.36 
3 .415 .310 1.000 -.40 1.23 
4 3.737* .246 .000 3.09 4.39 
2 1 -3.707* .246 .000 -4.36 -3.06 
3 -3.292* .195 .000 -3.81 -2.78 
4 .030 .051 1.000 -.11 .16 
3 1 -.415 .310 1.000 -1.23 .40 
2 3.292* .195 .000 2.78 3.81 
4 3.321* .195 .000 2.81 3.84 
4 1 -3.737* .246 .000 -4.39 -3.09 
2 -.030 .051 1.000 -.16 .11 
3 -3.321* .195 .000 -3.84 -2.81 
*. The mean difference is significant at the 0.05 level. 
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Table 170. One-Way ANOVA Descriptive Statistics – Non-Surgical IMMC VTE 
Patients, LOS 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 301 7.17 8.288 .478 6.23 8.11 0 72 
2 13506 3.46 3.792 .033 3.40 3.53 0 82 
3 488 6.75 7.007 .317 6.13 7.38 0 47 
4 13980 3.43 4.367 .037 3.36 3.51 0 190 
Total 28275 3.54 4.266 .025 3.49 3.59 0 190 
 
Table 171. One-Way ANOVA Post-Hoc Dunnett T-Tests – Non-Surgical IMMC VTE 
Patients, LOS 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 3.737* .246 .000 3.15 4.32 
2 4 .030 .051 .915 -.09 .15 
3 4 3.321* .195 .000 2.86 3.79 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 6. Mann-Whitney U Test of Independent Samples – Non-Surgical IMMC VTE 
Patients, LOS 
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LGH Surgical Calculations 
Table 172. One-Way ANOVA – Surgical LGH VTE Patients, LOS 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
69932.001 3 23310.667 686.291 .000 
Within Groups 588599.537 17329 33.966   
Total 658531.539 17332    
 
Table 173. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Surgical LGH 
VTE Patients, LOS 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
nation 
Mean 
Differe
nce (I-
J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 12.321* .685 .000 10.56 14.08 
3 3.572* .763 .000 1.61 5.53 
4 15.512* .675 .000 13.78 17.25 
2 1 -12.321* .685 .000 -14.08 -10.56 
3 -8.749* .382 .000 -9.73 -7.77 
4 3.192* .135 .000 2.84 3.54 
3 1 -3.572* .763 .000 -5.53 -1.61 
2 8.749* .382 .000 7.77 9.73 
4 11.941* .363 .000 11.01 12.87 
4 1 -15.512* .675 .000 -17.25 -13.78 
2 -3.192* .135 .000 -3.54 -2.84 
3 -11.941* .363 .000 -12.87 -11.01 
Bonferr
oni 
1 2 12.321* .685 .000 10.51 14.13 
3 3.572* .763 .000 1.56 5.59 
4 15.512* .675 .000 13.73 17.29 
2 1 -12.321* .685 .000 -14.13 -10.51 
3 -8.749* .382 .000 -9.76 -7.74 
4 3.192* .135 .000 2.83 3.55 
3 1 -3.572* .763 .000 -5.59 -1.56 
2 8.749* .382 .000 7.74 9.76 
4 11.941* .363 .000 10.98 12.90 
4 1 -15.512* .675 .000 -17.29 -13.73 
2 -3.192* .135 .000 -3.55 -2.83 
3 -11.941* .363 .000 -12.90 -10.98 
*. The mean difference is significant at the 0.05 level. 
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Table 174. One-Way ANOVA Descriptive Statistics – Surgical LGH VTE Patients, LOS 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 75 20.35 12.520 1.446 17.47 23.23 2 63 
2 2118 8.03 7.437 .162 7.71 8.34 0 79 
3 262 16.77 13.658 .844 15.11 18.44 1 77 
4 14878 4.83 5.257 .043 4.75 4.92 0 101 
Total 17333 5.47 6.164 .047 5.38 5.56 0 101 
 
Table 175. One-Way ANOVA Post-Hoc Dunnett T-Tests – Surgical LGH VTE Patients, 
LOS 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 15.512* .675 .000 13.90 17.12 
2 4 3.192* .135 .000 2.87 3.51 
3 4 11.941* .363 .000 11.07 12.81 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 7. Mann-Whitney U Test of Independent Samples – Surgical LGH VTE Patients, 
LOS 
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LGH Non-Surgical Calculations 
Table 176. One-Way ANOVA – Non-Surgical LGH VTE Patients, LOS 
 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
24710.266 3 8236.755 410.373 .000 
Within Groups 779029.917 38813 20.071   
Total 803740.184 38816    
 
Table 177. One-Way ANOVA Post-Hoc Bonferroni and Tukey Tests – Non-Surgical 
LGH VTE Patients, LOS 
 
 (I) 
VTE_
Combi
nation 
(J) 
VTE_
Combi
nation 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
 Lower 
Bound 
Upper 
Bound 
Tukey 
HSD 
1 2 7.071* .296 .000 6.31 7.83 
3 5.524* .326 .000 4.69 6.36 
4 8.012* .293 .000 7.26 8.77 
2 1 -7.071* .296 .000 -7.83 -6.31 
3 -1.547* .152 .000 -1.94 -1.16 
4 .941* .055 .000 .80 1.08 
3 1 -5.524* .326 .000 -6.36 -4.69 
2 1.547* .152 .000 1.16 1.94 
4 2.488* .146 .000 2.11 2.86 
4 1 -8.012* .293 .000 -8.77 -7.26 
2 -.941* .055 .000 -1.08 -.80 
3 -2.488* .146 .000 -2.86 -2.11 
Bonferr
oni 
1 2 7.071* .296 .000 6.29 7.85 
3 5.524* .326 .000 4.66 6.38 
4 8.012* .293 .000 7.24 8.79 
2 1 -7.071* .296 .000 -7.85 -6.29 
3 -1.547* .152 .000 -1.95 -1.15 
4 .941* .055 .000 .80 1.09 
3 1 -5.524* .326 .000 -6.38 -4.66 
2 1.547* .152 .000 1.15 1.95 
4 2.488* .146 .000 2.10 2.87 
4 1 -8.012* .293 .000 -8.79 -7.24 
2 -.941* .055 .000 -1.09 -.80 
3 -2.488* .146 .000 -2.87 -2.10 
*. The mean difference is significant at the 0.05 level. 
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Table 178. One-Way ANOVA Descriptive Statistics – Non-Surgical LGH VTE Patients, 
LOS 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
1 235 12.01 15.474 1.009 10.02 14.00 0 183 
2 8522 4.94 4.825 .052 4.84 5.04 0 75 
3 967 6.49 6.841 .220 6.06 6.92 0 66 
4 29093 4.00 4.059 .024 3.95 4.05 0 295 
Total 38817 4.32 4.550 .023 4.27 4.36 0 295 
 
Table 179. One-Way ANOVA Post-Hoc Dunnett T-Tests – Non-Surgical LGH VTE 
Patients, LOS 
 
(I) 
VTE_Combination 
(J) 
VTE_Combination 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
1 4 8.012* .293 .000 7.31 8.71 
2 4 .941* .055 .000 .81 1.07 
3 4 2.488* .146 .000 2.14 2.84 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Figure 8. Mann-Whitney U Test of Independent Samples – Non-Surgical LGH VTE 
Patients, LOS 
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VTE Study Descriptive Statistics 
Table 180. VTE Patient Statistics, by Sex and Order Set Utilization – IMMC 
 
Sex No Order Set Order Set Total 
F 20581 8448 29029 
M 13726 8466 22192 
 
Table 181. VTE Patient Statistics, by Sex and Order Set Utilization – LGH 
 
Sex No Order Set Order Set Total 
F 39801 5744 45545 
M 23007 5128 28135 
 
Table 182. VTE Patient Statistics, by Sex and Acute VTE – IMMC 
 
Sex Acute VTE No VTE Total 
F 447 18904 19351 
M 460 18664 19124 
 
Table 183. VTE Patient Statistics, by Sex and Acute VTE – LGH 
 
Sex Acute VTE No VTE Total 
F 813 29758 30571 
M 685 24406 25091 
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Table 184. VTE Patient Statistics, by Race and Order Set Utilization – IMMC 
 
Race Description No Order Set Order Set Total 
African American / 
Black 
7263 4432 11695 
American Indian / 
Alaska Native 
78 47 125 
Asian/Filipino 1063 447 1510 
Caucasian/White 12998 6933 19931 
Declined None None None 
Eastern Indian 113 58 171 
Hispanic 9862 3528 13390 
Middle East 124 44 168 
Other 1876 1060 2936 
Pacific Islander / 
Hawaiian  
15 7 22 
Unknown 815 306 1121 
    
Totals 34207 16862  
 
Table 185. VTE Patient Statistics, by Race and Order Set Utilization – LGH 
 
Race Description No Order Set Order Set Total 
African American / 
Black 
1463 323 1786 
American Indian / 
Alaska Native 
143 27 170 
Asian/Filipino 2876 448 3324 
Caucasian/White 51279 9185 60464 
Declined None None None 
Eastern Indian 1016 132 1148 
Hispanic 3920 392 4312 
Middle East 624 98 722 
Other 1071 198 1269 
Pacific Islander / 
Hawaiian  
47 4 51 
Unknown 334 59 393 
    
Totals 62773 10866 73639 
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Appendix G 
Supplemental Pneumonia Results 
 
Pneumonia Study Descriptive Statistics 
Table 186. Pneumonia Patient Statistics, by Sex and Order Set Utilization 
Sex No Order Set Order Set Total 
F 2455 260 2715 
M 2076 296 2372 
 
Table 187. Pneumonia Patient Statistics, by Race and Order Set Utilization 
Race Description No Order Set Order Set Total 
African American / 
Black 
1 0 1 
American Indian / 
Alaska Native 
19 1 20 
Asian/Filipino 79 15 94 
Caucasian/White 2637 283 2920 
Declined 2 0 2 
Eastern Indian 33 1 34 
Hispanic 186 60 246 
Middle East 3 0 3 
Other 171 47 218 
Pacific Islander / 
Hawaiian  
3 1 4 
Unknown 33 5 38 
    
Totals 4531 556 5087 
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Pneumonia Study – Length of Stay Independent Samples Report 
Figure 9. Mann-Whitney U Test of Independent Samples – All Pneumonia Patients, LOS 
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Pneumonia Study – Patient Complications Independent Samples Report 
Figure 10. Mann-Whitney U Test of Independent Samples – All Pneumonia Patients, CCI 
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Appendix H 
Supplemental CHF Results 
 
CHF Study Descriptive Statistics 
Table 188. CHF Patient Statistics, by Sex and Order Set Utilization 
Sex No Order Set Order Set Total 
F 5233 356 5589 
M 4986 363 5349 
 
Table 189. CHF Patient Statistics, by Race and Order Set Utilization 
Race Description No Order Set Order Set Total 
African American / 
Black 
3396 242 3638 
American Indian / 
Alaska Native 
29 2 31 
Asian/Filipino 119 11 130 
Caucasian/White 6070 322 6392 
Declined 7 0 7 
Eastern Indian 14 2 16 
Hispanic 181 50 231 
Middle East 59 2 61 
Other 291 82 373 
Pacific Islander / 
Hawaiian  
1 1 2 
Unknown 48 5 53 
Null 4 0 4 
Totals 10219 719 10938 
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CHF Study – Length of Stay Independent Samples Report 
Figure 11. Mann-Whitney U Test of Independent Samples – All CHF Patients, LOS 
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CHF Study – Charlson Comorbidity Index of Complications Independent Samples 
Report 
Figure 12. Mann-Whitney U Test of Independent Samples – All CHF Patients, CCI 
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Appendix I 
Supplemental AMI Results 
 
AMI Study Descriptive Statistics 
Table 190. AMI Patient Statistics, by Sex and Order Set Utilization 
Sex No Order Set Order Set Total 
F 564 17 581 
M 696 15 711 
 
Table 191. AMI Patient Statistics, by Race and Order Set Utilization 
Race No Order Set Order Set Total 
African American / 
Black 
323 9 332 
American Indian / 
Alaska Native 
1 0 1 
Asian/Filipino 9 0 9 
Caucasian/White 868 21 889 
Declined 0 0 0 
Eastern Indian 3 0 3 
Hispanic 21 0 21 
Middle East 2 0 2 
Other 26 2 28 
Pacific Islander / 
Hawaiian  
1 0 1 
Unknown 5 0 5 
Multi-Race 1 0 1 
Totals 1260 32 1292 
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AMI Study – Length of Stay Independent Samples Report 
Figure 13. Mann-Whitney U Test of Independent Samples – All AMI Patients, LOS 
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AMI Study – Charlson Comorbidity Index of Complications Independent Samples 
Report 
Figure 14. Mann-Whitney U Test of Independent Samples – All AMI Patients, CCI 
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